

Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM protein - protein search, using sw model

Run on: February 24, 2006, 10:29:45 ; Search time 18 Seconds

(without alignment)

7.444 Million cell updates/sec

Title: US-10-019-513-1

Perfect score: 49

Sequence: 1 STAPPVHN 9

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 117670 seqs, 14887254 residues

Total number of hits satisfying chosen parameters:

34777

Minimum DB seq length: 0

Maximum DB seq length: 9

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 1000 summaries

Database : Published_Applications_AA_New.*

1: /cgn2_6/ptodata/2/pubpaas/US08_NEWPUB.pep:*

2: /cgn2_6/ptodata/2/pubpaas/US06_NEWPUB.pep:*

3: /cgn2_6/ptodata/2/pubpaas/US07_NEWPUB.pep:*

4: /cgn2_6/ptodata/2/pubpaas/PCT_NEWPUB.pep:*

5: /cgn2_6/ptodata/2/pubpaas/US09_NEWPUB.pep:*

6: /cgn2_6/ptodata/2/pubpaas/US10_NEWPUB.pep:*

7: /cgn2_6/ptodata/2/pubpaas/US11_NEWPUB.pep:*

8: /cgn2_6/ptodata/2/pubpaas/US60_NEWPUB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	49	100.0	9	US-10-401-386B-52	Sequence 52, App1
2	49	100.0	9	US-10-517-784-35	Sequence 35, App1
3	39	79.6	9	US-10-401-386B-56	Sequence 36, App1
4	24	49.0	8	US-11-045-024-6286	Sequence 6286, App1
5	24	49.0	8	US-11-045-024-6385	Sequence 6385, App1
6	24	49.0	8	US-11-045-024-8860	Sequence 8860, App1
7	24	49.0	8	US-11-045-024-9105	Sequence 9105, App1
8	24	49.0	9	US-11-011-6665	Sequence 5, App1
9	24	49.0	9	US-11-045-024-146	Sequence 146, App1
10	24	49.0	9	US-11-045-024-148	Sequence 148, App1
11	24	49.0	9	US-11-045-024-2988	Sequence 2988, App1
12	24	49.0	9	US-11-045-024-4112	Sequence 4112, App1
13	24	49.0	9	US-11-045-024-4114	Sequence 4114, App1
14	24	49.0	9	US-11-045-024-5659	Sequence 5659, App1
15	24	49.0	9	US-11-045-024-6287	Sequence 6287, App1
16	24	49.0	9	US-11-045-024-6387	Sequence 6387, App1
17	24	49.0	9	US-11-045-024-8861	Sequence 8861, App1
18	24	49.0	7	US-11-045-024-8862	Sequence 8862, App1
19	24	49.0	9	US-11-045-024-9107	Sequence 9107, App1
20	24	49.0	9	US-11-045-024-11134	Sequence 11134, App1
21	23	46.9	7	US-11-031-73A-40	Sequence 40, App1
22	23	46.9	7	US-11-031-482-40	Sequence 482, App1
23	23	46.9	8	US-11-045-024-5300	Sequence 5300, App1
24	23	46.9	8	US-11-045-024-6267	Sequence 6267, App1
25	23	46.9	8	US-11-045-024-6353	Sequence 6353, App1

99	8	7	US-11-073-347-26	Sequence 26, App1
100	20	40.8	US-10-989-763-A-7	Sequence 7, App1
101	20	40.8	US-11-073-347-20	Sequence 20, App1
102	20	40.8	US-11-073-347-24	Sequence 24, App1
103	20	40.8	US-11-073-347-44	Sequence 44, App1
104	20	40.8	US-11-045-024-1837	Sequence 1837, App1
105	20	40.8	US-11-045-024-13835	Sequence 13835, A
106	20	40.8	US-11-026-403-9	Sequence 9, App1
107	20	40.8	US-11-039-534	Sequence 534, App1
108	19	38.8	US-11-122-612-392	Sequence 392, App1
109	19	38.8	US-11-121-612-393	Sequence 393, App1
110	19	38.8	US-10-893-064-1605	Sequence 1605, App1
111	19	38.8	US-10-893-064-1702	Sequence 1702, App1
112	19	38.8	US-11-129-741-1605	Sequence 1605, App1
113	19	38.8	US-11-129-741-1702	Sequence 1702, App1
114	19	38.8	US-10-893-064-2875	Sequence 2875, App1
115	19	38.8	US-11-045-024-1075	Sequence 1075, App1
116	19	38.8	US-11-045-024-5159	Sequence 5159, App1
117	19	38.8	US-11-045-024-7362	Sequence 7362, App1
118	19	38.8	US-11-045-024-9002	Sequence 9002, App1
119	19	38.8	US-11-045-024-9087	Sequence 9087, App1
120	19	38.8	US-11-045-024-9205	Sequence 9205, App1
121	19	38.8	US-11-045-024-10113	Sequence 10113, A
122	19	38.8	US-11-045-024-11227	Sequence 11227, A
123	19	38.8	US-11-045-024-11352	Sequence 11352, A
124	19	38.8	US-11-045-024-12002	Sequence 12002, A
125	19	38.8	US-11-129-741-2875	Sequence 2875, App1
126	19	38.8	US-10-855-643-33	Sequence 33, App1
127	19	38.8	US-10-855-643-287	Sequence 287, App1
128	19	38.8	US-10-855-643-368	Sequence 368, App1
129	19	38.8	US-10-855-643-654	Sequence 654, App1
130	19	38.8	US-10-985-767A-11	Sequence 11, App1
131	19	38.8	US-10-985-767A-467	Sequence 467, App1
132	19	38.8	US-10-989-767A-552	Sequence 552, App1
133	19	38.8	US-11-045-159-122	Sequence 122, App1
134	19	38.8	US-11-073-347-50	Sequence 50, App1
135	19	38.8	US-11-097-864-33	Sequence 33, App1
136	19	38.8	US-11-097-864-287	Sequence 11, App1
137	19	38.8	US-11-097-864-368	Sequence 368, App1
138	19	38.8	US-11-097-864-654	Sequence 654, App1
139	19	38.8	US-11-097-912-33	Sequence 33, App1
140	19	38.8	US-11-097-912-287	Sequence 287, App1
141	19	38.8	US-11-097-912-368	Sequence 368, App1
142	19	38.8	US-11-097-912-654	Sequence 654, App1
143	19	38.8	US-11-045-024-5182	Sequence 5182, App1
144	19	38.8	US-11-045-024-5193	Sequence 5193, App1
145	19	38.8	US-11-045-024-5196	Sequence 5196, App1
146	19	38.8	US-11-045-024-5644	Sequence 5644, App1
147	19	38.8	US-11-045-024-13697	Sequence 5645, App1
148	19	38.8	US-11-045-024-7204	Sequence 7204, App1
149	19	38.8	US-11-045-024-13726	Sequence 13726, A
150	19	38.8	US-11-045-024-13730	Sequence 13730, A
151	19	38.8	US-11-045-024-9209	Sequence 9209, AP
152	19	38.8	US-11-045-024-13686	Sequence 14450, A
153	19	38.8	US-11-045-024-13697	Sequence 13686, A
154	19	38.8	US-11-045-024-13697	Sequence 13697, A
155	19	38.8	US-11-045-024-13726	Sequence 13726, A
156	19	38.8	US-11-045-024-14333	Sequence 14333, A
157	19	38.8	US-11-129-741-2135	Sequence 2135, AP
158	19	38.8	US-10-939-890-503	Sequence 503, AP
159	19	38.8	US-11-033-039-288	Sequence 1058, AP
160	19	38.8	US-11-247-423-341	Sequence 341, AP
161	19	38.8	US-11-247-423-384	Sequence 384, AP
162	18	36.7	US-10-895-064-2135	Sequence 2135, AP
163	18	36.7	US-11-129-741-2135	Sequence 1451, AP
164	18	36.7	US-10-939-890-503	Sequence 503, AP
165	18	36.7	US-10-939-890-676	Sequence 676, AP
166	18	36.7	US-10-467-657-8837	Sequence 8337, AP
167	18	36.7	US-10-956-755A-44	Sequence 44, App1
168	18	36.7	US-10-895-064-1127	Sequence 1127, AP
169	18	36.7	US-10-895-064-2722	Sequence 2722, AP
170	18	36.7	US-11-129-741-1127	Sequence 1127, AP
171	18	36.7	US-11-129-741-2722	Sequence 2722, AP

172	18	36.7	US-10-485-788A-78	Sequence 78, App1
173	18	36.7	US-11-032-773-723	Sequence 723, App1
174	18	36.7	US-10-036-328-64	Sequence 64, App1
175	18	36.7	US-10-986-501-331	Sequence 331, App1
176	18	36.7	US-10-185-788A-79	Sequence 79, App1
177	18	36.7	US-10-501-292-39	Sequence 2743, AP
178	18	36.7	US-10-995-064-2743	Sequence 15, App1
179	18	36.7	US-11-051-433-15	Sequence 2743, AP
180	18	36.7	US-11-129-741-714	Sequence 80, App1
181	18	36.7	US-10-185-788A-80	Sequence 459, App1
182	18	36.7	US-10-995-064-1553	Sequence 1553, AP
183	18	36.7	US-10-895-064-1896	Sequence 1896, AP
184	18	36.7	US-11-045-024-457	Sequence 457, App1
185	18	36.7	US-11-045-024-458	Sequence 458, App1
186	18	36.7	US-11-045-024-5308	Sequence 5308, AP
187	18	36.7	US-11-045-024-7753	Sequence 7753, AP
188	18	36.7	US-11-045-024-8525	Sequence 8525, AP
189	18	36.7	US-11-045-024-8577	Sequence 8577, AP
190	18	36.7	US-11-045-024-8713	Sequence 8713, AP
191	18	36.7	US-11-045-024-8745	Sequence 8745, AP
192	18	36.7	US-11-045-024-8758	Sequence 8758, AP
193	18	36.7	US-11-045-024-9002	Sequence 9002, AP
194	18	36.7	US-11-045-024-9092	Sequence 10920, A
200	18	36.7	US-11-045-024-1032	Sequence 11032, A
201	18	36.7	US-11-045-024-11845	Sequence 11845, AP
203	18	36.7	US-11-126-798-57	Sequence 1553, AP
204	18	36.7	US-11-129-741-1553	Sequence 1896, AP
205	18	36.7	US-11-24-422-291	Sequence 231, App1
206	18	36.7	US-11-510-101-163	Sequence 163, App1
207	18	36.7	US-11-589-767A-15	Sequence 15, App1
208	18	36.7	US-10-859-643-364	Sequence 364, App1
209	18	36.7	US-10-859-643-465	Sequence 451, App1
210	18	36.7	US-10-859-643-566	Sequence 465, App1
211	18	36.7	US-10-859-643-561	Sequence 556, App1
212	18	36.7	US-10-859-643-561	Sequence 561, App1
213	18	36.7	US-10-899-767A-15	Sequence 163, App1
214	18	36.7	US-10-989-676A-43	Sequence 15, App1
215	18	36.7	US-10-989-767A-2345	Sequence 231, App1
216	18	36.7	US-10-989-767A-3134	Sequence 478, App1
217	18	36.7	US-10-989-767A-478	Sequence 556, App1
218	18	36.7	US-10-857-484-45	Sequence 45, App1
219	18	36.7	US-10-505-955-458	Sequence 58, App1
220	18	36.7	US-10-989-676A-43	Sequence 43, App1
221	18	36.7	US-11-071-062-8	Sequence 8, App1
222	18	36.7	US-11-097-864-364	Sequence 451, App1
223	18	36.7	US-11-097-864-451	Sequence 465, App1
224	18	36.7	US-11-097-912-556	Sequence 556, App1
225	18	36.7	US-11-097-864-561	Sequence 561, App1
226	18	36.7	US-11-097-912-664	Sequence 2481, AP
227	18	36.7	US-11-097-912-451	Sequence 2581, AP
228	18	36.7	US-11-097-912-451	Sequence 3722, AP
229	18	36.7	US-11-097-912-556	Sequence 5119, AP
230	18	36.7	US-11-045-024-5120	Sequence 5120, AP
231	18	36.7	US-11-045-024-5121	Sequence 5121, AP
232	18	36.7	US-11-045-024-5122	Sequence 5122, AP
233	18	36.7	US-11-045-024-5194	Sequence 5194, AP
234	18	36.7	US-11-045-024-5197	Sequence 5197, AP
235	18	36.7	US-11-045-024-5340	Sequence 5340, AP
241	18	36.7	US-11-045-024-5342	Sequence 5342, AP
242	18	36.7	US-11-045-024-5444	Sequence 5444, AP
243	18	36.7	US-11-045-024-5445	Sequence 5445, AP
244	18	36.7	US-11-045-024-6647	Sequence 6647, AP

2445	18	36.7	US-11-045-024-7195
2446	18	36.7	US-11-045-024-7266
2447	18	36.7	US-11-045-024-7749
2448	18	36.7	US-11-045-024-8069
2449	18	36.7	US-11-045-024-8071
250	18	36.7	US-11-045-024-11007
251	18	36.7	US-11-045-024-11044
252	18	36.7	US-11-045-024-11848
253	18	36.7	US-11-045-024-13546
254	18	36.7	US-11-045-024-13549
255	18	36.7	US-11-045-024-13601
256	18	36.7	US-11-045-024-13617
257	18	36.7	US-11-045-024-13859
258	18	36.7	US-11-045-024-13861
259	18	36.7	US-11-045-024-13959
260	18	36.7	US-11-045-024-14030
261	18	36.7	US-11-045-024-14327
262	18	36.7	US-11-045-024-14453
263	18	36.7	US-11-045-024-14455
264	18	36.7	US-11-045-024-14457
265	18	36.7	US-11-045-024-14459
266	18	36.7	US-11-045-024-14460
267	18	36.7	US-11-045-024-14462
268	18	36.7	US-11-045-024-14463
269	18	36.7	US-11-045-024-14464
270	18	36.7	US-11-045-024-14465
271	18	36.7	US-11-045-024-14466
272	18	36.7	US-11-045-024-14467
273	18	36.7	US-11-045-024-14468
274	18	36.7	US-11-045-024-14469
275	18	36.7	US-11-045-024-14470
276	18	36.7	US-11-045-024-14471
277	17	34.7	US-11-045-024-14472
278	17	34.7	US-11-045-024-14473
279	17	34.7	US-11-045-024-14474
280	17	34.7	US-11-045-024-14475
281	17	34.7	US-11-045-024-14476
282	17	34.7	US-11-045-024-14477
283	17	34.7	US-11-045-024-14478
284	17	34.7	US-11-045-024-14479
285	17	34.7	US-11-045-024-14480
286	17	34.7	US-11-045-024-14481
287	17	34.7	US-11-045-024-14482
288	17	34.7	US-11-045-024-14483
289	17	34.7	US-11-045-024-14484
290	17	34.7	US-11-045-024-14485
291	17	34.7	US-11-045-024-14486
292	17	34.7	US-11-045-024-14487
293	17	34.7	US-11-045-024-14488
294	17	34.7	US-11-045-024-14489
295	17	34.7	US-11-045-024-14490
296	17	34.7	US-11-045-024-14491
297	17	34.7	US-11-045-024-14492
298	17	34.7	US-11-045-024-14493
299	17	34.7	US-11-045-024-14494
300	17	34.7	US-11-045-024-14495
301	17	34.7	US-11-045-024-14496
302	17	34.7	US-11-045-024-14497
303	17	34.7	US-11-045-024-14498
304	17	34.7	US-11-045-024-14499
305	17	34.7	US-11-045-024-14500
306	17	34.7	US-11-045-024-14501
307	17	34.7	US-11-045-024-14502
308	17	34.7	US-11-045-024-14503
309	17	34.7	US-11-045-024-14504
310	17	34.7	US-11-045-024-14505
311	17	34.7	US-11-045-024-14506
312	17	34.7	US-11-045-024-14507
313	17	34.7	US-11-045-024-14508
314	17	34.7	US-11-045-024-14509
315	17	34.7	US-11-045-024-14510
316	17	34.7	US-11-045-024-14511
317	17	34.7	US-11-045-024-14512

Sequence 7195, AP	Sequence 7266, AP	Sequence 7748, AP	Sequence 7749, AP	Sequence 8069, AP	Sequence 8191, AP	Sequence 8680, AP	Sequence 8692, AP	Sequence 9885, AP	Sequence 11007, A	Sequence 11014, A	Sequence 11848, A	Sequence 13546, A	Sequence 13549, A	Sequence 13601, A	Sequence 13627, A	Sequence 13859, A	Sequence 13861, A	Sequence 13959, A	Sequence 14030, A	Sequence 14327, A	Sequence 14553, A	Sequence 14555, A	Sequence 20, App1	Sequence 32, App1	Sequence 30, App1	Sequence 308, App1	Sequence 664, App1	Sequence 657, App1	Sequence 78, App1	Sequence 84, App1	Sequence 31, App1	Sequence 70, App1	Sequence 11, App1	Sequence 16, App1	Sequence 77, App1	Sequence 216, App1	Sequence 391, App1	Sequence 215, App1	Sequence 321, App1	Sequence 724, App1	Sequence 404, App1	Sequence 4, App1	Sequence 9018, AP	Sequence 1514, AP	Sequence 1400, AP	Sequence 6, App11	Sequence 1514, AP	Sequence 2705, AP	Sequence 1051, AP	Sequence 1082, AP	Sequence 3172, AP	Sequence 3133, AP	Sequence 3194, AP	Sequence 404, AP	Sequence 405, AP	Sequence 5154, AP	Sequence 5165, AP	Sequence 5307, AP	Sequence 5414, AP	Sequence 6355, AP	Sequence 6811, AP	Sequence 7215, AP	Sequence 7216, AP	Sequence 7300, AP	Sequence 7355, AP	Sequence 7721, AP	Sequence 7998, AP	Sequence 9880, AP	Sequence 10655, A	Sequence 10301, A	Sequence 10334, A	Sequence 10355, A	Sequence 11829, A
-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	--------------------	--------------------	--------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	------------------	------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------

34.7	3.118	US-11-045-024-12115	Sequence 12115, A
17	31.19	US-11-045-024-12162	Sequence 12162, A-
17	32.20	US-11-045-024-12163	Sequence 12163, A
17	32.21	US-11-045-024-12168	Sequence 12168, A
17	32.22	US-11-045-024-12625	Sequence 12625, A
17	34.7	US-11-078-256-12	Sequence 12, App.
17	34.7	US-10-507-662-17	Sequence 17, App.
17	34.7	US-10-925-366A-33	Sequence 33, App.
17	34.7	US-10-959-543-577	Sequence 577, App.
17	34.7	US-10-857-484-385	Sequence 285, App.
17	34.7	US-10-857-484-387	Sequence 287, App.
17	34.7	US-10-857-484-397	Sequence 297, App.
17	34.7	US-10-857-484-404	Sequence 304, App.
17	34.7	US-10-857-484-412	Sequence 312, App.
17	34.7	US-10-857-484-4260	Sequence 360, App.
17	34.7	US-10-857-484-435	Sequence 435, App.
17	34.7	US-10-857-484-438	Sequence 438, App.
17	34.7	US-10-857-484-443	Sequence 443, App.
17	34.7	US-10-857-484-444	Sequence 444, App.
17	34.7	US-10-857-484-450	Sequence 450, App.
17	34.7	US-10-857-484-451	Sequence 451, App.
17	34.7	US-10-857-484-452	Sequence 452, App.
17	34.7	US-10-857-484-455	Sequence 455, App.
17	34.7	US-10-857-484-472	Sequence 872, App.
17	34.7	US-10-857-484-476	Sequence 876, App.
17	34.7	US-10-857-484-918	Sequence 918, App.
17	34.7	US-10-857-484-1020	Sequence 1020, App.
17	34.7	US-10-857-484-123	Sequence 1024, App.
17	34.7	US-10-857-484-1005	Sequence 1005, App.
17	34.7	US-10-857-484-1010	Sequence 1010, App.
17	34.7	US-10-857-484-1013	Sequence 1013, App.
17	34.7	US-10-857-484-1018	Sequence 1018, App.
17	34.7	US-10-857-484-1024	Sequence 1024, App.
17	34.7	US-10-857-484-1026	Sequence 1026, App.
17	34.7	US-10-857-484-1027	Sequence 1027, App.
17	34.7	US-10-857-484-1048	Sequence 1428, App.
17	34.7	US-10-857-484-1448	Sequence 1448, App.
17	34.7	US-10-857-484-1477	Sequence 1477, App.
17	34.7	US-10-857-484-1524	Sequence 1524, App.
17	34.7	US-10-857-484-1506	Sequence 1506, App.
17	34.7	US-10-857-484-1575	Sequence 1575, App.
17	34.7	US-10-857-484-1579	Sequence 1579, App.
17	34.7	US-10-857-484-1582	Sequence 1582, App.
17	34.7	US-10-857-484-1586	Sequence 1586, App.
17	34.7	US-10-857-484-1588	Sequence 1588, App.
17	34.7	US-10-857-484-1593	Sequence 1593, App.
17	34.7	US-10-857-484-1595	Sequence 1595, App.
17	34.7	US-10-857-484-1596	Sequence 1596, App.
17	34.7	US-10-857-484-1983	Sequence 1983, App.
17	34.7	US-10-857-484-2004	Sequence 2004, App.
17	34.7	US-10-857-484-2018	Sequence 2018, App.
17	34.7	US-10-857-484-2035	Sequence 2035, App.
17	34.7	US-10-857-484-2059	Sequence 2059, App.
17	34.7	US-10-857-484-2077	Sequence 2077, App.
17	34.7	US-10-857-484-2134	Sequence 2134, App.
17	34.7	US-10-857-484-2137	Sequence 2137, App.
17	34.7	US-10-857-484-2141	Sequence 2141, App.
17	34.7	US-10-857-484-2145	Sequence 2145, App.
17	34.7	US-10-857-484-2147	Sequence 2147, App.
17	34.7	US-10-857-484-2151	Sequence 2151, App.
17	34.7	US-10-857-484-2152	Sequence 2152, App.
17	34.7	US-10-857-484-2703	Sequence 2703, App.
17	34.7	US-10-857-484-2712	Sequence 2712, App.
17	34.7	US-10-857-484-2716	Sequence 2716, App.
17	34.7	US-10-857-484-2717	Sequence 2717, App.
17	34.7	US-10-857-484-3123	Sequence 3123, App.
17	34.7	US-10-857-484-3124	Sequence 3124, App.

391	6	US-10-057-484-3167
392	9	US-10-057-484-3181
393	9	US-10-057-484-3255
394	9	US-10-057-484-3257
395	9	US-10-057-484-3264
396	9	US-10-057-484-3266
397	9	US-10-057-484-3271
398	9	US-10-057-484-3273
399	9	US-10-057-484-3277
400	9	US-10-057-484-3278
401	9	US-10-057-484-3294
402	9	US-10-057-484-3274
403	9	US-10-057-484-3258
404	9	US-10-057-484-3260
405	9	US-10-057-484-3283
406	9	US-10-057-484-3225
407	9	US-10-057-484-3332
408	9	US-10-057-484-3253
409	9	US-10-057-484-3339
410	9	US-10-057-484-3840
411	9	US-10-057-484-3842
412	9	US-10-057-484-3846
413	9	US-10-057-484-4146
414	9	US-10-057-484-4153
415	9	US-10-057-484-4156
416	9	US-10-057-484-4195
417	9	US-10-057-484-4197
418	9	US-10-057-484-4199
419	9	US-10-057-484-4200
420	9	US-10-057-484-4202
421	9	US-10-057-484-4257
422	9	US-10-057-484-4258
423	9	US-10-057-484-4279
424	9	US-10-057-484-4296
425	9	US-10-057-484-4297
426	9	US-10-057-484-4442
427	9	US-10-057-484-4317
428	9	US-10-057-484-4351
429	9	US-10-057-484-4354
430	9	US-10-057-484-4359
431	9	US-10-057-484-4359
432	9	US-10-057-484-4360
433	9	US-10-057-484-4452
434	9	US-10-057-484-4453
435	9	US-10-057-484-4454
436	9	US-10-057-484-4459
437	9	US-10-057-484-4459
438	9	US-10-057-484-4522
439	9	US-10-057-484-4529
440	9	US-10-057-484-4572
441	9	US-10-057-484-4611
442	9	US-10-057-484-4680
443	9	US-10-057-484-4682
444	9	US-10-057-484-4684
445	9	US-10-057-484-4685
446	9	US-10-057-484-4689
447	9	US-10-057-484-4729
448	9	US-10-057-484-4756
449	9	US-10-057-484-4790
450	9	US-10-057-484-4822
451	9	US-10-057-484-4823
452	9	US-10-057-484-4829
453	9	US-10-057-484-4830
454	9	US-10-057-484-4836
455	9	US-10-057-484-4837
456	9	US-10-057-484-5009
457	9	US-10-057-484-5009
458	9	US-10-057-484-4891
459	9	US-10-057-484-4892
460	9	US-10-057-484-4924
461	9	US-10-057-484-5000
462	9	US-10-057-484-5009
463	9	US-10-057-484-5009

464	6	US-10-857-484-5104
465	17	US-10-857-484-5158
466	17	US-10-857-484-5161
467	17	US-10-857-484-5162
468	17	US-10-857-484-5165
469	17	US-10-857-484-5168
470	17	US-10-857-484-5169
471	17	US-10-857-484-5219
472	17	US-11-097-912-577
473	17	US-11-097-912-577
474	17	US-11-045-024-277
475	17	US-11-045-024-1198
476	17	US-11-045-024-1199
477	17	US-11-045-024-1838
478	17	US-11-045-024-2487
479	17	US-11-045-024-3257
480	17	US-11-045-024-3258
481	17	US-11-045-024-3464
482	17	US-11-045-024-4094
483	17	US-11-045-024-4095
484	17	US-11-045-024-4516
485	17	US-11-045-024-4886
486	17	US-11-045-024-5183
487	17	US-11-045-024-5184
488	17	US-11-045-024-5185
489	17	US-11-045-024-5186
490	17	US-11-045-024-5339
491	17	US-11-045-024-5341
492	17	US-11-045-024-6370
493	17	US-11-045-024-6386
494	17	US-11-045-024-6637
495	17	US-11-045-024-7210
496	17	US-11-045-024-7217
497	17	US-11-045-024-7348
498	17	US-11-045-024-7357
499	17	US-11-045-024-7709
500	17	US-11-045-024-7726
501	17	US-11-045-024-7957
502	17	US-11-045-024-7999
503	17	US-11-045-024-9832
504	17	US-11-045-024-10270
505	17	US-11-045-024-10307
506	17	US-11-045-024-10308
507	17	US-11-045-024-10319
508	17	US-11-045-024-10338
509	17	US-11-045-024-10339
510	17	US-11-045-024-12119
511	17	US-11-045-024-12145
512	17	US-11-045-024-12166
513	17	US-11-045-024-12186
514	17	US-11-045-024-12608
515	17	US-11-045-024-12623
516	17	US-11-045-024-12802
517	17	US-11-045-024-12703
518	17	US-11-045-024-13704
519	17	US-11-045-024-13716
520	17	US-11-045-024-13719
521	17	US-11-045-024-13864
522	17	US-11-045-024-13866
523	17	US-11-045-024-13956
524	17	US-11-045-024-13958
525	17	US-11-045-024-13958
526	17	US-11-045-024-13960
527	17	US-11-045-024-14152
528	17	US-11-045-024-14188
529	17	US-11-045-024-14194
530	17	US-11-045-024-14196
531	17	US-11-045-024-14287
532	17	US-11-045-024-14305
533	17	US-11-045-024-14321
534	17	US-11-045-024-14364
535	17	US-11-045-024-14374

537	9	7	US-11-146-854-4	Sequence 4, App1
538	17	9	US-11-078-256-13	Sequence 13, App1
539	17	9	US-11-078-256-13	Sequence 60, App1
540	17	9	US-11-078-256-61	Sequence 61, App1
541	17	9	US-11-078-256-147	Sequence 147, App1
542	17	9	US-11-250-411-14	Sequence 14, App1
543	16	32.7	US-11-031-737-48	Sequence 48, App1
544	16	32.7	US-11-031-482-48	Sequence 49, App1
545	16	32.7	US-11-036-256-98	Sequence 98, App1
546	16	32.7	US-11-197-038-24	Sequence 24, App1
547	16	32.7	US-11-249-847-81	Sequence 81, App1
548	16	32.7	US-11-145-861-290	Sequence 290, App1
549	16	32.7	US-10-982-891-77	Sequence 77, App1
550	16	32.7	US-10-467-657-8820	Sequence 8820, App1
551	16	32.7	US-10-895-064-2517	Sequence 2517, App1
552	16	32.7	US-11-225-686-1555	Sequence 155, App1
553	16	32.7	US-11-033-365-59	Sequence 60, App1
554	16	32.7	US-11-064-785-18	Sequence 18, App1
555	16	32.7	US-11-031-737A-36	Sequence 36, App1
556	16	32.7	US-11-031-737A-38	Sequence 38, App1
557	16	32.7	US-11-225-686-1551	Sequence 1551, App1
558	16	32.7	US-11-225-686-1555	Sequence 1555, App1
559	16	32.7	US-11-225-686-3593	Sequence 3593, App1
560	16	32.7	US-11-225-686-3594	Sequence 3594, App1
561	16	32.7	US-11-202-009-1551	Sequence 1551, App1
562	16	32.7	US-11-202-009-1555	Sequence 1555, App1
563	16	32.7	US-11-202-009-3593	Sequence 3593, App1
564	16	32.7	US-11-225-686-1555	Sequence 1555, App1
565	16	32.7	US-11-031-482-36	Sequence 36, App1
566	16	32.7	US-11-031-482-36	Sequence 38, App1
567	16	32.7	US-11-129-741-2517	Sequence 2517, App1
568	16	32.7	US-10-977-977-54	Sequence 54, App1
569	16	32.7	US-11-233-683-59	Sequence 54, App1
570	16	32.7	US-11-054-735-54	Sequence 3703, App1
571	16	32.7	US-11-045-024-2477	Sequence 2477, App1
572	16	32.7	US-11-045-024-4880	Sequence 4880, App1
573	16	32.7	US-11-045-024-5416	Sequence 5416, App1
574	16	32.7	US-11-116-698-5	Sequence 5, App1
575	16	32.7	US-11-123-741-3703	Sequence 3703, App1
576	16	32.7	US-11-045-024-2477	Sequence 2477, App1
577	16	32.7	US-10-895-635-26	Sequence 6, App1
578	16	32.7	US-10-511-101-49	Sequence 46, App1
579	16	32.7	US-10-511-101-51	Sequence 51, App1
580	16	32.7	US-10-511-101-166	Sequence 166, App1
581	16	32.7	US-10-895-064-1775	Sequence 1775, App1
582	16	32.7	US-10-895-064-2898	Sequence 2898, App1
583	16	32.7	US-10-988-767A-25	Sequence 25, App1
584	16	32.7	US-10-988-767A-46	Sequence 49, App1
585	16	32.7	US-10-988-767A-110	Sequence 110, App1
586	16	32.7	US-10-857-484-282	Sequence 204, App1
587	16	32.7	US-10-857-484-317	Sequence 317, App1
588	16	32.7	US-10-857-484-870	Sequence 210, App1
589	16	32.7	US-10-857-484-335	Sequence 335, App1
590	16	32.7	US-10-857-484-343	Sequence 343, App1
591	16	32.7	US-10-857-484-35	Sequence 483, App1
592	16	32.7	US-10-857-484-369	Sequence 35, App1
593	16	32.7	US-10-857-484-483	Sequence 48, App1
594	16	32.7	US-10-857-484-944	Sequence 944, App1
595	16	32.7	US-10-857-484-1430	Sequence 1430, App1
596	16	32.7	US-10-857-484-1440	Sequence 1440, App1
600	16	32.7	US-10-857-484-1442	Sequence 1442, App1
601	16	32.7	US-10-857-484-1443	Sequence 1443, App1
602	16	32.7	US-10-857-484-1444	Sequence 1444, App1
603	16	32.7	US-10-857-484-1445	Sequence 1445, App1
604	16	32.7	US-10-857-484-1446	Sequence 1446, App1
605	16	32.7	US-10-857-484-1447	Sequence 1447, App1
606	16	32.7	US-10-857-484-1448	Sequence 1448, App1
607	16	32.7	US-10-857-484-1511	Sequence 1511, App1
608	16	32.7	US-10-857-484-1999	Sequence 1999, App1
609	16	32.7	US-10-857-484-2001	Sequence 2001, App1

9	6	32.7	US-10-857-484-2033	Sequence 2033, App1
9	6	32.7	US-10-857-484-2057	Sequence 2057, App1
9	6	32.7	US-10-857-484-2069	Sequence 2069, App1
9	6	32.7	US-10-857-484-2254	Sequence 2254, App1
9	6	32.7	US-10-857-484-2567	Sequence 2567, App1
9	6	32.7	US-10-857-484-2602	Sequence 2602, App1
9	6	32.7	US-10-857-484-2607	Sequence 2607, App1
9	6	32.7	US-10-857-484-2620	Sequence 2620, App1
9	6	32.7	US-10-857-484-2622	Sequence 2622, App1
9	6	32.7	US-10-857-484-2637	Sequence 2637, App1
9	6	32.7	US-10-857-484-3103	Sequence 3103, App1
9	6	32.7	US-10-857-484-3138	Sequence 3138, App1
9	6	32.7	US-10-857-484-3141	Sequence 3141, App1
9	6	32.7	US-10-857-484-3161	Sequence 3161, App1
9	6	32.7	US-10-857-484-3176	Sequence 3176, App1
16	16	32.7	US-10-857-484-3182	Sequence 3182, App1
16	16	32.7	US-10-857-484-673	Sequence 3673, App1
16	16	32.7	US-10-857-484-677	Sequence 3677, App1
16	16	32.7	US-10-857-484-684	Sequence 3684, App1
16	16	32.7	US-10-857-484-694	Sequence 3727, App1
16	16	32.7	US-10-857-484-737	Sequence 3746, App1
16	16	32.7	US-10-857-484-746	Sequence 4550, App1
16	16	32.7	US-10-857-484-767	Sequence 4561, App1
16	16	32.7	US-10-857-484-814	Sequence 4572, App1
16	16	32.7	US-10-857-484-8620	Sequence 4600, App1
16	16	32.7	US-10-857-484-8625	Sequence 4625, App1
16	16	32.7	US-10-857-484-8628	Sequence 4635, App1
16	16	32.7	US-10-857-484-8635	Sequence 4652, App1
16	16	32.7	US-10-857-484-8652	Sequence 4650, App1
16	16	32.7	US-10-857-484-8709	Sequence 4715, App1
16	16	32.7	US-10-857-484-8715	Sequence 4792, App1
16	16	32.7	US-10-857-484-8794	Sequence 4794, App1
16	16	32.7	US-10-857-484-8822	Sequence 4882, App1
16	16	32.7	US-10-857-484-8882	Sequence 4893, App1
16	16	32.7	US-10-857-484-8993	Sequence 4905, App1
16	16	32.7	US-10-857-484-9006	Sequence 4906, App1
16	16	32.7	US-10-857-484-912	Sequence 4912, App1
16	16	32.7	US-10-857-484-9192	Sequence 4912, App1
16	16	32.7	US-10-857-484-9903	Sequence 5003, App1
16	16	32.7	US-10-857-484-9903	Sequence 5011, App1
16	16	32.7	US-10-857-484-9930	Sequence 5013, App1
16	16	32.7	US-10-857-484-9930	Sequence 5030, App1
16	16	32.7	US-10-857-484-9930	Sequence 5053, App1
16	16	32.7	US-10-857-484-9930	Sequence 5070, App1
16	16	32.7	US-10-857-484-9930	Sequence 5087, App1
16	16	32.7	US-10-857-484-9930	Sequence 5102, App1
16	16	32.7	US-10-857-484-9930	Sequence 5103, App1
16	16	32.7	US-10-857-484-9930	Sequence 5114, App1
16	16	32.7	US-10-857-484-9930	Sequence 5120, App1
16	16	32.7	US-10-857-484-9930	Sequence 5129, App1
16	16	32.7	US-10-857-484-9930	Sequence 5138, App1
16	16	32.7	US-10-857-484-9930	Sequence 5147, App1
16	16	32.7	US-10-857-484-9930	Sequence 5156, App1
16	16	32.7	US-10-857-484-9930	Sequence 5165, App1
16	16	32.7	US-10-857-484-9930	Sequence 5174, App1
16	16	32.7	US-10-857-484-9930	Sequence 5183, App1
16	16	32.7	US-10-857-484-9930	Sequence 5192, App1
16	16	32.7	US-10-857-484-9930	Sequence 5201, App1
16	16	32.7	US-10-857-484-9930	Sequence 5210, App1
16	16	32.7	US-10-857-484-9930	Sequence 5219, App1
16	16	32.7	US-10-857-484-9930	Sequence 5228, App1
16	16	32.7	US-10-857-484-9930	Sequence 5237, App1
16	16	32.7	US-10-857-484-9930	Sequence 5246, App1
16	16	32.7	US-10-857-484-9930	Sequence 5255, App1
16	16	32.7	US-10-857-484-9930	Sequence 5264, App1
16	16	32.7	US-10-857-484-9930	Sequence 5273, App1
16	16	32.7	US-10-857-484-9930	Sequence 5282, App1
16	16	32.7	US-10-857-484-9930	Sequence 5291, App1
16	16	32.7	US-10-857-484-9930	Sequence 5300, App1
16	16	32.7	US-10-857-484-9930	Sequence 5309, App1
16	16	32.7	US-10-857-484-9930	Sequence 5318, App1
16	16	32.7	US-10-857-484-9930	Sequence 5327, App1
16	16	32.7	US-10-857-484-9930	Sequence 5336, App1
16	16	32.7	US-10-857-484-9930	Sequence 5345, App1
16	16	32.7	US-10-857-484-9930	Sequence 5354, App1
16	16	32.7	US-10-857-484-9930	Sequence 5363, App1
16	16	32.7	US-10-857-484-9930	Sequence 5372, App1
16	16	32.7	US-10-857-484-9930	Sequence 5381, App1
16	16	32.7	US-10-857-484-9930	Sequence 5390, App1
16	16	32.7	US-10-857-484-9930	Sequence 5399, App1
16	16	32.7	US-10-857-484-9930	Sequence 5408, App1
16	16	32.7	US-10-857-484-9930	Sequence 5417, App1
16	16	32.7	US-10-857-484-9930	Sequence 5426, App1
16	16	32.7	US-10-857-484-9930	Sequence 5435, App1
16	16	32.7	US-10-857-484-9930	Sequence 5444, App1
16	16	32.7	US-10-857-484-9930	Sequence 5453, App1
16	16	32.7	US-10-857-484-9930	Sequence 5462, App1
16	16	32.7	US-10-857-484-9930	Sequence 5471, App1
16	16	32.7	US-10-857-484-9930	Sequence 5480, App1
16	16	32.7	US-10-857-484-9930	Sequence 5489, App1
16	16	32.7	US-10-857-484-9930	Sequence 5498, App1
16	16	32.7	US-10-857-484-9930	Sequence 5507, App1
16	16	32.7	US-10-857-484-9930	Sequence 5516, App1
16	16	32.7	US-10-857-484-9930	Sequence 5525, App1
16	16	32.7	US-10-857-484-9930	Sequence 5534, App1
16	16	32.7	US-10-857-484-9930	Sequence 5543, App1
16	16	32.7	US-10-857-484-9930	Sequence 5552, App1
16	16	32.7	US-10-857-484-9930	Sequence 5561, App1
16	16	32.7	US-10-857-484-9930	Sequence 5570, App1
16	16	32.7	US-10-857-484-9930	Sequence 5579, App1
16	16	32.7	US-10-857-484-9930	Sequence 5588, App1
16	16	32.7	US-10-857-484-9930	Sequence 5597, App1

683	16	32.7	US-11-233-683-7	Sequence 7, App1	US-11-045-024-5631
684	16	32.7	US-11-031-482-46	Sequence 18, App1	US-11-045-024-6007
685	16	32.7	US-11-031-482-46	Sequence 46, App1	US-11-045-024-6174
686	16	32.7	US-11-122-741-1775	Sequence 1775, App1	US-11-045-024-6787
687	16	32.7	US-11-129-741-2898	Sequence 2898, App1	US-11-045-024-6820
688	16	32.7	US-11-242-423-47	Sequence 47, App1	US-11-045-024-7203
689	16	32.7	US-11-242-423-531	Sequence 531, App1	US-11-045-024-7216
690	15	30.6	US-10-857-435A-596	Sequence 596, App1	US-11-045-024-7898
691	15	30.6	US-11-057-708-50	Sequence 50, App1	US-11-045-024-7917
692	15	30.6	US-11-162-576-72	Sequence 72, App1	US-11-045-024-7918
693	15	30.6	US-11-121-612-390	Sequence 390, App1	US-11-045-024-7983
694	15	30.6	US-11-847-180	Sequence 180, App1	US-11-045-024-7997
695	15	30.6	US-11-242-847-214	Sequence 214, App1	US-11-045-024-8144
696	15	30.6	US-11-242-847-254	Sequence 254, App1	US-11-045-024-8155
697	15	30.6	US-10-997-066-37	Sequence 37, App1	US-11-045-024-9191
698	15	30.6	US-10-467-033-104	Sequence 104, App1	US-11-045-024-10021
699	15	30.6	US-10-857-435A-491	Sequence 491, App1	US-11-045-024-11781
700	15	30.6	US-10-435A-592	Sequence 492, App1	US-11-045-024-11782
701	15	30.6	US-10-857-435A-493	Sequence 493, App1	US-11-045-024-11926
702	15	30.6	US-10-857-435A-494	Sequence 494, App1	US-11-045-024-11927
703	15	30.6	US-10-857-435A-495	Sequence 495, App1	US-11-045-024-12102
704	15	30.6	US-10-857-435A-496	Sequence 496, App1	US-11-045-024-12636
705	15	30.6	US-10-857-435A-497	Sequence 497, App1	US-11-045-024-12785
706	15	30.6	US-10-857-435A-498	Sequence 498, App1	US-11-045-024-14332
707	15	30.6	US-10-857-435A-499	Sequence 499, App1	US-11-045-024-14456
708	15	30.6	US-10-857-435A-500	Sequence 500, App1	US-11-045-024-14457
709	15	30.6	US-10-857-435A-501	Sequence 501, App1	US-11-045-024-14458
710	15	30.6	US-10-857-435A-502	Sequence 502, App1	US-11-045-024-14459
711	15	30.6	US-10-857-435A-519	Sequence 519, App1	US-11-045-024-1881
712	15	30.6	US-10-857-435A-523	Sequence 523, App1	US-10-997-201A-39
713	15	30.6	US-11-034-773-186	Sequence 186, App1	US-10-932-535A-44
714	15	30.6	US-11-234-424-25	Sequence 25, App1	US-10-119-096-8
715	15	30.6	US-10-842-977A-39	Sequence 39, App1	US-10-191-096-70
716	15	30.6	US-10-467-033-4	Sequence 4, App1	US-10-191-096-183
717	15	30.6	US-10-467-033-10	Sequence 10, App1	US-10-935-362A-21
718	15	30.6	US-10-467-033-12	Sequence 12, App1	US-10-936-552A-9
719	15	30.6	US-10-467-033-30	Sequence 20, App1	US-10-839-643-17
720	15	30.6	US-10-467-033-22	Sequence 22, App1	US-10-839-643-22
721	15	30.6	US-10-895-064-1791	Sequence 1791, App1	US-10-839-643-44
722	15	30.6	US-10-895-064-1791	Sequence 1813, App1	US-10-839-643-114
723	15	30.6	US-11-067-033-8	Sequence 8, App1	US-10-839-643-130
724	15	30.6	US-11-189-664-29	Sequence 29, App1	US-10-839-643-140
725	15	30.6	US-11-225-686-3253	Sequence 3253, App1	US-10-839-643-72
726	15	30.6	US-11-225-686-3267	Sequence 3267, App1	US-10-839-643-281
727	15	30.6	US-11-225-686-3282	Sequence 3282, App1	US-10-839-643-355
728	15	30.6	US-11-202-009-3253	Sequence 3253, App1	US-10-839-643-557
729	15	30.6	US-11-202-009-3267	Sequence 3267, App1	US-10-839-643-91
730	15	30.6	US-11-202-009-3282	Sequence 3282, App1	US-10-839-643-554
731	15	30.6	US-11-842-877A-31	Sequence 1781, App1	US-10-839-643-566
732	15	30.6	US-11-129-741-1781	Sequence 1813, App1	US-10-839-643-588
733	15	30.6	US-11-129-741-1813	Sequence 229, App1	US-10-839-643-660
734	15	30.6	US-11-129-741-229	Sequence 63, App1	US-10-839-643-663
735	15	30.6	US-10-989-226-9	Sequence 463, App1	US-10-839-643-697
736	15	30.6	US-10-989-226-81	Sequence 1697, App1	US-10-839-643-7475
737	15	30.6	US-10-842-877A-31	Sequence 81, App1	US-10-839-643-7776
738	15	30.6	US-10-622-246-69	Sequence 3130, App1	US-10-839-643-577
739	15	30.6	US-10-895-064-1881	Sequence 1881, App1	US-10-839-767A-37
740	15	30.6	US-11-045-024-463	Sequence 463, App1	US-10-839-767A-313
741	15	30.6	US-11-045-024-1697	Sequence 1697, App1	US-10-839-767A-475
742	15	30.6	US-11-045-024-1698	Sequence 1698, App1	US-10-839-767A-567
743	15	30.6	US-11-045-024-1730	Sequence 1730, App1	US-10-839-767A-577
744	15	30.6	US-11-045-024-2475	Sequence 2475, App1	US-10-837-484-284
745	15	30.6	US-11-045-024-3164	Sequence 3164, App1	US-10-837-484-309
746	15	30.6	US-11-045-024-3165	Sequence 3165, App1	US-10-837-484-316
747	15	30.6	US-11-045-024-4015	Sequence 4015, App1	US-10-837-484-352
748	15	30.6	US-11-045-024-4379	Sequence 4379, App1	US-10-837-484-374
749	15	30.6	US-11-045-024-4380	Sequence 4380, App1	US-10-837-484-377
750	15	30.6	US-11-045-024-4389	Sequence 4389, App1	US-10-837-484-390
751	15	30.6	US-11-045-024-5173	Sequence 5173, App1	US-10-837-484-396
752	15	30.6	US-11-045-024-5175	Sequence 5175, App1	US-10-837-484-910
753	15	30.6	US-11-045-024-5305	Sequence 5305, App1	US-10-837-484-916
754	15	30.6	US-11-045-024-5306	Sequence 5306, App1	US-10-837-484-919
755	15	30.6	US-11-045-024-5415	Sequence 5415, App1	US-10-837-484-950

829	9	6	US-10-857-484-1467	Sequence 1467, App	9	7	US-11-097-864-554
830	15	30.6	US-10-857-484-1469	Sequence 1469, App	903	15	30.6
831	15	30.6	US-10-857-484-1484	Sequence 1484, App	904	15	30.6
832	15	30.6	US-10-857-484-1488	Sequence 1488, App	905	15	30.6
833	15	30.6	US-10-857-484-1510	Sequence 1510, App	906	15	30.6
834	15	30.6	US-10-857-484-1516	Sequence 1516, App	907	15	30.6
835	15	30.6	US-10-857-484-1995	Sequence 1995, App	908	15	30.6
836	15	30.6	US-10-857-484-2014	Sequence 2014, App	909	15	30.6
837	15	30.6	US-10-857-484-2019	Sequence 2019, App	910	15	30.6
838	15	30.6	US-10-857-484-2022	Sequence 2022, App	911	15	30.6
839	15	30.6	US-10-857-484-2028	Sequence 2028, App	912	15	30.6
840	15	30.6	US-10-857-484-2042	Sequence 2042, App	913	15	30.6
841	15	30.6	US-10-857-484-2561	Sequence 2561, App	914	15	30.6
842	15	30.6	US-10-857-484-2591	Sequence 2591, App	915	15	30.6
843	15	30.6	US-10-857-484-2601	Sequence 2601, App	916	15	30.6
844	15	30.6	US-10-857-484-2604	Sequence 2604, App	917	15	30.6
845	15	30.6	US-10-857-484-2623	Sequence 2623, App	918	15	30.6
846	15	30.6	US-10-857-484-2624	Sequence 2624, App	919	15	30.6
847	15	30.6	US-10-857-484-2630	Sequence 2630, App	920	15	30.6
848	15	30.6	US-10-857-484-2641	Sequence 2641, App	921	15	30.6
849	15	30.6	US-10-857-484-2643	Sequence 2643, App	922	15	30.6
850	15	30.6	US-10-857-484-3118	Sequence 3118, App	923	15	30.6
851	15	30.6	US-10-857-484-3119	Sequence 3119, App	924	15	30.6
852	15	30.6	US-10-857-484-3126	Sequence 3126, App	925	15	30.6
853	15	30.6	US-10-857-484-3131	Sequence 3131, App	926	15	30.6
854	15	30.6	US-10-857-484-3156	Sequence 3156, App	927	15	30.6
855	15	30.6	US-10-857-484-3160	Sequence 3160, App	928	15	30.6
856	15	30.6	US-10-857-484-3174	Sequence 3174, App	929	15	30.6
857	15	30.6	US-10-857-484-3178	Sequence 3178, App	930	15	30.6
858	15	30.6	US-10-857-484-3179	Sequence 3179, App	931	15	30.6
859	15	30.6	US-10-857-484-3185	Sequence 3185, App	932	15	30.6
860	15	30.6	US-10-857-484-3681	Sequence 3681, App	933	15	30.6
861	15	30.6	US-10-857-484-3688	Sequence 3688, App	934	15	30.6
862	15	30.6	US-10-857-484-3706	Sequence 3706, App	935	15	30.6
863	15	30.6	US-10-857-484-3728	Sequence 3728, App	936	15	30.6
864	15	30.6	US-10-857-484-3732	Sequence 3732, App	937	15	30.6
865	15	30.6	US-10-857-484-4148	Sequence 4148, App	938	15	30.6
866	15	30.6	US-10-857-484-4605	Sequence 4605, App	939	15	30.6
867	15	30.6	US-10-857-484-4646	Sequence 4646, App	940	15	30.6
868	15	30.6	US-10-857-484-4666	Sequence 4666, App	941	15	30.6
869	15	30.6	US-10-857-484-4423	Sequence 4423, App	942	15	30.6
870	15	30.6	US-10-857-484-4441	Sequence 4441, App	943	15	30.6
871	15	30.6	US-10-857-484-4528	Sequence 4528, App	944	15	30.6
872	15	30.6	US-10-857-484-4621	Sequence 4621, App	950	15	30.6
873	15	30.6	US-10-857-484-4631	Sequence 4631, App	951	15	30.6
874	15	30.6	US-10-857-484-4643	Sequence 4643, App	952	15	30.6
875	15	30.6	US-10-857-484-4658	Sequence 4658, App	953	15	30.6
876	15	30.6	US-10-857-484-4669	Sequence 4669, App	954	15	30.6
877	15	30.6	US-10-857-484-4677	Sequence 4677, App	955	15	30.6
878	15	30.6	US-10-857-484-4782	Sequence 4782, App	956	15	30.6
879	15	30.6	US-10-857-484-4922	Sequence 4922, App	957	15	30.6
880	15	30.6	US-10-857-484-4928	Sequence 4928, App	958	15	30.6
881	15	30.6	US-10-857-484-5019	Sequence 5019, App	959	15	30.6
882	15	30.6	US-10-857-484-5028	Sequence 5028, App	960	15	30.6
883	15	30.6	US-10-857-484-5106	Sequence 5106, App	961	15	30.6
884	15	30.6	US-11-013-894A-2	Sequence 13, App	962	15	30.6
885	15	30.6	US-11-097-864-140	Sequence 140, App	963	15	30.6
886	15	30.6	US-11-097-864-17	Sequence 17, App	964	15	30.6
887	15	30.6	US-11-097-864-22	Sequence 22, App	965	15	30.6
888	15	30.6	US-11-097-864-44	Sequence 44, App	966	15	30.6
889	15	30.6	US-11-097-864-114	Sequence 114, App	967	15	30.6
890	15	30.6	US-11-097-864-130	Sequence 130, App	968	15	30.6
891	15	30.6	US-11-097-864-172	Sequence 172, App	969	15	30.6
892	15	30.6	US-11-097-864-281	Sequence 281, App	971	15	30.6
893	15	30.6	US-11-097-864-355	Sequence 355, App	972	15	30.6
894	15	30.6	US-11-097-864-457	Sequence 457, App	973	15	30.6
895	15	30.6	US-11-097-864-491	Sequence 491, App	974	15	30.6

RESULT 1
US-10-401-396B-52
; Sequence 52, Application US/10401396B
; Publication No. US20050261213A1
; GENERAL INFORMATION:
; APPLICANT: Patrick Branigan
; APPLICANT: Theresa J Goletz
; APPLICANT: David M McCarthy
; APPLICANT: Stephen G McCarthy
; APPLICANT: Bernard J Scallion
; APPLICANT: Linda A Snyder
; TITLE OF INVENTION: Nucleic Acid Compositions and Methods
; TITLE OF INVENTION: For Use
; FILE REFERENCE: CEN 310CIP
; CURRENT APPLICATION NUMBER: US/10/401,396B
; CURRENT FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: 10/247,203
; PRIOR FILING DATE: 2002-09-19
; PRIOR APPLICATION NUMBER: 60/328,371
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO: 52
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-401-396B-52

Query Match 100.0%; Score 49; DB 6; Length 9;
Best Local Similarity 100.0%; Pred. No. 8.3e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0;
Gaps 0;

Qy 1 STAPPVHN 9
Db 1 STAPPVHN 9

RESULT 2
US-10-517-784-35
; Sequence 35, Application US/10517784
; Publication No. US20060003315A1
; GENERAL INFORMATION:
; APPLICANT: Sette, Alessandro

; APPLICANT: GIDEON, Gideon
; APPLICANT: MARGALIT, Alon
; TITLE OF INVENTION: PEPTIDE ANCHORED BETA-2 MICROGLOBULIN COVALENTLY LINKED TO MHC (;
; FILE REFERENCE: GAVISH-004 US
; CURRENT APPLICATION NUMBER: US/10/517,784
; CURRENT FILING DATE: 2004-12-13
; PRIOR APPLICATION NUMBER: US 60/388,273
; PRIOR FILING DATE: 2002-06-12
; PRIOR APPLICATION NUMBER: PCT/IL03/00501
; PRIOR FILING DATE: 2003-06-12
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 35
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-517-784-35

Query Match 100.0%; Score 49; DB 6; Length 9;
Best Local Similarity 100.0%; Pred. No. 8.3e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0;
Gaps 0;

Qy 1 STAPPVHN 9
Db 1 STAPPVHN 9

RESULT 3
US-10-401-386B-56
; Sequence 56, Application US/10401386B
; Publication No. US20050261213A1
; GENERAL INFORMATION:
; APPLICANT: Patrick Branigan
; APPLICANT: Theresa J Goletz
; APPLICANT: David M McCarthy
; APPLICANT: Stephen G McCarthy
; APPLICANT: Linda A Snyder
; TITLE OF INVENTION: Nucleic Acid Compositions and Methods
; TITLE OF INVENTION: For Use
; FILE REFERENCE: CEN 310CIP
; CURRENT APPLICATION NUMBER: US/10/401,386B
; CURRENT FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: 10/247,203
; PRIOR FILING DATE: 2002-09-19
; PRIOR APPLICATION NUMBER: 60/328,371
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 56
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-401-386B-56

Query Match 79.6%; Score 39; DB 6; Length 9;
Best Local Similarity 77.8%; Pred. No. 8.3e+04;
Matches 7; Conservative 0; Mismatches 2; Indels 0;
Gaps 0;

Qy 1 STAPPVHN 9
Db 1 STAPPVHN 9

RESULT 4
US-11-045-024-6286
; Sequence 6286, Application US/11045024
; Publication No. US2005021676A1
; GENERAL INFORMATION:
; APPLICANT: Sette, Alessandro

APPLICANT: Sidney, John
 APPLICANT: Southwood, Scott
 APPLICANT: Livingston, Brian
 APPLICANT: Chesnut, Robert
 APPLICANT: Baker, Denise Marie
 APPLICANT: Celis, Esteban
 APPLICANT: Kubo, Ralph
 APPLICANT: Grey, Howard M.
 APPLICANT: Epimmune Inc.

TITLE OF INVENTION: Inducing Cellular Responses to Human Immunodeficiency Virus-1 Using Peptide and Nucleic Acid Compositions

FILE REFERENCE: 2060.0040007

CURRENT FILING DATE: 2005-01-28

PRIOR APPLICATION NUMBER: US 09/11/045,024

PRIOR FILING DATE: 1999-10-05

PRIOR APPLICATION NUMBER: US 08/027,146

PRIOR FILING DATE: 1993-03-05

PRIOR APPLICATION NUMBER: US 08/073,205

PRIOR FILING DATE: 1993-06-04

PRIOR APPLICATION NUMBER: US 08/103,396

PRIOR FILING DATE: 1993-08-06

PRIOR APPLICATION NUMBER: US 08/159,184

PRIOR FILING DATE: 1993-11-29

PRIOR FILING DATE: 1993-11-19

PRIOR APPLICATION NUMBER: US 08/205,713

PRIOR FILING DATE: 1994-03-04

PRIOR APPLICATION NUMBER: US 08/347,610

PRIOR FILING DATE: 1994-12-01

NUMBER OF SEQ ID NOS: 14528

SOFTWARE: FastSEQ for Windows Version 4.0

SEQ ID NO: 6286

LENGTH: 8

TYPE: PRT

ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS

US-11-045-024-6385

RESULT 5

Query Match 49.0%; Score 24; DB 7; Length 8;
 Best Local Similarity 57.1%; Pred. No. 8.3e+04;
 Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 2 TAPPVHN 8
 ||||:
 Db 1 TAPPAES 7

Query Match 49.0%; Score 24; DB 7; Length 8;
 Best Local Similarity 57.1%; Pred. No. 8.3e+04;
 Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 2 TAPPVHN 8
 ||||:
 Db 1 TAPPAES 7

RESULT 6

US-11-045-024-8860

Query Match 49.0%; Score 24; DB 7; Length 8;
 Best Local Similarity 57.1%; Pred. No. 8.3e+04;
 Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 2 TAPPVHN 8
 ||||:
 Db 1 TAPPAES 7

Query Match 49.0%; Score 24; DB 7; Length 8;
 Best Local Similarity 57.1%; Pred. No. 8.3e+04;
 Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 2 TAPPVHN 8
 ||||:
 Db 1 TAPPAES 7

RESULT 7

US-11-045-024-8860

Query Match 49.0%; Score 24; DB 7; Length 8;
 Best Local Similarity 57.1%; Pred. No. 8.3e+04;
 Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 2 TAPPVHN 8
 ||||:
 Db 1 TAPPAES 7

Query Match 49.0%; Score 24; DB 7; Length 8;
 Best Local Similarity 57.1%; Pred. No. 8.3e+04;
 Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 2 TAPPVHN 8
 ||||:
 Db 1 TAPPAES 7

Query Match 49.0%; Score 24; DB 7; Length 8;
 Best Local Similarity 57.1%; Pred. No. 8.3e+04;

Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 2 TAPPVHN 8
Db |||| :
1 TAPPAES 7

RESULT 7
US-11-045-024-9105
Sequence 9105, Application US/11045024
Publication No. US20050211676A1
GENERAL INFORMATION
APPLICANT: Sette, Alessandro
APPLICANT: Sidney, John
APPLICANT: Southwood, Scott
APPLICANT: Livingston, Brian
APPLICANT: Chesnut, Robert
APPLICANT: Celeris, Esteban
APPLICANT: Kubo, Ralph
APPLICANT: Grey, Howard M.
APPLICANT: Epimmune Inc.

TITLE OF INVENTION: Inducing Cellular Responses to Human Immunodeficiency Virus-1 Using Peptide and Nucleic Acid Compositions
FILE REFERENCE: 2000-0040007
CURRENT APPLICATION NUMBER: US/11/045, 024
CURRENT FILING DATE: 2005-01-28
PRIOR APPLICATION NUMBER: US 09/412, 863
PRIOR FILING DATE: 1999-10-05
PRIOR APPLICATION NUMBER: US 08/027, 146
PRIOR FILING DATE: 1993-03-05
PRIOR APPLICATION NUMBER: US 08/073, 205
PRIOR FILING DATE: 1993-06-04
PRIOR APPLICATION NUMBER: US 08/103, 396
PRIOR FILING DATE: 1993-08-06
PRIOR APPLICATION NUMBER: US 08/159, 184
PRIOR FILING DATE: 1993-11-29
PRIOR APPLICATION NUMBER: US 14528
PRIOR FILING DATE: 1993-11-29
PRIOR APPLICATION NUMBER: US 08/205, 713
PRIOR FILING DATE: 1994-03-04
PRIOR APPLICATION NUMBER: US 08/347, 610
PRIOR FILING DATE: 1994-12-01
NUMBER OF SEQ ID NOS: 14528
SOFTWARE: FastSEQ for Windows Version 4.0
SEQ ID NO: 9105
LENGTH: 8

TYPE: PRT
ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS

US-11-045-024-9105
Query Match 49.0%; Score 24; DB 7; Length 8;
Best Local Similarity 57.1%; Pred. No. 8.3e+04;
Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 2 TAPPVHN 8
Db |||| :
1 TAPPAES 7

RESULT 8
US-11-011-666-5
Sequence 5, Application US/11011666
Publication No. US20050244848A1
GENERAL INFORMATION
APPLICANT: Estell, David A.
APPLICANT: Paesch, Christian
APPLICANT: Paesch, Sigrid
TITLE OF INVENTION: Mass Spectrometric Analysis of Biopolymers
FILE REFERENCE: GC656-2
CURRENT APPLICATION NUMBER: US/11/011, 666

CURRENT FILING DATE: 2004-12-14
PRIOR APPLICATION NUMBER: US 60/228, 198
PRIOR FILING DATE: 2000-08-15
NUMBER OF SEQ ID NOS: 15
SOFTWARE: PasteSEQ for Windows Version 4.0
SEQ ID NO: 5
LENGTH: 9

TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE: tryptic co-digest of 15N-Subtilisin DAI and
OTHER INFORMATION: subtilisin
US-11-011-666-5

Query Match 49.0%; Score 24; DB 7; Length 9;
Best Local Similarity 66.7%; Pred. No. 8.3e+04;
Matches 4; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3 APPVHN 8
Db 3 APAHN 8

RESULT 9
US-11-045-024-146
Sequence 146, Application US/11045024
Publication No. US20050211676A1
GENERAL INFORMATION
APPLICANT: Sette, Alessandro
APPLICANT: Siney, John
APPLICANT: Southwood, Scott
APPLICANT: Livingston, Brian
APPLICANT: Chebrini, Robert
APPLICANT: Baker, Denise Marie
APPLICANT: Celis, Esteban
APPLICANT: Kubo, Ralph M.
APPLICANT: Grey, Howard M.
APPLICANT: Epimmune Inc.
TITLE OF INVENTION: Inducing Cellular Responses to Human Immunodeficiency Virus-1 Using Peptide and Nucleic Acid Compositions
FILE REFERENCE: 2000-0040007
CURRENT APPLICATION NUMBER: US/11/045, 024
CURRENT FILING DATE: 2005-01-28
PRIOR APPLICATION NUMBER: US 09/412, 863
PRIOR FILING DATE: 1993-03-05
PRIOR APPLICATION NUMBER: US 08/027, 146
PRIOR FILING DATE: 1993-06-04
PRIOR APPLICATION NUMBER: US 08/103, 396
PRIOR FILING DATE: 1993-08-06
PRIOR APPLICATION NUMBER: US 08/159, 184
PRIOR FILING DATE: 1993-11-29
PRIOR APPLICATION NUMBER: US 14528
PRIOR FILING DATE: 1993-11-29
PRIOR APPLICATION NUMBER: US 08/205, 713
PRIOR FILING DATE: 1994-03-04
PRIOR APPLICATION NUMBER: US 08/347, 610
PRIOR FILING DATE: 1994-12-01
NUMBER OF SEQ ID NOS: 14528
SOFTWARE: FastSEQ for Windows Version 4.0
SEQ ID NO: 146
LENGTH: 9

TYPE: PRT
ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS

US-11-045-024-146
Query Match 49.0%; Score 24; DB 7; Length 9;
Best Local Similarity 57.1%; Pred. No. 8.3e+04;
Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 2 TAPPVHN 8
Db |||| :

Db 2 TAPPAES 8

RESULT 10
 US-11-045-024-148
 ; Sequence 148, Application US/11045024
 ; Publication No. US20050271676A1
 ; GENERAL INFORMATION
 ; APPLICANT: Sette, Alessandro
 ; APPLICANT: Sidney, John
 ; APPLICANT: Southwood, Scott
 ; APPLICANT: Livingston, Brian
 ; APPLICANT: Chesnut, Robert
 ; APPLICANT: Baker, Denise Marie
 ; APPLICANT: Celis, Esteban
 ; APPLICANT: Kubo, Ralph
 ; APPLICANT: Grey, Howard M.
 ; APPLICANT: Epimmune Inc.
 TITLE OF INVENTION: Inducing Cellular Responses to Human Immunodeficiency Virus-1 Using Peptide and Nucleic Acid Compositions
 FILE REFERENCE: 2060.0040007
 CURRENT APPLICATION NUMBER: US/11/045,024
 CURRENT FILING DATE: 2005-01-28
 PRIOR APPLICATION NUMBER: US 09/412,863
 PRIOR FILING DATE: 1999-10-05
 PRIOR APPLICATION NUMBER: US 08/027,146
 PRIOR FILING DATE: 1993-03-05
 PRIOR APPLICATION NUMBER: US 08/073,205
 PRIOR FILING DATE: 1993-06-04
 PRIOR APPLICATION NUMBER: US 08/103,396
 PRIOR FILING DATE: 1993-08-06
 PRIOR APPLICATION NUMBER: US 08/027,146
 PRIOR FILING DATE: 1993-11-29
 PRIOR APPLICATION NUMBER: US 08/073,205
 PRIOR FILING DATE: 1993-06-04
 PRIOR APPLICATION NUMBER: US 08/205,713
 PRIOR FILING DATE: 1994-03-04
 NUMBER OF SEQ ID NOS: 14528
 SOFTWARE: FastSEQ for Windows Version 4.0
 SEQ ID NO: 148
 LENGTH: 9
 TYPE: PRT
 ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
 US-11-045-024-148
 PRIOR APPLICATION NUMBER: US 08/159,339
 PRIOR FILING DATE: 1993-11-29
 PRIOR APPLICATION NUMBER: US 08/347,610
 PRIOR FILING DATE: 1994-12-01
 NUMBER OF SEQ ID NOS: 1
 SOFTWARE: FastSEQ for Windows Version 4.0
 SEQ ID NO: 148
 LENGTH: 9
 TYPE: PRT
 ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
 US-11-045-024-148
 Query Match 2 TAPPVN 8
 Best Local Similarity 49.0%; Score 24; DB 7; Length 9;
 Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 Qy ||||| :
 Db 1 TAPPAES 7

RESULT 11
 US-11-045-024-2988
 ; Sequence 2988, Application US/11045024
 ; Publication No. US20050271676A1
 ; GENERAL INFORMATION
 ; APPLICANT: Sette, Alessandro
 ; APPLICANT: Sidney, John
 ; APPLICANT: Southwood, Scott
 ; APPLICANT: Livingston, Brian
 ; APPLICANT: Chesnut, Robert
 ; APPLICANT: Baker, Denise Marie
 ; APPLICANT: Celis, Esteban
 ; APPLICANT: Kubo, Ralph
 ; APPLICANT: Grey, Howard M.
 ; APPLICANT: Epimmune Inc.
 TITLE OF INVENTION: Inducing Cellular Responses to Human Immunodeficiency Virus-1 Using Peptide and Nucleic Acid Compositions
 TITLE OF INVENTION: Viral-1 Using Peptide and Nucleic Acid Compositions
 FILE REFERENCE: 2060.0040007
 CURRENT APPLICATION NUMBER: US/11/045,024
 CURRENT FILING DATE: 2005-01-28
 PRIOR APPLICATION NUMBER: US 09/412,863
 PRIOR FILING DATE: 1999-10-05
 PRIOR APPLICATION NUMBER: US 08/027,146
 PRIOR FILING DATE: 1993-03-05
 PRIOR APPLICATION NUMBER: US 08/073,205
 PRIOR FILING DATE: 1993-06-04
 PRIOR APPLICATION NUMBER: US 08/103,396
 PRIOR FILING DATE: 1993-08-06
 PRIOR APPLICATION NUMBER: US 08/205,713
 PRIOR FILING DATE: 1994-03-04
 NUMBER OF SEQ ID NOS: 1
 SOFTWARE: FastSEQ for Windows Version 4.0
 SEQ ID NO: 148
 LENGTH: 9
 TYPE: PRT
 ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
 US-11-045-024-2988
 Query Match 2 TAPPVN 8
 Best Local Similarity 57.1%; Score 24; DB 7; Length 9;
 Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 Qy ||||| :
 Db 2 TAPPAES 8

```

; GENERAL INFORMATION:
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Livingston, Brian
; APPLICANT: Chesnut, Robert
; APPLICANT: Baker, Denise Marie
; APPLICANT: Celis, Esteban
; APPLICANT: Kubo, Ralph
; APPLICANT: Grey, Howard M.
; APPLICANT: Edimmune Inc.
; TITLE OF INVENTION: Inducing Cellular Responses to Human Immunodeficiency Virus-1 Using Peptide and Nucleic Acid Compositions
; CURRENT APPLICATION NUMBER: US/11/045,024
; FILE REFERENCE: 2060_0040007
; CURRENT FILING DATE: 2005-01-28
; PRIORITY NUMBER: US 09/412,863
; PRIOR FILING DATE: 1999-10-05
; PRIORITY NUMBER: US 09/027,146
; PRIOR FILING DATE: 1993-03-05
; PRIORITY NUMBER: US 08/073,205
; PRIOR FILING DATE: 1993-06-04
; PRIORITY NUMBER: US 08/103,396
; PRIOR FILING DATE: 1993-08-06
; PRIORITY NUMBER: US 08/159,184
; PRIOR FILING DATE: 1993-11-29
; PRIORITY NUMBER: US 08/159,339
; PRIOR FILING DATE: 1993-11-29
; PRIORITY NUMBER: US 08/205,713
; PRIOR FILING DATE: 1994-03-04
; PRIORITY NUMBER: US 08/347,610
; PRIOR FILING DATE: 1994-12-01
; NUMBER OF SEQ ID NOS: 14528
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5659

RESULT 13
Query Match 49.0% Score 24; DB 7; Length 9;
Best Local Similarity 57.1%; Pred. No. 8.3e+04;
Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
Qy 2 TAPPVHN 8
      ||| : 2 TAPPAES 8
Db

RESUL 14
Query Match 49.0% Score 24; DB 7; Length 9;
Best Local Similarity 57.1%; Pred. No. 8.3e+04;
Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
Qy 2 TAPPVHN 8
      ||| : 2 TAPPAES 8
Db

```

```

; PRIOR APPLICATION NUMBER: US 08/073,205
; PRIOR FILING DATE: 1993-06-04
; PRIOR APPLICATION NUMBER: US 08/103,396
; PRIOR FILING DATE: 1993-08-06
; PRIOR APPLICATION NUMBER: US 08/159,184
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/159,339
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/205,713
; PRIOR FILING DATE: 1994-03-04
; PRIOR APPLICATION NUMBER: US 08/347,610
; PRIOR FILING DATE: 1994-12-01
; NUMBER OF SEQ ID NOS: 14528
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO: 6287
; LENGTH: 9
; TYPE: PRT
; ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
US-11-045-024-6287

Query Match          49.0%; Score 24; DB 7; Length 9;
Best Local Similarity 57.1%; Pred. No. 8.3e+04; Mismatches 2; Indels 0; Gaps 0;
Matches 4; Conservative 1; MisMatche 2; InDel 0;

Qy      2 TAPPVHN 8
Db      ||||| :
          2 TAPPAES 8

RESULT 16
US-11-045-024-6387
; Sequence 6387, Application US/11045024
; Publication No. US2005021676A1
; GENERAL INFORMATION:
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Livingston, Brian
; APPLICANT: Chesnut, Robert
; APPLICANT: Baker, Denise Marie
; APPLICANT: Celis, Esteban
; APPLICANT: Kubo, Ralph
; APPLICANT: Grey, Howard M.
; APPLICANT: Epimmune Inc.
; TITLE OF INVENTION: Inducing Cellular Responses to Human Immunodeficiency Virus-1 Using Peptide and Nucleic Acid Compositions
; FILE REFERENCE: 2060.0040007
; CURRENT APPLICATION NUMBER: US/11/045,024
; CURRENT FILING DATE: 2005-01-28
; PRIOR APPLICATION NUMBER: US 09/412,863
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: US 08/027,146
; PRIOR FILING DATE: 1993-03-05
; PRIOR APPLICATION NUMBER: US 08/073,205
; PRIOR FILING DATE: 1993-06-04
; PRIOR APPLICATION NUMBER: US 08/103,396
; PRIOR FILING DATE: 1993-08-06
; PRIOR APPLICATION NUMBER: US 08/159,184
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/205,713
; PRIOR FILING DATE: 1994-03-04
; PRIOR APPLICATION NUMBER: US 08/347,610
; PRIOR FILING DATE: 1994-12-01
; NUMBER OF SEQ ID NOS: 14528
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO: 8861
; LENGTH: 9
; TYPE: PRT
; ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
US-11-045-024-8861

Query Match          49.0%; Score 24; DB 7; Length 9;
Best Local Similarity 57.1%; Pred. No. 8.3e+04; Mismatches 2; Indels 0; Gaps 0;
Matches 4; Conservative 1; MisMatche 2; InDel 0;

Qy      2 TAPPVHN 8
Db      ||||| :
          2 TAPPAES 8

RESULT 18
US-11-045-024-8862
; Sequence 8862, Application US/11045024
; Publication No. US2005021676A1
; GENERAL INFORMATION:
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Livingston, Brian
; APPLICANT: Chesnut, Robert
; APPLICANT: Baker, Denise Marie
; APPLICANT: Epimmune Inc.
; TITLE OF INVENTION: Inducing Cellular Responses to Human Immunodeficiency Virus-1 Using Peptide and Nucleic Acid Compositions
; FILE REFERENCE: 2060.0040007
; CURRENT APPLICATION NUMBER: US/11/045,024
; CURRENT FILING DATE: 2005-01-28
; PRIOR APPLICATION NUMBER: US 09/412,863
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: US 08/073,205
; PRIOR FILING DATE: 1993-06-04
; PRIOR APPLICATION NUMBER: US 08/103,396
; PRIOR FILING DATE: 1993-08-06
; PRIOR APPLICATION NUMBER: US 08/159,184
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/159,339
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/205,713
; PRIOR FILING DATE: 1994-03-04
; PRIOR APPLICATION NUMBER: US 08/347,610
; PRIOR FILING DATE: 1994-12-01
; NUMBER OF SEQ ID NOS: 14528
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO: 6387
; LENGTH: 9
; TYPE: PRT
; ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
US-11-045-024-6387

```

APPLICANT: Celis, Esteban
 APPLICANT: Kubo, Ralph M.
 APPLICANT: Epimmune Inc.
 TITLE OF INVENTION: Inducing Cellular Responses to Human Immunodeficiency Virus-1 Using Peptide and Nucleic Acid Compositions
 FILE REFERENCE: 2000-0040007
 CURRENT APPLICATION NUMBER: US/11/045,024
 CURRENT FILING DATE: 2005-01-28
 PRIORITY APPLICATION NUMBER: US 09/412,863
 PRIORITY FILING DATE: 1999-10-05
 PRIORITY APPLICATION NUMBER: US 09/412,863
 PRIORITY FILING DATE: 1999-10-05
 PRIORITY APPLICATION NUMBER: US 08/027,146
 PRIORITY FILING DATE: 1993-03-05
 PRIORITY APPLICATION NUMBER: US 08/073,205
 PRIORITY FILING DATE: 1993-06-04
 PRIORITY APPLICATION NUMBER: US 08/103,396
 PRIORITY FILING DATE: 1993-08-06
 PRIORITY APPLICATION NUMBER: US 08/159,184
 PRIORITY FILING DATE: 1993-11-29
 PRIORITY APPLICATION NUMBER: US 08/159,339
 PRIORITY FILING DATE: 1993-11-29
 PRIORITY APPLICATION NUMBER: US 08/205,713
 PRIORITY FILING DATE: 1994-03-04
 PRIORITY FILING DATE: 1994-12-01.
 NUMBER OF SEQ ID NOS: 14528
 SEQ ID NO: 8862
 LENGTH: 9
 TYPE: PRT
 ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
 US-11-045-024-8862

Query Match 49.0% Score 24; DB 7; Length 9;
 Best Local Similarity 57.1%; Pred. No. 8.3e+04;
 Matches 4; Conservative 1; Mismatches 2; Indels 0;
 Gaps 0;

Qy 2 TAPPVHN 8
 Db 1 TAPPAES 7

RESULT 19
 US-11-045-024-9107
 Sequence 9107, Application US/11045024
 Publication No. US20050271676A1
 GENERAL INFORMATION:
 APPLICANT: Sette, Alessandro
 APPLICANT: Sidney, John
 APPLICANT: Southwood, Scott
 APPLICANT: Livingston, Brian
 APPLICANT: Cheesnut, Robert
 APPLICANT: Baker, Denise Marie
 APPLICANT: Celis, Esteban
 APPLICANT: Kubo, Ralph M.
 APPLICANT: Epimmune Inc.
 TITLE OF INVENTION: Inducing Cellular Responses to Human Immunodeficiency Virus-1 Using Peptide and Nucleic Acid Compositions
 FILE REFERENCE: 2000-0040007
 CURRENT APPLICATION NUMBER: US 09/412,863
 PRIORITY FILING DATE: 1999-10-05
 PRIORITY APPLICATION NUMBER: US 08/027,146
 PRIORITY FILING DATE: 1993-03-05
 PRIORITY APPLICATION NUMBER: US 08/073,205
 PRIORITY FILING DATE: 1993-06-04
 PRIORITY APPLICATION NUMBER: US 08/103,396
 PRIORITY FILING DATE: 1993-08-06
 PRIORITY APPLICATION NUMBER: US 08/159,184
 PRIORITY FILING DATE: 1993-11-29
 PRIORITY APPLICATION NUMBER: US 08/159,339
 PRIORITY FILING DATE: 1994-03-04
 PRIORITY APPLICATION NUMBER: US 08/205,713
 PRIORITY FILING DATE: 1994-12-01
 NUMBER OF SEQ ID NOS: 14528
 SOFTWARE: FastSEQ for Windows Version 4.0
 SEQ ID NO 11134

LENGTH: 9
 TYPE: PRT
 ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
 US-11-045-024-11134

Query Match 49.0% Score 24; DB 7; Length 9;
 Best Local Similarity 57.1%; Pred. No. 8.3e+04;
 Matches 4; Conservative 1; Mismatches 2; Indels 0;
 Gaps 0;

Qy 2 TAPPVHN 8
 Db 1 TAPPAES 7

RESULT 21
US-11-031-737A-40
; Sequence 40, Application US/11031737A
; Publication No. US20060019240A1
; GENERAL INFORMATION:
; APPLICANT: Alroy, Iris
; APPLICANT: Greener, Tsvika
; APPLICANT: Tuvia, Shmuel
; TITLE OF INVENTION: POSH NUCLEAR ACIDS, POLYPEPTIDES AND RELATED METHODS
; FILE REFERENCE: PRL-P03-010
; CURRENT APPLICATION NUMBER: US/11/031,737A
; CURRENT FILING DATE: 2005-01-07
; PRIOR APPLICATION NUMBER: 10/293,965
; PRIOR FILING DATE: 2002-11-12
; PRIOR APPLICATION NUMBER: 60/345,846
; PRIOR FILING DATE: 2001-11-09
; PRIOR APPLICATION NUMBER: 60/364,530
; PRIOR FILING DATE: 2002-03-15
; NUMBER OF SEQ ID NOS: 48
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 40
; LENGTH: 7
; TYPE: PRT
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: sequence motif
US-11-031-737A-40

Query Match Score 23; DB 7; Length 7;
Best Local Similarity 100.0%; Pred. No. 8.3e+00;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 TAPP 5
Db 2 TAPP 5

RESULT 22
US-11-031-482-40
; Sequence 40, Application US/11031482
; Publication No. US20060035213A1
; GENERAL INFORMATION:
; APPLICANT: Alroy, Iris
; APPLICANT: Greener, Tsvika
; APPLICANT: Ben-Avraham, Danny
; TITLE OF INVENTION: POSH NUCLEAR ACIDS, POLYPEPTIDES AND RELATED METHODS
; FILE REFERENCE: PRL-P04-010
; CURRENT APPLICATION NUMBER: US/11/031,482
; CURRENT FILING DATE: 2005-01-06
; PRIOR APPLICATION NUMBER: 10/293,965
; PRIOR FILING DATE: 2002-11-12
; PRIOR APPLICATION NUMBER: 60/345,846
; PRIOR FILING DATE: 2001-11-09
; PRIOR APPLICATION NUMBER: 60/364,530
; PRIOR FILING DATE: 2002-03-15
; NUMBER OF SEQ ID NOS: 48
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 40
; LENGTH: 7
; TYPE: PRT
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: sequence motif
US-11-031-482-40

Query Match Score 23; DB 7; Length 8;
Best Local Similarity 80.0%; Pred. No. 8.3e+00;
Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 5 PVHNV 9
Db 2 PVHGV 6

RESULT 23
US-11-045-024-5300
; Sequence 5300, Application US/11045024
; Publication No. US20050271676A1
; GENERAL INFORMATION:
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Livingston, Brian
; APPLICANT: Cheznut, Robert
; APPLICANT: Baker, Denise Marie
; APPLICANT: Celis, Esteban
; APPLICANT: Kubo, Ralph
; APPLICANT: Grey, Howard M.
; APPLICANT: Epimmune Inc.

Query Match Score 23; DB 7; Length 7;
Best Local Similarity 100.0%; Pred. No. 8.3e+00;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

TITLE OF INVENTION: Inducing Cellular Responses to Human Immunodeficiency Virus-1 Using Peptide and Nucleic Acid Compositions
FILE REFERENCE: 2050_0040007
CURRENT APPLICATION NUMBER: US/11/045,024
CURRENT FILING DATE: 2005-01-28
PRIORITY FILING DATE: 1999-10-05
PRIORITY APPLICATION NUMBER: US 08/027,146
PRIORITY FILING DATE: 1993-03-05
PRIORITY APPLICATION NUMBER: US 08/073,205
PRIORITY FILING DATE: 1993-06-04
PRIORITY APPLICATION NUMBER: US 08/103,396
PRIORITY FILING DATE: 1993-08-06
PRIORITY APPLICATION NUMBER: US 08/159,184
PRIORITY FILING DATE: 1993-11-29
PRIORITY APPLICATION NUMBER: US 08/159,339
PRIORITY FILING DATE: 1993-11-29
PRIORITY APPLICATION NUMBER: US 08/205,713
PRIORITY FILING DATE: 1994-03-04
PRIORITY APPLICATION NUMBER: US 08/347,610
PRIORITY FILING DATE: 1994-12-01
NUMBER OF SEQ ID NOS: 14528
SOFTWARE: FastSEQ for Windows Version 4.0
SEQ ID NO: 6267
LENGTH: 8
TYPE: PRT
ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS

US-11-045-04-6267

Query Match 46.9%; Score 23; DB 7; Length 8;
Best Local Similarity 100.0%; Pred. No. 8.3e+04;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 TAPP 5
Db 1 TAPP 4

RESULT 25
US-11-045-04-6353
Sequence 6353, Application US/11045024
Publication No. US2005021676A1
GENERAL INFORMATION:
APPLICANT: Sette, Alessandro
APPLICANT: Sidney, John
APPLICANT: Southwood, Scott
APPLICANT: Livingston, Brian
APPLICANT: Chesnut, Robert
APPLICANT: Baker, Denise Marie
APPLICANT: Celis, Esteban
APPLICANT: Kubo, Ralph
APPLICANT: Grey, Howard M.
APPLICANT: Epimmune Inc.

TITLE OF INVENTION: Inducing Cellular Responses to Human Immunodeficiency Virus-1 Using Peptide and Nucleic Acid Compositions
FILE REFERENCE: 2060_0040007
CURRENT APPLICATION NUMBER: US/11/045,024
CURRENT FILING DATE: 2005-01-28
PRIORITY APPLICATION NUMBER: US 09/412,863
PRIORITY FILING DATE: 1999-1-0-05
PRIORITY APPLICATION NUMBER: US 08/027,146
PRIORITY FILING DATE: 1993-03-05
PRIORITY APPLICATION NUMBER: US 08/073,205
PRIORITY FILING DATE: 1993-06-04
PRIORITY APPLICATION NUMBER: US 08/103,396
PRIORITY FILING DATE: 1993-08-06
PRIORITY APPLICATION NUMBER: US 08/159,184
PRIORITY FILING DATE: 1993-11-29
PRIORITY APPLICATION NUMBER: US 08/205,713
PRIORITY FILING DATE: 1994-03-04
PRIORITY APPLICATION NUMBER: US 08/347,610
PRIORITY FILING DATE: 1994-12-01
NUMBER OF SEQ ID NOS: 14528
SOFTWARE: FastSEQ for Windows Version 4.0
SEQ ID NO: 7822
LENGTH: 8
TYPE: PRT
ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS

US-11-045-04-7822

Query Match 46.9%; Score 23; DB 7; Length 8;
Best Local Similarity 80.0%; Pred. No. 8.3e+04;
Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 5 PVHNV 9
Db 2 PVHGV 6

RESULT 27
US-11-045-024-8826

Sequence 8826, Application US/11045024
 Publication No. US20050271676A1
 GENERAL INFORMATION:
 APPLICANT: Sette, Alessandro
 APPLICANT: Sidney, John
 APPLICANT: Southwood, Scott
 APPLICANT: Livingston, Brian
 APPLICANT: Chesnut, Robert
 APPLICANT: Baker, Denise Marie
 APPLICANT: Celis, Esteban
 APPLICANT: Kubo, Ralph
 APPLICANT: Grey, Howard M.
 APPLICANT: Epimmune Inc.

TITLE OF INVENTION: Inducing Cellular Responses to Human Immunodeficiency Virus-1 Using Peptide and Nucleic Acid Compositions

FILE REFERENCE: 2060.004007
 CURRENT APPLICATION NUMBER: US/11/045,024
 CURRENT FILING DATE: 2005-01-28
 PRIORITY NUMBER: US 09/412,863
 PRIORITY FILING DATE: 1999-10-05
 PRIORITY APPLICATION NUMBER: US 08/027,146
 PRIORITY FILING DATE: 1993-03-05
 PRIORITY APPLICATION NUMBER: US 08/073,205
 PRIORITY FILING DATE: 1993-06-04
 PRIORITY APPLICATION NUMBER: US 08/103,396
 PRIORITY FILING DATE: 1993-08-06
 PRIORITY APPLICATION NUMBER: US 08/159,184
 PRIORITY FILING DATE: 1993-11-29
 PRIORITY APPLICATION NUMBER: US 08/159,339
 PRIORITY FILING DATE: 1993-11-29
 PRIORITY FILING DATE: 1994-03-04
 PRIORITY APPLICATION NUMBER: US 08/205,713
 LENGTH: 8
 SEQ ID NO: 8826
 TYPE: PRT
 ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
 US-11-045-024-9004

Query Match 46.9%; Score 23; DB 7; Length 8;
 Best Local Similarity 100.0%; Pred. No. 8.3e+04;
 Matches 4; Conservative 0; Mismatches 0; Indels 0;
 Gaps 0;

Qy 2 TAPP 5
 Db 1 TAPP 4

RESULT 29
 US-10-510-101-57
 Sequence 57, Application US/10510101
 Publication No. US20060018915A1
 GENERAL INFORMATION:
 APPLICANT: Epimmune Inc.
 APPLICANT: Ishioka, Glenn
 APPLICANT: Fikes, John
 APPLICANT: Tangri, Shabnam
 APPLICANT: Sette, Alessandro
 TITLE OF INVENTION: Retrocyclic Analogs and Related Methods
 FILE REFERENCE: 2060.009PC05
 CURRENT APPLICATION NUMBER: US/10/510,101
 CURRENT FILING DATE: 2004-10-05
 PRIORITY FILING DATE: 2002-09-26
 PRIORITY APPLICATION NUMBER: US 06/413,471
 PRIORITY FILING DATE: 2002-04-05
 NUMBER OF SEQ ID NOS: 196
 SOFTWARE: PatentIn version 3.2
 SEQ ID NO 57
 LENGTH: 9
 TYPE: PRT
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Synthetic peptide derived from Human Immunodeficiency Virus
 US-10-510-101-57

Query Match 46.9%; Score 23; DB 6; Length 9;
 Best Local Similarity 80.0%; Pred. No. 8.3e+04;
 Matches 4; Conservative 0; Mismatches 1; Indels 0;
 Gaps 0;

Qy 5 PVHNV 9
 Db 5 PVHGV 9

RESULT 30
 US-10-510-101-58
 Sequence 58, Application US/10510101
 Publication No. US20060018915A1
 GENERAL INFORMATION:

APPLICANT: Epimmune Inc.
 APPLICANT: Ishioka, Glenn
 APPLICANT: Fikes, John
 APPLICANT: Tangri, Shabnam
 APPLICANT: Sette, Alessandro
 TITLE OF INVENTION: Heterococlitic Analogs and Related Methods
 FILE REFERENCE: 2000-009PC05
 CURRENT APPLICATION NUMBER: US/10/510,101
 CURRENT FILING DATE: 2004-10-05
 PRIOR APPLICATION NUMBER: US 60/413,471
 PRIOR FILING DATE: 2002-09-26
 PRIOR APPLICATION NUMBER: US 10/116,118
 PRIOR FILING DATE: 2002-04-05
 NUMBER OF SEQ ID NOS: 196
 SOFTWARE: Patentin version 3.2
 SEQ ID NO: 58
 LENGTH: 9
 TYPE: PRT
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Synthetic peptide derived from Human Immunodeficiency Virus
 US-10-510-101-58

Query Match Score 23; DB 6; Length 9;
 Best Local Similarity 80.0%; Pred. No. 8.3e+04;
 Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 SEQ 5 PVHNV 9
 Db 5 PVHGV 9

RESULT 31

US-10-510-101-59
 Sequence 59, Application US/10510101
 Publication No. US2006018915A1
 GENERAL INFORMATION:
 APPLICANT: Epimmune Inc.
 APPLICANT: Ishioka, Glenn
 APPLICANT: Fikes, John
 APPLICANT: Tangri, Shabnam
 APPLICANT: Sette, Alessandro
 TITLE OF INVENTION: Heterococlitic Analogs and Related Methods
 FILE REFERENCE: 2000-009PC05
 CURRENT APPLICATION NUMBER: US/10/510,101
 CURRENT FILING DATE: 2004-10-05
 PRIOR APPLICATION NUMBER: US 60/413,471
 PRIOR FILING DATE: 2002-09-26
 PRIOR APPLICATION NUMBER: US 10/116,118
 PRIOR FILING DATE: 2002-04-05
 NUMBER OF SEQ ID NOS: 196
 SOFTWARE: Patentin version 3.2
 SEQ ID NO: 59
 LENGTH: 9
 TYPE: PRT
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Synthetic peptide derived from Human Immunodeficiency Virus
 US-10-510-101-59

Query Match Score 23; DB 6; Length 9;
 Best Local Similarity 80.0%; Pred. No. 8.3e+04;
 Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 SEQ 5 PVHNV 9
 Db 5 PVHGV 9

RESULT 32

US-10-510-101-67
 Sequence 67, Application US/10510101
 Publication No. US2006018915A1
 GENERAL INFORMATION:
 APPLICANT: Epimmune Inc.
 APPLICANT: Ishioka, Glenn
 APPLICANT: Fikes, John
 APPLICANT: Tangri, Shabnam
 APPLICANT: Sette, Alessandro
 TITLE OF INVENTION: Heterococlitic Analogs and Related Methods
 FILE REFERENCE: 2000-009PC05
 CURRENT APPLICATION NUMBER: US/10/510,101
 CURRENT FILING DATE: 2004-10-05
 PRIOR APPLICATION NUMBER: US 60/413,471
 PRIOR FILING DATE: 2002-09-26
 PRIOR APPLICATION NUMBER: US 10/116,118
 PRIOR FILING DATE: 2002-04-05
 NUMBER OF SEQ ID NOS: 196
 SOFTWARE: Patentin version 3.2
 SEQ ID NO: 60
 LENGTH: 9
 TYPE: PRT
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Synthetic peptide derived from Homo sapiens melanoma antigens
 US-10-510-101-67

RESULT 34
 US-10-510-101-175
 Sequence 175, Application US/10510101
 Publication No. US2006018915A1

GENERAL INFORMATION:
 APPLICANT: Epimmune Inc.
 APPLICANT: Ishioka, Glenn
 APPLICANT: Fikes, John
 APPLICANT: Tangri, Shabnam
 APPLICANT: Sette, Alessandro
 TITLE OF INVENTION: Heterococlitic Analogs and Related Methods
 FILE REFERENCE: 2000-009PC05
 CURRENT APPLICATION NUMBER: US/10/510,101
 CURRENT FILING DATE: 2004-10-05
 PRIOR APPLICATION NUMBER: US 60/413,471
 PRIOR FILING DATE: 2002-09-26
 PRIOR APPLICATION NUMBER: US 10/116,118
 PRIOR FILING DATE: 2002-04-05
 NUMBER OF SEQ ID NOS: 196
 SOFTWARE: Patentin version 3.2
 SEQ ID NO: 67
 LENGTH: 9
 TYPE: PRT
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Synthetic peptide derived from Human Immunodeficiency Virus
 US-10-510-101-67

Query Match Score 23; DB 6; Length 9;
 Best Local Similarity 80.0%; Pred. No. 8.3e+04;
 Matches 4; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 SEQ 5 PVHNV 9
 Db 5 PVHGV 9

RESULT 33

US-10-510-101-83
 Sequence 83, Application US/10510101
 Publication No. US2006018915A1
 GENERAL INFORMATION:
 APPLICANT: Epimmune Inc.
 APPLICANT: Ishioka, Glenn
 APPLICANT: Fikes, John
 APPLICANT: Tangri, Shabnam
 APPLICANT: Sette, Alessandro
 TITLE OF INVENTION: Heterococlitic Analogs and Related Methods
 FILE REFERENCE: 2000-009PC05
 CURRENT APPLICATION NUMBER: US/10/510,101
 CURRENT FILING DATE: 2004-10-05
 PRIOR APPLICATION NUMBER: US 60/413,471
 PRIOR FILING DATE: 2002-09-26
 PRIOR APPLICATION NUMBER: US 10/116,118
 PRIOR FILING DATE: 2002-04-05
 NUMBER OF SEQ ID NOS: 196
 SOFTWARE: Patentin version 3.2
 SEQ ID NO: 83
 LENGTH: 9
 TYPE: PRT
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Synthetic peptide derived from Homo sapiens melanoma antigens
 US-10-510-101-83

Query Match Score 23; DB 6; Length 9;
 Best Local Similarity 75.0%; Pred. No. 8.3e+04;
 Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 4 PPVH 7
 Db 4 PPHH 7

; APPLICANT: Sidney, John
 ; APPLICANT: Southwood, Scott
 ; APPLICANT: Livingstone, Brian
 ; APPLICANT: Chesnut, Robert
 ; APPLICANT: Baker, Denise Marie
 ; APPLICANT: Celis, Esteban
 ; APPLICANT: Kubo, Ralph
 ; APPLICANT: Grey, Howard M.
 ; APPLICANT: Epimmune Inc.
 TITLE OF INVENTION: Inducing Cellular Responses to Human Immunodeficiency Virus-1 Using Peptide and Nucleic Acid Compositions
 FILE REFERENCE: 2060_0040007
 CURRENT APPLICATION NUMBER: US/11/045,024
 CURRENT FILING DATE: 2005-01-28
 PRIOR APPLICATION NUMBER: US/09/412,863
 PRIOR FILING DATE: 1999-10-05
 PRIOR APPLICATION NUMBER: US/08/027,146
 PRIOR FILING DATE: 1993-03-05
 PRIOR APPLICATION NUMBER: US/08/073,205
 PRIOR FILING DATE: 1993-08-04
 PRIOR APPLICATION NUMBER: US/08/113,396
 PRIOR FILING DATE: 1993-11-29
 PRIOR APPLICATION NUMBER: US/08/159,184
 PRIOR FILING DATE: 1993-06-04
 PRIOR APPLICATION NUMBER: US/08/159,339
 PRIOR FILING DATE: 1993-11-29
 PRIOR APPLICATION NUMBER: US/08/205,713
 PRIOR FILING DATE: 1994-03-04
 PRIOR APPLICATION NUMBER: US/08/347,610
 PRIOR FILING DATE: 1994-12-01
 NUMBER OF SEQ ID NOS: 14528
 SOFTWARE: FastSEQ for Windows Version 4.0
 SEQ ID NO: 1247
 LENGTH: 9
 TYPE: PRT
 ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
 US-11-045-024-1885

Query Match Score 23; DB 7; Length 9;
 Best Local Similarity 100.0%; Pred. No. 8.3e+04;
 Matches 4; Conservative 0; Mismatches 0; Indels 0;
 Gaps 0;

Qy 2 TAPP 5
 |||||
 Db 5 TAPP 8

RESULT 38
 US-11-045-024-1885
 ; Sequence 1885, Application US/11045024
 ; Publication No. US20050271676A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Sette, Alessandro
 ; APPLICANT: Sidney, John
 ; APPLICANT: Southwood, Scott
 ; APPLICANT: Livingston, Brian
 ; APPLICANT: Chesnut, Robert
 ; APPLICANT: Baker, Denise Marie
 ; APPLICANT: Celis, Esteban
 ; APPLICANT: Kubo, Ralph
 ; APPLICANT: Grey, Howard M.
 ; APPLICANT: Epimmune Inc.
 TITLE OF INVENTION: Inducing Cellular Responses to Human Immunodeficiency Virus-1 Using Peptide and Nucleic Acid Compositions
 FILE REFERENCE: 2060_0040007
 CURRENT APPLICATION NUMBER: US/11/045,024
 CURRENT FILING DATE: 2005-01-28
 PRIOR APPLICATION NUMBER: US/09/412,863
 PRIOR FILING DATE: 1999-10-05
 PRIOR APPLICATION NUMBER: US/09/412,863
 PRIOR FILING DATE: 1993-06-04
 PRIOR APPLICATION NUMBER: US/08/103,396
 PRIOR FILING DATE: 1993-08-06
 PRIOR APPLICATION NUMBER: US/08/159,184
 PRIOR FILING DATE: 1993-11-29
 PRIOR APPLICATION NUMBER: US/08/159,339
 PRIOR FILING DATE: 1993-11-29
 PRIOR APPLICATION NUMBER: US/08/205,713
 PRIOR FILING DATE: 1994-03-04
 PRIOR APPLICATION NUMBER: US/08/347,610
 PRIOR FILING DATE: 1994-12-01
 NUMBER OF SEQ ID NOS: 14528
 SOFTWARE: FastSEQ for Windows Version 4.0
 SEQ ID NO: 2987
 LENGTH: 9
 TYPE: PRT
 ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
 US-11-045-024-2987

Query Match Score 23; DB 7; Length 9;
 Best Local Similarity 100.0%; Pred. No. 8.3e+04;

```

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy      2 TAPP 5
Db      1 TAPP 4

RESULT 40
US-11-045-024-2989
; Sequence 2889, Application US/11045024
; Publication No. US20050271676A1
; GENERAL INFORMATION:
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Livingston, Brian
; APPLICANT: Chesnut, Robert
; APPLICANT: Baker, Denise Marie
; APPLICANT: Celis, Esteban
; APPLICANT: Kubo, Ralph
; APPLICANT: Grey, Howard M.
; APPLICANT: Epimmune Inc.
; TITLE OF INVENTION: Inducing Cellular Responses to Human Immunodeficiency Virus-1 Using Peptide and Nucleic Acid Compositions
; FILE REFERENCE: 2060_0040007
; CURRENT APPLICATION NUMBER: US/11/045,024
; CURRENT FILING DATE: 2005-01-28
; PRIORITY APPLICATION NUMBER: US 09/412,863
; PRIORITY FILING DATE: 1999-10-05
; PRIORITY APPLICATION NUMBER: US 08/027,146
; PRIORITY FILING DATE: 1993-03-05
; PRIORITY APPLICATION NUMBER: US 08/073,205
; PRIORITY FILING DATE: 1993-06-04
; PRIORITY APPLICATION NUMBER: US 09/412,863
; PRIORITY FILING DATE: 1999-10-05
; PRIORITY APPLICATION NUMBER: US 08/027,146
; PRIORITY FILING DATE: 1993-03-05
; PRIORITY APPLICATION NUMBER: US 08/073,205
; PRIORITY FILING DATE: 1993-06-04
; PRIORITY APPLICATION NUMBER: US 08/103,396
; PRIORITY FILING DATE: 1993-08-06
; PRIORITY APPLICATION NUMBER: US 08/159,184
; PRIORITY APPLICATION NUMBER: US 08/159,339
; PRIORITY FILING DATE: 1993-11-29
; PRIORITY APPLICATION NUMBER: US 08/205,713
; PRIORITY FILING DATE: 1994-03-04
; PRIORITY APPLICATION NUMBER: US 08/347,610
; PRIORITY FILING DATE: 1994-12-01
; NUMBER OF SEQ ID NOS: 14528
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO: 2989
; LENGTH: 9
; TYPE: PRT
; ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
US-11-045-024-2989

Query Match 46.9%; Score 23; DB 7; Length 9;
Best Local Similarity 100.0%; Pred. No. 8.3e+04;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 42
US-11-045-024-4113
; Sequence 4113, Application US/11045024
; Publication No. US20050271676A1
; GENERAL INFORMATION:
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Livingston, Brian
; APPLICANT: Chesnut, Robert
; APPLICANT: Baker, Denise Marie
; APPLICANT: Celis, Esteban
; APPLICANT: Kubo, Ralph M.
; APPLICANT: Grey, Howard M.
; APPLICANT: Epimmune Inc.
; TITLE OF INVENTION: Inducing Cellular Responses to Human Immunodeficiency Virus-1 Using Peptide and Nucleic Acid Compositions
; FILE REFERENCE: 2060_0040007
; CURRENT APPLICATION NUMBER: US/11/045,024
; CURRENT FILING DATE: 2005-01-28
; PRIORITY APPLICATION NUMBER: US 09/412,863
; PRIORITY FILING DATE: 1999-10-05
; PRIORITY APPLICATION NUMBER: US 08/073,205
; PRIORITY FILING DATE: 1993-03-05
; PRIORITY APPLICATION NUMBER: US 08/103,396
; PRIORITY FILING DATE: 1993-08-06
; PRIORITY APPLICATION NUMBER: US 08/159,184
; PRIORITY APPLICATION NUMBER: US 08/159,339
; PRIORITY FILING DATE: 1993-11-29
; PRIORITY APPLICATION NUMBER: US 08/205,713
; PRIORITY FILING DATE: 1994-03-04
; PRIORITY APPLICATION NUMBER: US 08/347,610
; PRIORITY FILING DATE: 1994-12-01
; NUMBER OF SEQ ID NOS: 14528
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO: 2989
; LENGTH: 9
; TYPE: PRT
; ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
US-11-045-024-4113

Query Match 46.9%; Score 23; DB 7; Length 9;
Best Local Similarity 100.0%; Pred. No. 8.3e+04;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 41
US-11-045-024-4113
; Sequence 4113, Application US/11045024
; GENERAL INFORMATION:
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Livingston, Brian
; APPLICANT: Chesnut, Robert
; APPLICANT: Baker, Denise Marie
; APPLICANT: Celis, Esteban
; APPLICANT: Kubo, Ralph
; APPLICANT: Grey, Howard M.
; APPLICANT: Epimmune Inc.
; TITLE OF INVENTION: Inducing Cellular Responses to Human Immunodeficiency Virus-1 Using Peptide and Nucleic Acid Compositions
; FILE REFERENCE: 2060_0040007
; CURRENT APPLICATION NUMBER: US/11/045,024
; CURRENT FILING DATE: 2005-01-28
; PRIORITY APPLICATION NUMBER: US 09/412,863
; PRIORITY FILING DATE: 1999-10-05
; PRIORITY APPLICATION NUMBER: US 08/073,205
; PRIORITY FILING DATE: 1993-03-05
; PRIORITY APPLICATION NUMBER: US 08/103,396
; PRIORITY FILING DATE: 1993-08-06
; PRIORITY APPLICATION NUMBER: US 08/159,184
; PRIORITY FILING DATE: 1993-11-29
; PRIORITY APPLICATION NUMBER: US 08/159,339
; PRIORITY FILING DATE: 1993-11-29
; PRIORITY APPLICATION NUMBER: US 08/205,713
; PRIORITY FILING DATE: 1994-03-04
; PRIORITY APPLICATION NUMBER: US 08/347,610
; PRIORITY FILING DATE: 1994-12-01
; NUMBER OF SEQ ID NOS: 14528
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO: 2989
; LENGTH: 9
; TYPE: PRT
; ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
US-11-045-024-4113

```

PRIOR FILING DATE: 1994-03-04
 PRIOR APPLICATION NUMBER: US 08/3447,610
 PRIOR FILING DATE: 1994-12-01.
 NUMBER OF SEQ ID NOS: 14528
 SOFTWARE: FastSEQ for Windows Version 4.0
 SEQ ID NO: 4115
 LENGTH: 9
 TYPE: PRT
 ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
 US-11-045-024-4115

Query Match 46.9%; Score 23; DB 7; Length 9;
 Best Local Similarity 100.0%; Pred. No. 8.3e+04;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 TAPP 5
 Db 2 TAPP 5

RESULT 43
 US-11-045-024-5192
 Sequence 5192, Application US/11045024
 Publication No. US2005021676A1
 GENERAL INFORMATION:
 APPLICANT: Sette, Alessandro
 APPLICANT: Sidney, John
 APPLICANT: Southwood, Scott
 APPLICANT: Livingston, Brian
 APPLICANT: Chasnut, Robert
 APPLICANT: Baker, Denise Marie
 APPLICANT: Celis, Esteban
 APPLICANT: Kubo, Ralph
 APPLICANT: Grey, Howard M.
 APPLICANT: Epimmune Inc.

TITLE OF INVENTION: Inducing Cellular Responses to Human Immunodeficiency Virus-1 Using Peptide and Nucleic Acid Compositions

FILE REFERENCE: 2060_000007
 CURRENT APPLICATION NUMBER: US/11/045,024
 CURRENT FILING DATE: 2005-01-28
 PRIOR APPLICATION NUMBER: US 09/412,863
 PRIOR FILING DATE: 1999-10-05
 PRIOR APPLICATION NUMBER: US 08/027,146
 PRIOR FILING DATE: 1993-03-05
 PRIOR APPLICATION NUMBER: US 08/073,205
 PRIOR FILING DATE: 1993-06-04
 PRIOR APPLICATION NUMBER: US 08/103,396
 PRIOR FILING DATE: 1993-08-06
 PRIOR APPLICATION NUMBER: US 08/159,184
 PRIOR FILING DATE: 1993-11-29
 PRIOR APPLICATION NUMBER: US 08/159,339
 PRIOR FILING DATE: 1993-11-29
 PRIOR APPLICATION NUMBER: US 08/205,713
 PRIOR FILING DATE: 1994-03-04
 PRIOR APPLICATION NUMBER: US 08/347,610
 NUMBER OF SEQ ID NOS: 14528
 SOFTWARE: FastSEQ for Windows Version 4.0
 SEQ ID NO: 5192
 LENGTH: 9
 TYPE: PRT
 ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
 US-11-045-024-5192

Query Match 46.9%; Score 23; DB 7; Length 9;
 Best Local Similarity 100.0%; Pred. No. 8.3e+04;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 44
 US-11-045-024-5195
 Sequence 5195, Application US/11045024
 Publication No. US2005021676A1
 GENERAL INFORMATION:
 APPLICANT: Sette, Alessandro
 APPLICANT: Sidney, John
 APPLICANT: Southwood, Scott
 APPLICANT: Livingston, Brian
 APPLICANT: Chasnut, Robert
 APPLICANT: Baker, Denise Marie
 APPLICANT: Celis, Esteban
 APPLICANT: Kubo, Ralph
 APPLICANT: Grey, Howard M.
 APPLICANT: Epimmune Inc.

TITLE OF INVENTION: Inducing Cellular Responses to Human Immunodeficiency Virus-1 Using Peptide and Nucleic Acid Compositions

FILE REFERENCE: 2060_000007
 CURRENT APPLICATION NUMBER: US/11/045,024
 CURRENT FILING DATE: 2005-01-28

```

; PRIOR APPLICATION NUMBER: US 09/412,863
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: US 08/027,146
; PRIOR FILING DATE: 1993-03-05
; PRIOR APPLICATION NUMBER: US 08/073,205
; PRIOR FILING DATE: 1993-06-04
; PRIOR APPLICATION NUMBER: US 08/103,396
; PRIOR FILING DATE: 1993-08-06
; PRIOR APPLICATION NUMBER: US 08/159,184
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/159,339
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/159,339
; PRIOR FILING DATE: 1994-03-04
; PRIOR APPLICATION NUMBER: US 08/347,610
; PRIOR FILING DATE: 1994-12-01
; NUMBER OF SEQ ID NOS: 14528
; SOFTWARE: FastSEQ For Windows Version 4.0
; SEQ ID NO: 5845
; LENGTH: 9
; TYPE: PRT
; ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
; US-11-045-024-5845

Query Match          46.9%; Score 23; DB 7; Length 9;
Best Local Similarity 100.0%; Pred. No. 8.3e+04;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2 TAPP 5
Db      2 TAPP 5

RESULT 4_7
US-11-045-024-6358
; Sequence 6358, Application US/11045024
; Publication No. US20050271676A1
; GENERAL INFORMATION:
; APPLICANT: Sette Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Livingston, Brian
; APPLICANT: Chesnut, Robert
; APPLICANT: Baker, Denise Marie
; APPLICANT: Celis, Esteban
; APPLICANT: Kubo, Ralph
; APPLICANT: Grey, Howard M.
; APPLICANT: Epimmune Inc.
; TITLE OF INVENTION: Inducing Cellular Responses to Human Immunodeficiency
; Virus-1 Using Peptide and Nucleic Acid Compositions
; FILE REFERENCE: 2060_0040007
; CURRENT APPLICATION NUMBER: US/11/045,024
; CURRENT FILING DATE: 2005-01-28
; PRIOR APPLICATION NUMBER: US 09/412,863
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: US 08/027,146
; PRIOR FILING DATE: 1993-03-05
; PRIOR APPLICATION NUMBER: US 08/073,205
; PRIOR FILING DATE: 1993-08-06
; PRIOR APPLICATION NUMBER: US 08/103,396
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/159,184
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/159,339
; PRIOR FILING DATE: 1994-03-04
; PRIOR APPLICATION NUMBER: US 08/347,610
; PRIOR FILING DATE: 1994-12-01
; NUMBER OF SEQ ID NOS: 14528
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO: 6358
; LENGTH: 9
; TYPE: PRT
; ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
; US-11-045-024-6358

Query Match          46.9%; Score 23; DB 7; Length 9;
Best Local Similarity 100.0%; Pred. No. 8.3e+04;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2 TAPP 5
Db      2 TAPP 5

RESULT 4_8
US-11-045-024-7824
; Sequence 7824, Application US/11045024
; Publication No. US20050271676A1
; GENERAL INFORMATION:
; APPLICANT: Sette Alessandro
; APPLICANT: Sidney, John

```

```

; APPLICANT: Southwood, Scott
; APPLICANT: Livingston, Brian
; APPLICANT: Chesnut, Robert
; APPLICANT: Baker, Denise Marie
; APPLICANT: Celis, Esteban
; APPLICANT: Kubo, Ralph
; APPLICANT: Grey, Howard M.
; APPLICANT: Epimmune Inc.
TITLE OF INVENTION: Inducing Cellular Responses to Human Immunodeficiency Virus-1 Using Peptide and Nucleic Acid Compositions
FILE REFERENCE: 2005-0040007
CURRENT FILING DATE: 2005-01-28
PRIORITY APPLICATION NUMBER: US 09/412,863
PRIORITY FILING DATE: 1999-10-05
PRIORITY APPLICATION NUMBER: US 08/027,146
PRIORITY FILING DATE: 1993-03-05
PRIORITY APPLICATION NUMBER: US 08/073,205
PRIORITY FILING DATE: 1993-06-04
PRIORITY APPLICATION NUMBER: US 08/103,396
PRIORITY FILING DATE: 1993-08-06
PRIORITY APPLICATION NUMBER: US 08/159,184
PRIORITY FILING DATE: 1993-11-29
PRIORITY APPLICATION NUMBER: US 08/159,339
PRIORITY FILING DATE: 1993-11-29
PRIORITY APPLICATION NUMBER: US 08/205,713
PRIORITY FILING DATE: 1994-03-04
PRIORITY APPLICATION NUMBER: US 08/347,610
PRIORITY FILING DATE: 1994-12-01
NUMBER OF SEQ ID NOS: 14528
SOFTWARE: Fast-SEQ for Windows Version 4.0
SEQ ID NO 8253
LENGTH: 9
TYPE: PRT
ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
US-11-045-024-8253
RESULT 49
US-11-045-024-8253
; Sequence 8253, Application US/11045024
; Publication No. US20050271676A1
; GENERAL INFORMATION
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Livingston, Brian
; APPLICANT: Chesnut, Robert
; APPLICANT: Baker, Denise Marie
; APPLICANT: Celis, Esteban
; APPLICANT: Kubo, Ralph
; APPLICANT: Grey, Howard M.
TITLE OF INVENTION: Inducing Cellular Responses to Human Immunodeficiency Virus-1 Using Peptide and Nucleic Acid Compositions
FILE REFERENCE: 2006-0040007
CURRENT FILING DATE: 2005-01-28
PRIORITY APPLICATION NUMBER: US/11/045 024
PRIORITY FILING DATE: 1999-11-29
PRIORITY APPLICATION NUMBER: US 09/412,863
PRIORITY FILING DATE: 1993-10-05
PRIORITY APPLICATION NUMBER: US 08/027,146
PRIORITY FILING DATE: 1993-03-05
PRIORITY APPLICATION NUMBER: US 08/073,205
PRIORITY FILING DATE: 1993-06-04
PRIORITY APPLICATION NUMBER: US 08/103,396
PRIORITY FILING DATE: 1993-08-06
PRIORITY APPLICATION NUMBER: US 08/159,184
PRIORITY FILING DATE: 1993-11-29
PRIORITY APPLICATION NUMBER: US 08/205,713
PRIORITY FILING DATE: 1994-03-04
PRIORITY APPLICATION NUMBER: US 08/347,610
NUMBER OF SEQ ID NOS: 14528
SOFTWARE: Fast-SEQ for Windows Version 4.0
SEQ ID NO 8830
LENGTH: 9
TYPE: PRT
ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
US-11-045-024-8830
Query Match 46.9%; Score 23; DB 7; Length 9;
Best Local Similarity 100.0%; Pred. No. 8.3e+04;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 2 TAPP 5
Db 2 TAPP 5

Search completed: February 24, 2006, 10:32:45
Job time : 23 secs

This Page Blank (uspto)

GenCore version 5.1.7
 Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM protein - protein search, using SW model

Run on: February 24, 2006, 10:29:20 ; Search time 161 Seconds

(without alignments)

Result No.	Score	Query Match	Length	DB ID	Description
1	49	100.0	4	US-10-147-161-98	Sequence 98, App1
2	39	79.6	9	US-09-309-460-55	Sequence 55, App1
3	39	79.6	9	US-10-972-816-55	Sequence 55, App1
4	39	79.6	9	US-10-447-161-97	Sequence 97, App1
5	39	79.6	9	US-10-396-317-44	Sequence 44, App1
6	39	79.6	9	US-10-758-970-55	Sequence 55, App1
7	37	75.5	8	US-10-973-922-19	Sequence 9, App1
8	32	65.3	8	US-09-394-466-10	Sequence 19, App1
9	31.5	64.3	8	US-10-080-013-20	Sequence 10, App1
10	31.5	64.3	8	US-10-389-566-20	Sequence 20, App1
11	27	55.1	9	US-11-055-119-9	Sequence 20, App1
12	26	53.1	8	US-10-473-127-175	Sequence 7, App1
13	25	63.3	6	US-09-394-466-7	Sequence 22, App1
14	28	57.1	9	US-10-234-726-100	Sequence 3, App1
15	27	55.1	9	US-09-077-234-28	Sequence 100, App1
16	27	55.1	9	US-10-080-013-20	Sequence 28, App1
17	26	53.1	8	US-10-389-566-20	Sequence 9, App1
18	25	51.0	9	US-09-879-916-22	Sequence 175, App1
19	25	51.0	9	US-10-001-546-67	Sequence 17, App1
20	25	51.0	9	US-10-182-252A-170	Sequence 172, App1
21	25	51.0	9	US-10-182-252A-172	Sequence 14, App1
22	24	49.0	7	US-10-611-440-14	Sequence 198, App1
23	24	49.0	7	US-09-554-385-198	Sequence 198, App1
24	24	49.0	7	US-10-912-512-198	Sequence 198, App1
25	24	49.0	7	US-10-315-043-198	Sequence 198, App1
26	24	49.0	8	US-10-786-850-33	Sequence 33, App1
27	24	49.0	8	US-11-051-411-80	Sequence 80, App1

101	23	46.9	US-10-116-275-89	Sequence 89, App1	US-10-223-172A-22
102	23	46.9	US-10-149-135-762	Sequence 762, App	US-10-149-135-762
103	23	46.9	US-10-149-135-802	Sequence 802, App	US-10-149-135-802
104	23	46.9	US-10-149-135-811	Sequence 811, App	US-10-149-135-811
105	23	46.9	US-10-149-135-841	Sequence 841, App	US-10-149-135-841
106	23	46.9	US-10-149-135-849	Sequence 849, App	US-10-149-135-849
107	23	46.9	US-10-149-135-1283	Sequence 1283, App	US-10-149-135-1283
108	23	46.9	US-10-149-135-1387	Sequence 1387, App	US-10-149-135-1387
109	23	46.9	US-10-149-135-1562	Sequence 1562, App	US-10-149-135-1562
110	23	46.9	US-10-149-135-1706	Sequence 1706, App	US-10-149-135-1706
111	23	46.9	US-10-149-135-1806	Sequence 1806, App	US-10-149-135-1806
112	23	46.9	US-10-149-135-1998	Sequence 1998, App	US-10-149-135-1998
113	23	46.9	US-10-149-135-2252	Sequence 2252, App	US-10-149-135-2252
114	23	46.9	US-10-163-407-19	Sequence 19, App1	US-10-163-407-19
115	23	46.9	US-10-163-407-21	Sequence 21, App1	US-10-163-407-21
116	23	46.9	US-10-657-022-337	Sequence 337, App	US-10-657-022-337
117	23	46.9	US-10-657-022-346	Sequence 346, App	US-10-657-022-346
118	23	46.9	US-10-657-022-348	Sequence 348, App	US-10-657-022-348
119	23	46.9	US-11-147-083-76	Sequence 76, App1	US-11-147-083-76
120	23	46.9	US-08-000-483-2	Sequence 2, App1	US-08-000-483-2
121	23	46.9	US-08-024-894-21	Sequence 21, App1	US-08-024-894-21
122	23	46.9	US-08-044-894-149	Sequence 149, App	US-08-044-894-149
123	23	46.9	US-08-344-894-156	Sequence 156, App	US-08-344-894-156
124	23	46.9	US-08-344-894-339	Sequence 339, App	US-08-344-894-339
125	23	46.9	US-09-080-053-464	Sequence 464, App	US-09-080-053-464
126	23	46.9	US-09-084-018-6	Sequence 6, App1	US-09-084-018-6
127	23	46.9	US-09-084-018-71	Sequence 71, App1	US-09-084-018-71
128	23	46.9	US-09-094-018-148	Sequence 148, App	US-09-094-018-148
129	23	46.9	US-09-912-787-81	Sequence 81, App1	US-09-912-787-81
130	23	46.9	US-09-117-380B-10	Sequence 10, App1	US-09-117-380B-10
131	23	46.9	US-09-117-380B-14	Sequence 14, App1	US-09-117-380B-14
132	23	46.9	US-09-117-380B-18	Sequence 18, App1	US-09-117-380B-18
133	23	46.9	US-09-117-380B-22	Sequence 22, App1	US-09-117-380B-22
134	23	46.9	US-09-972-015A-23	Sequence 23, App1	US-09-972-015A-23
135	23	46.9	US-09-977-064-5	Sequence 5, App1	US-09-977-064-5
136	23	46.9	US-09-977-064-5	Sequence 5, App1	US-09-977-064-5
137	23	46.9	US-09-978-019-176	Sequence 176, App	US-09-978-019-176
138	23	46.9	US-09-978-019-218	Sequence 218, App	US-09-978-019-218
139	23	46.9	US-09-978-019-292	Sequence 292, App	US-09-978-019-292
140	23	46.9	US-09-791-477-176	Sequence 176, App	US-09-791-477-176
141	23	46.9	US-09-791-477-218	Sequence 218, App	US-09-791-477-218
142	23	46.9	US-09-791-477-292	Sequence 292, App	US-09-791-477-292
143	23	46.9	US-09-785-019-176	Sequence 176, App	US-09-785-019-176
144	23	46.9	US-09-785-019-218	Sequence 218, App	US-09-785-019-218
145	23	46.9	US-09-785-019-292	Sequence 292, App	US-09-785-019-292
146	23	46.9	US-09-788-110A-7	Sequence 7, App1	US-09-788-110A-7
147	23	46.9	US-10-014-316-83	Sequence 83, App1	US-10-014-316-83
148	23	46.9	US-10-016-487-23	Sequence 23, App1	US-10-016-487-23
149	23	46.9	US-10-104-487-32	Sequence 32, App1	US-10-104-487-32
150	23	46.9	US-10-125-675A-2176	Sequence 176, App	US-10-125-675A-2176
151	23	46.9	US-10-125-675A-2176	Sequence 218, App	US-10-125-675A-2176
152	23	46.9	US-10-125-675A-222	Sequence 292, App	US-10-125-675A-222
153	23	46.9	US-10-105-200A-42	Sequence 42, App1	US-10-105-200A-42
154	23	46.9	US-10-114-524-18	Sequence 18, App1	US-10-114-524-18
155	23	46.9	US-10-105-500A-42	Sequence 42, App1	US-10-105-500A-42
156	23	46.9	US-10-105-678A-42	Sequence 42, App1	US-10-105-678A-42
157	23	46.9	US-10-102-603-176	Sequence 176, App	US-10-102-603-176
158	23	46.9	US-10-002-603-218	Sequence 218, App	US-10-002-603-218
159	23	46.9	US-10-002-603-292	Sequence 292, App	US-10-002-603-292
160	23	46.9	US-10-133-210-220	Sequence 5, App1	US-10-133-210-220
161	23	46.9	US-10-128-711-5	Sequence 76, App1	US-10-128-711-5
162	23	46.9	US-10-114-833B-23	Sequence 114, App1	US-10-114-833B-23
163	23	46.9	US-10-133-210-3	Sequence 3, App1	US-10-133-210-3
164	23	46.9	US-10-133-210-27	Sequence 27, App1	US-10-133-210-27
165	23	46.9	US-10-133-210-220	Sequence 220, App	US-10-133-210-220
166	23	46.9	US-10-128-711-5	Sequence 235, App	US-10-128-711-5
167	23	46.9	US-10-128-711-76	Sequence 6, App1	US-10-128-711-76
168	23	46.9	US-10-114-833B-23	Sequence 79, App1	US-10-114-833B-23
169	23	46.9	US-10-126-007-79	Sequence 92, App1	US-10-126-007-79
170	23	46.9	US-10-226-007-104	Sequence 104, App	US-10-226-007-104
171	23	46.9	US-10-168-833A-21	Sequence 21, App1	US-10-168-833A-21
172	23	46.9	US-10-219-833B-17	Sequence 17, App1	US-10-219-833B-17
173	23	46.9	US-10-147-910-7	Sequence 7, App1	US-10-147-910-7

247	46.9	9	4	US-10-167-668-119	Sequence 119, App	296	APP
248	46.9	9	4	US-10-182-252A-64	Sequence 64, App1	296	APP
249	46.9	9	4	US-10-182-252A-65	Sequence 65, App1	296	APP
250	46.9	9	4	US-10-182-252A-66	Sequence 66, App1	296	APP
251	46.9	9	4	US-10-182-252A-68	Sequence 68, App1	296	APP
252	46.9	9	4	US-10-182-252A-69	Sequence 69, App1	296	APP
253	46.9	9	4	US-10-182-252A-71	Sequence 71, App1	203	APP
254	46.9	9	4	US-10-182-252A-74	Sequence 74, App1	296	APP
255	46.9	9	4	US-10-182-252A-77	Sequence 77, App1	280	APP
256	46.9	9	4	US-10-182-252A-78	Sequence 78, App1	22	APP
257	46.9	9	4	US-10-182-252A-80	Sequence 80, App1	321	APP
258	46.9	9	4	US-10-182-252A-81	Sequence 81, App1	22	APP
259	46.9	9	4	US-10-182-252A-1375	Sequence 1375, Ap	203	APP
260	46.9	9	4	US-10-182-252A-1388	Sequence 1388, Ap	296	APP
261	46.9	9	4	US-10-182-252A-140-40	Sequence 40, App1	280	APP
262	46.9	9	4	US-10-333-410-45	Sequence 45, App1	320	APP
263	46.9	9	4	US-10-663-407-22	Sequence 22, App1	321	APP
270	46.9	9	4	US-10-663-407-23	Sequence 23, App1	322	APP
271	46.9	9	4	US-10-648-700-176	Sequence 176, App	323	APP
272	46.9	9	4	US-10-648-780-218	Sequence 218, App	324	APP
273	46.9	9	4	US-10-648-780-292	Sequence 292, App	325	APP
274	46.9	9	4	US-10-367-674-119	Sequence 119, App	326	APP
275	46.9	9	4	US-10-653-624-61	Sequence 61, App1	327	APP
276	46.9	9	4	US-10-777-053-115	Sequence 115, App1	328	APP
277	46.9	9	4	US-10-777-053-140	Sequence 140, App	329	APP
278	46.9	9	4	US-10-777-053-416	Sequence 416, App	330	APP
279	46.9	9	4	US-10-777-053-748	Sequence 748, App	331	APP
280	46.9	9	4	US-10-777-053-968	Sequence 968, App	332	APP
281	46.9	9	4	US-10-833-439-61	Sequence 61, App1	333	APP
282	46.9	9	4	US-10-175-417-11	Sequence 11, App1	334	APP
283	46.9	9	4	US-10-833-744-61	Sequence 73, App1	335	APP
284	46.9	9	4	US-10-833-744-61	Sequence 61, App1	336	APP
285	46.9	9	4	US-10-657-022-338	Sequence 338, App	337	APP
286	46.9	9	4	US-10-657-022-340	Sequence 340, App	338	APP
287	46.9	9	4	US-10-557-022-347	Sequence 347, App	339	APP
288	46.9	9	4	US-10-657-022-349	Sequence 61, App1	340	APP
289	46.9	9	4	US-10-833-217-73	Sequence 11, App1	341	APP
290	46.9	9	4	US-10-833-217-115	Sequence 115, App	342	APP
291	46.9	9	4	US-10-837-217-140	Sequence 140, App	343	APP
292	46.9	9	4	US-10-837-217-416	Sequence 416, App	344	APP
293	46.9	9	4	US-10-837-217-748	Sequence 748, App	345	APP
294	46.9	9	4	US-10-837-217-968	Sequence 968, App	346	APP
295	46.9	9	4	US-10-354-050-11	Sequence 11, App1	347	APP
296	46.9	9	4	US-10-386-943-61	Sequence 61, App1	348	APP
297	46.9	9	4	US-10-769-931-1	Sequence 1, App1	349	APP
298	46.9	9	5	US-10-776-521B-402	Sequence 6, App1	350	APP
299	46.9	9	5	US-10-474-980A-71	Sequence 71, App1	351	APP
300	46.9	9	5	US-10-474-980A-148	Sequence 148, App1	352	APP
301	46.9	9	5	US-10-884-8622-37	Sequence 37, App1	353	APP
302	46.9	9	5	US-10-948-707-475	Sequence 475, App	354	APP
303	46.9	9	5	US-10-953-769-13	Sequence 13, App1	355	APP
304	46.9	9	5	US-11-055-119-66	Sequence 66, App1	356	APP
305	46.9	9	5	US-11-005-750-42	Sequence 402, App	357	APP
306	46.9	9	6	US-11-050-959-574	Sequence 98, App1	358	APP
307	46.9	9	6	US-11-050-959-575	Sequence 574, App1	359	APP
308	46.9	9	6	US-10-999-364-81	Sequence 23, App1	360	APP
309	46.9	9	6	US-10-953-769-13	Sequence 76, App1	361	APP
310	46.9	9	6	US-11-055-119-66	Sequence 66, App1	362	APP
311	46.9	9	6	US-11-005-750-48	Sequence 48, App1	363	APP
312	46.9	9	6	US-11-050-959-575	Sequence 5, App1	364	APP
313	46.9	9	6	US-11-082-595-23	Sequence 203, App	365	APP
314	46.9	9	6	US-10-999-364-81	Sequence 75, App1	366	APP
315	46.9	9	6	US-10-953-769-13	Sequence 77, App1	367	APP
316	46.9	9	7	US-09-911-838-77	Sequence 79, App1	368	APP
317	46.9	9	7	US-09-911-838-81	Sequence 81, App1	369	APP
318	46.9	9	7	US-09-753-139C-4	Sequence 4, App1	370	APP
319	46.9	9	7	US-09-911-838-75	Sequence 5, App1	371	APP
320	46.9	9	7	US-09-911-838-79	Sequence 280, App	372	APP
321	46.9	9	7	US-09-911-838-80	Sequence 80, App1	373	APP
322	46.9	9	7	US-09-911-838-80	Sequence 5, App1	374	APP
323	46.9	9	7	US-09-911-838-80	Sequence 203, App	375	APP
324	46.9	9	7	US-09-911-838-80	Sequence 75, App1	376	APP
325	46.9	9	7	US-09-911-838-80	Sequence 76, App1	377	APP
326	46.9	9	7	US-09-911-838-80	Sequence 78, App1	378	APP
327	46.9	9	7	US-09-911-838-80	Sequence 79, App1	379	APP
328	46.9	9	7	US-09-911-838-80	Sequence 76, App1	380	APP
329	46.9	9	7	US-09-911-838-80	Sequence 77, App1	381	APP
330	46.9	9	7	US-09-911-838-80	Sequence 78, App1	382	APP
331	46.9	9	7	US-09-911-838-80	Sequence 79, App1	383	APP
332	46.9	9	7	US-09-911-838-80	Sequence 80, App1	384	APP
333	46.9	9	7	US-09-911-838-80	Sequence 5, App1	385	APP
334	46.9	9	7	US-09-911-838-80	Sequence 203, App	386	APP
335	46.9	9	7	US-09-911-838-80	Sequence 75, App1	387	APP
336	46.9	9	7	US-09-911-838-80	Sequence 76, App1	388	APP
337	46.9	9	7	US-09-911-838-80	Sequence 77, App1	389	APP
338	46.9	9	7	US-09-911-838-80	Sequence 78, App1	390	APP
339	46.9	9	7	US-09-911-838-80	Sequence 79, App1	391	APP
340	46.9	9	7	US-09-911-838-80	Sequence 280, App	392	APP

393	22	44.9	US-11-051-411-530	Sequence 530, APP	9	4	US-10-001-469-854
394	22	44.9	US-11-051-411-597	Sequence 597, APP	466	21	42.9
395	22	44.9	US-11-051-411-671	Sequence 671, APP	467	21	42.9
396	22	44.9	US-11-051-411-673	Sequence 673, APP	468	21	42.9
397	22	44.9	US-11-051-411-891	Sequence 891, APP	469	21	42.9
398	22	44.9	US-11-051-411-1126	Sequence 1126, APP	470	21	42.9
399	22	44.9	US-11-051-411-1153	Sequence 1153, APP	471	21	42.9
400	22	44.9	US-11-051-411-1154	Sequence 1154, APP	472	21	42.9
401	22	44.9	US-11-051-411-1159	Sequence 1159, APP	473	21	42.9
402	22	44.9	US-11-051-411-1181	Sequence 1181, APP	474	21	42.9
403	22	44.9	US-11-051-411-1228	Sequence 1228, APP	475	21	42.9
404	22	44.9	US-11-051-411-1229	Sequence 1229, APP	476	21	42.9
405	22	44.9	US-11-051-411-1255	Sequence 1255, APP	477	21	42.9
406	22	44.9	US-11-051-411-1331	Sequence 1331, APP	478	21	42.9
407	22	44.9	US-11-051-411-1339	Sequence 1339, APP	479	21	42.9
408	22	44.9	US-11-051-411-1439	Sequence 1439, APP	480	21	42.9
409	22	44.9	US-11-051-411-1454	Sequence 1454, APP	481	21	42.9
410	21	42.9	US-10-051-411-1454	Sequence 61, APP	482	21	42.9
411	21	42.9	US-10-051-411-1455	Sequence 11, APP	483	21	42.9
412	21	42.9	US-10-051-411-1456	Sequence 11, APP	484	21	42.9
413	21	42.9	US-10-051-411-1457	Sequence 139, APP	485	21	42.9
414	21	42.9	US-10-051-411-1458	Sequence 1987, APP	486	21	42.9
415	21	42.9	US-10-051-411-1459	Sequence 1987, APP	487	21	42.9
416	21	42.9	US-10-051-411-1460	Sequence 7, APP	488	21	42.9
417	21	42.9	US-10-051-411-1461	Sequence 247, APP	489	21	42.9
418	21	42.9	US-10-051-411-1462	Sequence 247, APP	490	21	42.9
419	21	42.9	US-10-051-411-1463	Sequence 247, APP	491	21	42.9
420	21	42.9	US-10-051-411-1464	Sequence 247, APP	492	21	42.9
421	21	42.9	US-10-051-411-1465	Sequence 247, APP	493	21	42.9
422	21	42.9	US-10-051-411-1466	Sequence 247, APP	494	21	42.9
423	21	42.9	US-10-051-411-1467	Sequence 247, APP	495	21	42.9
424	21	42.9	US-10-051-411-1468	Sequence 247, APP	496	21	42.9
425	21	42.9	US-10-051-411-1469	Sequence 247, APP	497	21	42.9
426	21	42.9	US-10-051-411-1470	Sequence 247, APP	498	21	42.9
427	21	42.9	US-10-051-411-1471	Sequence 247, APP	499	21	42.9
428	21	42.9	US-10-051-411-1472	Sequence 634, APP	500	21	42.9
429	21	42.9	US-10-051-411-1473	Sequence 725, APP	501	21	42.9
430	21	42.9	US-10-051-411-1474	Sequence 726, APP	502	21	42.9
431	21	42.9	US-10-051-411-1475	Sequence 726, APP	503	21	42.9
432	21	42.9	US-10-051-411-1476	Sequence 726, APP	504	21	42.9
433	21	42.9	US-10-051-411-1477	Sequence 727, APP	505	21	42.9
434	21	42.9	US-10-051-411-1478	Sequence 634, APP	506	21	42.9
435	21	42.9	US-10-051-411-1479	Sequence 56, APP	507	21	42.9
436	21	42.9	US-10-051-411-1480	Sequence 8, APP	508	21	42.9
437	21	42.9	US-10-051-411-1481	Sequence 156, APP	509	21	42.9
438	21	42.9	US-10-051-411-1482	Sequence 1, APP	510	21	42.9
439	21	42.9	US-10-051-411-1483	Sequence 156, APP	511	21	42.9
440	21	42.9	US-10-051-411-1484	Sequence 226, APP	512	21	42.9
441	21	42.9	US-10-051-411-1485	Sequence 56, APP	513	21	42.9
442	21	42.9	US-10-051-411-1486	Sequence 8, APP	514	21	42.9
443	21	42.9	US-10-051-411-1487	Sequence 156, APP	515	21	42.9
444	21	42.9	US-10-051-411-1488	Sequence 157, APP	516	21	42.9
445	21	42.9	US-10-051-411-1489	Sequence 157, APP	517	21	42.9
446	21	42.9	US-10-051-411-1490	Sequence 171, APP	518	21	42.9
447	21	42.9	US-10-051-411-1491	Sequence 290, APP	519	21	42.9
448	21	42.9	US-10-051-411-1492	Sequence 156, APP	520	21	42.9
449	21	42.9	US-10-051-411-1493	Sequence 157, APP	521	21	42.9
450	21	42.9	US-10-051-411-1494	Sequence 158, APP	522	21	42.9
451	21	42.9	US-10-051-411-1495	Sequence 158, APP	523	21	42.9
452	21	42.9	US-10-051-411-1496	Sequence 159, APP	524	21	42.9
453	21	42.9	US-10-051-411-1497	Sequence 159, APP	525	21	42.9
454	21	42.9	US-10-051-411-1498	Sequence 159, APP	526	21	42.9
455	21	42.9	US-10-051-411-1499	Sequence 159, APP	527	21	42.9
456	21	42.9	US-10-051-411-1500	Sequence 159, APP	528	21	42.9
457	21	42.9	US-10-051-411-1501	Sequence 45, APP	529	21	42.9
458	21	42.9	US-10-051-411-1502	Sequence 56, APP	530	21	42.9
459	21	42.9	US-10-051-411-1503	Sequence 91, APP	531	21	42.9
460	21	42.9	US-10-051-411-1504	Sequence 157, APP	532	21	42.9
461	21	42.9	US-10-051-411-1505	Sequence 158, APP	533	21	42.9
462	21	42.9	US-10-051-411-1506	Sequence 171, APP	534	21	42.9
463	21	42.9	US-10-051-411-1507	Sequence 286, APP	535	21	42.9
464	21	42.9	US-10-051-411-1508	Sequence 447, APP	536	21	42.9
465	21	42.9	US-10-051-411-1509	Sequence 465, APP	537	21	42.9
				Sequence 493, APP	538	21	42.9

539	42.9	9	US-10-182-252A-1116	Sequence 1116, APP1	7	US-10-509-307-85
540	42.9	9	US-10-182-252A-1117	Sequence 1117, APP1	7	US-10-591-532-3
541	42.9	9	US-10-182-252A-1118	Sequence 1118, APP1	7	US-10-662-195-1579
542	42.9	9	US-10-182-252A-1119	Sequence 1119, APP1	7	US-10-618-779-62
543	42.9	9	US-10-182-252A-1120	Sequence 1120, APP1	7	US-10-833-203-39
544	42.9	9	US-10-182-252A-1121	Sequence 1121, APP1	8	US-10-694-639-26
545	42.9	9	US-10-182-252A-1122	Sequence 1122, APP1	8	US-10-226-007-491
546	42.9	9	US-10-182-252A-1123	Sequence 1123, APP1	8	US-10-224-999A-2605
547	42.9	9	US-10-182-252A-1124	Sequence 1124, APP1	8	US-10-224-999A-2605
548	42.9	9	US-10-182-252A-1125	Sequence 1125, APP1	8	US-10-224-999A-2607
549	42.9	9	US-10-182-252A-1126	Sequence 1126, APP1	8	US-10-224-999A-2748
550	42.9	9	US-10-182-252A-1127	Sequence 1127, APP1	8	US-10-224-999A-2749
551	42.9	9	US-10-182-252A-1128	Sequence 1128, APP1	8	US-10-224-999A-2750
552	42.9	9	US-10-182-252A-1129	Sequence 1129, APP1	8	US-10-357-999A-43
553	42.9	9	US-10-182-252A-1130	Sequence 1130, APP1	8	US-10-117-937-53
554	42.9	9	US-10-182-252A-1131	Sequence 1131, APP1	8	US-10-121-456A-4
555	42.9	9	US-10-182-252A-1263	Sequence 1263, APP1	8	US-10-657-022-53
556	42.9	9	US-10-182-252A-1264	Sequence 1264, APP1	8	US-10-809-790-8
557	42.9	9	US-10-182-252A-1265	Sequence 1265, APP1	8	US-10-950-163-138
558	42.9	9	US-10-182-252A-1266	Sequence 1266, APP1	8	US-10-950-163-139
559	42.9	9	US-10-182-252A-1267	Sequence 1267, APP1	8	US-10-950-163-140
560	42.9	9	US-10-182-252A-1268	Sequence 1268, APP1	8	US-10-950-163-141
561	42.9	9	US-10-182-252A-1269	Sequence 1269, APP1	8	US-10-862-195-144
562	42.9	9	US-10-182-252A-1270	Sequence 1270, APP1	8	US-11-167-064-53
563	42.9	9	US-10-182-252A-1271	Sequence 1271, APP1	8	US-11-051-411-405
564	42.9	9	US-10-182-252A-1272	Sequence 1272, APP1	8	US-11-051-411-405
565	42.9	9	US-10-182-252A-1273	Sequence 1273, APP1	8	US-11-067-159-53
566	42.9	9	US-10-182-252A-1274	Sequence 1274, APP1	8	US-10-950-163-142
567	42.9	9	US-10-182-252A-1275	Sequence 1275, APP1	8	US-10-950-163-143
568	42.9	9	US-10-182-252A-1276	Sequence 1276, APP1	8	US-10-950-163-144
569	42.9	9	US-10-182-252A-1277	Sequence 1277, APP1	8	US-10-950-163-145
570	42.9	9	US-10-182-252A-1278	Sequence 1278, APP1	8	US-10-950-163-146
571	42.9	9	US-10-182-252A-1279	Sequence 1279, APP1	8	US-10-950-163-147
572	40.8	5	US-10-648-780-157	Sequence 157, APP1	20	40.8
573	40.8	5	US-10-648-780-158	Sequence 158, APP1	20	40.8
574	40.8	5	US-10-648-780-159	Sequence 159, APP1	20	40.8
575	40.8	5	US-10-862-195-291	Sequence 291, APP1	20	40.8
576	40.8	5	US-10-862-195-295	Sequence 295, APP1	20	40.8
577	40.8	5	US-10-862-195-299	Sequence 299, APP1	20	40.8
578	40.8	5	US-10-862-195-304	Sequence 304, APP1	20	40.8
579	40.8	5	US-10-862-195-305	Sequence 305, APP1	20	40.8
580	40.8	5	US-10-862-195-306	Sequence 306, APP1	20	40.8
581	40.8	5	US-10-862-195-307	Sequence 307, APP1	20	40.8
582	40.8	5	US-10-862-195-308	Sequence 308, APP1	20	40.8
583	40.8	5	US-10-862-195-309	Sequence 309, APP1	20	40.8
584	40.8	5	US-10-862-195-310	Sequence 310, APP1	20	40.8
585	40.8	5	US-10-862-195-311	Sequence 311, APP1	20	40.8
586	40.8	5	US-10-862-195-312	Sequence 312, APP1	20	40.8
587	40.8	5	US-10-862-195-313	Sequence 313, APP1	20	40.8
588	40.8	5	US-10-862-195-314	Sequence 314, APP1	20	40.8
589	40.8	5	US-10-862-195-315	Sequence 315, APP1	20	40.8
590	40.8	5	US-10-862-195-316	Sequence 316, APP1	20	40.8
591	40.8	5	US-10-862-195-317	Sequence 317, APP1	20	40.8
592	40.8	5	US-10-862-195-318	Sequence 318, APP1	20	40.8
593	40.8	5	US-10-862-195-319	Sequence 319, APP1	20	40.8
594	40.8	5	US-10-862-195-320	Sequence 320, APP1	20	40.8
595	40.8	5	US-10-862-195-321	Sequence 321, APP1	20	40.8
596	40.8	5	US-10-862-195-322	Sequence 322, APP1	20	40.8
597	40.8	5	US-10-862-195-323	Sequence 323, APP1	20	40.8
598	40.8	5	US-10-862-195-324	Sequence 324, APP1	20	40.8
599	40.8	5	US-10-862-195-325	Sequence 325, APP1	20	40.8
600	40.8	5	US-10-862-195-326	Sequence 326, APP1	20	40.8
601	40.8	5	US-10-862-195-327	Sequence 327, APP1	20	40.8
602	40.8	5	US-10-862-195-328	Sequence 328, APP1	20	40.8
603	40.8	5	US-10-862-195-329	Sequence 329, APP1	20	40.8
604	40.8	5	US-10-862-195-330	Sequence 330, APP1	20	40.8
605	40.8	5	US-10-862-195-331	Sequence 331, APP1	20	40.8
606	40.8	5	US-10-862-195-332	Sequence 332, APP1	20	40.8
607	40.8	5	US-10-862-195-333	Sequence 333, APP1	20	40.8
608	40.8	5	US-10-862-195-334	Sequence 334, APP1	20	40.8
609	40.8	5	US-10-862-195-335	Sequence 335, APP1	20	40.8
610	40.8	5	US-10-862-195-336	Sequence 336, APP1	20	40.8
611	40.8	5	US-10-862-195-337	Sequence 337, APP1	20	40.8

685	20	40.8	US-10-671-207-9	Sequence 9, App1	19	30.8	US-10-352-786-266
686	20	40.8	US-10-685-977-14	Sequence 14, App1	758	7	US-10-352-786-268
687	20	40.8	US-10-760-005-116	Sequence 11, App1	759	7	US-10-352-786-270
688	20	40.8	US-10-673-10-9	Sequence 9, App1	760	7	US-10-460-594-23
689	20	40.8	US-10-338-289-306	Sequence 306, App1	761	7	US-10-258-146A-16
690	20	40.8	US-10-607-555-249	Sequence 249, App1	762	7	US-10-258-146A-122
691	20	40.8	US-10-671-412-9	Sequence 9, App1	763	7	US-10-258-146A-156
692	20	40.8	US-10-671-853-9	Sequence 9, App1	764	7	US-10-423-543-512
693	20	40.8	US-10-671-106-9	Sequence 9, App1	765	7	US-10-423-543-512
694	20	40.8	US-10-671-106-9	Sequence 9, App1	766	7	US-10-328-953-191
695	20	40.8	US-10-948-70-425	Sequence 425, App1	767	7	US-10-328-953-267
696	20	40.8	US-10-390-137-7	Sequence 7, App1	768	7	US-10-328-953-301
697	20	40.8	US-11-067-064-47	Sequence 47, App1	769	7	US-10-610-927-7
701	20	40.8	US-11-067-064-51	Sequence 51, App1	770	7	US-10-610-927-10
702	20	40.8	US-11-067-159-243	Sequence 243, App1	771	7	US-10-610-927-12
703	19.5	39.8	US-10-149-13A-465	Sequence 465, App1	772	7	US-10-610-927-13
704	19	38.8	US-09-972-05A-10	Sequence 10, App1	773	7	US-10-610-927-13
699	20	40.8	US-11-066-687-1346	Sequence 1346, App1	774	7	US-10-610-927-14
700	20	40.8	US-11-067-159-47	Sequence 47, App1	775	7	US-10-610-927-15
701	20	40.8	US-11-067-159-51	Sequence 51, App1	776	7	US-10-610-927-16
702	20	40.8	US-11-067-159-243	Sequence 243, App1	777	7	US-10-258-144-81
698	20	40.8	US-11-067-064-243	Sequence 10, App1	778	7	US-10-258-144-157
705	19	38.8	US-10-099-895-25	Sequence 10, App1	779	7	US-10-258-144-191
706	19	38.8	US-10-185-050-233	Sequence 233, App1	780	7	US-10-663-407-18
707	19	38.8	US-10-223-172A-10	Sequence 10, App1	781	7	US-10-613-380-29
708	19	38.8	US-10-224-999A-10	Sequence 10, App1	782	7	US-10-912-512-86
709	19	38.8	US-10-552-786-129	Sequence 12, App1	783	7	US-10-912-512-288
710	19	38.8	US-10-663-407-10	Sequence 10, App1	784	7	US-10-258-144-191
711	19	38.8	US-10-705-195-30	Sequence 30, App1	785	7	US-10-235-043-39
712	19	38.8	US-10-653-708-8	Sequence 8, App1	786	7	US-10-613-380-20
713	19	38.8	US-10-553-706-9	Sequence 9, App1	787	7	US-10-862-195-1512
714	19	38.8	US-09-973-106B-10	Sequence 10, App1	788	7	US-10-820-167A-301
715	19	38.8	US-10-972-05A-12	Sequence 12, App1	789	7	US-10-912-512-577
716	19	38.8	US-10-663-407-10	Sequence 10, App1	790	7	US-10-820-067A-511
717	19	38.8	US-10-705-195-30	Sequence 30, App1	791	7	US-09-879-036-19
718	19	38.8	US-10-653-708-8	Sequence 8, App1	792	7	US-09-879-036-20
719	19	38.8	US-10-553-706-9	Sequence 9, App1	793	7	US-10-136-334-17
720	19	38.8	US-09-973-106B-10	Sequence 10, App1	794	7	US-10-235-552-6
721	19	38.8	US-10-972-05A-12	Sequence 12, App1	795	7	US-10-820-283-638-21
722	19	38.8	US-10-317-251A-392	Sequence 392, App1	796	7	US-10-126-007-26
723	19	38.8	US-10-223-172A-12	Sequence 12, App1	797	7	US-10-226-007-478
724	19	38.8	US-10-315-96A-392	Sequence 392, App1	798	7	US-10-052-578-23
725	19	38.8	US-10-315-96A-393	Sequence 12, App1	799	7	US-10-052-778-94
726	19	38.8	US-10-317-251A-392	Sequence 195, App1	800	7	US-10-233-172A-20
727	19	38.8	US-10-355-786-197	Sequence 197, App1	801	7	US-10-283-123-165
728	19	38.8	US-10-407-12	Sequence 21, App1	802	7	US-10-053-120-23
729	19	38.8	US-10-512-764-21	Sequence 393, App1	803	7	US-10-053-520-94
730	19	38.8	US-10-184-771-15	Sequence 15, App1	804	7	US-10-175-70-10
731	19	38.8	US-10-324-999A-195	Sequence 12, App1	805	7	US-10-224-999A-2604
732	19	38.8	US-10-552-766-195	Sequence 195, App1	806	7	US-10-008-524A-26
733	19	38.8	US-10-355-786-197	Sequence 197, App1	807	7	US-10-224-999A-747
734	19	38.8	US-10-663-407-12	Sequence 21, App1	808	7	US-10-008-524A-22
735	19	38.8	US-10-312-764-21	Sequence 15, App1	809	7	US-10-053-498B-94
736	19	38.8	US-11-064-196-15	Sequence 15, App1	810	7	US-10-181-546-1
737	19	38.8	US-11-066-697-1217	Sequence 12, App1	811	7	US-10-350-719-22
738	19	38.8	US-08-769-250A-15	Sequence 16, App1	812	7	US-10-350-719-23
739	19	38.8	US-08-769-250A-16	Sequence 6, App1	813	7	US-10-350-719-24
740	19	38.8	US-09-794-980-6	Sequence 12, App1	814	7	US-10-213-165
741	19	38.8	US-09-947-137-12	Sequence 27, App1	815	7	US-10-053-498B-23
742	19	38.8	US-09-972-05A-18	Sequence 18, App1	816	7	US-10-350-719-25
743	19	38.8	US-09-954-388-39	Sequence 39, App1	817	7	US-10-350-719-26
744	19	38.8	US-09-954-388-86	Sequence 86, App1	818	7	US-10-350-719-27
745	19	38.8	US-09-954-385-208	Sequence 208, App1	819	7	US-10-350-719-28
746	19	38.8	US-10-052-578-188	Sequence 188, App1	820	7	US-10-350-719-29
747	19	38.8	US-10-052-578-264	Sequence 264, App1	821	7	US-10-442-909-64
748	19	38.8	US-10-052-578-298	Sequence 298, App1	822	7	US-10-442-909-65
749	19	38.8	US-10-223-172A-18	Sequence 18, App1	823	7	US-10-352-786-339
750	19	38.8	US-10-286-417-220	Sequence 220, App1	824	7	US-10-352-786-341
751	19	38.8	US-10-053-520-188	Sequence 188, App1	825	7	US-10-352-786-345
752	19	38.8	US-10-053-520-264	Sequence 264, App1	826	7	US-10-352-786-345
753	19	38.8	US-10-053-520-298	Sequence 298, App1	827	7	US-10-442-909-64
754	19	38.8	US-10-224-999A-18	Sequence 18, App1	828	7	US-10-442-909-65
755	19	38.8	US-10-053-498B-184	Sequence 188, App1	829	7	US-10-328-553-104
756	19	38.8	US-10-053-498B-264	Sequence 264, App1	830	7	US-10-328-553-108
757	19	38.8	US-10-053-498B-298	Sequence 298, App1	831	7	US-10-0663-407-20

831	19	38.8	US-10-736-048-165	Sequence 165, App	9	38.8	US-10-280-340-11
832	19	38.8	US-10-714-45-1138	Sequence 1138, App	9	38.8	US-10-280-340-467
833	19	38.8	US-10-654-601-8	Sequence 8, Appli	9	38.8	US-10-280-340-552
834	19	38.8	US-10-654-601-201	Sequence 201, App	9	38.8	US-10-334-726-35
835	19	38.8	US-10-654-601-1326	Sequence 1326, App	9	38.8	US-10-334-726-187
836	19	38.8	US-10-773-012-1138	Sequence 1138, App	9	38.8	US-10-334-726-223
837	19	38.8	US-10-835-405-2	Sequence 2, Appli	9	38.8	US-10-371-069-370
838	19	38.8	US-10-862-195-157	Sequence 157, App	9	38.8	US-10-371-069-404
839	19	38.8	US-10-862-195-1511	Sequence 1511, App	9	38.8	US-10-371-645-370
840	19	38.8	US-10-876-521-B-232	Sequence 232, App	9	38.8	US-10-371-645-404
841	19	38.8	US-10-876-521B-308	Sequence 308, App	9	38.8	US-10-352-786-419
842	19	38.8	US-10-776-521B-342	Sequence 342, App	9	38.8	US-10-352-786-421
843	19	38.8	US-10-820-067A-414	Sequence 414, App	9	38.8	US-10-352-786-424
844	19	38.8	US-10-820-067A-448	Sequence 448, App	9	38.8	US-10-352-786-425
845	19	38.8	US-10-820-067A-742	Sequence 742, App	9	38.8	US-10-245-871-288
846	19	38.8	US-10-820-067A-818	Sequence 818, App	9	38.8	US-10-442-909-118
847	19	38.8	US-10-820-067A-852	Sequence 852, App	9	38.8	US-10-057-475B-10923
848	19	38.8	US-10-806-062-191	Sequence 191, App	9	38.8	US-10-352-786-424
849	19	38.8	US-08-801-405B-4	Sequence 4, Appli	9	38.8	US-10-154-884B-10870
850	19	38.8	US-08-854-825-43	Sequence 43, Appli	9	38.8	US-10-154-884B-10923
851	19	38.8	US-08-820-067A-448	Sequence 17, Appli	9	38.8	US-10-245-871-288
852	19	38.8	US-09-065-902-17	Sequence 742, App	9	38.8	US-10-352-786-419
853	19	38.8	US-09-061-294-37	Sequence 37, Appli	9	38.8	US-10-352-786-421
854	19	38.8	US-09-084-018-170	Sequence 170, App	9	38.8	US-10-352-786-421
855	19	38.8	US-09-094-018-332	Sequence 332, App	9	38.8	US-10-352-786-421
856	19	38.8	US-09-073-831-7	Sequence 7, Appli	9	38.8	US-10-352-786-421
857	19	38.8	US-09-097-035A-24	Sequence 24, Appli	9	38.8	US-10-352-786-421
858	19	38.8	US-09-017-743C-11	Sequence 11, Appli	9	38.8	US-10-352-786-421
859	19	38.8	US-09-017-743C-76	Sequence 76, Appli	9	38.8	US-10-352-786-421
860	19	38.8	US-09-017-743C-77	Sequence 77, Appli	9	38.8	US-10-352-786-421
861	19	38.8	US-09-017-743C-78	Sequence 5, Appli	9	38.8	US-10-352-786-421
862	19	38.8	US-09-035-440-11	Sequence 11, Appli	9	38.8	US-10-352-786-421
863	19	38.8	US-09-035-440-467	Sequence 467, App	9	38.8	US-10-352-786-421
864	19	38.8	US-09-035-440-552	Sequence 552, App	9	38.8	US-10-352-786-421
865	19	38.8	US-09-083-802-312	Sequence 312, App	9	38.8	US-10-352-786-421
866	19	38.8	US-09-017-743C-77	Sequence 4, Appli	9	38.8	US-10-352-786-421
867	19	38.8	US-09-017-743C-78	Sequence 1, Appli	9	38.8	US-10-352-786-421
868	19	38.8	US-09-084-440-312	Sequence 312, App	9	38.8	US-10-352-786-421
869	19	38.8	US-09-095-440-552	Sequence 39, Appli	9	38.8	US-10-352-786-421
870	19	38.8	US-09-083-802-312	Sequence 43, Appli	9	38.8	US-10-352-786-421
871	19	38.8	US-09-017-743C-77	Sequence 11, Appli	9	38.8	US-10-352-786-421
872	19	38.8	US-09-017-743C-78	Sequence 20, Appli	9	38.8	US-10-352-786-421
873	19	38.8	US-09-017-743C-79	Sequence 297, App	9	38.8	US-10-352-786-421
874	19	38.8	US-10-094-659-50	Sequence 50, Appli	9	38.8	US-10-352-786-421
875	19	38.8	US-10-062-710-59	Sequence 59, Appli	9	38.8	US-10-352-786-421
876	19	38.8	US-10-026-007-479	Sequence 479, App	9	38.8	US-10-352-786-421
877	19	38.8	US-10-054-446A-109	Sequence 109, App	9	38.8	US-10-352-786-421
878	19	38.8	US-10-023-172A-24	Sequence 24, App	9	38.8	US-10-352-786-421
879	19	38.8	US-10-023-172A-27	Sequence 27, App	9	38.8	US-10-352-786-421
880	19	38.8	US-10-116-118-47	Sequence 47, App	9	38.8	US-10-352-786-421
881	19	38.8	US-10-062-710-59	Sequence 37, App	9	38.8	US-10-352-786-421
882	19	38.8	US-10-062-109A-33	Sequence 33, App	9	38.8	US-10-352-786-421
883	19	38.8	US-10-062-109A-287	Sequence 287, App	9	38.8	US-10-352-786-421
884	19	38.8	US-10-022-109A-366	Sequence 368, App	9	38.8	US-10-352-786-421
885	19	38.8	US-10-062-109A-654	Sequence 654, App	9	38.8	US-10-352-786-421
886	19	38.8	US-10-022-056-341	Sequence 3, Appli	9	38.8	US-10-352-786-421
887	19	38.8	US-10-022-056-37	Sequence 384, App	9	38.8	US-10-352-786-421
888	19	38.8	US-10-062-109A-33	Sequence 33, App	9	38.8	US-10-352-786-421
889	19	38.8	US-10-022-109A-24	Sequence 227, App	9	38.8	US-10-352-786-421
890	19	38.8	US-10-022-109A-27	Sequence 269, App	9	38.8	US-10-352-786-421
891	19	38.8	US-10-022-109A-2752	Sequence 2752, App	9	38.8	US-10-352-786-421
892	19	38.8	US-10-022-109A-654	Sequence 654, App	9	38.8	US-10-352-786-421
893	19	38.8	US-10-022-109A-24	Sequence 11, Appli	9	38.8	US-10-352-786-421
894	19	38.8	US-10-022-109A-27	Sequence 20, Appli	9	38.8	US-10-352-786-421
895	19	38.8	US-10-022-109A-33	Sequence 33, Appli	9	38.8	US-10-352-786-421
896	19	38.8	US-10-022-109A-287	Sequence 287, App	9	38.8	US-10-352-786-421
897	19	38.8	US-10-005-480A-368	Sequence 368, App	9	38.8	US-10-352-786-421
898	19	38.8	US-10-005-480A-654	Sequence 654, App	9	38.8	US-10-352-786-421
899	19	38.8	US-10-022-109A-24	Sequence 11, Appli	9	38.8	US-10-352-786-421
900	19	38.8	US-10-022-109A-27	Sequence 20, Appli	9	38.8	US-10-352-786-421
901	19	38.8	US-10-022-109A-33	Sequence 33, Appli	9	38.8	US-10-352-786-421
902	19	38.8	US-10-022-109A-287	Sequence 287, App	9	38.8	US-10-352-786-421
903	19	38.8	US-10-022-109A-654	Sequence 654, App	9	38.8	US-10-352-786-421
904	19	38.8	US-10-022-109A-27	Sequence 27, App	9	38.8	US-10-352-786-421
905	19	38.8	US-10-022-109A-33	Sequence 33, App	9	38.8	US-10-352-786-421
906	19	38.8	US-10-022-109A-287	Sequence 287, App	9	38.8	US-10-352-786-421
907	19	38.8	US-10-022-109A-654	Sequence 654, App	9	38.8	US-10-352-786-421
908	19	38.8	US-10-022-109A-27	Sequence 27, App	9	38.8	US-10-352-786-421
909	19	38.8	US-10-022-109A-33	Sequence 33, App	9	38.8	US-10-352-786-421
910	19	38.8	US-10-022-109A-287	Sequence 287, App	9	38.8	US-10-352-786-421
911	19	38.8	US-10-022-109A-654	Sequence 654, App	9	38.8	US-10-352-786-421
912	19	38.8	US-10-022-109A-27	Sequence 27, App	9	38.8	US-10-352-786-421
913	19	38.8	US-10-022-109A-33	Sequence 33, App	9	38.8	US-10-352-786-421
914	19	38.8	US-10-022-109A-287	Sequence 287, App	9	38.8	US-10-352-786-421
915	19	38.8	US-10-022-109A-654	Sequence 654, App	9	38.8	US-10-352-786-421
916	19	38.8	US-10-022-109A-27	Sequence 27, App	9	38.8	US-10-352-786-421
917	19	38.8	US-10-022-109A-33	Sequence 33, App	9	38.8	US-10-352-786-421
918	19	38.8	US-10-022-109A-287	Sequence 287, App	9	38.8	US-10-352-786-421
919	19	38.8	US-10-022-109A-654	Sequence 654, App	9	38.8	US-10-352-786-421
920	19	38.8	US-10-022-109A-27	Sequence 27, App	9	38.8	US-10-352-786-421
921	19	38.8	US-10-022-109A-33	Sequence 33, App	9	38.8	US-10-352-786-421
922	19	38.8	US-10-022-109A-287	Sequence 287, App	9	38.8	US-10-352-786-421
923	19	38.8	US-10-022-109A-654	Sequence 654, App	9	38.8	US-10-352-786-421
924	19	38.8	US-10-022-109A-27	Sequence 27, App	9	38.8	US-10-352-786-421
925	19	38.8	US-10-022-109A-33	Sequence 33, App	9	38.8	US-10-352-786-421
926	19	38.8	US-10-022-109A-287	Sequence 287, App	9	38.8	US-10-352-786-421
927	19	38.8	US-10-022-109A-654	Sequence 654, App	9	38.8	US-10-352-786-421
928	19	38.8	US-10-022-109A-27	Sequence 27, App	9	38.8	US-10-352-786-421
929	19	38.8	US-10-022-109A-33	Sequence 33, App	9	38.8	US-10-352-786-421
930	19	38.8	US-10-022-109A-287	Sequence 287, App	9	38.8	US-10-352-786-421
931	19	38.8	US-10-022-109A-654	Sequence 654, App	9	38.8	US-10-352-786-421
932	19	38.8	US-10-022-109A-27	Sequence 27, App	9	38.8	US-10-352-786-421
933	19	38.8	US-10-022-109A-33	Sequence 33, App	9	38.8	US-10-352-786-421
934	19	38.8	US-10-022-109A-287	Sequence 287, App	9	38.8	US-10-352-786-421
935	19	38.8	US-10-022-109A-654	Sequence 654, App	9	38.8	US-10-352-786-421
936	19	38.8	US-10-022-109A-27	Sequence 27, App	9	38.8	US-10-352-786-421
937	19	38.8	US-10-022-109A-33	Sequence 33, App	9	38.8	US-10-352-786-421
938	19	38.8	US-10-022-109A-287	Sequence 287, App	9	38.8	US-10-352-786-421
939	19	38.8	US-10-022-109A-654	Sequence 654, App	9	38.8	US-10-352-786-421
940	19	38.8	US-10-022-109A-27	Sequence 27, App	9	38.8	US-10-352-786-421
941	19	38.8	US-10-022-109A-33	Sequence 33, App	9	38.8	US-10-352-786-421
942	19	38.8	US-10-022-109A-287	Sequence 287, App	9	38.8	US-10-352-786-421
943	19	38.8	US-10-022-109A-654	Sequence 654, App	9	38.8	US-10-352-

977	38.8	9	4	US-10-114-669-5274	Sequence 5274 , AP
978	38.8	9	4	US-10-114-669-5275	Sequence 5275 , AP
979	38.8	9	4	US-10-114-669-5317	Sequence 5317 , AP
980	38.8	9	4	US-10-114-669-5327	Sequence 5327 , AP
981	38.8	9	4	US-10-114-669-5350	Sequence 5350 , AP
982	38.8	9	4	US-10-114-669-5354	Sequence 5354 , AP
983	38.8	9	4	US-10-114-669-5365	Sequence 5365 , AP
984	38.8	9	4	US-10-114-669-5385	Sequence 5385 , AP
985	38.8	9	4	US-10-114-669-5404	Sequence 5404 , AP
986	38.8	9	4	US-10-114-669-5418	Sequence 5418 , AP
987	38.8	9	4	US-10-114-669-5430	Sequence 5430 , AP
988	38.8	9	4	US-10-114-669-5431	Sequence 5431 , AP
989	38.8	9	4	US-10-114-669-5471	Sequence 5471 , AP
990	38.8	9	4	US-10-114-669-5493	Sequence 5493 , AP
991	38.8	9	4	US-10-114-669-5494	Sequence 5494 , AP
992	38.8	9	4	US-10-114-669-5495	Sequence 5495 , AP
993	38.8	9	4	US-10-114-669-5535	Sequence 5535 , AP
994	38.8	9	4	US-10-114-669-5548	Sequence 5548 , AP
995	38.8	9	4	US-10-114-669-5568	Sequence 5568 , AP
996	38.8	9	4	US-10-114-669-5609	Sequence 5569 , AP
997	38.8	9	4	US-10-114-669-5616	Sequence 5609 , AP
998	38.8	9	4	US-10-365-761B-75	Sequence 5616 , AP
999	38.8	9	4	US-10-620-462-5	Sequence 5 , APP1
1.000	38.8	9	4	US-10-620-462-5	Sequence 5 , APP1

ALIGNMENTS

SUIT 1
-10-447-161-98
Sequence 98, Application US/10447161
Publication No. US20040023314A1

GENERAL INFORMATION:

APPLICANT: Wang, Rong-fu
TITLE OF INVENTION: Mutant Fibronectin and Tumor Metastasis
FILE REFERENCE: HO/P02484US1
CURRENT APPLICATION NUMBER: US/10/447,161
CURRENT FILING DATE: 2003-05-28
PRIOR APPLICATION NUMBER: 60/583,530
PRIOR FILING DATE: 2002-05-28
NUMBER OF SEQ ID NOS: 148
SOFTWARE: PatentIn version 3.1
SEQ ID NO: 98
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Peptide

```

; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US/09/321,346
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-05-27
; NUMBER OF SEQ ID NOS: 114
; SOFTWARE: FastSEQ for Windows Version 3.0
SEQ ID NO 55
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-909-460-55

Query Match          79.6%; Score 39; DB 3e+06; Length 9;
Best Local Similarity 77.8%; Pred. No. 1.7e+06;
Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0
Qy      1 STAPPYHNV 9
          ||||| |
          1 STAPPAHGV 9
Db

RESULT 3
US-09-872-836-55
; Sequence 55, Application US/09872836
; Publication No. US20040142475A1
; GENERAL INFORMATION:
; APPLICANT: Barman, Shikha P.
; APPLICANT: McKeever, Una
; APPLICANT: Heddle, Mary Lynne
; TITLE OF INVENTION: DELIVERY SYSTEMS FOR BIOACTIVE AGENTS
; FILE REFERENCE: 08191-018001
; CURRENT APPLICATION NUMBER: US/09/872,836
; CURRENT FILING DATE: 2001-06-01
; PRIOR APPLICATION NUMBER: US 60/208,830
; PRIOR FILING DATE: 2000-05-02
; NUMBER OF SEQ ID NOS: 120
; SOFTWARE: FastSEQ for Windows Version 4.0
SEQ ID NO 55
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-872-836-55

Query Match          79.6%; Score 39; DB 3e+06; Length 9;
Best Local Similarity 77.8%; Pred. No. 1.7e+06;
Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0
Qy      1 STAPPYHNV 9
          ||||| |
          1 STAPPAHGV 9
Db

RESULT 4
US-10-447-161-97
; Sequence 97, Application US/10447161
; Publication No. US2004023314A1
; GENERAL INFORMATION:
; APPLICANT: Wang, Rong-fu
; TITLE OF INVENTION: Mutant Fibronectin and Tumor Metastasis
; FILE REFERENCE: HO-PO2484US1
; CURRENT APPLICATION NUMBER: US/10/447,161
; CURRENT FILING DATE: 2003-05-28
; PRIOR APPLICATION NUMBER: 60/383,530
; PRIOR FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 148
; SOFTWARE: PatentIn version 3.1
SEQ ID NO 97
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Peptide
US-10-447-161-97

Query Match          79.6%; Score 39; DB 4; Length 9;

```

Best Local Similarity 77.8%; Pred. No. 1.7e+06; 0; Mismatches 2; Indels 0; Gaps 0; Db 1 STAPPAHGV 9

Qy 1 STAPPVHN 9
Db 1 STAPPAHGV 9

RESULT 5
US-10-296-317-44
Sequence 44, Application US/10296317
Publication No. US20040057968A1
GENERAL INFORMATION:
APPLICANT: CEBI-SCI Corp
TITLE OF INVENTION: T CELL BINDING LIGAND PEPTIDES, PEPTIDE
FILE REFERENCE: CS-112
CURRENT APPLICATION NUMBER: US/10/296,317
CURRENT FILING DATE: 2002-11-22
PRIOR APPLICATION NUMBER: US 60/206548
PRIOR FILING DATE: 2000-05-24
PRIOR APPLICATION NUMBER: PCT/US07/16793
PRIOR FILING DATE: 2001-05-24
NUMBER OF SEQ ID NOS: 96
SOFTWARE: PatentIn version 3.1
SEQ ID NO 44
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Muc1 Peptide Mb
US-10-296-317-44

Qy 1 STAPPVHN 9
Db 1 STAPPAHGV 9

Query Match Score 39; DB 4; Length 9;
Best Local Similarity 77.8%; Pred. No. 1.7e+06; 0; Mismatches 2; Indels 0; Gaps 0;

RESULT 7
US-10-751-845-9
Sequence 9, Application US/10751845
Publication No. US20050100928A1
GENERAL INFORMATION:
APPLICANT: Hedley, Mary Lynne
APPLICANT: Urban, Robert G.
APPLICANT: Chicz, Roman M.
TITLE OF INVENTION: NUCLEIC ACIDS ENCODING POLYPEPTIDE POLYPEPTIDES
FILE REFERENCE: 08191-013001
CURRENT APPLICATION NUMBER: US/10/751,845
CURRENT FILING DATE: 2004-01-05
PRIOR APPLICATION NUMBER: US/09/664,225
PRIOR FILING DATE: 2000-08-18
PRIOR APPLICATION NUMBER: US 60/169,846
PRIOR FILING DATE: 1999-12-09
PRIOR APPLICATION NUMBER: US 60/154,665
PRIOR FILING DATE: 1999-09-16
NUMBER OF SEQ ID NOS: 163
SOFTWARE: FastSEQ for Windows Version 4.0
SEQ ID NO 9
LENGTH: 9
TYPE: PRT
ORGANISM: Homo sapiens
US-10-751-845-9

Query Match Score 39; DB 5; Length 9;
Best Local Similarity 77.8%; Pred. No. 1.7e+06; 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 STAPPVHN 9
Db 1 STAPPAHGV 9

RESULT 8
US-10-973-927-19
Sequence 19, Application US/10973927
Publication No. US20050215501A1
GENERAL INFORMATION:
APPLICANT: Lipford, Grayson
APPLICANT: Whinrant, John
TITLE OF INVENTION: METHODS AND PRODUCTS FOR ENHANCING EPITOPE SPREADING
FILE REFERENCE: C1037.70054US01
CURRENT APPLICATION NUMBER: US/10/973,927
CURRENT FILING DATE: 2004-10-25
PRIOR APPLICATION NUMBER: US 60/514,255
PRIOR FILING DATE: 2003-10-24
NUMBER OF SEQ ID NOS: 40
SEQ ID NO 19
SOFTWARE: PatentIn version 3.3
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial sequence
FEATURE:
OTHER INFORMATION: Synthetic peptide
US-10-973-927-19

Query Match Score 37; DB 5; Length 8;
Best Local Similarity 75.5%; Pred. No. 1.7e+06; 1; Mismatches 1; Indels 0; Gaps 0;

Qy 2 TAPPVHN 9
Db 1 STPPVHN 8

RESULT 9
US-09-994-466-10
Sequence 10, Application US/09994466

Qy 1 STAPPVHN 9
Db 1 STAPPVHN 9

Query Match Score 39; DB 5; Length 9;
Best Local Similarity 77.8%; Pred. No. 1.7e+06; 2; Indels 0; Gaps 0;

Qy 1 STAPPVHN 9
Db 1 STAPPVHN 9

Publication No. US20020132771A1
 GENERAL INFORMATION:
 APPLICANT: Madiyalakan, R.
 TITLE OF INVENTION: THERAPEUTIC BINDING AGENTS AGAINST MUC-1 ANTIGEN AND METHODS FOR
 TREATMENT OF TUMORS
 FILE REFERENCE: ALEX_P03_002
 CURRENT APPLICATION NUMBER: US/09/994,466
 CURRENT FILING DATE: 2001-11-26
 PRIOR APPLICATION NUMBER: US/724094
 PRIOR FILING DATE: 2000-11-28
 NUMBER OF SEQ ID NOS: 11
 SOFTWARE: PatentIn version 3.2
 SEQ ID NO: 10
 LENGTH: 8
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-09-994-466-10

Query Match Score 65.3%; Length 8;
 Best Local Similarity 71.4%; Pred. No. 1.7e+06;
 Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 STAPPVH 7
 Db 2 TIAPPAH 8

RESULT 10
 US-10-080-013-20
 Sequence 20, Application US/10080013
 Publication No. US20030077248A1
 GENERAL INFORMATION:
 APPLICANT: Moriarty, Ann
 APPLICANT: Leturcq, Didier
 APPLICANT: Degraw, Juli
 APPLICANT: Heiskala, Maria
 APPLICANT: Peterson, Per
 APPLICANT: Jackson, Michael
 TITLE OF INVENTION: A CELL THERAPY METHOD FOR THE TREATMENT OF TUMORS
 FILE REFERENCE: ORT-1557
 CURRENT APPLICATION NUMBER: US/10/080,013
 CURRENT FILING DATE: 2002-02-19
 NUMBER OF SEQ ID NOS: 42
 SOFTWARE: PatentIn version 3.1
 SEQ ID NO: 20
 LENGTH: 8
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-10-080-013-20

Query Match Score 64.3%; Length 8;
 Best Local Similarity 88.9%; Pred. No. 1.7e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 1; Gaps 1;

Qy 1 STAPPVH 9
 Db 1 STA-PVHN 8

RESULT 11
 US-10-289-566-20
 Sequence 20, Application US/10289566
 Publication No. US20040071671A1
 GENERAL INFORMATION:
 APPLICANT: Leturcq, Didier J.
 APPLICANT: Moriarty, Ann M.
 APPLICANT: Jackson, Michael R.
 APPLICANT: Peterson, Per A.
 APPLICANT: Richards, Jon M.
 TITLE OF INVENTION: A CELL THERAPY METHOD FOR THE TREATMENT OF TUMORS
 FILE REFERENCE: ORT-132CIP
 CURRENT APPLICATION NUMBER: US/10/289,566
 CURRENT FILING DATE: 2002-11-07

Query Match Score 64.3%; Length 8;
 Best Local Similarity 88.9%; Pred. No. 1.7e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 1; Gaps 1;

Qy 1 STAPPVH 9
 Db 1 STA-PVHN 8

RESULT 12
 US-09-994-466-7
 Sequence 7, Application US/0994466
 Publication No. US20020132771A1
 GENERAL INFORMATION:
 APPLICANT: Madiyalakan, R.
 TITLE OF INVENTION: THERAPEUTIC BINDING AGENTS AGAINST MUC-1 ANTIGEN AND METHODS FOR
 TREATMENT OF TUMORS
 FILE REFERENCE: AREX_P03-002
 CURRENT APPLICATION NUMBER: US/09/994,466
 CURRENT FILING DATE: 2001-11-26
 PRIOR APPLICATION NUMBER: 09/724094
 PRIOR FILING DATE: 2000-11-28
 NUMBER OF SEQ ID NOS: 11
 SOFTWARE: PatentIn version 3.2
 SEQ ID NO: 7
 LENGTH: 6
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-09-994-466-7

Query Match Score 63.3%; Length 6;
 Best Local Similarity 83.3%; Pred. No. 1.7e+06;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 TAPPVH 7
 Db 1 TAPPAH 6

RESULT 13
 US-11-055-119-3
 Sequence 3, Application US/11055119
 Publication No. US2005014240A1
 GENERAL INFORMATION:
 APPLICANT: Taylor-Papadimitriou, Joyce
 APPLICANT: Heukamp, Lukas Carl
 APPLICANT: Offringa, Rienk
 APPLICANT: Melief, Cornelis Johanna Maria
 APPLICANT: Acres, Bruce
 APPLICANT: Thomas, Mireille
 TITLE OF INVENTION: MUC-1 derived peptides
 FILE REFERENCE: 029395-017
 CURRENT APPLICATION NUMBER: US/11/055,119
 CURRENT FILING DATE: 2005-02-11
 PRIOR APPLICATION NUMBER: US/09/658,621
 PRIOR FILING DATE: 2000-09-08
 PRIOR APPLICATION NUMBER: US 60/187,215
 PRIOR FILING DATE: 2000-03-03
 PRIOR APPLICATION NUMBER: GB 9921242.5

PRIOR FILING DATE: 1999-09-08
 PRIOR APPLICATION NUMBER: EP 99 40 2237.4
 PRIOR FILING DATE: 1999-09-10
 NUMBER OF SEQ ID NOS: 80
 SOFTWARE: PatentIn version 3.1
 SEQ ID NO 3
 LENGTH: 9
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-11-055-119-3

Query Match 63.3%; Score 31; DB 6; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.7e+06;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 STAPPV 6
 Db 4 STAPPV 9

RESULT 14
 US-10-334-726-100
 Sequence 100, Application US/10334726
 Publication No. US2003011521A1
 GENERAL INFORMATION:
 APPLICANT: TAYLOR-PAPADIMITRIOU, JOYCE
 TITLE OF INVENTION: BREAST CANCER ANTIGEN
 FILE REFERENCE: 1090-36
 CURRENT APPLICATION NUMBER: US/10/334,726
 CURRENT FILING DATE: 2003-01-02
 PRIOR APPLICATION NUMBER: US/09/645,446
 PRIOR FILING DATE: 2000-08-25
 PRIOR APPLICATION NUMBER: PCT/GB99/00866
 PRIOR FILING DATE: 1999-03-19
 PRIOR APPLICATION NUMBER: GB 9805877.9
 PRIOR FILING DATE: 1998-09-20
 NUMBER OF SEQ ID NOS: 324
 SOFTWARE: PatentIn Ver. 2.0
 SEQ ID NO 100
 LENGTH: 9
 TYPE: PRT
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Description of Artificial Sequence:predicted
 OTHER INFORMATION: peptide

US-10-334-726-100

Query Match 57.1%; Score 28; DB 4; Length 9;
 Best Local Similarity 66.7%; Pred. No. 1.7e+06;
 Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 4 PPVHN 9
 Db 4 PPLHDV 9

RESULT 15
 US-09-077-214-28
 Sequence 28, Application US/09077214
 Publication No. US2008599A1
 GENERAL INFORMATION:
 APPLICANT: Schmidt, Walter
 APPLICANT: Birnstiel, Max
 APPLICANT: Schweighoffer, Tamas
 APPLICANT: Steinlein, Peter
 APPLICANT: Buschle, Michael
 TITLE OF INVENTION: Tumor Vaccine And Process For the Preparation Thereof
 NUMBER OF SEQUENCES: 33
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Sterne, Kessler, Goldstein & Fox P.L.L.C.
 STREET: 1100 New York Avenue N.W.
 CITY: Washington

STATE: D.C.
 COUNTRY: U.S.A.
 ZIP: 20005
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent In Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/077,214
 FILING DATE:
 CLASSIFICATION: 424
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: DE 195 43 649.0
 FILING DATE: 23-NOV-1995
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: DE 196 07 044.9
 FILING DATE: 24-FEB-1996
 ATTORNEY/AGENT INFORMATION:
 NAME: Flechner, Raz E.
 REGISTRATION NUMBER: 34,333
 REFERENCE/DOCKET NUMBER: 0652.1710000
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 202-371-2600
 TELEFAX: 202-371-2540
 INFORMATION FOR SEQ ID NO: 28:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 9 amino acids
 STRANDEDNESS: single
 TYPE: amino acid
 TOPOLOGY: not relevant
 MOLECULE TYPE: peptide
 US-09-077-214-28

Query Match 55.1%; Score 27; DB 3; Length 9;
 Best Local Similarity 57.1%; Pred. No. 1.7e+06;
 Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 3 APPVHN 9
 Db 3 APPQHEI 9

RESULT 16
 US-11-055-119-9
 Sequence 9, Application US/11055119
 Publication No. US2005142610A1
 GENERAL INFORMATION:
 APPLICANT: Taylor-Papadimitriou, Joyce
 APPLICANT: Heukamp, Lukas Carl
 APPLICANT: Offringa, Rienk
 APPLICANT: Melief, Cornelis Johanna Maria
 APPLICANT: Acres, Bruce
 APPLICANT: Thomas, Mireille
 TITLE OF INVENTION: MUC-1 derived peptides
 FILE REFERENCE: 029395-017
 CURRENT APPLICATION NUMBER: US/11/055,119
 CURRENT FILING DATE: 2005-02-11
 PRIOR APPLICATION NUMBER: US/09/658,621
 PRIOR FILING DATE: 2000-09-08
 PRIOR APPLICATION NUMBER: US 60/187,215
 PRIOR FILING DATE: 2000-03-03
 PRIOR APPLICATION NUMBER: GB 9921242.5
 PRIOR FILING DATE: 1999-09-08
 PRIOR APPLICATION NUMBER: EP 99 40 2237.4
 PRIOR FILING DATE: 1999-09-10
 NUMBER OF SEQ ID NOS: 80
 SOFTWARE: PatentIn version 3.1
 SEQ ID NO 9
 LENGTH: 9
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-11-055-119-9

Query Match 55.1%; Score 27; DB 6; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.7e+06;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 STAPP 5
 Db. 4 STAPP 8

RESULT 17
 ; Sequence 175, Application US/10473127
 ; Publication No. US20040236091A1

GENERAL INFORMATION:
 ; APPLICANT: Zycos Inc.
 ; TITLE OF INVENTION: TRANSLATIONAL PROFILING
 ; FILE REFERENCE: 08191-026W01
 ; CURRENT APPLICATION NUMBER: US/10/473,127
 ; CURRENT FILING DATE: 2003-09-26
 ; PRIOR APPLICATION NUMBER: 60/279,495
 ; PRIOR FILING DATE: 2001-03-28
 ; PRIOR APPLICATION NUMBER: 60/292,544
 ; PRIOR FILING DATE: 2001-05-21
 ; PRIOR APPLICATION NUMBER: 60/310,801
 ; PRIOR FILING DATE: 2001-08-08
 ; PRIOR APPLICATION NUMBER: 60/326,370
 ; PRIOR FILING DATE: 2001-10-01
 ; PRIOR APPLICATION NUMBER: 60/336,780
 ; PRIOR FILING DATE: 2001-12-04
 ; PRIOR APPLICATION NUMBER: 60/358,985
 ; PRIOR FILING DATE: 2002-02-20
 ; NUMBER OF SEQ ID NOS: 2041
 ; SOFTWARE: FASTSEQ for Windows Version 4.0
 ; SEQ ID NO: 175
 ; LENGTH: 8
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 ; USE-ID: 10-473-127-175

Query Match 53.1%; Score 26; DB 5; Length 8;
 Best Local Similarity 66.7%; Pred. No. 1.7e+06;
 Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 4 PRPVHNV 9
 Db 3 PSVFN1 8

RESULT 18
 ; Sequence 22, Application US/09879336
 ; Patent No. US20040556A1

GENERAL INFORMATION:
 ; APPLICANT: Van Eyk, Jennifer E.
 ; APPLICANT: Mak, Alan S.
 ; APPLICANT: Cote, Graham P.
 ; TITLE OF INVENTION: Methods of Modulating Muscle Contraction
 ; FILE REFERENCE: 1997-021-03US
 ; CURRENT APPLICATION NUMBER: US/09/879,936
 ; CURRENT FILING DATE: 2001-06-14
 ; PRIOR APPLICATION NUMBER: 60/050,478
 ; PRIOR FILING DATE: 1997-06-23
 ; PRIOR APPLICATION NUMBER: 60/089,505
 ; PRIOR FILING DATE: 1998-06-16
 ; NUMBER OF SEQ ID NOS: 26
 ; SOFTWARE: PatentIn Ver. 2.1
 ; SEQ ID NO: 22
 ; LENGTH: 9
 ; TYPE: PRT
 ; ORGANISM: Unknown
 ; NAME/KEY: PEPTIDE

Query Match 51.0%; Score 25; DB 3; Length 9;
 Best Local Similarity 66.6%; Pred. No. 1.7e+06;
 Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 3 APPVN 8
 Db 2 APPMN 7

RESULT 19
 ; Sequence 67, Application US/10001546
 ; Publication No. US20030027766A1

GENERAL INFORMATION:
 ; APPLICANT: IOANNIDES, CONSTANTIN G.
 ; APPLICANT: FISK, BRYAN A.
 ; APPLICANT: IOANNIDES, MARIA G.
 ; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR STIMULATING
 ; FILE REFERENCE: UTSC-3901SC2
 ; CURRENT APPLICATION NUMBER: US/10/001,546
 ; CURRENT FILING DATE: 2001-10-31
 ; PRIOR APPLICATION NUMBER: 08/403,459
 ; PRIOR FILING DATE: 1995-03-14
 ; NUMBER OF SEQ ID NOS: 68
 ; SOFTWARE: PatentIn Ver. 2.1
 ; SEQ ID NO: 67
 ; LENGTH: 9
 ; TYPE: PRT
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 ; OTHER INFORMATION: Peptide
 ; SEQ ID NO: 67

Query Match 51.0%; Score 25; DB 4; Length 9;
 Best Local Similarity 55.6%; Pred. No. 1.7e+06;
 Matches 5; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1 STAPPVHN 9
 Db 1 SLADPAHGV 9

RESULT 20
 ; Sequence 170, Application US/10182252A
 ; Publication No. US2004072162A1

GENERAL INFORMATION:
 ; APPLICANT: FOMSGAARD, ANDERS
 ; APPLICANT: BRUNAK, SOREN
 ; APPLICANT: BUUS, SOREN
 ; APPLICANT: CORBET, SYLVIE
 ; APPLICANT: LAEMMELER, SANNE LISE
 ; APPLICANT: HANSEN, JAN
 ; TITLE OF INVENTION: HIV PEPTIDE AND NUCLEIC ACIDS ENCODING THEM FOR DIAGNOSIS AND
 ; FILE REFERENCE: 030307/0205
 ; CURRENT APPLICATION NUMBER: US/10/182,252A
 ; CURRENT FILING DATE: 2003-04-10
 ; PRIOR APPLICATION NUMBER: PCT/DK01/00059
 ; PRIOR FILING DATE: 2001-01-29
 ; PRIOR APPLICATION NUMBER: EP 00610017.6
 ; PRIOR FILING DATE: 2000-01-28
 ; PRIOR APPLICATION NUMBER: US 60/179,333
 ; PRIOR FILING DATE: 2000-01-31

NUMBER OF SEQ ID NOS: 1388
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 170
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: HIV peptide
US-10-182-252A-170

Query Match Score 25; DB 4; Length 9;
Best Local Similarity 57.1%; Pred. No. 1.7e+06;
Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 3 APPVHNV 9
Db 3 APIQGV 9

RESULT 21
US-10-182-252A-172
Publication No. US20040072162A1

GENERAL INFORMATION
; APPLICANT: FONSGAARD, ANDERS
; APPLICANT: BRUNAK, SOREN
; APPLICANT: BUUS, SOREN
; APPLICANT: CORBET, SYLVIE
; APPLICANT: LAUENMOELLER, SANNE LISE
; APPLICANT: HANSEN, JAN

TITLE OF INVENTION: HIV PEPTIDE AND NUCLEIC ACIDS ENCODING THEM FOR DIAGNOSIS AND CONTROL OF HIV INFECTIONS
FILE REFERENCE: 031307/0205

CURRENT APPLICATION NUMBER: US/10/182,252A
CURRENT FILING DATE: 2003-04-10
PRIOR APPLICATION NUMBER: PCT/DK01/00059
PRIOR FILING DATE: 2001-01-29
PRIOR APPLICATION NUMBER: EP 00610017.6
PRIOR FILING DATE: 2000-01-28
PRIOR APPLICATION NUMBER: US 60/179,333
NUMBER OF SEQ ID NOS: 1388
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 172
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: HIV peptide
US-10-182-252A-172

Query Match Score 25; DB 4; Length 9;
Best Local Similarity 57.1%; Pred. No. 1.7e+06;
Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 3 APPVHNV 9
Db 3 APIQGV 9

RESULT 22
US-10-611-440-14
; Sequence 14, Application US/10611440
GENERAL INFORMATION
; APPLICANT: Berinstein, Neil
; APPLICANT: Gallichan, Scott
; APPLICANT: Lovitt, Corey
; APPLICANT: Parrington, Mark
; APPLICANT: Pedyczek, Artur
; APPLICANT: Radvanyi, Laszlo
; APPLICANT: Singh-Sandhu, Devender
; APPLICANT: Omen, Raymond P

APPLICANT: Cao, Shi-Kian
TITLE OF INVENTION: Tumor Antigens BFA4 and BCY1 for Prevention and/or Treatment of Cancer
FILE REFERENCE: API-02-11-US
CURRENT FILING DATE: 2003-07-01
PRIOR APPLICATION NUMBER: US 60/394,346
PRIOR FILING DATE: 2002-07-03
PRIOR APPLICATION NUMBER: US 60/394,503
PRIOR FILING DATE: 2002-07-09
PRIOR APPLICATION NUMBER: US 60/411,833
PRIOR FILING DATE: 2002-09-18
PRIOR APPLICATION NUMBER: US 60/445,342
PRIOR FILING DATE: 2003-02-06
NUMBER OF SEQ ID NOS: 218
SEQ ID NO 14
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: CLP-24222
US-10-611-440-14

Query Match Score 25; DB 4; Length 9;
Best Local Similarity 66.7%; Pred. No. 1.7e+06;
Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 4 PPVHN 9
Db 4 PDLRN 9

RESULT 23
US-09-954-385-198
Sequence 198, Application US/09954385
Publication No. US20030100467A1

GENERAL INFORMATION
; APPLICANT: Ahlie, Wolfgang
; APPLICANT: Baldwin, Toby L.
; APPLICANT: Van Gastel, Franciscus J.C.
; APPLICANT: Janssen, Giselle G.
; APPLICANT: Murray, Christopher J.
; APPLICANT: Wang, Huaming
; APPLICANT: Winetcky, Deborah S.
; TITLE OF INVENTION: Binding Phenol Oxidizing Enzyme-peptide
; FILE REFERENCE: GC690
; CURRENT APPLICATION NUMBER: US/09/954,385
; CURRENT FILING DATE: 2001-09-12
; NUMBER OF SEQ ID NOS: 433
; SEQ ID NO 198
; LENGTH: 7
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: binding peptide
US-09-954-385-198

Query Match Score 24; DB 3; Length 7;
Best Local Similarity 80.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 STAPP 5
Db 1 :|||
Db 1 TTAPP 5

RESULT 24
US-10-912-512-198
Sequence 198, Application US/10912512
Publication No. US200504268A1

GENERAL INFORMATION:
 APPLICANT: Ahle, Wolfgang
 APPLICANT: Baldwin, Toby L.
 APPLICANT: Van Gassel, Franciscus J.C.
 APPLICANT: Janssen, Giselle G.
 APPLICANT: Murray, Christopher J.
 APPLICANT: Wang, Huaming
 APPLICANT: Winetzy, Deborah S.
 TITLE OF INVENTION: Binding Phenol Oxidizing Enzyme-peptide
 CURRENT APPLICATION NUMBER: US/10/912,512
 CURRENT FILING DATE: 2004-08-05
 PRIORITY APPLICATION NUMBER: US/09/954,385
 PRIOR FILING DATE: 2001-09-12
 NUMBER OF SEQ ID NOS: 433
 SOFTWARE: FastSEQ for Windows Version 4.0
 SEQ ID NO: 198
 LENGTH: 7
 TYPE: PRT
 ORGANISM: Artificial Sequence
 OTHER INFORMATION: binding peptide
 US-10-912-512-198

Query Match Score 49.0%; Best Local Similarity 80.0%; Pred. No. 1.7e+06; Length 7;
 Matches 4; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

RESULT 25
 US-10-235-043-198
 Sequence 198, Application US/10235043
 GENERAL INFORMATION
 APPLICANT: Baldwin, Toby M.
 APPLICANT: Van Gassel, Franciscus J.C.
 APPLICANT: Janssen, Giselle G.
 APPLICANT: Murray, Christopher J.
 APPLICANT: Wang, Huaming
 APPLICANT: Winetzy, Deborah S.
 TITLE OF INVENTION: Binding Phenol Oxidizing Enzyme-Peptide
 FILE REFERENCE: GC690-2
 CURRENT FILING DATE: 2002-09-03
 NUMBER OF SEQ ID NOS: 446
 SOFTWARE: FastSEQ for Windows Version 4.0
 SEQ ID NO: 198
 LENGTH: 7
 TYPE: PRT
 ORGANISM: Artificial Sequence
 OTHER INFORMATION: binding peptide
 US-10-235-043-198

Query Match Score 49.0%; Best Local Similarity 80.0%; Pred. No. 1.7e+06; Length 7;
 Matches 4; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

GENERAL INFORMATION:
 Publication No. US20040209343A1
 GENERAL INFORMATION:
 APPLICANT: Svendsen, Allan
 APPLICANT: Draborg, Henrik
 TITLE OF INVENTION: Subtilase variants
 FILE REFERENCE: 10203
 CURRENT APPLICATION NUMBER: US/10/786,850
 CURRENT FILING DATE: 2004-02-24
 NUMBER OF SEQ ID NOS: 51
 SOFTWARE: Patentin version 3.2
 SEQ ID NO: 33
 LENGTH: 8
 TYPE: PRT
 ORGANISM: Artificial sequence
 FEATURE:
 OTHER INFORMATION: Highly mobile region of Savinase
 US-10-786-850-33

Query Match Score 49.0%; Best Local Similarity 66.7%; Pred. No. 1.7e+06;
 Matches 4; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3 APPVHN 8
 Db 3 APAAHN 8

RESULT 27
 US-11-051-411-80
 Sequence 80, Application US/11051411
 Publication No. US20050196403A1
 GENERAL INFORMATION:
 APPLICANT: Fikes, John
 APPLICANT: Sette, Alessandro
 APPLICANT: Sidney, John
 APPLICANT: Southwood, Scott
 APPLICANT: Chensaut, Robert
 APPLICANT: Celis, Esteban
 APPLICANT: Keogh, Elissa
 TITLE OF INVENTION: Inducing Cellular Immune Responses To
 FILE REFERENCE: P53 Using Peptide And Nucleic Acid Compositions
 CURRENT APPLICATION NUMBER: US/11/051,411
 CURRENT FILING DATE: 2005-02-07
 PRIOR APPLICATION NUMBER: US/09/458,297
 PRIOR FILING DATE: 1999-12-10
 PRIOR APPLICATION NUMBER: US 09/017,735
 PRIOR FILING DATE: 1998-02-03
 PRIOR APPLICATION NUMBER: PCT/US99/13789
 PRIOR APPLICATION NUMBER: US 09/098,584
 PRIOR FILING DATE: 1998-06-17
 NUMBER OF SEQ ID NOS: 1492
 SOFTWARE: FastSEQ for Windows Version 4.0
 SEQ ID NO: 80
 LENGTH: 8
 TYPE: PRT
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Synthetic Peptide
 US-11-051-411-80

Query Match Score 49.0%; Best Local Similarity 80.0%; Pred. No. 1.7e+06;
 Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3 APPVH 7
 Db 3 APPNH 7

RESULT 26
 US-10-786-850-33
 Sequence 33, Application US/10786850

RESULT 28
 US-11-051-411-107

Sequence 107, Application US/11051411
 Publication No. US20050196403A1
 GENERAL INFORMATION:
 APPLICANT: Fikes, John
 APPLICANT: Sette, Alessandro
 APPLICANT: Sidney, John
 APPLICANT: Southwood, Scott
 APPLICANT: Chesnut, Robert
 APPLICANT: Celis, Esteban
 APPLICANT: Keogh, Elissa
 TITLE OF INVENTION: Inducing Cellular Immune Responses To Peptide And Nucleic Acid Compositions
 FILE REFERENCE: 2005.0120000
 CURRENT APPLICATION NUMBER: US/11/051,411
 CURRENT FILING DATE: 2005-02-07
 PRIORITY NUMBER: US 09 458,297
 PRIOR FILING DATE: 1999-12-10
 PRIORITY NUMBER: US 09/017,735
 PRIOR FILING DATE: 1998-02-03
 PRIORITY NUMBER: PCT/US99/13789
 PRIOR FILING DATE: 1999-06-17
 PRIORITY NUMBER: PCT/US99/13789
 PRIOR FILING DATE: 1998-06-17
 NUMBER OF SEQ ID NOS: 1492
 SOFTWARE: FastSEQ for Windows Version 4.0
 SEQ ID NO: 107
 LENGTH: 8
 TYPE: PRT
 ORGANISM: Artificial Sequence
 FEATURE: Synthetic Peptide
 OTHER INFORMATION: Synthetic Peptide
 us-11-051-411-107

Query Match 49.0%; Score 24; DB 6; Length 8;
 Best Local Similarity 80.0%; Pred. No. 1.7e+06;
 Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3 APPVH 7
 Db 2 APPQH 6

RESULT 29
 US-11-051-411-287
 ; Sequence 287, Application US/11051411
 ;
 ; GENERAL INFORMATION:
 ; APPLICANT: Fikes, John
 ; APPLICANT: Sette, Alessandro
 ; APPLICANT: Sidney, John
 ; APPLICANT: Southwood, Scott
 ; APPLICANT: Chesnut, Robert
 ; APPLICANT: Celis, Esteban
 ; APPLICANT: Keogh, Elissa
 ; TITLE OF INVENTION: Inducing Cellular Immune Responses To Peptide And Nucleic Acid Compositions
 ; FILE REFERENCE: 2005.0120000
 ; CURRENT FILING DATE: 2005-02-07
 ; PRIORITY NUMBER: US 09 458,297
 ; PRIORITY NUMBER: PCT/US99/13789
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIORITY NUMBER: PCT/US99/13789
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIORITY NUMBER: US 09/098,584
 ; PRIOR FILING DATE: 1998-06-17
 ; NUMBER OF SEQ ID NOS: 1492
 ; SOFTWARE: FastSEQ for Windows Version 4.0
 ; SEQ ID NO: 287
 ; LENGTH: 8
 ; TYPE: PRT
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Synthetic Peptide
 ; US-11-051-411-287

Query Match 49.0%; Score 24; DB 6; Length 8;
 Best Local Similarity 80.0%; Pred. No. 1.7e+06;
 Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3 APPVH 7
 Db 2 APPQH 6

RESULT 31
 US-11-051-411-667
 ; Sequence 667, Application US/11051411
 ;
 ; GENERAL INFORMATION:
 ; APPLICANT: Fikes, John
 ; APPLICANT: Sette, Alessandro
 ; APPLICANT: Sidney, John
 ; APPLICANT: Southwood, Scott
 ; APPLICANT: Chesnut, Robert
 ; APPLICANT: Celis, Esteban
 ; APPLICANT: Keogh, Elissa
 ; TITLE OF INVENTION: Inducing Cellular Immune Responses To Peptide And Nucleic Acid Compositions
 ; FILE REFERENCE: 2005.0120000
 ; CURRENT FILING DATE: 2005-02-07
 ; PRIORITY NUMBER: US 09 458,297
 ; PRIORITY NUMBER: PCT/US99/13789
 ; PRIOR FILING DATE: 1999-12-10
 ; PRIORITY NUMBER: US 09/017,735
 ; PRIOR FILING DATE: 1998-02-03
 ; PRIORITY NUMBER: PCT/US99/13789
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIORITY NUMBER: US 09/098,584
 ; NUMBER OF SEQ ID NOS: 1492
 ; SOFTWARE: FastSEQ for Windows Version 4.0
 ; SEQ ID NO: 287
 ; LENGTH: 8
 ; TYPE: PRT
 ; ORGANISM: Artificial Sequence

```

CURRENT FILING DATE: 2005-02-07
PRIORITY APPLICATION NUMBER: US 09/458,297
PRIOR FILING DATE: 1999-12-10
PRIORITY APPLICATION NUMBER: US 09/017,735
PRIOR FILING DATE: 1998-02-03
PRIOR FILING DATE: PCT/US99/13789
PRIOR FILING DATE: 1999-06-17
PRIOR FILING DATE: US 09/098,584
PRIOR FILING DATE: 1998-06-17
NUMBER OF SEQ ID NOS: 1492
SOFTWARE: FastSEQ for Windows Version 4.0
SEQ ID NO: 667
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Peptide
US-11-051-411-667
||| |
3 APPVH 7
4 APPQH 8

Query Match Score 24; DB 6; Length 8;
Best Local Similarity 80.0%; Pred. No. 1.7e+06; Indels 0; Gaps 0;
Matches 4; Conservative 0; Mismatches 1; Delins 0; Gaps 0;

Qy 3 APPVH 7
Db 4 APPQH 8

RESULT 32
Sequence 887, Application US/11051411
PRIORITY APPLICATION NUMBER: US2005019640341
GENERAL INFORMATION
APPLICANT: Sette, Alessandro
APPLICANT: Sidney, John
APPLICANT: Southwood, Scott
APPLICANT: Chesnut, Robert
APPLICANT: Celia, Esteban
APPLICANT: Keogh, Elissa
TITLE OF INVENTION: Inducing Cellular Immune Responses To
P53 Using Peptide And Nucleic Acid Compositions
FILE REFERENCE: 2005.0120000
CURRENT APPLICATION NUMBER: US/11/051.411
CURRENT FILING DATE: 2005-02-07
PRIOR APPLICATION NUMBER: US 09/458,297
PRIOR FILING DATE: 1999-12-10
PRIOR APPLICATION NUMBER: US 09/017,735
PRIOR FILING DATE: 1998-02-03
PRIOR APPLICATION NUMBER: PCT/US99/13789
PRIOR FILING DATE: 1999-06-17
PRIOR APPLICATION NUMBER: US 09/098,584
PRIOR FILING DATE: 1998-06-17
NUMBER OF SEQ ID NOS: 1492
SOFTWARE: FastSEQ for Windows Version 4.0
SEQ ID NO: 887
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Peptide
US-11-051-411-887
||| |
3 APPVH 7
4 APPQH 8

RESULT 33
Sequence 7, Application US/10809790
PRIORITY APPLICATION NUMBER: US004210037A1
GENERAL INFORMATION

```

; APPLICANT: Zauderer, Maurice
 ; APPLICANT: Paris, Mark J.
 ; APPLICANT: Smith, Ernest S.
 ; TITLE OF INVENTION: Targeted MHC Class I Alpha3 Vaccine Delivery Systems
 ; FILE REFERENCE: 1843_0120001
 ; CURRENT APPLICATION NUMBER: US/10/809,790
 ; CURRENT FILING DATE: 2004-03-26
 ; PRIOR APPLICATION NUMBER: US/09/457,896
 ; PRIOR FILING DATE: 2003-03-28
 ; NUMBER OF SEQ ID NOS: 53
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO: 7
 ; LENGTH: 9
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 US-10-809-790-7
 Query Match 49.0%; Score 24; DB 4; Length 9;
 Best Local Similarity 55.6%; Prod. No. 1.7e+06;
 Matches 5; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 Qy 1 STAPPVH 9
 Db 1 SVAPPPEEV 9

RESULT 36
 US-10-862-195-1350
 Sequence 1350, Application US/10862195
 Publication No. US20050164324A1
 GENERAL INFORMATION:
 ; APPLICANT: GVG1, STEVEN P.
 ; TITLE OF INVENTION: SYSTEMS, METHODS AND KITS FOR CHARACTERIZING PHOSPHOPROTEOMES
 ; FILE REFERENCE: 58390 (70207)
 ; CURRENT APPLICATION NUMBER: US/10/862,195
 ; CURRENT FILING DATE: 2004-05-04
 ; PRIOR APPLICATION NUMBER: 60/476,010
 ; PRIOR FILING DATE: 2003-06-04
 ; NUMBER OF SEQ ID NOS: 2245
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO: 1350
 ; LENGTH: 9
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 ; FEATURE:
 ; OTHER INFORMATION: See specification as filed for preferred embodiments
 ; OTHER INFORMATION: and description of phosphorylation sites
 US-10-862-195-1350

Query Match 49.0%; Score 24; DB 5; Length 9;
 Best Local Similarity 80.0%; Prod. No. 1.7e+06;
 Matches 4; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 STAPP 5
 Db 2 STSPP 6

RESULT 37
 US-11-051-411-81
 Sequence 81, Application US/11051411
 Publication No. US20050196403A1
 GENERAL INFORMATION:
 ; APPLICANT: Files, John
 ; APPLICANT: Sette, Alessandro
 ; APPLICANT: Sidney, John
 ; APPLICANT: Southwood, Scott
 ; APPLICANT: Chesnut, Robert
 ; APPLICANT: Celis, Esteban
 ; APPLICANT: Keogh, Elissa
 ; TITLE OF INVENTION: Inducing Cellular Immune Responses To
 ; OTHER INFORMATION: Peptide And Nucleic Acid Compositions
 ; FILE REFERENCE: 2060_0120000

Query Match 49.0%; Score 24; DB 6; Length 9;
 Best Local Similarity 80.0%; Prod. No. 1.7e+06;
 Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 3 APPVH 7
 Db 2 APPQH 6

; CURRENT APPLICATION NUMBER: US/11/051,411
 ; CURRENT FILING DATE: 2005-02-07
 ; PRIOR APPLICATION NUMBER: US/09/458,297
 ; PRIOR FILING DATE: 1999-12-10
 ; PRIOR APPLICATION NUMBER: US/09/17735
 ; PRIOR FILING DATE: 1998-02-03
 ; PRIOR APPLICATION NUMBER: PCT/US99/13789
 ; PRIOR FILING DATE: 1999-06-17
 ; PRIOR APPLICATION NUMBER: US/09/098,584
 ; PRIOR FILING DATE: 1998-06-17
 ; NUMBER OF SEQ ID NOS: 1492
 ; SOFTWARE: FastSEQ for Windows Version 4.0
 ; SEQ ID NO: 81
 ; LENGTH: 9
 ; TYPE: PRT
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Synthetic Peptide
 US-11-051-411-81

Query	Match	Score	DB	Length	%
Qy	3 APPVH 7	49.0%	6	9	
Db	3 APPQH 7	49.0%	6	9	

RESULT 38
 US-11-051-411-219
 Sequence 219, Application US/11051411
 Publication No. US20050196403A1
 GENERAL INFORMATION:
 ; APPLICANT: Files, John
 ; APPLICANT: Sette, Alessandro
 ; APPLICANT: Sidney, John
 ; APPLICANT: Southwood, Scott
 ; APPLICANT: Chesnut, Robert
 ; APPLICANT: Celis, Esteban
 ; APPLICANT: Keogh, Elissa
 ; TITLE OF INVENTION: Inducing Cellular Immune Responses To
 ; OTHER INFORMATION: Peptide And Nucleic Acid Compositions
 ; FILE REFERENCE: 2060_0120000

Query Match 49.0%; Score 24; DB 6; Length 9;
 Best Local Similarity 80.0%; Prod. No. 1.7e+06;
 Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 3 APPVH 7
 Db 3 APPQH 7

RESULT 39
 US-11-051-411-219
 Sequence 219, Application US/11051411
 Publication No. US20050196403A1
 GENERAL INFORMATION:
 ; APPLICANT: Files, John
 ; APPLICANT: Sette, Alessandro
 ; APPLICANT: Sidney, John
 ; APPLICANT: Southwood, Scott
 ; APPLICANT: Chesnut, Robert
 ; APPLICANT: Celis, Esteban
 ; APPLICANT: Keogh, Elissa
 ; TITLE OF INVENTION: Inducing Cellular Immune Responses To
 ; OTHER INFORMATION: Peptide And Nucleic Acid Compositions
 ; FILE REFERENCE: 2060_0120000

Query Match 49.0%; Score 24; DB 6; Length 9;
 Best Local Similarity 80.0%; Prod. No. 1.7e+06;
 Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 3 APPVH 7
 Db 2 APPQH 6

RESULT 39
 US-11-051-411-288
 Sequence 288, Application US/11051411
 Publication No. US20050196403A1
 GENERAL INFORMATION
 APPLICANT: Fikes, John
 APPLICANT: Sette, Alessandro
 APPLICANT: Sidney, John
 APPLICANT: Southwood, Scott
 APPLICANT: Chesnut, Robert
 APPLICANT: Celis, Esteban
 APPLICANT: Keogh, Elissa
 TITLE OF INVENTION: Inducing Cellular Immune Responses To Peptides Using Peptide And Nucleic Acid Compositions
 FILE REFERENCE: 2000_0120000
 CURRENT APPLICATION NUMBER: US/11/051,411
 CURRENT FILING DATE: 2005-02-07
 PRIOR APPLICATION NUMBER: US/09/458,297
 PRIOR FILING DATE: 1999-12-10
 PRIOR APPLICATION NUMBER: US 09/017,735
 PRIOR FILING DATE: 1998-02-03
 PRIOR APPLICATION NUMBER: PCT/US99/13789
 PRIOR FILING DATE: 1999-06-17
 PRIOR APPLICATION NUMBER: US 09/098,584
 PRIOR FILING DATE: 1998-06-17
 NUMBER OF SEQ ID NOS: 1492
 SOFTWARE: Fast-SEQ for Windows Version 4.0
 SEQ ID NO: 288
 LENGTH: 9
 TYPE: PRT
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Synthetic Peptide
 US-11-051-411-288

Query Match 49.0%; Score 24; DB 6; Length 9;
 Best Local Similarity 80.0%; Prod. No. 1.7e+05;
 Matches 4; Conservative 0; Mismatches 1; Indels 0;
 Gaps 0;

Qy 3 APPVH 7
 Db 3 APPQH 7

RESULT 40
 US-11-051-411-368
 Sequence 368, Application US/11051411
 Publication No. US20050196403A1
 GENERAL INFORMATION
 APPLICANT: Fikes, John
 APPLICANT: Sette, Alessandro
 APPLICANT: Sidney, John
 APPLICANT: Southwood, Scott
 APPLICANT: Chesnut, Robert
 APPLICANT: Celis, Esteban
 APPLICANT: Keogh, Elissa
 TITLE OF INVENTION: Inducing Cellular Immune Responses To Peptides Using Peptide And Nucleic Acid Compositions
 FILE REFERENCE: 2000_0120000
 CURRENT APPLICATION NUMBER: US/11/051,411
 CURRENT FILING DATE: 2005-02-07
 PRIOR APPLICATION NUMBER: US/09/458,297
 PRIOR FILING DATE: 1999-12-10
 PRIOR APPLICATION NUMBER: PCT/US99/13789
 PRIOR FILING DATE: 1999-06-17
 PRIOR APPLICATION NUMBER: US 09/098,584
 PRIOR FILING DATE: 1998-06-17
 NUMBER OF SEQ ID NOS: 1492
 SOFTWARE: Fast-SEQ for Windows Version 4.0
 LENGTH: 9

TYPE: PRT ; ORGANISM: Artificial Sequence
 FEATURE: ; OTHER INFORMATION: Synthetic Peptide
 US-11-051-411-368

Query Match 49.0%; Score 24; DB 6; Length 9;
 Best Local Similarity 80.0%; Prod. No. 1.7e+06;
 Matches 4; Conservative 0; Mismatches 1; Indels 0;
 Gaps 0;

Qy 3 APPVH 7
 Db 1 APPQH 5

RESULT 41
 US-11-051-411-544
 Sequence 544, Application US/11051411
 Publication No. US20050196403A1
 GENERAL INFORMATION
 APPLICANT: Fikes, John
 APPLICANT: Sette, Alessandro
 APPLICANT: Sidney, John
 APPLICANT: Southwood, Scott
 APPLICANT: Chesnut, Robert
 APPLICANT: Celis, Esteban
 APPLICANT: Keogh, Elissa
 TITLE OF INVENTION: Inducing Cellular Immune Responses To Peptides Using Peptide And Nucleic Acid Compositions
 FILE REFERENCE: 2000_0120000
 CURRENT APPLICATION NUMBER: US/11/051,411
 CURRENT FILING DATE: 2005-02-07
 PRIOR APPLICATION NUMBER: US/09/458,297
 PRIOR FILING DATE: 1999-12-10
 PRIOR APPLICATION NUMBER: PCT/US99/13789
 PRIOR FILING DATE: 1999-06-17
 PRIOR APPLICATION NUMBER: US 09/098,584
 PRIOR FILING DATE: 1998-06-17
 NUMBER OF SEQ ID NOS: 1492
 SOFTWARE: Fast-SEQ for Windows Version 4.0
 SEQ ID NO: 544

TYPE: PRT ; ORGANISM: Artificial Sequence
 FEATURE: ; OTHER INFORMATION: Synthetic Peptide
 US-11-051-411-544

Query Match 49.0%; Score 24; DB 6; Length 9;
 Best Local Similarity 80.0%; Prod. No. 1.7e+06;
 Matches 4; Conservative 0; Mismatches 1; Indels 0;
 Gaps 0;

Qy 3 APPVH 7
 Db 1 APPQH 5

RESULT 42
 US-11-051-411-557
 Sequence 557, Application US/11051411
 Publication No. US20050196403A1
 GENERAL INFORMATION
 APPLICANT: Fikes, John
 APPLICANT: Sette, Alessandro
 APPLICANT: Sidney, John
 APPLICANT: Southwood, Scott
 APPLICANT: Chesnut, Robert
 APPLICANT: Celis, Esteban
 APPLICANT: Keogh, Elissa
 TITLE OF INVENTION: Inducing Cellular Immune Responses To Peptides Using Peptide And Nucleic Acid Compositions
 FILE REFERENCE: 2000_0120000
 CURRENT APPLICATION NUMBER: US/11/051,411
 CURRENT FILING DATE: 2005-02-07
 PRIOR APPLICATION NUMBER: US/09/458,297
 PRIOR FILING DATE: 1999-12-10
 PRIOR APPLICATION NUMBER: PCT/US99/13789
 PRIOR FILING DATE: 1999-06-17
 PRIOR APPLICATION NUMBER: US 09/098,584
 PRIOR FILING DATE: 1998-06-17
 NUMBER OF SEQ ID NOS: 1492
 SOFTWARE: Fast-SEQ for Windows Version 4.0
 LENGTH: 9

```

FILE REFERENCE: 2060_0120000
; CURRENT APPLICATION NUMBER: US/11/051,411
; CURRENT FILING DATE: 2005-02-07
; PRIOR APPLICATION NUMBER: US/09/458,297
; PRIOR FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: US 09/017,735
; PRIOR FILING DATE: 1998-02-03
; PRIOR APPLICATION NUMBER: PCT/US99/13789
; PRIOR FILING DATE: 1999-06-17
; PRIOR APPLICATION NUMBER: US 09/098,584
; PRIOR FILING DATE: 1998-06-17
; NUMBER OF SEQ ID NOS: 1492
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO: 557
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Peptide
US-11-051-411-557

Query Match Score 24; DB 6; Length 9;
Best Local Similarity 80%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3 APPVH 7
   ||| |
Db 3 APPQH 7
   ||| |
```

RESULT 44

```

; Sequence 817, Application US/11051411
; Publication No. US20050196403A1
; GENERAL INFORMATION:
; APPLICANT: Fikes, John
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Chesnut, Robert
; APPLICANT: Celis, Esteban
; APPLICANT: Keogh, Elissa
; TITLE OF INVENTION: Inducing Cellular Immune Responses To Peptides And Nucleic Acid Compositions
; CURRENT FILING DATE: 2005-02-07
; PRIOR APPLICATION NUMBER: US/09/458,297
; FILE REFERENCE: 2060_0120000
; CURRENT APPLICATION NUMBER: US/11/051,411
; CURRENT FILING DATE: 2005-02-07
; PRIOR APPLICATION NUMBER: US/09/458,297
; PRIOR FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: PCT/US99/13789
; PRIOR FILING DATE: 1998-02-03
; PRIOR APPLICATION NUMBER: PCT/US99/13789
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: US 09/098,584
; PRIOR FILING DATE: 1998-06-17
; NUMBER OF SEQ ID NOS: 1492
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO: 817
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Peptide
US-11-051-411-817
```

```

Query Match Score 24; DB 6; Length 9;
Best Local Similarity 80%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3 APPVH 7
   ||| |
Db 5 APPQH 9
```

RESULT 45

```

; Sequence 939, Application US/11051411
; Publication No. US20050196403A1
; GENERAL INFORMATION:
; APPLICANT: Fikes, John
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Chesnut, Robert
; APPLICANT: Celis, Esteban
; APPLICANT: Keogh, Elissa
; TITLE OF INVENTION: Inducing Cellular Immune Responses To Peptides And Nucleic Acid Compositions
; CURRENT FILING DATE: 2005-02-07
; PRIOR APPLICATION NUMBER: US/09/458,297
; PRIOR FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: US 09/017,735
; PRIOR FILING DATE: 1998-02-03
; PRIOR APPLICATION NUMBER: PCT/US99/13789
; PRIOR FILING DATE: 1999-06-17
; PRIOR APPLICATION NUMBER: US 09/098,584
; PRIOR FILING DATE: 1998-06-17
; NUMBER OF SEQ ID NOS: 1492
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO: 733
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Peptide
US-11-051-411-733
```

```

Query Match Score 24; DB 6; Length 9;
Best Local Similarity 80%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3 APPVH 7
   ||| |
Db 2 APPQH 6
```

```

; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Peptide
; US-11-051-411-939

Query Match      49.0%; Score 24; DB 6; Length 9;
Best Local Similarity 80.0%; Pred. No. 1.e+06; Indels 0; Gaps 0;
Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy   3 APPVH 7
Db   2 APPQH 6

RESULT 46
US-11-051-411-998
; Sequence 998, Application US/11051411
; Publication No. US20050196403A1
; GENERAL INFORMATION:
; APPLICANT: Flies, John
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Chesnut, Robert
; APPLICANT: Hobden, Adrian
; APPLICANT: Keogh, Elissa
; TITLE OF INVENTION: Inducing Cellular Immune Responses To
; TITLE OF INVENTION: P53 Using Peptide And Nucleic Acid Compositions
; FILE REFERENCE: 2005.0120000
; CURRENT APPLICATION NUMBER: US/11/051,411
; CURRENT FILING DATE: 2005-02-07
; PRIOR APPLICATION NUMBER: US/09/458,297
; PRIOR FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: US 09/017,735
; PRIOR FILING DATE: 1998-02-03
; PRIOR APPLICATION NUMBER: PCT/US99/13749
; PRIOR FILING DATE: 1999-06-17
; PRIOR APPLICATION NUMBER: US 09/098,584
; NUMBER OF SEQ ID NOS: 1492
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO: 998
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Peptide
; US-11-051-411-998

Query Match      49.0%; Score 24; DB 6; Length 9;
Best Local Similarity 80.0%; Pred. No. 1.7e+06; Indels 0; Gaps 0;
Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy   3 APPVH 7
Db   2 APPQH 6

RESULT 47
US-09-972-035A-9
; Sequence 9, Application US/09972035A
; Patent No. US2002013622A1
; GENERAL INFORMATION:
; APPLICANT: Zavitz, Kenton
; APPLICANT: Hobden, Adrian
; APPLICANT: Scott, Moran
; APPLICANT: Daniel A.
; APPLICANT: Myriad Genetics, Inc.
; TITLE OF INVENTION: Tsg101-GagP6 Interaction And Use Thereof
; FILE REFERENCE: 1907.03
; CURRENT APPLICATION NUMBER: US/09/972,035A
; PRIOR APPLICATION NUMBER: US 60/276,259

Query Match      46.9%; Score 23; DB 3; Length 5;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy   2 TAPP 5
Db   2 TAPP 5

RESULT 48
US-10-223-172A-9
; Sequence 9, Application US/10223172A
; Publication No. US2003013844A1
; GENERAL INFORMATION:
; APPLICANT: Myriad Genetics, Inc.
; APPLICANT: Zavitz, Kenton
; APPLICANT: Wetstein, Daniel Albert
; APPLICANT: Moran, Scott
; APPLICANT: Hobden, Adrian
; TITLE OF INVENTION: COMPOSITION AND METHOD FOR TREATING HIV INFECTION
; FILE REFERENCE: 5003.01
; CURRENT APPLICATION NUMBER: US/10/223,172A
; CURRENT FILING DATE: 2002-08-19
; PRIOR APPLICATION NUMBER: US 60/313,239
; PRIOR FILING DATE: 2001-08-18
; NUMBER OF SEQ ID NOS: 42
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO: 9
; LENGTH: 5
; TYPE: PRT
; ORGANISM: Human immunodeficiency virus
; US-10-223-172A-9

Query Match      46.9%; Score 23; DB 4; Length 5;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy   2 TAPP 5
Db   2 TAPP 5

RESULT 49
US-10-224-999A-9
; Sequence 9, Application US/10224999A
; Publication No. US20030171318A1
; GENERAL INFORMATION:
; APPLICANT: Myriad Genetics, Inc.
; APPLICANT: Zavitz, Kenton
; APPLICANT: Hobden, Adrian
; TITLE OF INVENTION: Composition and Method for Treating Viral Infection
; FILE REFERENCE: 5004.01
; CURRENT APPLICATION NUMBER: US/10/224,999A
; CURRENT FILING DATE: 2003-03-03
; PRIOR APPLICATION NUMBER: US 60/313,695
; PRIOR FILING DATE: 2001-08-20
; NUMBER OF SEQ ID NOS: 344
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO: 9
; LENGTH: 5
; TYPE: PRT
; ORGANISM: Human immunodeficiency virus
; US-10-224-999A-9

```

```

Query Match      46.9%;  Score 23;  DB 4; Length 5;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy          2 TAPP 5
           |||||
Db          2 TAPP 5

```

```

RESULT 50
US-10-663-407-9
; Sequence 9, Application US/10663407
; Publication No. US20040109861A1
; GENERAL INFORMATION:
; APPLICANT: Myriad Genetics, Incorporated
; APPLICANT: Wettstein, Daniel A
; APPLICANT: Morham, Scott
; APPLICANT: Zavitz, Kenton
; TITLE OF INVENTION: TSG101-GRG INTERACTION AND USE THEREOF
; FILE REFERENCE: 1907.04-1
; CURRENT APPLICATION NUMBER: US/10/663,407
; CURRENT FILING DATE: 2003-09-15
; PRIOR APPLICATION NUMBER: PCT/US02/08146
; PRIOR FILING DATE: 2002-03-14
; PRIOR APPLICATION NUMBER: US 10/223,172
; PRIOR FILING DATE: 2002-08-19
; PRIOR APPLICATION NUMBER: US 10/224,999
; PRIOR FILING DATE: 2002-08-20
; NUMBER OF SEQ ID NOS: 42
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 5
; TYPE: PRT
; ORGANISM: Human immunodeficiency virus
;US-10-663-407-9

```

```

Query Match      46.9%;  Score 23;  DB 4; Length 5;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy          2 TAPP 5
           |||||
Db          2 TAPP 5

```

Search completed: February 24, 2006, 10:32:25
Job time : 170 secs

This Page Blank (uspto)

GenCore version 5.1.7
(c) 1993 - 2006 Biocceleration Ltd.

OM protein - protein search, using sw model

Run on: February 24, 2006, 10:18:31 ; Search time 46 Seconds

(without alignments)

16.176 Million cell updates/sec

Title: US-10-019-513-1

Perfect score: 49 Sequence: 1 STAPPVHN 9

Scoring table: BLASTM62 Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 111694

Post-processing: Minimum Match 0% Maximum Match 100% Listing first 1000 summaries

Database : Isolated Patents AA:*

- 1: /cgn2_6.ptodata/1/iaa/5 COMB.pep:*
- 2: /cgn2_6.ptodata/1/iaa/6 COMB.pep:*
- 3: /cgn2_6.ptodata/1/iaa/H COMB.pep:*
- 4: /cgn2_6.ptodata/1/iaa/HETUS COMB.pep:*
- 5: /cgn2_6.ptodata/1/iaa/RE COMB.pep:*
- 6: /cgn2_6.ptodata/1/iaa/backflesi.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query	Match	Length	DB	ID	Description
1	39	79.6	9	1	US-08-787-547-55	Sequence 55, App1	
2	39	79.6	9	1	US-08-288-059-19	Sequence 19, App1	
3	39	79.6	9	2	US-09-593-870A-45	Sequence 45, App1	
4	39	79.6	9	2	US-09-497-232-1	Sequence 1, App1	
5	39	79.6	9	2	US-10-296-317-44	Sequence 44, App1	
6	36	73.5	9	2	US-09-497-232-25	Sequence 25, App1	
7	35	71.4	9	1	US-08-288-059-17	Sequence 17, App1	
8	35	71.4	9	1	US-08-288-059-18	Sequence 18, App1	
9	35	71.4	9	1	US-08-288-059-20	Sequence 20, App1	
10	35	71.4	9	2	US-09-593-870A-68	Sequence 68, App1	
11	31	63.3	6	2	US-08-134-198E-3	Sequence 23, App1	
12	30	61.2	9	1	US-08-288-059-21	Sequence 21, App1	
13	30	61.2	9	2	US-09-593-870A-67	Sequence 67, App1	
14	27	55.1	6	2	US-08-134-198E-21	Sequence 21, App1	
15	27	55.1	6	2	US-08-134-198E-12	Sequence 22, App1	
16	27	55.1	9	1	US-08-288-059-16	Sequence 16, App1	
17	27	55.1	9	2	US-09-593-870A-43	Sequence 43, App1	
18	26	53.1	6	2	US-08-134-198E-24	Sequence 24, App1	
19	26	53.1	6	2	US-08-134-198E-25	Sequence 25, App1	
20	26	53.1	7	1	US-08-472-453-4	Sequence 4, App1	
21	25	51.0	8	1	US-08-210-266A-1	Sequence 1, App1	
22	25	51.0	8	1	US-08-210-266A-8	Sequence 8, App1	
23	25	51.0	8	1	US-08-134-198E-24	Sequence 1, App1	
24	25	51.0	8	1	US-08-688-675-1	Sequence 8, App1	
25	25	51.0	8	2	US-08-477-860C-1	Sequence 1, App1	
26	25	51.0	9	2	US-09-100-930A-22	Sequence 22, App1	
27	25	51.0	9	2	US-08-323-686-6	Sequence 6, App1	

9	2	51.0	6	1	US-08-403-459-67	Sequence 67, App1	
29	24	49.0	7	1	US-08-666-778-1	Sequence 1, App1	
30	24	49.0	7	1	US-08-666-773-24	Sequence 24, App1	
31	24	49.0	8	2	US-08-444-818-340	Sequence 340, App1	
32	24	49.0	9	1	US-08-338-634-16	Sequence 98, App1	
33	24	49.0	9	2	US-09-601-729-98	Sequence 102, App1	
34	24	49.0	9	2	US-09-601-729-102	Sequence 1, App1	
35	23	46.9	6	1	US-08-228-228-1	Sequence 1, App1	
36	23	46.9	6	1	US-08-332-633-1	Sequence 1, App1	
37	23	46.9	6	1	US-08-332-638-1	Sequence 1, App1	
38	23	46.9	6	1	US-09-215-29	Sequence 29, App1	
39	23	46.9	8	2	US-09-706-774A-29	Sequence 91, App1	
40	23	46.9	7	2	US-09-192-854-91	Sequence 21, App1	
41	23	46.9	9	1	US-09-511-939-159	Sequence 81, App1	
42	23	46.9	8	1	US-08-615-881-21	Sequence 8, App1	
43	23	46.9	8	1	US-08-615-881-81	Sequence 341, App1	
44	23	46.9	8	2	US-08-477-880C-8	Sequence 76, App1	
45	23	46.9	9	1	US-08-144-818-341	Sequence 31, App1	
46	23	46.9	8	1	US-10-185-815A-16	Sequence 31, App1	
47	23	46.9	9	1	US-07-941-662-31	Sequence 31, App1	
48	23	46.9	9	1	US-08-209-797-31	Sequence 19, App1	
49	23	46.9	9	1	US-08-146-145-19	Sequence 34, App1	
50	23	46.9	9	1	US-08-69-685-31	Sequence 63, App1	
51	23	46.9	9	1	US-08-340-283-34	Sequence 145, App1	
52	23	46.9	9	1	US-08-986-234-33	Sequence 3, App1	
53	23	46.9	9	2	US-09-103-84-31	Sequence 42, App1	
54	23	46.9	9	2	US-08-481-985B-145	Sequence 153, App1	
55	23	46.9	9	2	US-08-501-987-3	Sequence 42, App1	
56	23	46.9	9	2	US-09-339-982A-42	Sequence 9, App1	
57	23	46.9	9	2	US-08-920-413-9	Sequence 42, App1	
58	23	46.9	9	2	US-09-039-641-42	Sequence 42, App1	
59	23	46.9	9	2	US-09-039-762A-42	Sequence 42, App1	
60	23	46.9	9	2	US-09-042-492D-42	Sequence 42, App1	
61	23	46.9	9	2	US-08-197-484-5	Sequence 5, App1	
62	23	46.9	9	2	US-08-191-484-76	Sequence 42, App1	
63	23	46.9	9	2	US-08-913-612A-42	Sequence 48, App1	
64	23	46.9	9	2	US-08-913-612A-48	Sequence 101, App1	
65	23	46.9	9	2	US-09-311-784A-101	Sequence 61, App1	
66	23	46.9	9	2	US-09-454-204A-61	Sequence 153, App1	
67	23	46.9	9	2	US-09-601-729-153	Sequence 42, App1	
68	23	46.9	9	2	US-10-266-463A-42	Sequence 48, App1	
69	23	46.9	9	2	US-10-266-463A-48	Sequence 31, App1	
70	23	46.9	9	4	PCT-US93-01557-31	Sequence 66, App1	
71	23	46.9	9	4	PCT-US95-02121-5	Sequence 76, App1	
72	23	46.9	9	4	PCT-US95-02121-76	Sequence 16, App1	
73	23	46.9	9	4	PCT-US95-04975-16	Sequence 5, App1	
74	23	46.9	9	4	PCT-US95-16415-5	Sequence 3, App1	
75	23	46.9	9	4	US-08-160-317-3	Sequence 3, App1	
76	22	44.9	4	1	US-08-471-154-3	Sequence 3, App1	
77	22	44.9	4	1	US-08-471-154-3	Sequence 5, App1	
78	22	44.9	4	1	US-08-891-271-5	Sequence 5, App1	
79	22	44.9	7	2	US-08-526-589-11	Sequence 11, App1	
80	22	44.9	7	2	US-08-130-915A-203	Sequence 5, App1	
81	22	44.9	7	2	US-08-428-082B-296	Sequence 296, App1	
82	22	44.9	7	2	US-09-879-987-203	Sequence 203, App1	
83	22	44.9	7	2	US-10-394-980-280	Sequence 280, App1	
84	22	44.9	8	2	US-09-011-769A-66	Sequence 66, App1	
85	22	44.9	9	1	US-07-626-589-11	Sequence 69, App1	
86	22	44.9	9	1	US-08-236-410-11	Sequence 11, App1	
87	22	44.9	9	1	US-08-338-634-5	Sequence 4, App1	
88	22	44.9	9	1	US-08-338-634-7	Sequence 10, App1	
89	22	44.9	9	1	US-07-888-943-5	Sequence 5, App1	
90	22	44.9	9	1	US-08-787-547-66	Sequence 88, App1	
91	22	44.9	9	1	US-08-787-547-69	Sequence 11, App1	
92	22	44.9	9	1	US-08-465-421-11	Sequence 4, App1	
93	22	44.9	9	2	US-09-425-194-4	Sequence 10, App1	
94	22	44.9	9	2	US-09-422-375-0	Sequence 85, App1	
95	22	44.9	9	2	US-09-601-729-95	Sequence 88, App1	
96	22	44.9	9	2	US-09-601-729-98	Sequence 105, App1	
97	22	44.9	9	2	PCT-US95-16415-2	Sequence 2, App1	
98	22	44.9	9	2	PCT-US95-16415-2	Sequence 3, App1	
99	22	44.9	5	1	US-08-323-686-6	Sequence 6, App1	

101	21	42.9	US-08-615-181-35	Sequence 35, App1	174	19	30.8	8 1	US-08-064-693-7
102	21	42.9	US-08-340-233-51	Sequence 51, App1	175	19	38.8	8 1	US-08-419-594-3
103	21	42.9	US-08-776-558-15	Sequence 15, App1	176	19	38.8	8 1	US-08-465-421-12
104	21	42.9	US-09-101-146-20	Sequence 20, App1	177	19	38.8	8 1	US-08-919-089-3
105	20	40.8	US-09-110-934A-1	Sequence 1, App1	178	19	38.8	8 1	US-08-340-283-25
106	20	40.8	US-08-325-509-49	Sequence 49, App1	179	19	38.8	8 2	US-08-444-818-342
107	20	40.8	US-08-477-509B-3	Sequence 3, App1	180	19	38.8	8 2	US-08-444-818-343
108	20	40.8	US-08-482-055B-3	Sequence 3, App1	181	19	38.8	8 2	US-08-444-818-343
109	20	40.8	US-09-144-791A-3	Sequence 3, App1	182	19	38.8	8 2	US-09-190-930-9
110	20	40.8	US-09-119-507B-4	Sequence 4, App1	183	19	38.8	8 2	US-08-885-366-7
111	20	40.8	US-08-397-556A-4	Sequence 4, App1	184	19	38.8	8 2	US-09-314-268-22
112	20	40.8	US-09-547-693-4	Sequence 4, App1	185	19	38.8	8 2	US-09-314-268-23
113	20	40.8	US-08-134-198E-20	Sequence 20, App1	186	19	38.8	8 2	US-09-314-268-24
114	20	40.8	US-09-186-316-24	Sequence 24, App1	187	19	38.8	8 2	US-09-314-268-25
115	20	40.8	US-09-536-252A-14	Sequence 14, App1	188	19	38.8	8 2	US-09-314-268-25
116	20	40.8	US-09-577-538B-24	Sequence 24, App1	189	19	38.8	8 2	US-08-695-592B-21
117	20	40.8	US-10-008-557-24	Sequence 24, App1	190	19	38.8	8 2	US-09-239-043D-8
118	20	40.8	US-10-317-252B-103	Sequence 403, App1	191	19	38.8	8 2	US-09-239-043D-201
119	20	40.8	US-08-472-453-57	Sequence 57, App1	192	19	38.8	8 2	US-09-239-043D-326
120	20	40.8	US-08-301-316-24	Sequence 62, App1	193	19	38.8	8 2	US-09-239-043D-326
121	20	40.8	US-09-331-242A-22	Sequence 22, App1	194	19	38.8	8 2	US-09-693-746-155
122	20	40.8	US-09-351-10304-62	Sequence 62, App1	195	19	38.8	8 2	US-10-181-546-1
123	20	40.8	US-08-444-818-339	Sequence 339, App1	196	19	38.8	8 2	US-09-788-308E-4
124	20	40.8	US-08-417-174-14	Sequence 14, App1	197	19	38.8	8 2	US-10-655-201-6
125	20	40.8	US-08-231-555A-14	Sequence 14, App1	198	19	38.8	8 4	PCT-US93-04754-7
126	20	40.8	US-09-007-961-14	Sequence 14, App1	199	19	38.8	8 6	5171845-8
127	20	40.8	US-09-101-146-36	Sequence 36, App1	200	19	38.8	8 6	5171847-10
128	20	40.8	US-09-558-154-249	Sequence 249, App1	201	19	38.8	9 1	US-08-1470-179-103
129	20	40.8	US-09-042-107-249	Sequence 249, App1	202	19	38.8	9 1	US-08-214-650-13
130	20	40.8	US-09-267-139-14	Sequence 14, App1	203	19	38.8	9 1	US-08-615-181-18
131	20	40.8	US-09-073-138-14	Sequence 14, App1	204	19	38.8	9 1	US-08-615-181-18
132	20	40.8	US-09-722-20D-249	Sequence 249, App1	205	19	38.8	9 1	US-08-290-268-17
133	20	40.8	US-09-676-475A-249	Sequence 249, App1	206	19	38.8	9 1	US-08-340-283-18
134	20	40.8	US-09-677-475A-249	Sequence 1346, App1	207	19	38.8	9 1	US-08-340-283-144
135	20	40.8	US-09-557-226-1346	Sequence 7, App1	208	19	38.8	9 1	US-08-146-028-148
136	20	40.8	US-09-716-964B-9	Sequence 1346, App1	209	19	38.8	9 1	US-08-146-028-148
137	20	40.8	US-10-007-555-249	Sequence 9, App1	210	19	38.8	9 1	US-08-146-028-149
138	20	40.8	US-10-007-555-249	Sequence 249, App1	211	19	38.8	9 1	US-08-146-028-149
139	20	40.8	US-09-641-808-16	Sequence 16, App1	212	19	38.8	9 1	US-08-146-028-151
140	19	38.8	US-09-006-428A-22	Sequence 22, App1	213	19	38.8	9 1	US-08-146-028-152
141	19	38.8	US-08-333-330-7	Sequence 8, App1	214	19	38.8	9 1	US-08-350-260A-180
142	19	38.8	US-08-433-411A-9	Sequence 9, App1	215	19	38.8	9 2	US-08-723-425A-447
143	19	38.8	US-09-615-387C-22	Sequence 22, App1	216	19	38.8	9 2	US-08-723-425A-448
144	19	38.8	US-09-607-033-30	Sequence 30, App1	217	19	38.8	9 2	US-08-723-425A-449
145	19	38.8	US-08-089-939A-9	Sequence 9, App1	218	19	38.8	9 2	US-08-723-425A-450
146	19	38.8	US-08-079-812-134	Sequence 134, App1	219	19	38.8	9 2	US-08-723-425A-451
147	19	38.8	US-08-187-006-49	Sequence 49, App1	220	19	38.8	9 2	US-08-723-425A-452
148	19	38.8	US-08-188-659A-49	Sequence 49, App1	221	19	38.8	9 2	US-09-112-206-447
149	19	38.8	US-08-134-198E-26	Sequence 26, App1	222	19	38.8	9 2	US-09-112-206-448
150	19	38.8	US-09-636-222A-15	Sequence 15, App1	223	19	38.8	9 2	US-09-112-206-449
151	19	38.8	US-09-006-128A-21	Sequence 21, App1	224	19	38.8	9 2	US-09-112-206-450
152	19	38.8	US-09-615-387C-21	Sequence 21, App1	225	19	38.8	9 2	US-09-112-206-451
153	19	38.8	US-09-623-548A-1217	Sequence 1217, App1	226	19	38.8	9 2	US-09-112-206-452
154	19	38.8	US-08-545-228-1	Sequence 1217, App1	227	19	38.8	9 2	US-09-227-357-312
155	19	38.8	US-09-788-308E-1	Sequence 1, App1	228	19	38.8	9 2	US-09-023-905A-20
156	19	38.8	US-10-017-222B-392	Sequence 392, App1	229	19	38.8	9 2	US-09-102-023-905A-18
157	19	38.8	US-10-317-222B-393	Sequence 393, App1	230	19	38.8	9 2	US-09-104-337A-180
158	19	38.8	PCT-US94-0705-9	Sequence 9, App1	231	19	38.8	9 2	US-09-311-784A-370
159	19	38.8	US-08-301-046A-12	Sequence 49, App1	232	19	38.8	9 2	US-09-311-784A-104
160	19	38.8	US-08-545-228-1	Sequence 1, App1	233	19	38.8	9 2	US-09-344-040C-20
161	19	38.8	US-08-666-473-28	Sequence 28, App1	234	19	38.8	9 2	US-08-801-405B-4
162	19	38.8	US-08-946-339A-23	Sequence 23, App1	235	19	38.8	9 2	US-09-508-330D-14
163	19	38.8	US-09-567-337A-23	Sequence 23, App1	236	19	38.8	9 2	US-09-790-497A-395
164	19	38.8	US-08-729-743A-23	Sequence 23, App1	237	19	38.8	9 2	US-09-497A-396
165	19	38.8	US-09-605B-1217	Sequence 1217, App1	238	19	38.8	9 2	US-09-790-497A-397
166	19	38.8	US-09-084-605B-27	Sequence 27, App1	239	19	38.8	9 2	US-09-790-497A-398
167	19	38.8	US-09-794-980-6	Sequence 6, App1	240	19	38.8	9 2	US-09-790-497A-399
168	19	38.8	US-09-508-910D-11	Sequence 11, App1	241	19	38.8	9 2	US-09-790-497A-400
169	19	38.8	US-09-562-914-23	Sequence 23, App1	242	19	38.8	9 2	US-09-576-824A-396
170	19	38.8	US-07-526-589-12	Sequence 12, App1	243	19	38.8	9 2	US-09-576-824A-396
171	19	38.8	US-08-072-063-7	Sequence 7, App1	244	19	38.8	9 2	US-09-576-824A-397
172	19	38.8	US-08-323-444A-5	Sequence 5, App1	245	19	38.8	9 2	US-09-576-824A-398
173	19	38.8	US-08-236-410-12	Sequence 12, App1	246	19	38.8	9 2	US-09-576-824A-398

247	38.8	US-09-576-824A-399	Sequence 399, App	4	App1
248	38.8	US-09-576-824A-400	Sequence 400, App	2	App1
249	38.8	US-09-533-039A-20	Sequence 20, App1	2	App1
250	38.8	US-09-239-043D-341	Sequence 541, App	2	App1
251	38.8	US-09-239-043D-1350	Sequence 1350, App	2	App1
252	38.8	US-09-239-043D-1779	Sequence 1779, App	2	App1
253	38.8	US-09-239-043D-1831	Sequence 1831, App	2	App1
254	38.8	US-09-239-043D-1933	Sequence 1933, App	2	App1
255	38.8	US-09-239-043D-2022	Sequence 447, App	2	App1
256	38.8	US-09-680-497-448	Sequence 448, App	2	App1
257	38.8	US-09-680-497-449	Sequence 449, App	2	App1
258	38.8	US-09-680-497-450	Sequence 450, App	2	App1
259	38.8	US-09-680-497-451	Sequence 451, App	2	App1
260	38.8	US-09-680-497-452	Sequence 452, App	2	App1
261	38.8	US-09-680-497-453	Sequence 28, App1	2	App1
262	38.8	US-09-367-703B-5	Sequence 5, App1	2	App1
263	38.8	US-09-935-430-11	Sequence 11, App1	2	App1
264	38.8	US-09-935-430-467	Sequence 467, App	2	App1
265	38.8	US-09-935-430-552	Sequence 552, App	2	App1
266	38.8	US-09-680-497-452	Sequence 452, App	2	App1
267	38.8	US-09-108-036B-28	Sequence 43, App1	2	App1
268	38.8	US-09-065-502-17	Sequence 17, App1	2	App1
269	38.8	US-09-978-309A-39	Sequence 39, App1	2	App1
270	38.8	US-09-978-109A-43	Sequence 43, App1	2	App1
271	38.8	US-09-973-778-297	Sequence 297, App	2	App1
272	38.8	US-09-641-808-14	Sequence 14, App1	2	App1
273	38.8	US-09-544-143A-22	Sequence 22, App1	2	App1
274	38.8	US-08-477-09B-12	Sequence 12, App1	2	App1
275	38.8	US-08-482-085B-12	Sequence 12, App1	2	App1
276	38.8	US-08-904-1760B-24	Sequence 24, App1	2	App1
277	38.8	US-09-444-791A-12	Sequence 12, App1	2	App1
278	38.8	US-09-547-178-178	Sequence 178, App	2	App1
279	38.8	US-09-547-693-214	Sequence 214, App	2	App1
280	38.8	US-09-095-639A-7	Sequence 7, App1	2	App1
281	38.8	US-09-825-561A-70	Sequence 12, App1	2	App1
282	38.8	US-10-185-115A-99	Sequence 99, App1	2	App1
283	38.8	US-08-171-137-2	Sequence 2, App1	2	App1
284	38.8	US-08-201-178-2	Sequence 12, App1	2	App1
285	38.8	US-08-299-636-37	Sequence 37, App1	2	App1
286	38.8	US-08-279-155-36	Sequence 36, App1	2	App1
287	38.8	US-08-713-484-2	Sequence 2, App1	2	App1
288	38.8	US-08-477-509B-13	Sequence 13, App1	2	App1
289	38.8	US-08-703-988A-36	Sequence 3, App1	2	App1
290	38.8	US-08-592-294-1	Sequence 36, App1	2	App1
291	38.8	US-08-454-559-1	Sequence 1, App1	2	App1
292	38.8	US-08-72-453-27	Sequence 27, App1	2	App1
293	38.8	US-08-666-473-6	Sequence 6, App1	2	App1
294	38.8	US-08-166-473-10	Sequence 10, App1	2	App1
295	38.8	US-08-340-283-3	Sequence 3, App1	2	App1
296	38.8	US-08-595-263-2	Sequence 2, App1	2	App1
297	38.8	US-08-454-559-1	Sequence 12, App1	2	App1
298	38.8	US-08-72-453-27	Sequence 36, App1	2	App1
299	38.8	US-08-666-473-6	Sequence 27, App1	2	App1
300	38.8	US-08-166-473-10	Sequence 13, App1	2	App1
301	38.8	US-08-972-760-27	Sequence 12, App1	2	App1
302	38.8	US-08-972-760-27	Sequence 85, App1	2	App1
303	38.8	US-08-167-506-12	Sequence 12, App1	2	App1
304	38.8	US-08-904-142-36	Sequence 25, App1	2	App1
305	38.8	US-08-915-189-27	Sequence 13, App1	2	App1
306	38.8	US-08-182-085B-13	Sequence 85, App1	2	App1
307	38.8	US-08-810-172-12	Sequence 12, App1	2	App1
308	38.8	US-08-950-998-27	Sequence 27, App1	2	App1
309	38.8	US-08-167-506-12	Sequence 85, App1	2	App1
310	38.8	US-09-144-791A-13	Sequence 13, App1	2	App1
311	38.8	US-09-373-694-27	Sequence 27, App1	2	App1
312	38.8	US-09-136-874-11	Sequence 11, App1	2	App1
313	38.8	US-09-119-307B-6	Sequence 6, App1	2	App1
314	38.8	US-08-897-556A-6	Sequence 6, App1	2	App1
315	38.8	US-09-939-181-27	Sequence 27, App1	2	App1
316	38.8	US-09-939-481-85	Sequence 85, App1	2	App1
317	38.8	US-08-817-832B-11	Sequence 11, App1	2	App1
318	38.8	US-08-877-005-294	Sequence 294, App	2	App1
319	38.8	US-09-547-693-6	Sequence 6, App1	2	App1
320	38.7	US-09-823-240A-4	Sequence 1, App1	2	App1
321	38.7	US-09-095-639A-1	Sequence 1, App1	2	App1
322	38.7	US-09-608-892-35	Sequence 35, App1	2	App1
323	38.7	US-10-346-927-27	Sequence 27, App1	2	App1
324	38.7	US-10-346-127-85	Sequence 8, App1	2	App1
325	38.7	PCT-US94-01840-13	PCT-US94-01840-13	4	App1
326	38.7	PCT-US94-02552-12	PCT-US94-02552-12	4	App1
327	38.7	US-07-989-290-2	US-07-989-290-2	2	App1
328	38.7	US-08-271-698-2	US-08-271-698-2	2	App1
329	38.7	US-08-171-337-18	US-08-171-337-18	2	App1
330	38.7	US-08-117-491-16	US-08-117-491-16	2	App1
331	38.7	US-08-014-579-88	US-08-014-579-88	2	App1
332	38.7	US-08-201-046A-6	US-08-201-046A-6	2	App1
333	38.7	US-08-468-596-2	US-08-468-596-2	2	App1
334	38.7	US-08-299-536-38	US-08-299-536-38	2	App1
335	38.7	US-08-279-155-37	US-08-279-155-37	2	App1
336	38.7	US-08-271-364A-16	US-08-271-364A-16	2	App1
337	38.7	US-08-703-388A-17	US-08-703-388A-17	2	App1
338	38.7	US-08-209-261B-6	US-08-209-261B-6	2	App1
339	38.7	US-08-478-386A-64	US-08-478-386A-64	2	App1
340	38.7	US-08-472-453-11	US-08-472-453-11	2	App1
341	38.7	US-08-472-453-16	US-08-472-453-16	2	App1
342	38.7	US-08-472-453-18	US-08-472-453-18	2	App1
343	38.7	US-08-472-453-19	US-08-472-453-19	2	App1
344	38.7	US-08-472-453-28	US-08-472-453-28	2	App1
345	38.7	US-08-472-453-40	US-08-472-453-40	2	App1
346	38.7	US-08-472-453-42	US-08-472-453-42	2	App1
347	38.7	US-08-472-453-50	US-08-472-453-50	2	App1
348	38.7	US-08-472-453-53	US-08-472-453-53	2	App1
349	38.7	US-08-292-597-64	US-08-292-597-64	2	App1
350	38.7	US-08-222-115B-16	US-08-222-115B-16	2	App1
351	38.7	US-08-466-473-108	US-08-466-473-108	2	App1
352	38.7	US-08-360-784B-18	US-08-360-784B-18	2	App1
353	38.7	US-08-388-653-64	US-08-388-653-64	2	App1
354	38.7	US-08-473-985-64	US-08-473-985-64	2	App1
355	38.7	US-08-612-442-37	US-08-612-442-37	2	App1
356	38.7	US-08-483-898-64	US-08-483-898-64	2	App1
357	38.7	US-09-087-811-64	US-09-087-811-64	2	App1
358	38.7	US-08-156-855-64	US-08-156-855-64	2	App1
359	38.7	US-09-054-308A-16	US-09-054-308A-16	2	App1
360	38.7	US-09-157-753-64	US-09-157-753-64	2	App1
361	38.7	US-09-157-230-64	US-09-157-230-64	2	App1
362	38.7	US-08-602-999A-249	US-08-602-999A-249	2	App1
363	38.7	US-09-221-013-6	US-09-221-013-6	2	App1
364	38.7	US-08-819-101-11	US-08-819-101-11	2	App1
365	38.7	US-08-904-760B-26	US-08-904-760B-26	2	App1
366	38.7	US-09-158-010-64	US-09-158-010-64	2	App1
367	38.7	US-09-157-644-64	US-09-157-644-64	2	App1
368	38.7	US-09-087-640-64	US-09-087-640-64	2	App1
369	38.7	US-09-211-551-737C-15	US-09-211-551-737C-15	2	App1
370	38.7	US-09-302-629-64	US-09-302-629-64	2	App1
371	38.7	US-09-295-996B-12	US-09-295-996B-12	2	App1
372	38.7	US-09-520-254-11	US-09-520-254-11	2	App1
373	38.7	US-09-551-254-11	US-09-551-254-11	2	App1
374	38.7	US-09-599-287A-19	US-09-599-287A-19	2	App1
375	38.7	US-09-551-737C-15	US-09-551-737C-15	2	App1
376	38.7	US-08-897-556A-103	US-08-897-556A-103	2	App1
377	38.7	US-09-295-497A-143	US-09-295-497A-143	2	App1
378	38.7	US-09-500-124-249	US-09-500-124-249	2	App1
379	38.7	US-09-551-254-11	US-09-551-254-11	2	App1
380	38.7	US-09-599-287A-19	US-09-599-287A-19	2	App1
381	38.7	US-09-551-737C-15	US-09-551-737C-15	2	App1
382	38.7	US-09-547-993-171	US-09-547-993-171	2	App1
383	38.7	US-09-295-497A-2	US-09-295-497A-2	2	App1
384	38.7	US-09-500-124-249	US-09-500-124-249	2	App1
385	38.7	US-09-551-254-11	US-09-551-254-11	2	App1
386	38.7	US-09-599-287A-19	US-09-599-287A-19	2	App1
387	38.7	US-09-551-737C-15	US-09-551-737C-15	2	App1
388	38.7	US-09-547-802-13	US-09-547-802-13	2	App1
389	38.7	US-09-295-497A-2	US-09-295-497A-2	2	App1
390	38.7	US-09-500-124-249	US-09-500-124-249	2	App1
391	38.7	US-09-551-254-11	US-09-551-254-11	2	App1
392	38.7	US-09-454-651B-26	US-09-454-651B-26	2	App1
393	38.7	US-09-454-651B-27	US-09-454-651B-27	2	App1
394	38.7	US-09-454-651B-27	US-09-454-651B-27	2	App1
395	38.7	US-09-454-651B-27	US-09-454-651B-27	2	App1
396	38.7	US-09-454-651B-27	US-09-454-651B-27	2	App1
397	38.7	US-09-454-651B-27	US-09-454-651B-27	2	App1
398	38.7	US-09-454-651B-27	US-09-454-651B-27	2	App1
399	38.7	US-09-454-651B-27	US-09-454-651B-27	2	App1
400	38.7	US-09-454-651B-27	US-09-454-651B-27	2	App1
401	38.7	US-09-454-651B-27	US-09-454-651B-27	2	App1
402	38.7	US-09-454-651B-27	US-09-45		

393	18	36.7	US-10-054-712-64	Sequence 64, App1	466	18	36.7	US-09-458-631-17
394	18	36.7	US-09-641-001-13	Sequence 13, App1	467	18	36.7	US-09-493-940-01
395	18	36.7	US-10-078-547-3	Sequence 3, App1	468	18	36.7	US-09-520-254-6
396	18	36.7	US-10-078-547-19	Sequence 19, App1	469	18	36.7	US-09-520-254-8
397	18	36.7	US-10-281-652-13	Sequence 13, App1	470	18	36.7	US-09-520-254-9
398	18	36.7	US-09-688-017-131	Sequence 131, App1	471	18	36.7	US-09-551-738B-13
399	18	36.7	US-07-989-950-3	Sequence 3, App1	472	18	36.7	US-09-599-987A-26
400	18	36.7	US-07-968-1781A-65	Sequence 65, App1	473	18	36.7	US-09-599-987A-26
401	18	36.7	US-08-271-598-3	Sequence 2, App1	474	18	36.7	US-09-599-991-562-26
402	18	36.7	US-08-151-249-3	Sequence 3, App1	475	18	36.7	US-08-861-153A-48
403	18	36.7	US-08-168-596-3	Sequence 3, App1	476	18	36.7	US-09-731-242A-19
404	18	36.7	US-08-188-223-10	Sequence 10, App1	477	18	36.7	US-10-062-623B-27
405	18	36.7	US-08-472-453-1	Sequence 1, App1	478	18	36.7	US-09-951-002-11
406	18	36.7	US-08-472-453-3	Sequence 3, App1	479	18	36.7	US-09-516-052-5
407	18	36.7	US-08-472-453-5	Sequence 5, App1	480	18	36.7	US-09-516-052-17
408	18	36.7	US-08-472-453-10	Sequence 10, App1	481	18	36.7	US-09-774-639-227
409	18	36.7	US-08-472-453-12	Sequence 12, App1	482	18	36.7	US-09-701-947A-80
410	18	36.7	US-08-472-453-13	Sequence 13, App1	483	18	36.7	US-10-078-547-26
411	18	36.7	US-08-472-453-14	Sequence 14, App1	484	18	36.7	US-09-688-017-132
412	18	36.7	US-08-472-453-38	Sequence 38, App1	485	18	36.7	US-09-902-481B-12
413	18	36.7	US-08-472-453-39	Sequence 39, App1	486	18	36.7	US-09-902-481B-12
414	18	36.7	US-08-472-453-41	Sequence 41, App1	487	18	36.7	US-09-902-481B-13
415	18	36.7	US-08-472-453-49	Sequence 49, App1	488	18	36.7	PCT-US94-101840-11
416	18	36.7	US-08-472-453-54	Sequence 54, App1	489	18	36.7	PCT-US94-13205-3
417	18	36.7	US-08-472-453-55	Sequence 55, App1	490	18	36.7	Patent No. 5194592
418	18	36.7	US-08-472-453-56	Sequence 56, App1	491	18	36.7	Sequence 12, App1
419	18	36.7	US-08-472-453-7	Sequence 7, App1	492	18	36.7	Sequence 4, App1
420	18	36.7	US-08-472-453-9	Sequence 109, App1	493	18	36.7	Sequence 6, App1
421	18	36.7	US-08-493-053-20	Sequence 20, App1	494	18	36.7	Sequence 4, App1
422	18	36.7	US-08-493-053-50	Sequence 50, App1	495	18	36.7	Sequence 14, App1
423	18	36.7	US-08-726-206A-130	Sequence 130, App1	496	18	36.7	Sequence 15, App1
424	18	36.7	US-08-727-995-17	Sequence 17, App1	497	18	36.7	Sequence 21, App1
425	18	36.7	US-08-727-995-17	Sequence 6, App1	498	18	36.7	Sequence 4, App1
426	18	36.7	US-08-666-473-7	Sequence 8, App1	499	18	36.7	Sequence 6, App1
427	18	36.7	US-08-666-473-109	Sequence 10, App1	500	18	36.7	Sequence 2, App1
428	18	36.7	US-08-693-053-20	Sequence 25, App1	501	18	36.7	Sequence 86, App1
429	18	36.7	US-08-726-206A-130	Sequence 17, App1	502	18	36.7	Sequence 4, App1
430	18	36.7	US-08-771-986A-13	Sequence 13, App1	503	18	36.7	Sequence 14, App1
431	18	36.7	US-08-944-479-6	Sequence 6, App1	504	18	36.7	Sequence 15, App1
432	18	36.7	US-08-944-479-8	Sequence 8, App1	505	18	36.7	Sequence 6, App1
433	18	36.7	US-08-944-479-9	Sequence 9, App1	506	18	36.7	Sequence 2, App1
434	18	36.7	US-08-817-547A-25	Sequence 27, App1	507	18	36.7	Sequence 9, App1
435	18	36.7	US-08-207-575A-17	Sequence 50, App1	508	18	36.7	Sequence 39, App1
436	18	36.7	US-08-771-986A-13	Sequence 12, App1	509	18	36.7	Sequence 12, App1
437	18	36.7	US-08-771-986A-13	Sequence 10, App1	510	18	36.7	Sequence 19, App1
438	18	36.7	US-08-819-101-6	Sequence 50, App1	511	18	36.7	Sequence 19, App1
439	18	36.7	US-08-819-101-8	Sequence 8, App1	512	18	36.7	Sequence 19, App1
440	18	36.7	US-08-819-101-9	Sequence 9, App1	513	18	36.7	Sequence 24, App1
441	18	36.7	US-08-804-166-27	Sequence 5, App1	514	18	36.7	Sequence 8, App1
442	18	36.7	US-08-846-141A-50	Sequence 5, App1	515	18	36.7	Sequence 54, App1
443	18	36.7	US-09-303-055-5	Sequence 10, App1	516	18	36.7	Sequence 19, App1
444	18	36.7	US-09-319-010-6	Sequence 2, App1	517	18	36.7	Sequence 54, App1
445	18	36.7	US-09-319-013-2	Sequence 3, App1	518	18	36.7	Sequence 54, App1
446	18	36.7	US-09-319-013-3	Sequence 4, App1	519	18	36.7	Sequence 54, App1
447	18	36.7	US-09-211-013-4	Sequence 5, App1	520	18	36.7	Sequence 54, App1
448	18	36.7	US-09-211-013-5	Sequence 17, App1	521	18	36.7	Sequence 54, App1
449	18	36.7	US-09-211-013-6	Sequence 1, App1	522	18	36.7	Sequence 10, App1
450	18	36.7	US-09-211-013-7	Sequence 10, App1	523	18	36.7	Sequence 10, App1
451	18	36.7	US-09-211-013-8	Sequence 5, App1	524	18	36.7	Sequence 19, App1
452	18	36.7	US-09-211-013-9	Sequence 17, App1	525	18	36.7	Sequence 61, App1
453	18	36.7	US-09-305-984-41	Sequence 41, App1	526	18	36.7	Sequence 19, App1
454	18	36.7	US-09-318-150-5	Sequence 5, App1	527	18	36.7	Sequence 19, App1
455	18	36.7	US-09-461-697-298	Sequence 13, App1	528	18	36.7	Sequence 19, App1
456	18	36.7	US-09-343-011B-8	Sequence 8, App1	529	18	36.7	Sequence 19, App1
457	18	36.7	US-09-478-546B-10	Sequence 41, App1	530	18	36.7	Sequence 17, App1
458	18	36.7	US-09-396-91C-5	Sequence 15, App1	531	18	36.7	Sequence 49, App1
459	18	36.7	US-09-551-067-50	Sequence 50, App1	532	18	36.7	Sequence 8, App1
460	18	36.7	US-09-026-221-5	Sequence 17, App1	533	18	36.7	Sequence 9, App1
461	18	36.7	US-09-026-221-7	Sequence 3, App1	534	18	36.7	Sequence 49, App1
462	18	36.7	US-09-295-346B-16	Sequence 16, App1	535	18	36.7	Sequence 13, App1
463	18	36.7	US-09-551-17	Sequence 17, App1	536	18	36.7	Sequence 13, App1
464	18	36.7	US-09-295-324B-3	Sequence 3, App1	537	18	36.7	Sequence 13, App1
465	18	36.7	US-08-845-381E-5	Sequence 5, App1	538	18	36.7	Sequence 17, App1

539	18	36.7	US-08-467-344A-491	Sequence 491, App
540	18	36.7	US-09-295-928B-4	Sequence 4, App
541	18	36.7	US-09-551-798B-10	Sequence 10, App
542	18	36.7	US-09-551-798B-14	Sequence 14, App
543	18	36.7	US-08-475-955-195	Sequence 195, App
544	18	36.7	US-08-475-955-196	Sequence 196, App
545	18	36.7	US-08-475-955-197	Sequence 197, App
546	18	36.7	US-08-475-955-198	Sequence 198, App
547	18	36.7	US-08-475-955-199	Sequence 199, App
548	18	36.7	US-08-475-955-200	Sequence 200, App
549	18	36.7	US-08-475-955-201	Sequence 201, App
550	18	36.7	US-08-475-955-202	Sequence 202, App
551	18	36.7	US-09-576-824A-598	Sequence 598, App
552	18	36.7	US-09-576-824A-598	Sequence 4, App
553	18	36.7	US-09-576-824A-598	Sequence 199, App
554	18	36.7	US-09-576-824A-598	Sequence 200, App
555	18	36.7	US-09-576-824A-598	Sequence 201, App
556	18	36.7	US-09-576-824A-598	Sequence 202, App
557	18	36.7	US-09-576-824A-598	Sequence 203, App
558	18	36.7	US-10-062-623B-28	Sequence 28, App
559	18	36.7	US-10-062-623B-28	Sequence 110, App
560	18	36.7	US-07-067-819D-110	Sequence 111, App
561	18	36.7	US-07-067-819D-111	Sequence 112, App
562	18	36.7	US-07-067-819D-142	Sequence 143, App
563	18	36.7	US-07-067-819D-144	Sequence 144, App
564	18	36.7	US-07-067-819D-145	Sequence 145, App
565	18	36.7	US-07-067-819D-146	Sequence 146, App
566	18	36.7	US-07-067-819D-147	Sequence 113, App
567	18	36.7	US-07-067-819D-148	Sequence 148, App
568	18	36.7	US-07-067-819D-149	Sequence 149, App
569	18	36.7	US-07-067-819D-150	Sequence 150, App
570	18	36.7	US-07-067-819D-151	Sequence 151, App
571	18	36.7	US-07-067-819D-152	Sequence 152, App
572	18	36.7	US-07-067-819D-153	Sequence 153, App
573	18	36.7	US-08-568-017-133	Sequence 57, App
574	18	36.7	US-08-568-017-133	Sequence 97, App
575	18	36.7	US-08-568-017-133	Sequence 9, App
576	18	36.7	US-08-568-017-133	Sequence 1, App
577	18	36.7	US-08-279-155-1	Sequence 1, App
578	18	36.7	US-08-279-155-1	Sequence 38, App
579	18	36.7	US-08-279-155-1	Sequence 87, App
580	18	36.7	US-08-408-604A-87	Sequence 2, App
581	18	36.7	US-08-454-859-2	Sequence 111, App
582	18	36.7	US-08-515-151-97	Sequence 112, App
583	18	36.7	US-08-566-473-111	Sequence 112, App
584	18	36.7	US-08-566-473-112	Sequence 7, App
585	18	36.7	US-08-566-473-112	Sequence 13, App
586	18	36.7	US-08-566-473-112	Sequence 17, App
587	18	36.7	US-07-828-789-12	Sequence 4, App
588	18	36.7	US-08-389-011-5	Sequence 12, App
589	18	36.7	US-08-389-011-5	Sequence 5, App
590	18	36.7	US-08-340-233-11	Sequence 11, App
591	18	36.7	US-08-340-233-11	Sequence 13, App
592	18	36.7	US-08-340-233-13	Sequence 19, App
593	18	36.7	US-08-340-233-13	Sequence 134, App
594	18	36.7	US-08-340-233-141	Sequence 141, App
595	18	36.7	US-08-340-233-141	Sequence 13, App
596	18	36.7	US-08-340-233-141	Sequence 433, App
597	18	36.7	US-08-146-028-433	Sequence 434, App
598	18	36.7	US-08-146-028-433	Sequence 435, App
599	18	36.7	US-08-146-028-433	Sequence 436, App
600	18	36.7	US-08-146-028-433	Sequence 437, App
601	18	36.7	US-08-146-028-433	Sequence 438, App
602	18	36.7	US-08-146-028-433	Sequence 439, App
603	18	36.7	US-08-146-028-433	Sequence 453, App
604	18	36.7	US-08-146-028-433	Sequence 56, App
605	18	36.7	US-08-146-028-433	Sequence 57, App
606	18	36.7	US-08-146-028-433	Sequence 17, App
607	18	36.7	US-08-146-028-433	Sequence 23, App
608	18	36.7	US-08-612-842-1	Sequence 1, App
609	18	36.7	US-08-512-842-38	Sequence 38, App
610	18	36.7	US-08-386-234-77	Sequence 77, App
611	18	36.7	US-09-007-961-13	Sequence 13, App
612	18	36.7	US-08-369-643-59	Sequence 59, App

9	2	US-08-403-917A-5	Sequence 5, App	
9	2	US-08-817-547A-23	Sequence 23, App	
9	2	US-08-159-339A-629	Sequence 629, App	
9	2	US-08-159-339A-1080	Sequence 1080, App	
9	2	US-08-723-425A-433	Sequence 433, App	
9	2	US-08-723-425A-434	Sequence 434, App	
9	2	US-08-723-425A-435	Sequence 435, App	
9	2	US-09-113-921-22	Sequence 22, App	
9	2	US-09-112-206-433	Sequence 433, App	
9	2	US-09-112-206-434	Sequence 434, App	
9	2	US-09-112-206-435	Sequence 435, App	
9	2	US-09-112-206-436	Sequence 436, App	
9	2	US-09-112-206-437	Sequence 437, App	
18	36.7	US-08-723-425A-438	Sequence 438, App	
613	18	36.7	US-08-723-425A-439	Sequence 439, App
614	18	36.7	US-09-112-206-437	Sequence 437, App
615	18	36.7	US-09-112-206-438	Sequence 438, App
616	18	36.7	US-09-112-206-439	Sequence 439, App
617	18	36.7	US-09-112-206-440	Sequence 440, App
618	18	36.7	US-09-112-206-441	Sequence 441, App
619	18	36.7	US-09-112-206-442	Sequence 442, App
620	18	36.7	US-09-112-206-443	Sequence 443, App
621	18	36.7	US-09-112-206-444	Sequence 444, App
622	18	36.7	US-09-112-206-445	Sequence 445, App
623	18	36.7	US-09-112-206-446	Sequence 446, App
624	18	36.7	US-09-112-206-447	Sequence 447, App
625	18	36.7	US-09-112-206-448	Sequence 448, App
626	18	36.7	US-09-112-206-449	Sequence 449, App
627	18	36.7	US-09-112-206-450	Sequence 450, App
628	18	36.7	US-09-112-206-451	Sequence 451, App
629	18	36.7	US-09-112-206-452	Sequence 452, App
630	18	36.7	US-09-112-206-453	Sequence 453, App
631	18	36.7	US-09-112-206-454	Sequence 454, App
632	18	36.7	US-09-112-206-455	Sequence 455, App
633	18	36.7	US-09-112-206-456	Sequence 456, App
634	18	36.7	US-09-112-206-457	Sequence 457, App
635	18	36.7	US-09-112-206-458	Sequence 458, App
636	18	36.7	US-09-112-206-459	Sequence 459, App
637	18	36.7	US-09-112-206-460	Sequence 460, App
638	18	36.7	US-09-112-206-461	Sequence 461, App
639	18	36.7	US-09-112-206-462	Sequence 462, App
640	18	36.7	US-09-112-206-463	Sequence 463, App
641	18	36.7	US-09-112-206-464	Sequence 464, App
642	18	36.7	US-09-112-206-465	Sequence 465, App
643	18	36.7	US-09-112-206-466	Sequence 466, App
644	18	36.7	US-09-112-206-467	Sequence 467, App
645	18	36.7	US-09-112-206-468	Sequence 468, App
646	18	36.7	US-09-112-206-469	Sequence 469, App
647	18	36.7	US-09-112-206-470	Sequence 470, App
648	18	36.7	US-09-112-206-471	Sequence 471, App
649	18	36.7	US-09-112-206-472	Sequence 472, App
650	18	36.7	US-09-112-206-473	Sequence 473, App
651	18	36.7	US-09-112-206-474	Sequence 474, App
652	18	36.7	US-09-112-206-475	Sequence 475, App
653	18	36.7	US-09-112-206-476	Sequence 476, App
654	18	36.7	US-09-112-206-477	Sequence 477, App
655	18	36.7	US-09-112-206-478	Sequence 478, App
656	18	36.7	US-09-112-206-479	Sequence 479, App
657	18	36.7	US-09-112-206-480	Sequence 480, App
658	18	36.7	US-09-112-206-481	Sequence 481, App
659	18	36.7	US-09-112-206-482	Sequence 482, App
660	18	36.7	US-09-112-206-483	Sequence 483, App
661	18	36.7	US-09-112-206-484	Sequence 484, App
662	18	36.7	US-09-112-206-485	Sequence 485, App
663	18	36.7	US-09-112-206-486	Sequence 486, App
664	18	36.7	US-09-112-206-487	Sequence 487, App
665	18	36.7	US-09-112-206-488	Sequence 488, App
666	18	36.7	US-09-112-206-489	Sequence 489, App
667	18	36.7	US-09-112-206-490	Sequence 490, App
668	18	36.7	US-09-112-206-491	Sequence 491, App
669	18	36.7	US-09-112-206-492	Sequence 492, App
670	18	36.7	US-09-112-206-493	Sequence 493, App
671	18	36.7	US-09-112-206-494	Sequence 494, App
672	18	36.7	US-09-112-206-495	Sequence 495, App
673	18	36.7	US-09-112-206-496	Sequence 496, App
674	18	36.7	US-09-112-206-497	Sequence 497, App
675	18	36.7	US-09-112-206-498	Sequence 498, App
676	18	36.7	US-09-112-206-499	Sequence 499, App
677	18	36.7	US-09-112-206-500	Sequence 500, App
678	18	36.7	US-09-112-206-501	Sequence 501, App
679	18	36.7	US-09-112-206-502	Sequence 502, App
680	18	36.7	US-09-112-206-503	Sequence 503, App
681	18	36.7	US-09-112-206-504	Sequence 504, App
682	18	36.7	US-09-112-206-505	Sequence 505, App
683	18	36.7	US-09-112-206-506	Sequence 506, App
684	18	36.7	US-09-112-206-507	Sequence 507, App

Sequence 50,	App1
Sequence 17,	App1
Sequence 20,	App1
Sequence 1,	App1
Sequence 50,	App1
Sequence 8,	App1
Sequence 8,	App1
Sequence 14,	App1
Sequence 104,	App1
Sequence 44,	App1
Sequence 8,	App1
Sequence 11,	App1
Patent No. 5255287	
Sequence 7,	App1
Sequence 7,	App1
Sequence 8,	App1
Sequence 9,	App1
Sequence 4,	App1
Sequence 9,	App1
Sequence 14,	App1
Sequence 31,	App1
Sequence 14,	App1
Sequence 31,	App1
Sequence 9,	App1
Sequence 14,	App1
Sequence 9,	App1
Sequence 14,	App1
Sequence 22,	App1
Sequence 20,	App1
Sequence 9,	App1
Sequence 14,	App1
Sequence 9,	App1
Sequence 20,	App1
Sequence 20,	App1
Sequence 62,	App1
Sequence 62,	App1
Sequence 7,	App1
Sequence 9,	App1
Sequence 23,	App1
Sequence 7,	App1
Sequence 8,	App1
Sequence 54,	App1
Sequence 70,	App1
Sequence 110,	App1
Sequence 14,	App1
Sequence 10,	App1
Sequence 10,	App1
Sequence 37,	App1
Sequence 99,	App1
Sequence 110,	App1
Sequence 123,	App1
Sequence 197,	App1
Sequence 440,	App1
Sequence 133,	App1
Sequence 133,	App1
Sequence 133,	App1
Sequence 245,	App1
Sequence 522,	App1
Sequence 1199,	App1
Sequence 133,	App1
Sequence 397,	App1
Sequence 440,	App1
Sequence 362,	App1
Sequence 397,	App1

831	9	2	US-09-112-206-440
832	17	9	US-08-583-883-7
833	17	9	US-09-042-107-362
834	17	9	US-09-413-492-133
835	17	9	US-08-556-578B-38
836	17	9	US-09-203-921-7
837	17	9	US-09-424-414C-9
838	17	9	US-09-502-600-68
839	17	9	US-09-502-600-133
840	17	9	US-09-343-011B-7
841	17	9	US-08-634-32A-37
842	17	9	US-09-311-784A-328
843	17	9	US-09-311-784A-330
844	17	9	US-09-311-784A-334
845	17	9	US-09-125-641-24
846	17	9	US-09-722-250D-562
847	17	9	US-09-918-243-68
848	17	9	US-09-918-243-133
849	17	9	US-09-424-414C-9
850	17	9	US-09-790-497A-388
851	17	9	US-09-790-497A-772
852	17	9	US-09-454-204A-45
853	17	9	US-09-576-824A-388
854	17	9	US-09-647-372B-59
855	17	9	US-09-601-729-24
856	17	9	US-09-192-854-98
857	17	9	US-09-920-195A-12
858	17	9	US-09-60-497-397
859	17	9	US-09-680-497-440
860	17	9	US-09-281-760E-17
861	17	9	US-09-192-854-98
862	17	9	US-09-676-475A-362
863	17	9	US-09-631-863A-67
864	17	9	US-09-631-863A-98
865	17	9	US-09-959-548-6
866	17	9	US-09-511-939-174
867	17	9	US-09-865-548A-82
868	17	9	US-10-607-595-362
869	17	9	US-09-977-831-4
870	17	9	PCT-US92-0-865-5
871	17	9	PCT-US94-10480-12
872	17	9	PCT-US94-14106-36
873	17	9	5395760-12
874	16	32.7	US-08-048-164A-13
875	16	32.7	US-08-358-160-174
876	16	32.7	US-08-451-240-1
877	16	32.7	US-08-460-462-13
878	16	32.7	US-08-460-457-13
879	16	32.7	US-08-460-458-13
880	16	32.7	US-08-737-9227-5
881	16	32.7	US-08-776-665-1
882	16	32.7	US-08-460-455-13
883	16	32.7	US-08-470-846A-1
884	16	32.7	US-08-320-294A-13
885	16	32.7	US-08-954-915A-30
886	16	32.7	US-09-154-390-1
887	16	32.7	PCT-US94-12591-1
888	16	32.7	US-08-014-979-54
889	16	32.7	US-08-477-509B-9
890	16	32.7	US-08-591-632-25
891	16	32.7	US-08-687-706-56
892	16	32.7	US-08-482-085B-9
893	16	32.7	US-08-649-100-19
894	16	32.7	US-08-976-255-50
895	16	32.7	US-08-591-632-25
896	16	32.7	US-08-296-089-3
897	16	32.7	US-09-444-791A-9
898	16	32.7	US-09-099-053-4
899	16	32.7	US-09-611-451-25
900	16	32.7	US-09-119-507B-3
901	16	32.7	US-08-897-5556A-3
902	16	32.7	US-08-897-5556A-3
903	16	32.7	US-08-897-5556A-3

Sequence 440, App
Sequence 7, Appl1
Sequence 362, App
Sequence 133, App
Sequence 38, Appl1
Sequence 7, Appl1
Sequence 9, Appl1
Sequence 68, App
Sequence 133, App
Sequence 7, Appl1
Sequence 37, Appl1
Sequence 328, App
Sequence 330, App
Sequence 334, App
Sequence 24, Appl1
Sequence 362, App
Sequence 68, App
Sequence 133, App
Sequence 388, App
Sequence 572, App
Sequence 45, Appl1
Sequence 12, Appl1
Sequence 12, Appl1
Sequence 388, App
Sequence 59, Appl1
Sequence 244, App
Sequence 98, Appl1
Sequence 12, Appl1
Sequence 12, Appl1
Sequence 397, App
Sequence 440, App
Sequence 17, Appl1
Sequence 24, Appl1
Sequence 362, App
Sequence 4, Appl1
Sequence 67, Appl1
Sequence 88, Appl1
Sequence 6, Appl1
Sequence 174, Appl1
Sequence 36, Appl1
Agent No. 5,395760
Sequence 13, Appl1
Sequence 174, App
Sequence 5, Appl1
Sequence 1, Appl1
Sequence 13, Appl1
Sequence 1, Appl1
Sequence 13, Appl1
Sequence 13, Appl1
Sequence 13, Appl1
Sequence 30, Appl1
Sequence 1, Appl1
Sequence 1, Appl1
Sequence 54, Appl1
Sequence 9, Appl1
Sequence 56, Appl1
Sequence 56, App
Sequence 9, Appl1
Sequence 4, Appl1
Sequence 19, Appl1
Sequence 35, Appl1
Sequence 50, Appl1
Sequence 25, Appl1
Sequence 3, Appl1
Sequence 9, Appl1
Sequence 4, Appl1
Sequence 25, Appl1
Sequence 3, Appl1
Sequence 105, App

977	8	1	US-08-189-331-152	Sequence 152, App
978	8	1	US-08-206-185-23	Sequence 23, App
979	8	1	US-08-469-526A-45	Sequence 45, App
980	8	1	US-08-666-473-12	Sequence 12, App
981	8	1	US-08-734-591A-45	Sequence 45, App
982	8	1	US-08-469-660-45	Sequence 45, App
983	8	1	US-08-471-068-151	Sequence 151, App
984	8	1	US-08-471-068-152	Sequence 152, App
985	8	2	US-08-341-018-78	Sequence 78, App
986	8	2	US-08-863-813A-19	Sequence 19, App
987	8	2	US-08-863-813A-20	Sequence 20, App
988	8	2	US-08-863-813A-20	Sequence 45, App
989	8	2	US-09-181-083-89	Sequence 89, App
990	8	2	US-08-735-021-45	Sequence 45, App
991	8	2	US-08-734-664A-45	Sequence 45, App
992	8	2	US-08-470-339-45	Sequence 45, App
993	8	2	US-08-676-318A-19	Sequence 20, App
994	8	2	US-08-676-318A-20	Sequence 10, App
995	8	2	US-09-296-089-10	Sequence 11, App
996	8	2	US-09-296-089-11	Sequence 12, App
997	8	2	US-09-296-089-12	Sequence 13, App
998	8	2	US-09-296-089-13	Sequence 22, App
999	8	2	US-09-296-089-13	Sequence 38, App
1000	8	2	US-09-561-500-38	App

ARTICLES

RESULT 1
-08-787-547-55
Sequence 55, Application US/08787547
Patent No. 5783567

GENERAL INFORMATION:

APPLICANT: Hadley, Mary Lynne
APPLICANT: Curley, Joanne M.
APPLICANT: Langer, Robert S.
TITLE OF INVENTION: MICROPARTICLES FOR DELIVERY OF NUCLEIC ACID
NUMBER OF SEQUENCES: 107
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson, P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FastSSO for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/787,547
FILING DATE: 22-JAN-1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Fraser, Janis K.
DECORATION NUMBER: 24-010

TITLE OF INVENTION: Use in Immunotherapy
FILE REFERENCE: 2368-McKenzie US/09/593,870A
CURRENT APPLICATION NUMBER: US/09/593,870A
CURRENT FILING DATE: 2000-06-14
PRIOR APPLICATION NUMBER: 09/223,043
PRIOR FILING DATE: 1998-12-30
NUMBER OF SEQ ID NOS: 69
SOFTWARE: FastSEQ for Windows Version 3.0
SEQ ID NO: 45
LENGTH: 9
TYPE: PRT
ORGANISM: Homo sapiens
US-09-593-870A-45

Query Match 79.6%; Score 39; DB 2; Length 9;
Best Local Similarity 77.8%; Pred. No. 4.6e+05;
Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1 STAPPVHN 9
Db 1 STAPPAHGV 9

RESULT 4

US-09-497-232-1
Sequence 1, Application US/09497232
GENERAL INFORMATION:
Patent No. 6600012
APPLICANT: AGRAWAL, Babita
KRANTZ, Mark J.
REDDISH, Mark A.
LONGENECKER, B. Michael
TITLE OF INVENTION: METHOD FOR GENERATING ACTIVATED T-CELLS
AND ANTIGEN-PULSED ANTIGEN-PRESENTING CELLS

NUMBER OF SEQUENCES: 34
CORRESPONDENCE ADDRESS:
ADDRESSEE: FOLEY & LARDNER
STREET: 3000 K Street, N.W.
CITY: Washington
STATE: D.C.
COUNTRY: U.S.A.
ZIP: 20007-5109

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/497,232
FILING DATE: 03-Feb-2000
CLASSIFICATION: <Unknown>

PRIORITY/AGENT INFORMATION:

NAME: Saxe, Bernhard D.
APPLICATION NUMBER: US/09/074,410
FILING DATE: 08-MAY-1998
APPLICATION NUMBER: US 60/045,949
FILING DATE: 08-MAY-1997

ATTORNEY/AGENT INFORMATION:

NAME: Saxe, Bernhard D.
REGISTRATION NUMBER: 28,665
REFERENCE/DOCKET NUMBER: 042881/0114
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 672-5300
TELEFAX: (202) 672-5399

INFORMATION FOR SEQ ID NO: 1:

SEQUENCE CHARACTERISTICS:
LENGTH: 9 amino acids
TYPE: amino acid
STRANDBNESS: <Unknown>
TOPOLOGY: Linear
MOLECULE TYPE: peptide
SEQUENCE DESCRIPTION: SEQ ID NO: 1:

US-09-497-232-1

Query Match 79.6%; Score 39; DB 2; Length 9;
Best Local Similarity 77.8%; Pred. No. 4.6e+05;
Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1 STAPPVHN 9
Db 1 STAPPAHGV 9

RESULT 5

US-10-296-317-44
Sequence 44, Application US/10296317
Patient No. 695167
GENERAL INFORMATION:
APPLICANT: Zimmermann, Daniel S
APPLICANT: Sarin, Prem S
TITLE OF INVENTION: T CELL BINDING LIGAND PEPTIDES, PEPTIDE
FILE REFERENCE: CS-112
CURRENT APPLICATION NUMBER: US/10/296,317
CURRENT FILING DATE: 2002-11-22
PRIORITY APPLICATION NUMBER: US 60/206548
PRIOR FILING DATE: 2000-05-24
PRIORITY APPLICATION NUMBER: PCT/US07/16793
PRIOR FILING DATE: 2001-05-24
NUMBER OF SEQ ID NOS: 96
SOFTWARE: PatentIn version 3.1
SEQ ID NO 44
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Muc1 Peptide M1b

US-10-296-317-44

Query Match 79.6%; Score 39; DB 2; Length 9;
Best Local Similarity 77.8%; Pred. No. 4.6e+05;
Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1 STAPPVHN 9
Db 1 STAPPAHGV 9

RESULT 6

US-09-497-232-25
Sequence 25, Application US/09497232
Patent No. 6600012
GENERAL INFORMATION:
APPLICANT: AGRAWAL, Babita
KRANTZ, Mark J.
REDDISH, Mark A.
LONGENECKER, B. Michael
TITLE OF INVENTION: METHOD FOR GENERATING ACTIVATED T-CELLS
AND ANTIGEN-PULSED ANTIGEN-PRESENTING CELLS
NUMBER OF SEQUENCES: 34
CORRESPONDENCE ADDRESS:
ADDRESSEE: Foley & Lardner
STREET: 3000 K Street, N.W.
CITY: Washington
STATE: D.C.
COUNTRY: U.S.A.
ZIP: 20007-5109

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/497,232
FILING DATE: 03-Feb-2000
CLASSIFICATION: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Saxe, Bernhard D.
REGISTRATION NUMBER: 28,665
REFERENCE/DOCKET NUMBER: 042881/0114
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 672-5300
TELEFAX: (202) 672-5399

SEQUENCE CHARACTERISTICS:
LENGTH: 9 amino acids
TYPE: amino acid
STRANDBNESS: <Unknown>
TOPOLOGY: Linear
MOLECULE TYPE: peptide
SEQUENCE DESCRIPTION: SEQ ID NO: 1:

US-09-497-232-2

FILING DATE: 03-Feb-2000

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/09/074,410
 FILING DATE: 08-MAY-1998
 APPLICATION NUMBER: US 60/045,949
 FILING DATE: 08-MAY-1997
 ATTORNEY/AGENT INFORMATION:
 NAME: Saxe, Bernhard D.
 REGISTRATION NUMBER: 28,665
 REFERENCE/DOCKET NUMBER: 042881/0114
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (202) 672-5300
 TELEFAX: (202) 672-5399
 INFORMATION FOR SEQ ID NO: 25:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 9 amino acids
 TYPE: amino acid
 STRANDEDNESS: <unknown>
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 SEQUENCE DESCRIPTION: SEQ ID NO: 25:
 US-09-497-232-25

Query Match Score 35; DB 1; Length 9;
 Best Local Similarity 85.7%; Pred. No. 4.6e+05;
 Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 STAPPVH 7
 Db 3 STAPPAH 9

RESULT 8
 US-08-288-059-18
 Sequence 18, Application US/08288059
 Patent No. 5827666
 GENERAL INFORMATION:
 APPLICANT: FINN, OLIVERA J.
 APPLICANT: FONTENOT, J. D.
 APPLICANT: MONTELLARO, RONALD C.
 TITLE OF INVENTION: SYNTHETIC MULTIPLE TANDEM REPEAT MUCIN
 NUMBER OF INVENTION: AND MUCIN-LIKE PEPTIDES, AND USES THEREOF
 NUMBER OF SEQUENCES: 36
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: CUSHMAN DARBY & CUSHMAN, L.L.P.
 STREET: 1100 NEW YORK AVENUE, N.W.
 CITY: WASHINGTON
 STATE: D.C.
 COUNTRY: U.S.A
 ZIP: 20005
 COMPUTER READABLE FORM:
 MEDIUM TYPE: FLOPPY disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/288,059
 FILING DATE: 08-AUG-1994
 ATTORNEY/AGENT INFORMATION:
 NAME: CHAPIN, MARIANA K.
 REGISTRATION NUMBER: 35,843
 REFERENCE/DOCKET NUMBER: 61137/205204
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 202-861-3711
 TELEFAX: 202-822-0944
 TELEX: 6714627 CUSH
 INFORMATION FOR SEQ ID NO: 18:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 9 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: peptide

US-08-288-059-18

RESULT 9
 US-08-288-059-20
 Sequence 20, Application US/08288059
 Patent No. 5827666
 GENERAL INFORMATION:
 APPLICANT: FINN, OLIVERA J.
 APPLICANT: FONTENOT, J. D.
 APPLICANT: MONTELLARO, RONALD C.
 TITLE OF INVENTION: SYNTHETIC MULTIPLE TANDEM REPEAT MUCIN
 NUMBER OF INVENTION: AND MUCIN-LIKE PEPTIDES, AND USES THEREOF

NUMBER OF SEQUENCES: 36
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: CUSHMAN DARBY & CUSHMAN, L.L.P.
 STREET: 1100 NEW YORK AVENUE, N.W.
 CITY: WASHINGTON
 STATE: D.C.
 ZIP: 20005
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patentn Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/288,059
 FILING DATE: 08-AUG-1994
 CLASSIFICATION: 424
 ATTORNEY/AGENT INFORMATION:
 NAME: CHAPIN, MARLANA K.
 REGISTRATION NUMBER: 35,843
 REFERENCE/DOCKET NUMBER: 61137/205204
 TELEPHONE: 202-861-3711
 TELEFAX: 202-822-0944
 TELEX: 6714627 CUSH
 INFORMATION FOR SEQ ID NO: 20:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 9 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 US-08-288-059-20

Query Match 71.4% Score 35; DB 1; Length 9;
 Best Local Similarity 75.0%; Pred. No. 4.6e+05;
 Matches 6; Conservative 0; Mismatches 2; Indels 0;
 Gaps 0;

Qy 2 TAPPVHNV 9
 Db 1 TAPPAHGV 8

RESULT 10
 US-09-593-870A-68
 Sequence 68, Application US/09593870A
 Patent No. 6548643
 GENERAL INFORMATION:
 APPLICANT: McKenzie, Ian F.C.
 APPLICANT: Apostolopoulos, Vassilis
 APPLICANT: Petersz, Geoff Allan
 TITLE OF INVENTION: Use in Immunotherapy
 FILE REFERENCE: 3368-McKenzie
 CURRENT APPLICATION NUMBER: US/09/593,870A
 CURRENT FILING DATE: 2000-06-14
 PRIOR APPLICATION NUMBER: 09/223,043
 NUMBER OF SEQ ID NOS: 69
 SOFTWARE: PastSEQ for Windows Version 3.0
 SEQ ID NO 68
 LENGTH: 9
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-09-593-870A-68

Query Match 71.4% Score 35; DB 2; Length 9;
 Best Local Similarity 75.0%; Pred. No. 4.6e+05;
 Matches 6; Conservative 0; Mismatches 2; Indels 0;
 Gaps 0;

Qy 2 TAPPVHNV 9
 Db 1 TAPPAHGV 8

RESULT 11
 US-08-134-198E-23
 Sequence 23, Application US/08134198E
 Patent No. 6190855
 GENERAL INFORMATION:
 APPLICANT: CANCER RESEARCH FUND
 APPLICANT: OF CONTRA COSTA
 APPLICANT: PETERSON, JERRY A.
 APPLICANT: LAROCCA, DAVID J.
 TITLE OF INVENTION: PROTEIN CONTAINING HMFG
 NUMBER OF SEQUENCES: 42
 CURRENT APPLICATION DATA:
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Pretty, Schroeder & Poplawski
 STREET: 444 South Flower Street, Suite 1900
 CITY: Los Angeles
 STATE: California
 COUNTRY: USA
 ZIP: 90071
 COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5" FLOPPY DISK
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0,
 SOFTWARE: Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/134,198E
 FILING DATE: October 8, 1993
 CLASSIFICATION: 530
 ATTORNEY/AGENT INFORMATION:
 NAME: Amzel, Viviana
 REGISTRATION NUMBER: 30,930
 REFERENCE/DOCKET NUMBER: P66 38208 (CRFC-003C)
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (213) 622-7700
 TELEFAX: (213) 489-4210
 INFORMATION FOR SEQ ID NO: 23:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 6
 TYPE: amino acid
 STRANDEDNESS:
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 US-08-134-198E-23

Query Match 63.3% Score 31; DB 2; Length 6;
 Best Local Similarity 63.3%; Pred. No. 4.6e+05;
 Matches 5; Conservative 0; Mismatches 1; Indels 0;
 Gaps 0;

Qy 2 TAPPVH 7
 Db 1 TAPPAH 6

RESULT 12
 US-08-288-059-21
 Sequence 21, Application US/08288059
 Patent No. 5827666
 GENERAL INFORMATION:
 APPLICANT: FINN, OLIVERA J.
 APPLICANT: PONTENOT, J. D.
 APPLICANT: MONTELARO, RONALD C.
 TITLE OF INVENTION: SYNTHETIC MULTIPLE TANDEM REPEAT MUCIN
 NUMBER OF SEQUENCES: 36
 CURRENT APPLICATION DATA:
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: CUSHMAN DARBY & CUSHMAN, L.L.P.
 STREET: 1100 NEW YORK AVENUE, N.W.
 CITY: WASHINGTON
 STATE: D.C.
 COUNTRY: USA
 ZIP: 20005

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC Compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/288,059
 FILING DATE: 08-AUG-1994
 CLASSIFICATION: 424
 ATTORNEY/AGENT INFORMATION:
 NAME: CHAPIN, MARLANA K.
 REGISTRATION NUMBER: 35,843
 REFERENCE/DOCKET NUMBER: 61137/205204
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 202-861-3711
 TELEXFAX: 205-822-0944
 TELEX: 6714627 CUSH
 INFORMATION FOR SEQ ID NO: 21:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 9 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 US-08-288-059-21

Query Match Best Local Similarity Score DB Length
 Matches 5; Conservative 71.4%; 30; 1; 9;
 0; Mismatches 4.6e+05; Pred. No. 0;
 2; Indels 0; Gaps 0;

Qy 3 APPHNV 9
 Db ||| |
 Qy 1 APPAHGV 7

RESULT 13
 US-09-593-870A-67
 Sequence 67, Application US/09593870A
 ; Patent No. 6548643
 ; GENERAL INFORMATION:
 ; APPLICANT: McKenzie, Ian F.C.
 ; APPLICANT: Apostolopoulos, Vassos
 ; APPLICANT: Pietersz, Geoff Allan
 ; TITLE OF INVENTION: Antigen Carbohydrate Compounds and Their
 ; FILE REFERENCE: 236-McKenzie
 ; CURRENT APPLICATION NUMBER: US/09/593,870A
 ; CURRENT FILING DATE: 2000-06-14
 ; PRIOR APPLICATION NUMBER: 09/223,043
 ; PRIOR FILING DATE: 1998-12-30
 ; NUMBER OF SEQ ID NOS: 69
 ; SOFTWARE: FastSEQ for Windows Version 3.0
 ; SEQ ID NO: 67
 ; LENGTH: 9
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 ; US-09-593-870A-67

Query Match Best Local Similarity Score DB Length
 Matches 5; Conservative 71.4%; 30; 2; 9;
 0; Mismatches 4.6e+05; Pred. No. 0;
 2; Indels 0; Gaps 0;

Qy 3 APPHNV 9
 Db ||| |
 Qy 1 APPAHGV 7

RESULT 14
 US-08-134-198E-21
 Sequence 21, Application US/08134198E
 ; Paten No. 6190885
 ; GENERAL INFORMATION:
 ; APPLICANT: CANCER RESEARCH FUND

Query Match Best Local Similarity Score DB Length
 Matches 5; Conservative 71.4%; 30; 2; 9;
 0; Mismatches 4.6e+05; Pred. No. 0;
 2; Indels 0; Gaps 0;

Qy 3 APPHNV 9
 Db ||| |
 Qy 1 APPAHGV 7

RESULT 15
 US-08-134-198E-22
 Sequence 22, Application US/08134198E
 ; Patent No. 6190885
 ; GENERAL INFORMATION:
 ; APPLICANT: CANCER RESEARCH FUND
 ; APPLICANT: OF CONTRA COSTA
 ; APPLICANT: PETERSON, JERRY A.
 ; APPLICANT: LAROCCA, DAVID J.
 ; TITLE OF INVENTION: Fusion Protein Containing HMFG
 ; NUMBER OF SEQUENCES: 42
 ; SEQUENCE 22, Application US/08134198E
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: 3.5" Floppy disk
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: PatentIn Release #1.0,
 ; SOFTWARE: Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/134,198E

FILING DATE: October 8, 1993
 CLASSIFICATION: 530
 ATTORNEY/AGENT INFORMATION:
 NAME: Amzel, Viviana
 REGISTRATION NUMBER: 30,930
 REFERENCE/DOCKET NUMBER: P66 38208 (CRFC-003C)
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (213) 622-7700
 TELEFAX: (213) 489-4210
 LENGTH: 6
 SEQUENCE CHARACTERISTICS:
 TYPE: amino acid
 STRANDEDNESS:
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 US-08-134-198E-22

Query Match 55.1%; Score 27; DB 2; Length 6;
 Best Local Similarity 100.0%; Pred. No. 4.6e+05;
 Matches 5; Conservative 0; Mismatches 0;
 Indels 0; Gaps 0;

Qy 1 STAPP 5
 Db 1 STAPP 5

RESULT 16
 US-08-288-059-16
 Sequence 16, Application US/08288059
 GENERAL INFORMATION:
 APPLICANT: FINN, OLIVERA J.
 APPLICANT: FONTENOT, J. D.
 APPLICANT: MONTELARO, RONALD C.
 TITLE OF INVENTION: SYNTHETIC MULTIPLE TANDEM REPEAT MUCIN
 TITLE OF INVENTION: AND MUCIN-LIKE PEPTIDES, AND USES THEREOF
 NUMBER OF SEQUENCES: 36
 CORRESPONDENCE ADDRESS:
 ADDRESS: CUSHMAN DARBY & CUSHMAN, L.L.P.
 STREET: 1100 NEW YORK AVENUE, N.W.
 CITY: WASHINGTON
 STATE: D.C.
 COUNTRY: USA
 ZIP: 20005

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patentin Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/288,059
 FILING DATE: 08-AUG-1994
 CLASSIFICATION: 424
 ATTORNEY/AGENT INFORMATION:
 NAME: CHAPIN, MARLANA K.
 REGISTRATION NUMBER: 35,843
 REFERENCE/DOCKET NUMBER: 61137/205204

SEQUENCE CHARACTERISTICS:
 LENGTH: 9 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: peptide

Query Match 55.1%; Score 27; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 4.6e+05;

Match 5; Conservative 0; Mismatches 0;
 Indels 0; Gaps 0;

Qy 1 STAPP 5
 Db 4 STAPP 8

RESULT 17
 US-09-593-870A-43
 Sequence 43, Application US/09593870A
 GENERAL INFORMATION:
 APPLICANT: McKenzie, Ian F. C.
 APPLICANT: Apoptolopous, Geoff Allan
 APPLICANT: Pietersz, Geoff Allan
 TITLE OF INVENTION: Antigen Carbohydrate Compounds and Their
 FILE INVENTION: Use in Immunotherapy
 CURRENT APPLICATION NUMBER: US/09/593,870A
 CURRENT FILING DATE: 2000-06-14
 PRIORITY NUMBER: 09/223,043
 PRIORITY FILING DATE: 1998-12-30
 NUMBER OF SEQ ID NOS: 69
 SOFTWARE: FastSeq for Windows Version 3.0
 SEQ ID NO 43
 LENGTH: 9
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-09-593-870A-43

Query Match 55.1%; Score 27; DB 2; Length 9;
 Best Local Similarity 100.0%; Pred. No. 4.6e+05;
 Matches 5; Conservative 0; Mismatches 0;
 Indels 0; Gaps 0;

Qy 1 STAPP 5
 Db 4 STAPP 8

RESULT 18
 US-08-134-198E-24
 Sequence 24, Application US/08134198E
 GENERAL INFORMATION:
 APPLICANT: CANCER RESEARCH FUND
 APPLICANT: OF CONTRA COSTA
 APPLICANT: PETTERSON, JERRY A.
 APPLICANT: LARROCCA, DAVID J.
 TITLE OF INVENTION: FUSION PROTEIN CONTAINING HMFG
 NUMBER OF SEQUENCES: 42
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Pretty, Schroeder & Poplawski
 STREET: 444 South Flower Street, Suite 1900
 CITY: Los Angeles
 STATE: California
 COUNTRY: USA
 ZIP: 90071

COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5" Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0,
 VERSION #: 1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/134,198E
 FILING DATE: October 8, 1993
 CLASSIFICATION: 530
 ATTORNEY/AGENT INFORMATION:
 NAME: Amzel, Viviana
 REGISTRATION NUMBER: 30,330
 REFERENCE/DOCKET NUMBER: P66 38208 (CRFC-003C)
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (213) 622-7700

; INFORMATION FOR SEQ ID NO: 24:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 6
 ; TYPE: amino acid
 ; STRANDEDNESS:
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: peptide
 US-08-134-198E-24

Query Match 53.1%; Score 26; DB 2; Length 6;
 Best Local Similarity 80.0%; Pred. No. 4.6e+05;
 Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3 APPVH 7
 |||
 Db 1 APPAH 5

RESULT 19
 US-08-134-198E-25
 Sequence 25, Application US/08134198E
 Patent No. 6190885
 GENERAL INFORMATION:
 APPLICANT: CANCER RESEARCH FUND
 APPLICANT: OF CONTRA COSTA, J.
 APPLICANT: PETERSON, JERRY A.
 APPLICANT: LAROCCA, DAVID J.
 TITLE OF INVENTION: FUSION PROTEIN CONTAINING HMFG
 NUMBER OF SEQUENCES: 42
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Pretty, Schroeder & Poplawski
 STREET: 444 South Flower Street, Suite 1900
 CITY: Los Angeles
 STATE: California
 COUNTRY: USA
 ZIP: 90071

COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5" FLOPPY DISK
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent In Release #1.0,
 SOFTWARE: Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/134,198E
 FILING DATE: October 8, 1993
 CLASSIFICATION: 530
 ATTORNEY/AGENT INFORMATION:
 NAME: Anzel, Viviana
 REGISTRATION NUMBER: 30,930
 REFERENCE DOCKET NUMBER: P66 38208 (CRFC-003C)

TELECOMMUNICATION INFORMATION:
 TELEFAX: (213) 622-7700
 INFORMATION FOR SEQ ID NO: 25:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 6
 TYPE: amino acid
 STRANDEDNESS:
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 US-08-134-198E-25

Query Match 53.1%; Score 26; DB 2; Length 6;
 Best Local Similarity 66.7%; Pred. No. 4.6e+05;
 Matches 4; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4 PPVHN 9
 |||
 Db 1 PPAHGV 6

US-08-472-453-4
 ; Sequence 4, Application US/08472453
 ; Patent No. 581002
 ; GENERAL INFORMATION:
 ; APPLICANT: Haupt, Andreas
 ; APPLICANT: Emeling, Franz
 ; APPLICANT: Romerdahl, Cynthia
 ; TITLE OF INVENTION: No. 5831002ei Compounds, The Preparation and Use
 ; NUMBER OF SEQUENCES: 59
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Patricia Granahan, Esq., Hamilton, Brook, Smith &
 ; STREET: Two Milita Drive
 ; CITY: Lexington
 ; STATE: MA
 ; COUNTRY: USA
 ; ZIP: 02173

COMPUTER READABLE FORM:
 MEDIUM TYPE: FLOPPY disk
 COMPUTER: IBM PC Compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent In Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/472,453
 FILING DATE: 07-JUN-1995
 CLASSIFICATION: 514
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 08/431,795
 FILING DATE: 05-JAN-1995
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US/07/985,696
 FILING DATE: 25-NOV-1992
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 07/885,788
 ATTORNEY/AGENT INFORMATION:
 NAME: Granahan, Patricia
 REGISTRATION NUMBER: 32,227
 REFERENCE/DOCKET NUMBER: BBC-029C
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 781 8616240
 TELEFAX: 781 8619540

INFORMATION FOR SEQ ID NO: 4:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 7 amino acids
 TYPE: amino acid
 STRANDEDNESS:
 TOPOLOGY: Linear
 MOLECULE TYPE: peptide

US-08-472-453-4
 Query Match 53.1%; Score 26; DB 1; Length 7;
 Best Local Similarity 100.0%; Pred. No. 4.6e+05;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 PPVH 7
 |||
 Db 4 PPVH 7

RESULT 21
 US-08-288-059-22
 ; Sequence 22, Application US/08288059
 ; Patent No. 5827666
 ; GENERAL INFORMATION:
 ; APPLICANT: FINN, OLIVERA J.
 ; APPLICANT: FONTENOT, J. D.
 ; APPLICANT: MONTELARO, RONALD C.
 ; TITLE OF INVENTION: SYNTHETIC MULTIPLE TANDEM REPEAT MUCIN
 ; TITLE OF INVENTION: AND MUCIN-LIKE PEPTIDES, AND USES THEREOF
 ; NUMBER OF SEQUENCES: 36
 ; CORRESPONDENCE ADDRESS:

ADDRESSEE: CUSHMAN DARBY & CUSHMAN, L.L.P.
 STREET: 1100 NEW YORK AVENUE, N.W.
 CITY: WASHINGTON
 STATE: D.C.
 COUNTRY: USA
 ZIP: 20005
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent In Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICANT NUMBER: US/08/288,059
 FILING DATE: 08-AUG-1994
 CLASSIFICATION: 424
 ATTORNEY/AGENT INFORMATION:
 NAME: CHAPIN, MARLANA K.
 REGISTRATION NUMBER: 35,843
 REFERENCE/DOCKET NUMBER: 61137/205204
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 202-861-3711
 TELEX: 6714527 CUSH
 INFORMATION FOR SEQ ID NO: 22:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 9 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 US-08-288-059-22

Query Match 53.1%; Score 26; DB 1; Length 9;
 Best Local Similarity 66.7%; Pred. No. 4.6e-05;
 Matches 4; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Qy 4 PPVHN 9
 Db 1 PPARGV 6

RESULT 22
 US-08-210-266A-1
 Sequence 1, Application US/08210266A
 Patent No. 5545619

GENERAL INFORMATION:
 APPLICANT: Atkinson, John P.
 APPLICANT: Hourcade, Dennis
 APPLICANT: Krych, Malgorzata
 TITLE OF INVENTION: Modified Complement System
 TITLE OF INVENTION: Regulators
 NUMBER OF SEQUENCES: 18

CORRESPONDENCE ADDRESS:
 ADDRESSEE: Patrea L. Pabst
 STREET: 2800 One Atlantic Center, 1201 West Peachtree
 STREET: Street
 CITY: Atlanta
 STATE: Georgia
 COUNTRY: US
 ZIP: 30309-3450

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent In Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/210,266A
 FILING DATE: 18-MAR-1994
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 07/695,514
 FILING DATE: 03-MAY-1991
 ATTORNEY/AGENT INFORMATION:
 NAME: Pabst, Patrea L.
 REGISTRATION NUMBER: 31,284
 REFERENCE/DOCKET NUMBER: WU101
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (404) 873-3794
 TELEFAX: (404) 873-8735

INFORMATION FOR SEQ ID NO: 8:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 8 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 FEATURE:
 NAME/KEY: Modified-site
 LOCATION: 3
 OTHER INFORMATION: /note= "K/R"
 NAME/KEY: Modified-site

REGISTRATION NUMBER: 31,284
 REFERENCE/DOCKET NUMBER: WU101
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (404) 873-3794
 TELEFAX: (404) 873-8795
 INFORMATION FOR SEQ ID NO: 1:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 8 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 US-08-210-266A-1

Query Match 51.0%; Score 25; DB 1; Length 8;
 Best Local Similarity 66.7%; Pred. No. 4.6e-05;
 Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 Qy 1 STAPPY 6
 Db 1 STKPKPI 6

RESULT 23
 US-08-210-266A-8
 Sequence 8, Application US/08210266A
 Patent No. 5545619

GENERAL INFORMATION:

APPLICANT: Atkinson, John P.
 APPLICANT: Hourcade, Dennis
 APPLICANT: Krych, Malgorzata
 TITLE OF INVENTION: Modified Complement System
 TITLE OF INVENTION: Regulators

NUMBER OF SEQUENCES: 18

CORRESPONDENCE ADDRESS:
 ADDRESSEE: Patrea L. Pabst
 STREET: 2800 One Atlantic Center, 1201 West Peachtree
 STREET: Street
 CITY: Atlanta
 STATE: Georgia
 COUNTRY: US
 ZIP: 30309-3450

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent In Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/210,266A
 FILING DATE: 18-MAR-1994
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 07/695,514
 FILING DATE: 03-MAY-1991
 ATTORNEY/AGENT INFORMATION:
 NAME: Pabst, Patrea L.
 REGISTRATION NUMBER: 31,284
 REFERENCE/DOCKET NUMBER: WU101
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (404) 873-3794
 TELEFAX: (404) 873-8735

INFORMATION FOR SEQ ID NO: 8:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 8 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 FEATURE:
 NAME/KEY: Modified-site
 LOCATION: 3
 OTHER INFORMATION: /note= "K/R"
 NAME/KEY: Modified-site

Query Match Score 51.0%; Score 25; DB 1; Length 8;
 Best Local Similarity 66.7%; Pred. No. 4.6e+05; Indels 0; Gaps 0;
 Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 STAPPY 6
 Db 1 STKPKI 6

RESULT 25
 US-08-688-675-8
 / Sequence 8, Application US/08688675
 / Parent No. 5719127
 / GENERAL INFORMATION:
 / APPLICANT: Atkinson, John P.
 / APPLICANT: Hourcade, Dennis
 / APPLICANT: Krych, Malgorzata
 / TITLE OF INVENTION: Modified Complement System Regulators
 / NUMBER OF SEQUENCES: 18
 / CORRESPONDENCE ADDRESS:
 / ADDRESSEE: Patrea L. Pabst
 / STREET: 2800 One Atlantic Center, 1201 West Peachtree
 / STREET: Street
 / CITY: Atlanta
 / STATE: Georgia
 / COUNTRY: US
 / ZIP: 30309-3450
 / COMPUTER READABLE FORM:
 / MEDIUM TYPE: Floppy disk
 / COMPUTER: IBM PC compatible
 / OPERATING SYSTEM: PC-DOS/MS-DOS
 / SOFTWARE: Patent In Release #1.0, Version #1.25
 / CURRENT APPLICATION DATA:
 / APPLICATION NUMBER: US/08/688,675
 / FILING DATE: 30-JUN-1996
 / PRIOR APPLICATION DATA:
 / APPLICATION NUMBER: US 08/210,266
 / FILING DATE: 18-MAR-1994
 / PRIOR APPLICATION DATA:
 / APPLICATION NUMBER: US 07/695,514
 / FILING DATE: 03-MAY-1991
 / ATTORNEY/AGENT INFORMATION:
 / NAME: Pabst, Patrea L.
 / REGISTRATION NUMBER: 31,284
 / REFERENCE/DOCKET NUMBER: WU101div2
 / TELECOMMUNICATION INFORMATION:
 / TELEPHONE: (404)873-8794
 / TELEFAX: (404)873-8795
 / INFORMATION FOR SEQ ID NO: 8:
 / SEQUENCE CHARACTERISTICS:
 / LENGTH: 8 amino acids
 / TYPE: amino acid
 / STRANDEDNESS: single
 / TOPOLOGY: linear
 / MOLECULE TYPE: Peptide
 / FEATURE:
 / NAME/KEY: Modified-site
 / LOCATION: 6
 / OTHER INFORMATION: /note= "I/L/V"
 / FEATURE:
 / NAME/KEY: Modified-site
 / LOCATION: 8
 / OTHER INFORMATION: /note= "Q/N"
 US-08-688-675-8

Query Match Score 51.0%; Score 25; DB 1; Length 8;
 Best Local Similarity 66.7%; Pred. No. 4.6e+05; Indels 0; Gaps 0;

Qy 1 STAPPY 6
 Db 1 STKPKI 6

RESULT 26
 US-08-477-860C-1
 ; Sequence 1, Application US/08477860C

Patent No. 6010873
 GENERAL INFORMATION:
 APPLICANT: Atkinson, John P.
 APPLICANT: Hourcade, Dennis
 APPLICANT: Krych, Małgorzata
 TITLE OF INVENTION: Modified Complement System Regulators
 NUMBER OF SEQUENCES: 14
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Patrea L. Pabst
 STREET: 2800 One Atlantic Center, 1201 West Peachtree
 Street, Street: Atlanta
 CITY: Atlanta
 STATE: Georgia
 COUNTRY: US
 ZIP: 30309-3450

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/477,860C
 FILING DATE: 7-JUN-1995
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 08/210,266
 FILING DATE: 18-MAR-1994
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 07/695,514
 FILING DATE: 03-MAY-1991
 ATTORNEY/AGENT INFORMATION:
 NAME: Pabst, Patrea L.
 REGISTRATION NUMBER: 31,284
 REFERENCE/DOCKET NUMBER: WU 101 DIV
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (404) 873-8794
 TELEFAX: (404) 871-8795
 INFORMATION FOR SEQ ID NO: 1:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 8 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 US-08-477-860C-1

Query Match 51.0%; Score 25; DB 2; Length 8;
 Best Local Similarity 66.7%; Pred. No. 4.6e+05;
 Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 STAPPY 6
 Db 1 STKPKI 6

RESULT 27
 US-09-100-930A-22
 ; Sequence 22, Application US/09100930A
 ; GENERAL INFORMATION:
 ; APPLICANT: Van Byk, Jennifer E.
 ; APPLICANT: Mak, Alan S.
 ; APPLICANT: Cote, Graham P.
 ; TITLE OF INVENTION: Methods of Modulating Muscle Contraction
 ; FILE REFERENCE: 1997-021-03US
 ; CURRENT APPLICATION NUMBER: US/09/100,930A
 ; CURRENT FILING DATE: 1998-06-22
 ; PRIOR APPLICATION NUMBER: 60/050,478
 ; PRIOR FILING DATE: 1997-06-23
 ; PRIOR APPLICATION NUMBER: 60/089,505
 ; NUMBER OF SEQ ID NOS: 26
 ; SOFTWARE: PatentIn Ver. 2.1
 ; SEQ ID NO 22

; LENGTH: 9
 ; TYPE: PRT
 ; ORGANISM: Unknown
 ; FEATURE:
 ; NAME/KEY: PEPTIDE
 ; LOCATION: (1) .(9)
 ; OTHER INFORMATION: PAK site A autop phosphorylation
 ; NAME/KEY: PEPTIDE
 ; LOCATION: (9)
 ; OTHER INFORMATION: Targeted Ser phospho-amino acid
 ; US-09-100-930A-22

Query Match 51.0%; Score 25; DB 2; Length 9;
 Best Local Similarity 66.7%; Pred. No. 4.6e+05;
 Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 3 APPVAN 8
 Db 2 APPMRN 7

RESULT 28
 US-08-403-459-67
 ; Sequence 67, Application US/08403459
 ; Patent No. 6514942
 ; GENERAL INFORMATION:
 ; APPLICANT: Ioannides, Constantin G.
 ; APPLICANT: Fisk, Bryan A.
 ; APPLICANT: Ioannides, Maria G.
 ; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR STIMULATING T-LYMPHOCYTES
 ; NUMBER OF SEQUENCES: 68
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Arnold, White & Durkee
 ; STREET: P.O. Box 4433
 ; CITY: Houston
 ; STATE: Texas
 ; COUNTRY: United States of America
 ; ZIP: 77210
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS/ASCII
 ; SOFTWARE: PatentIn Release #1.0, Version #1.30
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/403-459
 ; FILING DATE: Concurrently Herewith
 ; CLASSIFICATION: 514
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Kitchell, Barbara S.
 ; REGISTRATION NUMBER: 33,928
 ; REFERENCE/DOCKET NUMBER: UTSC:390/KIT
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (512) 418-3000
 ; TELEFAX: (713) 789-2679
 ; TELEX: 79-0924
 ; INFORMATION FOR SEQ ID NO: 67:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 9 amino acids
 ; TYPE: amino acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: Peptide
 ; US-08-403-459-67

Query Match 51.0%; Score 25; DB 2; Length 9;
 Best Local Similarity 55.6%; Pred. No. 4.6e+05;
 Matches 5; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1 STAPPYHNV 9
 Db 1 SLADDAHGV 9

RESULT 29
US-08-836-778-1
; Sequence 1, Application US/08836778
; Patient No. 6451368
; GENERAL INFORMATION:
; APPLICANT: ELLIOTT, ROBERT BARTLETT
; TITLE OF INVENTION: METHOD OF SELECTING NON-DIABETOGENIC MILK OR MILK PRODUCTS AND MILK PRODUCTS SO SELECTED
; FILE REFERENCE: P3 9648 DCC
; CURRENT APPLICATION NUMBER: US/08/836,778
; CURRENT FILING DATE: 1995-11-03
; PRIOR FILING DATE: 1994-11-04
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO: 1
; LENGTH: 6
; TYPE: PRT
; FEATURE: Artificial Sequence
; OTHER INFORMATION: Description of Artificial Sequence:BOVINE MILK
; OTHER INFORMATION: PROTEIN
US-08-836-778-1

Query Match 49.0%; Score 24; DB 1; Length 7;
Best Local Similarity 80.0%; Pred. No. 4.6e+05;
Matches 4; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 STAPP 5
Db 3 ATAPP 7

RESULT 31
US-08-444-818-340
; Sequence 340, Application US/08444818
; Patent No. 6150087
; GENERAL INFORMATION:
; APPLICANT: Chien, David Y.
; TITLE OF INVENTION: NAMBV Diagnostics and Vaccines
; NUMBER OF SEQUENCES: 777
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Chiron Corporation
; STREET: 4550 Horton Street
; CITY: Emeryville
; STATE: CA
; COUNTRY: USA
; ZIP: 94608-2916
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC Compatible
; OPERATING SYSTEM: PC DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/444,818
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/403,590
; FILING DATE: 14-MAR-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Harbin, Alisa A.
; REGISTRATION NUMBER:
; TELEPHONE: (508)359-3885
; INFORMATION FOR SEQ ID NO: 340:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 8 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-444-818-340

Query Match 49.0%; Score 24; DB 2; Length 8;
Best Local Similarity 50.0%; Pred. No. 4.6e+05;
Matches 4; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 1 STAPPVHN 8
Db 3 :|||:

ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
 STREET: Burn
 CITY: Chicago
 STATE: Illinois
 COUNTRY: USA
 ZIP: 60606

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/188,228
 FILING DATE:
 CLASSIFICATION: 435
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 08/049,460
 FILING DATE: 19 APR 1993
 ATTORNEY/AGENT INFORMATION:
 APPLICATION NUMBER: US 07/872,643
 FILING DATE: 17 APR 1992
 NAME: No. 5597725and, Greta E.
 REGISTRATION NUMBER: 35,302
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (312) 474-6300
 TELEX: (312) 474-0448
 IN INFORMATION FOR SEQ ID NO: 1:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 6 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 US-08-188-228-1

Query Match 46.9%; Score 23; DB 1; Length 6;
 Best Local Similarity 100.0%; Pred. No. 4.6e+05;
 Matches 4; Conservative 0; Missmatches 0; Indels 0; Gaps 0;

RESULT 37
 US-08-332-643-1
 ; Sequence 1, Application US/08332638
 ; Patent No. 5646230
 ; GENERAL INFORMATION:
 ; APPLICANT: Suzuki, Shintaro
 ; TITLE OF INVENTION: CADHERIN MATERIALS AND METHODS
 ; NUMBER OF SEQUENCES: 62
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
 ; STREET: 6300 Sears Tower, 233 S. Wacker Drive
 ; CITY: Chicago
 ; STATE: Illinois
 ; COUNTRY: USA
 ; ZIP: 60606
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/332,638
 ; FILING DATE: 01-NOV-1994
 ; CLASSIFICATION: 435
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US 07/872,643
 ; FILING DATE: 17 APR 1992
 ; APPLICATION NUMBER: US/08/049,460
 ; FILING DATE:
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: No. 5646230and, Greta E.
 ; REGISTRATION NUMBER: 35,302
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (312) 474-6300
 ; TELEX: (312) 474-0448
 ; INFORMATION FOR SEQ ID NO: 1:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 6 amino acids
 ; TYPE: amino acid
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: peptide
 US-08-332-638-1

Query Match Score 23; DB 1; Length 6;
 Best Local Similarity 100.0%; Pred. No. 4.6e+05;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 TAPP 5
 Db 1 TAPP 4

RESULT 38
 US-09-005-215-29
 / Sequence 29, Application US/09005215
 / GENERAL INFORMATION:
 / APPLICANT: Ingram, Vernon M.
 / PATENT NO: 6172043
 / TITLE OF INVENTION: TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE CAUSED BY DISEASE CAUSED BY -AMYLOID PEPTIDES
 / NUMBER OF SEQUENCES: 30
 / CORRESPONDENCE ADDRESS:
 / ADDRESSEE: WOLF, GREENFIELD & SACKS, P.C.
 / STREET: 600 ATLANTIC AVENUE
 / CITY: BOSTON
 / STATE: MASSACHUSETTS
 / COUNTRY: UNITED STATES OF AMERICA
 / ZIP: 02110
 / COMPUTER READABLE FORM:
 / MEDIUM TYPE: Floppy disk
 / COMPUTER: IBM PC compatible
 / OPERATING SYSTEM: PC-DOS/MS-DOS
 / SOFTWARE: PatentIn Release #1.0, Version #1.25
 / CURRENT APPLICATION DATA:
 / APPLICATION NUMBER: US/09/005,215
 / FILING DATE:
 / CLASSIFICATION:
 / PRIOR APPLICATION DATA:
 / APPLICATION NUMBER: 60/035,847
 / FILING DATE: 10-JAN-1987
 / PRIOR APPLICATION DATA:
 / APPLICATION NUMBER: 08/960,188
 / FILING DATE: 29-OCT-1987
 / ATTORNEY/AGENT INFORMATION:
 / NAME: Gates, Edward R.
 / REGISTRATION NUMBER: 31,616
 / REFERENCE/DOCKET NUMBER: M0656/7035
 / TELECOMMUNICATION INFORMATION:
 / TELEPHONE: 617-720-3500
 / TELEFAX: 617-720-2441
 / INFORMATION FOR SEQ ID NO: 29:
 / SEQUENCE CHARACTERISTICS:
 / LENGTH: 6 amino acids
 / TYPE: amino acid
 / STRANDEDNESS: single
 / TOPOLOGY: linear
 / MOLECULE TYPE: Peptide
 / HYPOTHETICAL: NO

US-09-005-215-29

Query Match Score 23; DB 2; Length 6;
 Best Local Similarity 80.0%; Pred. No. 4.6e+05;
 Matches 4; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 STAPP 5
 Db 1 SSAPP 5

RESULT 39
 US-09-005-215-29
 / Sequence 29, Application US/09005215
 / GENERAL INFORMATION:

US-09-019-513-1.sz1m9.rai

Query Match Score 23; DB 2; Length 7;
 Best Local Similarity 100.0%; Pred. No. 4.6e+05;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 TAPP 5
 Db 1 TAPP 4

RESULT 41
 US-09-511-939-159
 / Sequence 159, Application US/09511939
 / Patent No. 6846634
 / GENERAL INFORMATION:
 / APPLICANT: Tomlinson, Ian M
 / TITLE OF INVENTION: Method to Screen Phage Display Libraries with Different Ligands
 / FILE REFERENCE: 8039/1070
 / CURRENT APPLICATION NUMBER: US/09/511,939
 / CURRENT FILING DATE: 2002-04-10

```

; PRIOR APPLICATION NUMBER: GB 9722131.1
; PRIOR FILING DATE: 1997-10-20
; PRIOR APPLICATION NUMBER: US 60/065,248
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: US 60/066,729
; PRIOR FILING DATE: 1997-11-11
; PRIOR APPLICATION NUMBER: PCT/GB98/03135
; PRIOR FILING DATE: 1998-10-20
; NUMBER OF SEQ ID NOS: 350
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO: 159
; LENGTH: 7
; TYPE: PRT
; ORGANISM: Homo sapiens
us-09-511-939-159

; ORIGINAL SOURCE:
; ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
; US-08-615-181-21

Query Match          46.9%; Score 23; DB 1; Length 8;
Best Local Similarity 80.0%; Pred. No. 4.6e+05;
Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      5 PVHNV 9
Db      2 PVHGV 6

RESULT 43
US-08-615-181-81
; Sequence 81, Application US/08615181
; Patent No. 5756666
; GENERAL INFORMATION:
; APPLICANT: MASAFUMI, TAKIGUCHI
; APPLICANT: MIWA, KIYOSHI
; TITLE OF INVENTION: PEPTIDES CAPABLE OF INDUCING IMMUNE
; RESPONSE TO HIV AND ANTI-AIDS AGENT FOR PREVENTING AND
; CURING AIDS
; NUMBER OF SEQUENCES: 115
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
; ADDRESSEE: P.C.
; STREET: 1755 S. JEFFERSON DAVIS HIGHWAY, SUITE 400
; CITY: ARLINGTON
; STATE: VA
; COUNTRY: USA
; ZIP: 22202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/615.181
; FILING DATE: 04-APR-1996
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/JP94/01756
; FILING DATE: 19-OCT-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 261302/1993
; FILING DATE: 19-OCT-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: OBLON, NORMAN F.
; REGISTRATION NUMBER: 24,618
; PREFERENCE/DOCKET NUMBER: 10-796-0 PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-413-3000
; TELEFAX: 703-413-2220
; INFORMATION FOR SEQ ID NO: 81:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 8 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; ORIGINAL SOURCE:
; ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
; US-08-615-181-81

Query Match          46.9%; Score 23; DB 1; Length 8;
Best Local Similarity 80.0%; Pred. No. 4.6e+05;
Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      5 PVHNV 9
Db      2 PVHGV 6

```

RESULT 44
US-08-477-860C-8
Sequence 8, Application US/08477860C

GENERAL INFORMATION:
Patent No.: 6010873
APPLICANT: Atkinson, John P.
APPLICANT: Hourcade, Dennis S.
APPLICANT: Krych, Malgorzata
TITLE OF INVENTION: Modified Complement System Regulators
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESS: Patrea L. Pabst
STREET: 2800 One Atlantic Center, 1201 West Peachtree
STREET: Street
CITY: Atlanta
STATE: Georgia
COUNTRY: US
ZIP: 30309-3450

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/477,860C
FILING DATE: 7-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/210,266
FILING DATE: 18-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/695,514
FILING DATE: 03-MAY-1991
ATTORNEY/AGENT INFORMATION:
NAME: Pabst, Patrea L.
REGISTRATION NUMBER: 31,284
REFERENCE/DOCKET NUMBER: WU 101 DIV
TELECOMMUNICATION INFORMATION:
TELEPHONE: (404) 873-8794
TELEFAX: (404) 873-8795

INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 8 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
FEATURE:
NAME/KEY: Modified-site
LOCATION: 3 OTHER INFORMATION: /note= Xaa can be Lys or Arg
FEATURE:
NAME/KEY: Modified-site
LOCATION: 6 OTHER INFORMATION: /note= Xaa can be Ile, Leu, or Val
FEATURE:
NAME/KEY: Modified-site
LOCATION: 8 OTHER INFORMATION: /note= Xaa can be Gln or Asn

US-08-477-860C-8
Query Match Best Local Similarity 46.9%; Score 23; DB 2; Length 8;
Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 STAPP 5
Db 1 STXPP 5

RESULT 45
US-08-444-818-341
Sequence 341, Application US/08444818

Parent No. 6150087
GENERAL INFORMATION:
APPLICANT: Rutter, William J.
TITLE OF INVENTION: NANBV Diagnostics and Vaccines
NUMBER OF SEQUENCES: 777
CORRESPONDENCE ADDRESS:
ADDRESSEE: Chiron Corporation
STREET: 4560 Horton Street
CITY: Emeryville
STATE: CA
COUNTRY: USA
ZIP: 94608-2916
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/444,818
FILING DATE:
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/403,590
FILING DATE: 14-MAR-1995
ATTORNEY/AGENT INFORMATION:
NAME: Harbin, Alisa A.
REGISTRATION NUMBER: 33,895
REFERENCE/DOCKET NUMBER: 0110.002
TELECOMMUNICATION INFORMATION:
TELEPHONE: (508)359-3876
TELEFAX: (508)359-3885
INFORMATION FOR SEQ ID NO: 341:
SEQUENCE CHARACTERISTICS:
LENGTH: 8 amino acids
TYPE: amino acid
STRANDEDNESS: Single
TOPOLOGY: linear
MOLECULE TYPE: Peptide
US-08-444-818-341

Query Match Best Local Similarity 46.9%; Score 23; DB 2; Length 8;
Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 2 TAPPEN 8
Db 1 TRPPLGN 7

RESULT 46
US-10-185-815A-76
Sequence 76, Application US/10185815A
Patent No. 6916789
GENERAL INFORMATION:
APPLICANT: Elan Corporation, plc
APPLICANT: O'Mahony, Daniel
APPLICANT: Lambkin, Imelda
APPLICANT: Higgins, Lisa
TITLE OF INVENTION: Peyer's Patch And/Or M-Cell Targeting Ligands
FILE REFERENCE: P26_480-A USA
CURRENT APPLICATION NUMBER: US/10/185,815A
CURRENT FILING DATE: 2002-06-28
PRIOR APPLICATION NUMBER: 60/302,591
PRIOR FILING DATE: 2001-07-02
NUMBER OF SEQ ID NOS: 100
SOFTWARE: PatentIn version 3.1
SEQ ID NO 76
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Segment of xenla epithelial-cadherin precursor (e-cadherin)

US-10-185-815A-76

RESULT 47
US-07-841-662-31
Query Match 46.9%; Score 23; DB 2; Length 8;
Best Local Similarity 100.0%; Pred. No. 4.6e+05;
Matches 4; Conservative 0; Mismatches 0; Indels 0;

Qy	2 TAPP 5	
Db	4 TAPP 7	

RESULT 48
US-07-841-662-31
Query Match 46.9%; Score 23; DB 1; Length 9;
Best Local Similarity 80.0%; Pred. No. 4.6e+05;
Matches 4; Conservative 0; Mismatches 1; Indels 1;

Qy	5 PVHNV 9	
Db	5 PVHGV 9	

GENERAL INFORMATION:
 APPLICANT: Peterson, Per A
 APPLICANT: Jackson, Michael
 APPLICANT: Lenglaude-Demoyen, Pierre
 TITLE OF INVENTION: IN VITRO ACTIVATION OF CYTOTOXIC T CELLS
 NUMBER OF SEQUENCES: 36
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: The Scripps Research Institute
 STREET: 10666 No. 5314813th Torrey Pines Road, TPC 8
 CITY: La Jolla
 STATE: California
 ZIP: 92037
 COMPUTER READABLE FORM:
 MEDIUM TYPE: FLOPPY DISK
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent In Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/07/841,662
 FILING DATE: 1992/21/9
 CLASSIFICATION: 435
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER:
 FILING DATE:
 ATTORNEY/AGENT INFORMATION:
 NAME: Logan, April
 REGISTRATION NUMBER: 33,950
 REFERENCE/DOCKET NUMBER: SPF0001P
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (619) 554-2337
 TELEFAX: (619) 554-6312
 INFORMATION FOR SEQ ID NO: 31:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 9 amino acids
 TYPE: AMINO ACID
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 HYPOTHETICAL: NO
 ANTI-SENSE: NO
 FRAGMENT TYPE: internal
 US-07-841-662-31

MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent in Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/146,145
 FILING DATE: 17-NOV-1993
 CLASSIFICATION: 435
 ATTORNEY/AGENT INFORMATION:
 NAME: Kitts, Monica C.
 REGISTRATION NUMBER: 36,105
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (202) 638-5000
 TELEFAX: (202) 638-4810
 INFORMATION FOR SEQ ID NO: 19:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 9 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 US-08-146-145-19

Query Match 46.9%; Score 23; DB 1; Length 9;
 Best Local Similarity 80.0%; Pred. No. 4.6e+05;
 Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 5 PVHNV 9
 Db 5 PVHGV 9

RESULT 50
 US-08-669-685-31
 Sequence 31, Application US/08669685
 Patent No. 5827737
 GENERAL INFORMATION:
 APPLICANT: Peterson, Per A
 APPLICANT: Jackson, Michael
 APPLICANT: Langladd-Demoyen, Pierre
 TITLE OF INVENTION: IN VITRO ACTIVATION OF CYTOTOXIC T CELLS
 NUMBER OF SEQUENCES: 36
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: The Scripps Research Institute
 STREET: 10666 No. 5827737 Torrey Pines Road, TPC 8
 CITY: La Jolla
 STATE: California
 COUNTRY: USA
 ZIP: 92037
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent in Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/669,685
 FILING DATE:
 CLASSIFICATION: 435
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 08/209,797
 FILING DATE: 10-MAR-1994
 APPLICATION NUMBER: US 07/841,662
 FILING DATE: 19-FEB-1992
 ATTORNEY/AGENT INFORMATION:
 NAME: Logan, April
 REGISTRATION NUMBER: 33,950
 REFERENCE/DOCKET NUMBER: SPF0001P
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (619) 554-2937
 TELEFAX: (619) 554-6312
 INFORMATION FOR SEQ ID NO: 31:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 9 amino acids
 TYPE: amino acid

This Page Blank (USP10)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Biocceleration Ltd.

105	28.6	P84497 TRASC	Q7JIS9 LAGAC
106	28.6	061754 CYNPY	Q7JIT0 LAGAC
107	28.6	Q7IZ50 _TRICK	Q7JIT1 LAGAC
108	28.6	Q7IZJ8 RANTE	Q9JIV1 LAGAC
109	28.6	Q9PRJ4 LEPOS	Q9JIV2 LAGAC
110	28.6	Q7IZI7 9NEOB	Q9JIV3 LAGAC
111	26.5	MAF SCHNA	Q9DQJ7 nequa pumil
112	26.5	CHOX ALCSP	QSDQK7 hygriastele
113	26.5	UC24 MAIZE	Q5dqm6 gronophyllu
114	26.5	050556 ACTAC	Q5dqm8 gronophyllu
115	26.5	QBKRNS3 9BNTR	Q5dqm9 gronophyllu
116	26.5	Q9T2W0 YEAST	Q5dqn4 ammandra rheop
117	26.5	Q6LD47 HUMAN	Q5dqn6 areca catec
118	26.5	Q42507 WHEAT	Q5dqp1 manicaria s
119	26.5	Q81802 ZAIZE	Q5dqp2 leopoldinia
120	26.5	PB532 LACSN	Q5dqp3 kentziopsis
121	26.5	Q7X4Q5 NODSP	Q5dqp4 ignanura wa
122	26.5	Q9R9E0 _BACSU	Q5dqn4 bacillus su
123	26.5	Q90345 9FLAV	Q5dqn5 bacillus su
124	26.5	PVK2 MUSDO	Q5dqn6 bacillus su
125	26.5	Q7WRU6 NODSP	Q5dqn7 bacillus su
126	26.5	Q67A06 HUMAN	Q5dqn8 bacillus su
127	26.5	Q67AR0 HUMAN	Q5dqn9 bacillus su
128	26.5	Q67AS0 HUMAN	Q5dqn10 bacillus su
129	26.5	Q67AS3 HUMAN	Q5dqn11 bacillus su
130	26.5	Q7WRU6 NODSP	Q5dqn12 bacillus su
131	24.5	E103 LITRU	Q5dqn13 bacillus su
132	24.5	E104 LITRU	Q5dqn14 bacillus su
133	24.5	SUGA ACIDO	Q5dqn15 bacillus su
134	24.5	ALL1 CYDDO	Q5dqn16 bacillus su
135	24.5	KIN15 PERAM	Q5dqn17 bacillus su
136	24.5	LCKL LEUMA	Q5dqn18 bacillus su
137	24.5	Q7Z6G0 HUMAN	Q5dqn19 bacillus su
138	24.5	Q9BXY5 _HUMAN	Q5dqn20 bacillus su
139	24.5	Q9uhk1 HUMAN	Q5dqn21 bacillus su
140	24.5	Q53TM6 _HUMAN	Q5dqn22 bacillus su
141	24.5	Q28866 MBGNO	Q5dqn23 bacillus su
142	24.5	Q9bf99 HYLCO	Q5dqn24 bacillus su
143	24.5	Q9BFA0 MACMU	Q5dqn25 bacillus su
144	24.5	Q9GRH3 _LAGOB	Q5dqn26 bacillus su
145	24.5	Q9PTT78 CANFA	Q5dqn27 bacillus su
146	24.5	Q5DOK1_9ILILI	Q5dqn28 bacillus su
147	24.5	Q5DOK8_9ILILI	Q5dqn29 bacillus su
148	24.5	Q5DOM2_9ILILI	Q5dqn30 bacillus su
149	24.5	Q5DM7_9ILILI	Q5dqn31 bacillus su
150	24.5	Q5DN2_9ILILI	Q5dqn32 bacillus su
151	24.5	Q5DQN3_9ILILI	Q5dqn33 bacillus su
152	24.5	Q5DOP5_9ILILI	Q5dqn34 bacillus su
153	24.5	Q5DOK8_9ILILI	Q5dqn35 bacillus su
154	24.5	Q5DOM2_9ILILI	Q5dqn36 bacillus su
155	24.5	Q5DM7_9ILILI	Q5dqn37 bacillus su
156	24.5	Q5DN2_9ILILI	Q5dqn38 bacillus su
157	24.5	Q5DQN3_9ILILI	Q5dqn39 bacillus su
158	24.5	Q5DOP5_9ILILI	Q5dqn40 bacillus su
159	24.5	Q5DOK8_9ILILI	Q5dqn41 bacillus su
160	24.5	Q5DOM2_9ILILI	Q5dqn42 bacillus su
161	24.5	Q5DM7_9ILILI	Q5dqn43 bacillus su
162	24.5	Q5DN2_9ILILI	Q5dqn44 bacillus su
163	24.5	Q5DQN3_9ILILI	Q5dqn45 bacillus su
164	24.5	Q5DOP5_9ILILI	Q5dqn46 bacillus su
165	24.5	Q5DOK8_9ILILI	Q5dqn47 bacillus su
166	24.5	Q5DOM2_9ILILI	Q5dqn48 bacillus su
167	24.5	Q5DM7_9ILILI	Q5dqn49 bacillus su
168	24.5	Q5DN2_9ILILI	Q5dqn50 bacillus su
169	24.5	Q5DQN3_9ILILI	Q5dqn51 bacillus su
170	24.5	Q5DOP5_9ILILI	Q5dqn52 bacillus su
171	24.5	Q5DOK8_9ILILI	Q5dqn53 bacillus su
172	24.5	Q5DOM2_9ILILI	Q5dqn54 bacillus su
173	24.5	Q5DM7_9ILILI	Q5dqn55 bacillus su
174	24.5	Q5DN2_9ILILI	Q5dqn56 bacillus su
175	24.5	Q5DQN3_9ILILI	Q5dqn57 bacillus su
176	24.5	Q5DOP5_9ILILI	Q5dqn58 bacillus su
177	24.5	Q5DOK8_9ILILI	Q5dqn59 bacillus su
178	24.5	P84497 trachemys	Q7JIS9 LAGAC
179	24.5	061754 cynops	Q7JIT0 LAGAC
180	24.5	Q71Z50 galus gall	Q7JIT1 LAGAC
181	24.5	Q71ZJ8 rana tempor	Q9JIV1 LAGAC
182	24.5	Q9PRJ4 lepisosteus	Q9JIV2 LAGOL
183	24.5	Q71ZJ7 helophryne	Q9JIV3 LAGOL
184	24.5	P84575 schistosoma	Q5dqq7 nequa pumil
185	24.5	P16101 alcaligenes	Q5dqm6 gronophyllu
186	24.5	P90630 sea mays	Q5dqm8 gronophyllu
187	24.5	050556 actinobacil	Q5dqm9 gronophyllu
188	24.5	Q8kbm8 klebsiella	Q5dqn4 ammandra rheop
189	24.5	Q9t2w0 saccharomy	Q70y80 plectranchu
190	24.5	Q61d47 homo sapien	Q50110 xenopus lae
191	24.5	Q42507 triticum ae	Q6vfg2 eugenia ros
192	24.5	Q81802 zea mays	Q5dqp2 viburnum
193	24.5	P83532 lacticibacil	Q9r7n9 haemophilus
194	24.5	Q7x4q5 nodularia s	Q7m0h1 mus musculus
195	24.5	Q9r9e0 bacillus su	Q8cg39 ratetus norv
196	24.5	Q90345 gba virus c	Q50110 xenopus lae
197	24.5	P84335 musca domes	Q4vn46 fugue rubrip
198	24.5	Q67aq6 homo sapien	P01858 homopteran
199	24.5	Q67ar0 homo sapien	P36515 sacccharomy
200	24.5	Q67ar1 homo sapien	P30425 bothrops
201	24.5	Q67as0 homo sapien	P13737 mytilus edu
202	24.5	Q67as3 homo sapien	P83781 candida alb
203	24.5	Q7wr06 nodularia s	P72081 taraxacum
204	24.5	P82093 littoria rub	P66205 transmissib
205	24.5	P82100 littoria rub	Q10582 bothrops ja
206	24.5	P19991 acheta dome	BPP7 rotin
207	24.5	Q67ar1 lydia ponion	CIP2 MYTED
208	24.5	P82152 periplaneta	Q8Mfy6
209	24.5	P72081 NOCLIA	P72081 NOCLIA
210	24.5	P82095 homoptera	Q66205 9ICORO
211	24.5	Q9by5 homo sapien	Q10582 homoptera
212	24.5	Q9uhk1 homo sapien	Q44K BORGII
213	24.5	P82152 lydia ponion	CAP4 CANAL
214	24.5	P82689 megaptera n	CLP THICU
215	24.5	P21140 leucophaea	CAR4 MACRS
216	24.5	Q766g0 homo sapien	RS7 MCRT
217	24.5	Q9by5 homo sapien	UPA1 HUMAN
218	24.5	Q9uhk1 homo sapien	P81886 porphyromon
219	24.5	P82152 lydia ponion	P83781 candida alb
220	24.5	Q28866 megaloptera n	P02032 lytrechinus
221	24.5	Q9bf99 hylobates c	Q8mung6 heciconia hum
222	24.5	Q9bf99 homoptera	Q9rbn4 9NEOP
223	24.5	Q766g0 homoptera	Q9trx8 bos taurus
224	24.5	Q9uhk1 homoptera	Q70kg9 sun scrofa
225	24.5	P82152 homoptera	Q19957 GOSH
226	24.5	Q9uhk1 homoptera	Q96QF9 HUMAN
227	24.5	P82152 homoptera	Q02032 LYTPPI
228	24.5	P82152 homoptera	Q9MUN6 9NEOP
229	24.5	P82152 homoptera	Q70kg9 PIG
230	24.5	P82152 homoptera	Q7M1U0 ORYSA
231	24.5	P82152 homoptera	Q9MSX4 9ASTR
232	24.5	P82152 homoptera	Q9MSX4 9NEOP
233	24.5	P82152 homoptera	Q4QYNT7 TOBAC
234	24.5	P82152 homoptera	Q56246 bacillus ps
235	24.5	P82152 homoptera	Q4Qyn9 sacccharum
236	24.5	P82152 homoptera	Q91957 GOSH
237	24.5	P82152 homoptera	Q7m041 ratetus norv
238	24.5	P82152 homoptera	Q8K3Z7 MOUSE
239	24.5	P82152 homoptera	Q5xpV7 MOUSE
240	24.5	P82152 homoptera	Q89498 murine hepa
241	24.5	P82152 homoptera	Q56153 campyllobact
242	24.5	P82152 homoptera	Q8awv8 anas platyr
243	24.5	P82152 homoptera	Q8awv8 cygnus colu
244	24.5	P82152 homoptera	Q8awv9 anser caerule
245	24.5	P82152 homoptera	Q8aww0 coscoroba c
246	24.5	P82152 homoptera	Q4pav5 lepidolamp
247	24.5	P82152 homoptera	Q85562 moloney mur
248	24.5	P82152 homoptera	Q81813 carcinus ma
249	24.5	P82152 homoptera	P41873 PANRE
250	24.5	P82152 homoptera	FAR5 CALIVO

251	11	22.4	9 1	ISOT_CYPCA	P42993 cyprinus ca	324	10	20.4	1	TRPI_PSEPU
252	11	22.4	9 1	OXVA_SCVCA	P42996 scyliorhinu	325	10	20.4	6	UN06_CLOPA
253	11	22.4	9 1	OXYT_SCVCA	P42997 scyliorhinu	326	10	20.4	6	VP19_HHV1K
254	11	22.4	9 1	OXYT_RAJCL	P42994 raja clavat	327	10	20.4	7	P10420 mytilus edu
255	11	22.4	9 1	OXYT_SQUAC	P43000 squalius aca	328	10	20.4	7	P84620 concholepis
256	11	22.4	9 1	TAUJ_PICJA	P17440 pichia jadi	329	10	20.4	7	HCBP_CONCC
257	11	22.4	9 1	TALI3_PICJA	P17441 pichia jadi	330	10	20.4	7	TY51_LITRA
258	11	22.4	9 1	TMK1_CALVO	P41517 calliphora	331	10	20.4	8	Q28742 orcytolagus
259	11	22.4	9 1	TRP4_LEIMA	P81736 leucophase	332	10	20.4	8	Q81809 carcinus ma
260	11	22.4	9 1	Q61DB5_HUMAN	P61db5 homo sapien	333	10	20.4	8	P82082 limnodynaest.
261	11	22.4	9 1	Q61E76_HUMAN	P61e76 homo sapien	334	10	20.4	8	TRPI_periplaneta
262	11	22.4	9 1	Q70SM2_HUMAN	P70sm2 homo sapien	335	10	20.4	8	P80632 zea mays (im
263	11	22.4	9 1	Q7M4R6_HUMAN	P7m4r6 homo sapien	336	10	20.4	8	UC26_MAIZE
264	11	22.4	9 1	Q86SFO_HUMAN	P86sfo homo sapien	337	10	20.4	8	VGLG_JHV2B
265	11	22.4	9 1	Q94AM8_HUMAN	P94am8 homo sapien	338	10	20.4	8	P81780 human herpe
266	11	22.4	9 1	Q9UCN5_HUMAN	P9ucn5 homo sapien	339	10	20.4	2	P82323 alovr
267	11	22.4	9 1	Q9UMF3_HUMAN	P9umf3 homo sapien	340	10	20.4	2	Q15894 homo sapien
268	11	22.4	9 1	P82208_BOMMO	P82208 bombyx mori	341	10	20.4	2	Q16468 homo sapien
269	11	22.4	9 1	Q7M3L3_PENSA	P7m3l3 penaeus van	342	10	20.4	8	Q5mxdi trypanosoma
270	11	22.4	9 1	Q7M2N7_BOSNA	P7m2n7 bos indicus	343	10	20.4	8	Q86BS9 strongyloce
271	11	22.4	9 1	Q6QVK7_PHAVU	P6qvk7 phaseolus v	344	10	20.4	8	Q7RH3_PLAYO
272	11	22.4	9 1	Q9TXL0_LILLO	P9txl0 liliium long	345	10	20.4	8	Q4Yj93 plasmoidium
273	11	22.4	9 1	Q56SS9L_SALMCA	P56ss9 sambucus ca	346	10	20.4	8	Q6r4q8 bubulus bub
274	11	22.4	9 1	Q55ST0_9DIPS	P55st0 viburnum ut	347	10	20.4	8	Q8vn81 bos taurus
275	11	22.4	9 1	Q56ST1_9DIPS	P56st1 viburnum ur	348	10	20.4	8	Q7m390 baenopter
276	11	22.4	9 1	Q56ST2_9DIPS	P56st2 viburnum tr	349	10	20.4	8	Q37854 bacteriophila
277	11	22.4	9 1	Q56ST3_VIBOP	P56st3 viburnum op	350	10	20.4	8	Q6jvp1 walachitam
278	11	22.4	9 1	Q56ST4_9DIPS	P56st4 viburnum ti	351	10	20.4	8	Q71v47 pseudomonas
279	11	22.4	9 1	Q56ST5_9DIPS	P56st5 viburnum su	352	10	20.4	8	Q7au44 acinetobact.
280	11	22.4	9 1	Q56ST6_9DIPS	P56st6 viburnum st	353	10	20.4	8	Q7M066 pseudomonas
281	11	22.4	9 1	Q56ST7_9DIPS	P56st7 viburnum si	354	10	20.4	8	Q80xv8 ratius sp.
282	11	22.4	9 1	Q56ST8_9DIPS	P56st8 viburnum sa	355	10	20.4	8	Q99mn0 mus musculus
283	11	22.4	9 1	Q56ST9_9DIPS	P56st9 viburnum ra	356	10	20.4	8	Q9md43 rattus norvegicus
284	11	22.4	9 1	Q56SU1_9DIPS	P56su1 viburnum pr	357	10	20.4	8	Q6xfw6 anthreptes
285	11	22.4	9 1	Q56SU2_9DIPS	P56su2 viburnum p1	358	10	20.4	8	P80027 octopus vul
286	11	22.4	9 1	Q56SU3_9DIPS	P56su3 viburnum od	359	10	20.4	8	P83318 spinacia ol
287	11	22.4	9 1	Q56ST7_9DIPS	P56st7 viburnum ur	360	10	20.4	8	P87093 penaeus monodon
288	11	22.4	9 1	Q56SU4_9DIPS	P56su4 viburnum nu	361	10	20.4	9	P29177 bos taurus
289	11	22.4	9 1	Q56SU5_9DIPS	P56su5 viburnum mo	362	10	20.4	9	Q7m666 mouse
290	11	22.4	9 1	Q56SU6_9DIPS	P56su6 viburnum me	363	10	20.4	9	Q96t449 giammarus
291	11	22.4	9 1	Q56SU7_9DIPS	P56su7 viburnum lo	364	10	20.4	9	P82321 spinacia ol
292	11	22.4	9 1	Q56SU8_9DIPS	P56su8 viburnum le	365	10	20.4	9	P83093 homalopeltis
293	11	22.4	9 1	Q56SU9_VIBLN	P56su9 viburnum la	366	10	20.4	9	P29177 bos taurus
294	11	22.4	9 1	Q56SV0_VIBLA	P56sv0 viburnum la	367	10	20.4	9	Q61b30 homalopeltis
295	11	22.4	9 1	Q56SV1_9DIPS	P56sv1 viburnum ka	368	10	20.4	9	P42999 squalus acanthias
296	11	22.4	9 1	Q56SV2_9DIPS	P56sv2 viburnum ju	369	10	20.4	9	P42998 eisenia fetida
297	11	22.4	9 1	Q56SV3_9DIPS	P56sv3 viburnum ja	370	10	20.4	9	P80027 octopus vulgaris
298	11	22.4	9 1	Q56SV4_9DIPS	P56sv4 viburnum ha	371	10	20.4	9	P82321 spinacia ol
299	11	22.4	9 1	Q56SV5_9DIPS	P56sv5 viburnum fu	372	10	20.4	9	P83093 homalopeltis
300	11	22.4	9 1	Q56SV6_9DIPS	P56sv6 viburnum fa	373	10	20.4	9	P29177 bos taurus
301	11	22.4	9 1	Q56SV7_9DIPS	P56sv7 viburnum er	374	10	20.4	9	Q7m666 mouse
302	11	22.4	9 1	Q56SV8_9DIPS	P56sv8 viburnum er	375	10	20.4	9	P96t78 human herpe
303	11	22.4	9 1	Q56SV9_9DIPS	P56sv9 viburnum el	376	10	20.4	9	P82321 spinacia ol
304	11	22.4	9 1	Q56SV10_VIBLN	P56sv10 viburnum ed	377	10	20.4	9	P82321 spinacia ol
305	11	22.4	9 1	Q56SV2_9DIPS	P56sv2 viburnum di	378	10	20.4	9	P82321 spinacia ol
306	11	22.4	9 1	Q56SV3_9DIPS	P56sv3 viburnum de	379	10	20.4	9	P82321 spinacia ol
307	11	22.4	9 1	Q56SV4_9DIPS	P56sv4 viburnum da	380	10	20.4	9	P82321 spinacia ol
308	11	22.4	9 1	Q56SV5_9DIPS	P56sv5 viburnum cy	381	10	20.4	9	P82321 spinacia ol
309	11	22.4	9 1	Q56SV6_9DIPS	P56sv6 viburnum el	382	10	20.4	9	P82321 spinacia ol
310	11	22.4	9 1	Q56SV7_9DIPS	P56sv7 viburnum ed	383	10	20.4	9	P82321 spinacia ol
311	11	22.4	9 1	Q56SV8_9DIPS	P56sv8 viburnum ci	384	10	20.4	9	P82321 spinacia ol
312	11	22.4	9 1	Q56SV9_VIBCA	P56sv9 viburnum ca	385	10	20.4	9	P82321 spinacia ol
313	11	22.4	9 1	Q56SV10_VIBAC	P56sv10 viburnum ac	386	10	20.4	9	P82321 spinacia ol
314	11	22.4	9 1	Q56SV11_VIBRA	P56sv11 viburnum ra	387	10	20.4	9	P82321 spinacia ol
315	11	22.4	9 1	Q56SV12_VIBRA	P56sv12 nodularia h	388	10	20.4	9	P82321 spinacia ol
316	11	22.4	9 1	Q56SV13_VIBRA	P56sv13 nodularia s	389	10	20.4	9	P82321 spinacia ol
317	11	22.4	9 1	Q56SV14_VIBRA	P56sv14 staphylococci	390	10	20.4	9	P82321 spinacia ol
318	11	22.4	9 1	Q56SV15_VIBRA	P56sv15 mus musculus	391	10	20.4	9	P82321 spinacia ol
319	11	22.4	9 1	Q56SV16_VIBRA	P56sv16 fundulus he	392	10	20.4	9	P82321 spinacia ol
320	11	22.4	9 1	Q56IX3_FUNHE	P56ix3 rattus sp.	393	10	20.4	9	P82321 spinacia ol
321	10	20.4	9 1	Q89491_MUMIVI	P82096 litoria rubra	394	10	20.4	9	P82321 spinacia ol
322	10	20.4	9 1	E101_LTTRU	P83569 sepiia officinalis	395	10	20.4	9	P82321 spinacia ol
323	10	20.4	6 1	SAPP_SEEOF	P83569 sepiia officinalis	396	10	20.4	9	P82321 spinacia ol

397	10	20.4	Q765Y9-CHICK	Q765Y9 gallus gall	Q7m1c5 ACIFC	8	2
398	10	20.4	Q4PU39-9ICICH	Q4pu39 lepidioleamp	Q8g940 borbu	8	2
399	9	18.4	BLOB_CTRR	P12905 citrobacter	Q9r517 cletridium	9	18.4
400	5	1	PYF1_PENMO	P84005 penaeus mon	Q9s6d5 escherichia	9	18.4
401	9	18.4	TMOF_SARBU	P41495 sarcophaga	Q62933 ratetus norv	9	18.4
402	9	18.4	E105_LITRU	P82101 licornia rub	Q78dx6 ratetus norv	9	18.4
403	7	1	HY7_PIG	P01153 suis scrofa	Q9j1d7 meocricetus	8	2
404	9	18.4	098866_SP1OL	098866 spinacia ol	Q9qvks ractitus sp.	8	2
405	9	18.4	08GL04_BORBU	089104 borrelia bu	Q5qnv2 mus musculus	9	18.4
406	9	18.4	08GL12_BORBU	Q89112 borrelia bu	Q35835 9MURJ	9	18.4
407	9	18.4	P70804_AZOVI	P70804 azotobacter	Q62527 MUSSP	9	18.4
408	9	18.4	AKH_ROMMI	P65578 bovine herp	Q80wds 5_MUSSP	9	18.4
409	9	18.4	AKH_TABAT	Q67113 influenza a	Qsydb9 xiphister m	9	18.4
410	9	18.4	007624_9RETR	007624 rous sarcom	Q715l5 VARDU	8	2
411	9	18.4	QJEB81_9HIV1	QJEB81 human immun	Q94v88 varanus tri	9	18.4
412	9	18.4	AKHG_GRYBI	P67785 gryllus bim	Q94v91 varanus tim	9	18.4
413	8	1	AKH_PROTE	P61856 protoporphri	Q94vao varanus sem	8	2
414	9	18.4	AKH_ROMMI	P67786 romalea mic	Q94va7 varanus sal	9	18.4
415	9	18.4	AKH_TABAT	P14595 tabanus atr	Q94vb2 varanus sal	9	18.4
416	9	18.4	AUJ12_CARMA	P81815 carcinus ma	Q94vb5 varanus sal	9	18.4
417	9	18.4	AUJ15_CARMA	P81818 carcinus ma	Q94ve4 varanus mel	9	18.4
418	9	18.4	AUJ4_CYDPO	P82155 cydia pomon	Q94ve4 varanus kei	9	18.4
419	9	18.4	AUJ8_CARMA	P81811 carcinus ma	Q94vf3 varanus saur	9	18.4
420	9	18.4	C125_CYPDO	P83661 cyphonoxyx	Q94vf9 varanus ind	9	18.4
421	9	18.4	DY85_LIMSA	P82083 limnodynast	Q94v4 varanus ben	9	18.4
422	9	18.4	FAR7_ASICSU	P81717 ascaris suu	Q94v55 varanus ben	9	18.4
423	9	18.4	GJUR_HUMAN	P02729 homo sapien	Q94v64 varanus leu	9	18.4
424	9	18.4	HTF2_BLAOR	P84258 biatta orie	Q94v74 varanus leu	9	18.4
425	9	18.4	HTF2_LBPDDE	P84257 leprinotars	Q94v75 varren	9	18.4
426	9	18.4	HTF2_PERAM	P84256 periplaneta	Q94v74 varren	9	18.4
427	9	18.4	LCK4_LBUMA	P21143 leucophaea	Q76vd6 bovine leuk	9	18.4
428	9	18.4	LCK6_LBUMA	P19988 leucophaea	P02100 balanoper	9	18.4
429	9	18.4	LJK_TEUMA	P13049 leucophaea	P84119 carcinus ma	9	18.4
430	9	18.4	LMNS_STABP	P23211 staphylococ	P4121 spodoptera	9	18.4
431	9	18.4	TXV1_PHONEI	P7m3p1 phoneutria	P94057 orcytobius	9	18.4
432	9	18.4	UP06_MOUSE	P84256 periplaneta	P84120 tenibrio mo	9	18.4
433	9	18.4	Q7LJH2_YEAST	P70mx3 trypanosoma	PCCAP_SEOBR	9	18.4
434	9	18.4	Q15889_HUMAN	Q71inh2 saccharomyc	P05486 conus geogr	9	18.4
435	9	18.4	Q53ST6_HUMAN	Q15889 homo sapien	P05487 conus stria	9	18.4
436	9	18.4	Q5B865_SCJHA	Q53st6 homo sapien	P69056 perimyzon	9	18.4
437	9	18.4	06TYEE3_9NEOP	Q5b865 schistosoma	P69056 hippopotamu	9	18.4
438	9	18.4	Q70MX3_TRYOP	Q6vyee3 heliconius	P90408 peneus mon	9	18.4
439	9	18.4	Q7M3N2_MANSE	Q70mx3 trypanosoma	P84004 loigo vulg	9	18.4
440	9	18.4	Q8WGD7_9FEUCA	Q7m3n2 manduca sex	P82926 posidonia	9	18.4
441	9	18.4	QAX617_PLACH	Q8wgd7 lomis hirta	P82926 taurulus	9	18.4
442	9	18.4	QKXT27_PLACH	Q4xt27 plasmoidium	P82926 taurulus	9	18.4
443	9	18.4	RAB51213_RABIT	Q95213 orcytobius	P84502 annelida. 1	9	18.4
444	9	18.4	O9TRY3_9CETA	Q9try3 sus sp. ins	Q9h326 homo sapien	9	18.4
445	9	18.4	Q8H9K1_CAUD	Q8h9k1 bacteriophila	Q9uc36 homo sapien	9	18.4
446	9	18.4	QBSBJ0_BPR69	Q8sbj0 bacteriophila	Q9ukj6 homo sapien	9	18.4
447	9	18.4	Q19956_GOSAR	Q19956 gossypium a	Q9uma0 homo sapien	9	18.4
448	9	18.4	Q19958_GOSBA	Q19958 gossypium b	Q9uqw0 homo sapien	9	18.4
449	9	18.4	Q19959_GOSTU	Q19959 gossypium t	Q15891 homo sapien	9	18.4
450	9	18.4	Q19960_GOSMU	Q19960 gossypium m	Q15896 homo sapien	9	18.4
451	9	18.4	Q19961_GOSDA	Q19961 gossypium m	Q15896 homo sapien	9	18.4
452	9	18.4	Q40659_ORYSA	Q40659 orzya sativ	Q15897 homo sapien	9	18.4
453	9	18.4	Q5D4X1_9MYRT	Q5d4x1 physocalym	Q15898 homo sapien	9	18.4
454	9	18.4	Q5D4X2_9MYRT	Q5d4x2 pehria comp	Q15899 homo sapien	9	18.4
455	9	18.4	Q5D4X4_9MYRT	Q5d4x4 koehneria m	Q15900 schistosoma	9	18.4
456	9	18.4	Q659Q3_9CARY	Q659q3 silene oste	P84502 macrospus eu	9	18.4
457	9	18.4	Q659Q5_9CARY	Q659q5 silene invo	Q9xjno bacteriophila	9	18.4
458	9	18.4	Q70Y57_9LAMI	Q70y57 fuerstia af	Q76fu9 pliocamium t	9	18.4
459	9	18.4	Q7XB03_MAIZE	Q7xb03 zea maya (m	Q76fu9 pliocamium r	9	18.4
460	9	18.4	Q9SD00_JILLI	Q9gd00 mascalpa mad	Q78x8p7 MAIZB	9	18.4
461	9	18.4	Q9RAY7_9LILI	Q9ray7 diocoreia t	Q78x8p7 MAIZB	9	18.4
462	9	18.4	Q4JLA6_BETVU	Q4jal6 beta vulgar	Q78x8p7 MAIZB	9	18.4
463	9	18.4	Q68485_KLEPN	Q68485 klebsiella	Q78x8p7 MAIZB	9	18.4
464	9	18.4	P72221_PSEESP	P72221 pseudomonas	Q78x8p7 MAIZB	9	18.4
465	9	18.4	P77556_ECOLI	P77556 escherichia	Q30790 erwinia amy	9	18.4
466	9	18.4	Q56140_STTRR	Q56140 streptococc	Q43928 aeromonas p	9	18.4
467	9	18.4	P81152_ANASL	P81152 anabaena sp	Q44001 aeromonas e	9	18.4
468	9	18.4	Q61dp8_PSEAE	Q61dp8 pseudomonas	Q44377 aeromonas t	9	18.4
469	9	18.4	Q7dkl7_STAUU	Q7dkl7 staphylococ	Q44466 aeromonas v	9	18.4

543	9	18.4	2	Q57328_AERSO	057328 aeromonas s	616	8	16.3	2
544	9	18.4	2	Q61AR8_ARBLY	Q61ar8 aeromonas h	617	8	16.3	2
545	9	18.4	2	Q8GIZ6_LACDL	Q8giz6 lacticibacil	618	8	16.3	2
546	9	18.4	2	Q8GHJ26_BORBU	Q8ghj26 borrelia bu	619	8	16.3	2
547	9	18.4	2	Q8AKU3_BORBU	Q8aku3 borrelia bu	620	8	16.3	2
548	9	18.4	2	Q9ZN16_STRPY	Q9zn16 streptococc	621	8	16.3	2
549	9	18.4	2	Q9R635_CHLTR	Q9r635 chlamydia t	622	8	16.3	2
550	9	18.4	2	Q9R9C4_BORBU	Q9r9c4 borrelia bu	623	8	16.3	2
551	9	18.4	2	Q8AF20_BACSU	Q8af20 bacillus su	624	8	16.3	2
552	9	18.4	2	Q47556_ECOLI	Q47556 escherichia	625	8	16.3	2
553	9	18.4	2	Q31353_BORG	Q31353 borgesius	626	8	16.3	2
554	9	18.4	2	Q924N8_MOUSE	Q924n8 mus musculu	627	8	16.3	2
555	9	18.4	2	Q61723_MOUSE	Q61723 mus musculu	628	8	16.3	2
556	9	18.4	2	Q71069_SPARA	Q71069 canine dist	629	8	16.3	2
557	9	18.4	2	Q61473_HHV1	Q61473 human herpes	630	8	16.3	2
558	9	18.4	2	Q82622_9OCRO	Q82622 avian infec	631	8	16.3	2
559	9	18.4	2	Q31415_CHICK	Q31415 gallus galli	632	8	16.3	2
560	9	18.4	2	Q61A69_TRITG	Q61a69 trimersurus	633	8	16.3	2
561	9	18.4	2	Q61A76_9SAUR	Q61a76 trimeresurus	634	8	16.3	2
562	9	18.4	2	Q71DX2_9SAUR	Q71dx2 urotoxophis	635	8	16.3	2
563	9	18.4	2	Q71Z81_RANPI	Q71z81 rana pipien	636	8	16.3	2
564	9	18.4	2	Q8SHF0_CHANA	Q8shf0 chamaeleo n	637	8	16.3	2
565	9	18.4	2	Q94VC6_9SAUR	Q94vc6 varanus pil	638	8	16.3	2
566	9	18.4	2	Q9VV1_9TARD	Q9vv1 varanus dor	639	8	16.3	2
567	9	18.4	2	QSPS68_CHICK	Qsp68 gallus galli	640	8	16.3	2
568	9	18.4	2	Q97688_GECKO	Q97688 gecko gecko	641	8	16.3	2
569	9	18.4	2	Q53EB6_9NEOB	Q53eb6 eleutherodactylus	642	8	16.3	2
570	9	18.4	2	Q4TU46_9AVES	Q4tu46 anser anser	643	8	16.3	2
571	9	18.4	2	Q8AEW8_9HIV1	Q8aew8 human immun	644	8	16.3	2
572	8	16.3	3	GRW_HUMAN	P01157 homo sapien	645	8	16.3	2
573	8	16.3	3	TEYL_BOMOR	P62970 bombina ori	646	8	16.3	2
574	8	16.3	3	THYL_NOTV1	P62971 nocophthalmus	647	8	16.3	2
575	8	16.3	3	THYL_PIG	P62968 sus scrofa	648	8	16.3	2
576	8	16.3	3	THYL_SHEEP	P62969 ovis aries	649	8	16.3	2
577	8	16.3	4	DGML_PSECH	P19916 pseudomonas	650	8	16.3	2
578	8	16.3	5	FARP_CHICK	P83308 gallus galli	651	8	16.3	2
579	8	16.3	5	TPIS_CANFA	P54714 canis familiaris	652	8	16.3	2
580	8	16.3	5	Q99007_HORVU	Q99007 hordeum vulgare	653	8	16.3	2
581	8	16.3	6	ASP2_LACSN	P82655 lactobacill	654	8	16.3	2
582	8	16.3	6	CIP1_MYTED	P13736 mytilus edulis	655	8	16.3	2
583	8	16.3	6	FAF2_ASCSU	P67879 ascaris suum	656	8	16.3	2
584	8	16.3	7	FAF2_PANRB	P67880 panagrellus	657	8	16.3	2
585	8	16.3	7	LANC_CARDE	P369660 carnobacterium	658	8	16.3	2
586	8	16.3	7	MNP1_LGPDE	P42984 leptinotarsa	659	8	16.3	2
587	8	16.3	7	UF03_MOUSE	P38641 mus musculus	660	8	16.3	2
588	8	16.3	7	Q8TAQ4_HUMAN	Q8taq4 homo sapiens	661	8	16.3	2
589	8	16.3	7	P32333_LYCSES	P93233 lycopersicum	662	8	16.3	2
590	8	16.3	7	P82445_TOBAC	P82445 nicotiana tabacum	663	8	16.3	2
591	8	16.3	7	Q8K3H6_RATTUS	Q8k3h6 rattus norvegicus	664	8	16.3	2
592	8	16.3	7	042564_FUGRU	O42564 fugi rubripes	665	8	16.3	2
593	8	16.3	7	059182_9SMEG	O99182 gnatholebia	666	8	16.3	2
594	8	16.3	7	AKH_GEOGST	P84241 geotrichum	667	8	16.3	2
595	8	16.3	8	AKH_MEMLM	P84240 melolontha	668	8	16.3	2
596	8	16.3	8	AKH_PACNA	P84242 pacifonia macrostoma	669	8	16.3	2
597	8	16.3	8	COX6B_RAT	P80430 rat	670	8	16.3	2
598	8	16.3	8	HTP1_BLAIR	P08939 pandalus borealis	671	8	16.3	2
599	8	16.3	8	HTP1_LBDPE	P84260 leptocephalus	672	8	16.3	2
600	8	16.3	8	Q35792_YEAST	Q35792 saccharomyces	673	8	16.3	2
601	8	16.3	8	HTP1_PERAM	P67789 tenebrio molitor	674	8	16.3	2
602	8	16.3	8	HTP1_TENMO	P67790 zophobas rufus	675	8	16.3	2
603	8	16.3	8	HTP1_ZOPRU	P08939 zophobas roseus	676	8	16.3	2
604	8	16.3	8	HTP1_BLAIR	P08939 zophobas	677	8	16.3	2
605	8	16.3	8	UH09_RAT	P08939 zophobas	678	8	16.3	2
606	8	16.3	8	Q15893_HUMAN	P15893 homo sapiens	679	8	16.3	2
607	8	16.3	8	Q15900_HUMAN	P15900 homo sapiens	680	8	16.3	2
608	8	16.3	8	Q59A66_HUMAN	P59a66 homo sapiens	681	8	16.3	2
609	8	16.3	8	Q52EY7_HUMAN	P52ey7 homo sapiens	682	8	16.3	2
610	8	16.3	8	Q9IMC7_HUMAN	P9imc7 homo sapiens	683	8	16.3	2
611	8	16.3	8	Q9V4J4_HUMAN	P9v4j4 homo sapiens	684	8	16.3	2
612	8	16.3	8	Q9Y4X6_HUMAN	P9y4x6 homo sapiens	685	8	16.3	2
613	8	16.3	8	Q61DS6_HUMAN	P61ds6 homo sapiens	686	8	16.3	2
614	8	16.3	8	Q53SB0_HUMAN	P53sb0 homo sapiens	687	8	16.3	2
615	8	16.3	8	Q548H6_HUMAN	P548h6 homo sapiens	688	8	16.3	2

689	8	16.3	2	Q99NS4	9HYST	cavia tachu	Q99NS4	cavia tachu	Q95DS6	9MAGN	magnolia wi
690	8	16.3	2	Q99NS5	DIPHE	dipodomys h	Q99NS5	dipodomys h	Q95DS7	9MAGN	magnolia si
691	8	16.3	2	Q99NS6	EREDO	erethizon d	Q99NS6	erethizon d	Q95DS7	9MAGN	magnolia si
692	8	16.3	2	Q99NS7	CRIGR	crictetus lili	Q99NS7	crictetus lili	Q95DS7	9MAGN	magnolia si
693	8	16.3	2	Q99NS8	RAT	rattus norv	Q99NS8	rattus norv	Q9GCV6	sclerostepm	
694	8	16.3	2	Q99NS9	MOUSE	mus musculu	Q99NS9	mus musculu	Q9GDL2	linospadix	
695	8	16.3	2	Q99NT0	PEDCA	pedetes cap	Q99NT0	pedetes cap	Q9T3P3	MAGNI	magnolia vi
696	8	16.3	2	Q99NT1	CASCN	castor cana	Q99NT1	castor cana	Q9THL5	MAGNA	magnolia ma
697	8	16.3	2	Q99NT2	YAMST	tamias stri	Q99NT2	tamias stri	Q9THL6	MAGNI	magnolia li
698	8	16.3	2	Q96LD23	MOUSE	mus musculu	Q61d23	mus musculu	Q9THL7	MAGN	magnolia si
699	8	16.3	2	Q9WJ33	9RALPH	swid herpes	Q9wJ33	swid herpes	Q9THL8	MAGN	magnolia si
700	8	16.3	2	Q8IGN4	_HEV1	meleagrid h	P79940	xenopus lae	Q9THL9	MAGN	magnolia py
701	8	16.3	2	P79940	XENBLA	papilio hexace	P94v82	xenopus lae	Q9THM0	MAGN	magnolia fr
702	8	16.3	2	Q94v82	9SAUR	papilio hanad	P19343	papilio hanad	Q9TNND7	LIRITU	lirioidendro
703	8	16.3	2	DNF1	LOCMI	litotria aur	P09495	litotria aur	Q9TNND8	LIRCH	lirioidendro
704	8	16.3	2	FAR3	CALIVO	papilio medea	P41858	calliphora	Q9TNND9	MICP1	lirioidendro
705	8	16.3	2	P43	ASCUSU	papilio medea	P43170	ascaris suu	Q9TNNE6	MAGN	magnolia fi
706	8	16.3	2	P43	ASCUSU	ascaris suu	P43172	ascaris suu	Q9TNNE7	MAGN	magnolia co
707	8	16.3	2	P43	CALUSI	calinectes	P38495	calinectes	Q9TNNE8	MAGN	magnolia co
708	8	16.3	2	FIBB	PAPHA	callophaga	P19343	papilio hanad	Q9TNNE9	MAGS1	magnolia sa
709	8	16.3	2	LITO	LITLU	callophaga	P09495	litotria aur	Q9TNNE4	MAGN	magnolia sa
710	8	16.3	2	LITR	PHTRD	phyliomedus	P08946	phyliomedus	Q9TNNE5	MAGN	magnolia ko
711	8	16.3	2	MOSH	CLYJJA	clypearaster	P19852	clypearaster	Q9TNNE6	MAGN	magnolia ko
712	8	16.3	2	NSK1	SARBU	cyathocarpa	P41492	cyathocarpa	Q9TNNE7	MAGN	magnolia li
713	8	16.3	2	ULAD	HUMAN	homo sapien	P31929	homo sapien	Q9TNNE8	MAGN	magnolia ac
714	8	16.3	2	UPA3	HUMAN	homo sapien	P30089	homo sapien	Q9TNNE9	MAGN	magnolia ac
715	8	16.3	2	Q51LX3	MAGGR	homo sapien	P09495	homo sapien	Q9TNF0	MAGN	magnolia tr
716	8	16.3	2	Q14277	HUMAN	homo sapien	Q14277	homo sapien	Q9TNF1	MAGN	magnolia he
717	8	16.3	2	Q16220	HUMAN	homo sapien	Q16220	homo sapien	Q9TNF2	MAGN	magnolia ta
718	8	16.3	2	Q61EH2	HUMAN	homo sapien	Q61eh2	homo sapien	Q9TNF3	MAGN	magnolia ni
719	8	16.3	2	Q61LBK1	HUMAN	homo sapien	Q61ek1	homo sapien	Q9TNF4	MAGN	magnolia sc
720	8	16.3	2	Q99887	HUMAN	homo sapien	Q99887	homo sapien	Q9TNF5	MAGN	magnolia gu
721	8	16.3	2	Q99H5	HUMAN	homo sapien	Q99H5	homo sapien	Q9TNF6	MAGG	magnolia gr
722	8	16.3	2	Q7m3N6	GRYBI	gryllus bim	Q7m3N6	gryllus bim	Q40UF2	MALDO	malus domes
723	8	16.3	2	QTRHC2	PLAYO	plasmoidium	QTRHC2	plasmoidium	Q45533	BACSU	bacillus su
724	8	16.3	2	QTRSP2	PLAYO	plasmoidium	QTRSP2	plasmoidium	P83157	ANABAENA	anabaena sp
725	8	16.3	2	QBH8X4	9EBCHN	diadema mex	Q8w8x4	diadema mex	Q8R514	TAPHYLOC	osidell7
726	8	16.3	2	QAY590	PLACH	diplodium mex	Q4Y590	diplodium mex	Q612A6	SINHIZOB	sinhizobizi
727	8	16.3	2	QBHZY2	2ANFA	dipturus zebra	QBHZY2	dipturus zebra	Q563E0	9CYAN	uncultured
728	8	16.3	2	QBWJN1	_CBPY	dipturus zebra	QBWJN1	cebula py	Q35953	MUS	musculus
729	8	16.3	2	QBWJN2	CALJA	dipturus zebra	QBWJN2	callithrix	Q78E72	MOUSE	mus musculu
730	8	16.3	2	QBWJN3	CALGO	dipturus zebra	QBWJN3	callimico g	Q7m078	RATTUS	rattus norv
731	8	16.3	2	QBWJN4	LEORO	dipturus zebra	QBWJN4	leontopithe	Q7m079	RATTUS	rattus norv
732	8	16.3	2	QBWJN5	SAGFU	dipturus zebra	QBWJN5	saguinus fu	Q99mg3	MUS	mus musculu
733	8	16.3	2	QBWJN6	AOTFU	dipturus zebra	QBWJN6	aotus azarae	Q9QW50	MOUSE	mus musculu
734	8	16.3	2	QBWJN7	SAISC	dipturus zebra	QBWJN7	saimiri sci	Q62530	MUS	mus musculu
735	8	16.3	2	QBWJN8	CEBAP	dipturus zebra	QBWJN8	cebus apell	Q71067	RATTUS	rattus norv
736	8	16.3	2	QBWJN9	ATEFU	dipturus zebra	QBWJN9	ateles fusc	Q71068	CANINE	canine dist
737	8	16.3	2	Q9tT77	BOVIN	bos taurus	Q9tT77	bos taurus	Q71068	RATTUS	rattus vall
738	8	16.3	2	Q3XSL0	CAPHI	capra hircus	Q9xsl0	capra hircus	Q83622	MELFLAV	murray vall
739	8	16.3	2	Q6IDL5	CANFA	canis familiaris	Q6IDL5	canis familiaris	Q71zz6	MELEAGRIS	rana esculle
740	8	16.3	2	Q6LAP2	_SMIMA	canis familiaris	Q6LAP2	smilhopis	Q71zz5	RANES	rana esculle
741	8	16.3	2	Q5DAY6	9MYRT	catonema aqu	Q5Day6	catonema aqu	Q94VIO	VARGI	varanus gig
742	8	16.3	2	Q5EFY1	9BRYO	capromys apell	Q5EfY1	capromys apell	P58707	PERIP	periplaneta
743	8	16.3	2	Q5VH65	-ASPA	carpobrotus edulis	Q5VH65	carpobrotus edulis	P41875	PANRE	anthipotera
744	8	16.3	2	Q5YH71	9ASPA	chondrilla	Q5YH71	chondrilla	P41875	PANRE	anthipotera
745	8	16.3	2	Q6Ex64	9IAMI	chondrilla	Q6Ex64	hyparis flor	P41875	PANRE	anthipotera
746	8	16.3	2	Q6PT73	-9ORYZ	chondrilla	Q6Pt73	zizania aqu	P41875	PANRE	anthipotera
747	8	16.3	2	Q6P774	9POAL	chondrilla	Q6P774	streptochaet	P41875	PANRE	anthipotera
748	8	16.3	2	Q6P775	SORBI	chondrilla	Q6P775	sorghum bic	P41875	PANRE	anthipotera
749	8	16.3	2	Q6PT76	-LOLPR	chondrilla	Q6P776	lolium pere	P41875	PANRE	anthipotera
750	8	16.3	2	Q6P777	DANSP	chondrilla	Q6P777	dianthus barbatus	P41875	PANRE	anthipotera
751	8	16.3	2	Q6P778	9APAL	chondrilla	Q6P778	chamaemelum	P41875	PANRE	anthipotera
752	8	16.3	2	Q6P779	9POAL	chondrilla	Q6P779	bouteloua	P41875	PANRE	anthipotera
753	8	16.3	2	Q7x6A3	_MAIZE	chondrilla	Q7x6A3	zea mays	P41875	PANRE	anthipotera
754	8	16.3	2	Q8NmE3	9ROSI	chondrilla	Q8NmE3	howittia tr	P41875	PANRE	anthipotera
755	8	16.3	2	Q93DR8	-MAGN	chondrilla	Q93DR8	magnolia	P41875	PANRE	anthipotera
756	8	16.3	2	Q95DR9	9MAGN	chondrilla	Q95DR9	manglietia	P41875	PANRE	anthipotera
757	8	16.3	2	Q95DS0	9MAGN	chondrilla	Q95DS0	manglietia	P41875	PANRE	anthipotera
758	8	16.3	2	Q95DS1	9MAGN	chondrilla	Q95DS1	manglietia	P41875	PANRE	anthipotera
759	8	16.3	2	Q95DS2	9MAGN	chondrilla	Q95DS2	manglietia	P41875	PANRE	anthipotera
760	8	16.3	2	Q95DS4	9MAGN	chondrilla	Q95DS4	manglietia	P41875	PANRE	anthipotera
761	8	16.3	2	Q95DS5	9MAGN	chondrilla	Q95DS5	manglietia	P41875	PANRE	anthipotera

835	7	14.3	8	1	ALL4_CALVO	P41840 calliphora	P80975 thunnus obe
836	7	14.3	8	1	ALL9_CARMA	P81812 carcinus ma	P41856 calliphora
837	7	14.3	8	1	COW2_CONPU	P58785 conus purpu	P41857 calliphora
838	7	14.3	8	1	FAR1_PANRE	P21872 panagrellus	P41859 calliphora
839	7	14.3	8	1	LCK2_LEMMA	P21141 leucophasa	P41859 calliphora
840	7	14.3	8	1	LCK7_LEMONA	P19989 leucophasa	P82661 panacrellus
841	7	14.3	8	1	LMT2_LOCMI	P22396 locusta mig	P83320 penaeus mon
842	7	14.3	8	1	NPM2_BOVIN	P15507 bos taurus	P41865 calliphora
843	7	14.3	8	1	PPK3_PERAM	P82618 periplaneta	P83350 sarcophaga
844	7	14.3	8	1	UPA10_HUMAN	P30096 homo sapien	P84007 penaeus mon
845	7	14.3	8	2	QTM4U2_ASPEFI	P07m4u aspergilus	P41865 calliphora
846	7	14.3	8	2	Q15888_HUMAN	P15888 homo sapien	P84007 penaeus mon
847	7	14.3	8	2	QL5901_HUMAN	P15901 homo sapien	P84007 penaeus mon
848	7	14.3	8	2	QEBCL29_HUMAN	P81ub8 homo sapien	P84007 penaeus mon
849	7	14.3	8	2	Q6LCL2_HUMAN	P08ivk3 homo sapien	P84007 penaeus mon
850	7	14.3	8	2	Q7LUR9_HUMAN	P09pk3 homo sapien	P84007 penaeus mon
851	7	14.3	8	2	Q7KYV5_HUMAN	P07lur9 homo sapien	P84007 penaeus mon
852	7	14.3	8	2	Q12719_HUMAN	P07kyv5 homo sapien	P84007 penaeus mon
853	7	14.3	8	2	Q81UB8_HUMAN	P07z19 homo sapien	P84007 penaeus mon
854	7	14.3	8	2	Q8IVK3_HUMAN	P08iub8 homo sapien	P84007 penaeus mon
855	7	14.3	8	2	Q980K3_HUMAN	P08ivk3 homo sapien	P84007 penaeus mon
856	7	14.3	8	2	Q9UJ50_HUMAN	P0980k3 homo sapien	P84007 penaeus mon
857	7	14.3	8	2	Q9X4J3_HUMAN	P09uj50 homo sapien	P84007 penaeus mon
858	7	14.3	8	2	Q9RCQ0_HUMAN	P09x4j3 homo sapien	P84007 penaeus mon
859	7	14.3	8	2	QTM3S3_9TRYP	P09hcq0 homo sapien	P84007 penaeus mon
860	7	14.3	8	2	Q94623_MANSE	P07m3s3 trypansoma	P84007 penaeus mon
861	7	14.3	8	2	Q97WH6_YANNE	P094623 manduca sex	P84007 penaeus mon
862	7	14.3	8	2	OTREE2_PLAYO	P09twh6 perineurus	P84007 penaeus mon
863	7	14.3	8	2	QTM4H6_9DODON	P07ree2 plasmoidium	P84007 penaeus mon
864	7	14.3	8	2	QTM4H7_9DODON	P07m4h6 ischnura se	P84007 penaeus mon
865	7	14.3	8	2	Q18854_CANFA	P07m4h7 pseudagrion	P84007 penaeus mon
866	7	14.3	8	2	Q5RLS9_PIG	P018854 canis famili	P84007 penaeus mon
867	7	14.3	8	2	Q5B8U13_SECST	P05rls9 sus scrofa	P84007 penaeus mon
868	7	14.3	8	2	Q5B8U18_PSAFR	P05b8u13 secale stri	P84007 penaeus mon
869	7	14.3	8	2	Q5B8U19_9POAL	P05b8u18 psathyrosta	P84007 penaeus mon
870	7	14.3	8	2	Q5BX87_9LAMI	P05b8u19 psathyrosta	P84007 penaeus mon
871	7	14.3	8	2	Q5TA47_9MAGN	P05bx87 streptocarp	P84007 penaeus mon
872	7	14.3	8	2	Q5EX51_9LAMIC	P05ta47 laurus nobi	P84007 penaeus mon
873	7	14.3	8	2	Q5H0C6_9TRACI	P05ex51 isodon hisp	P84007 penaeus mon
874	7	14.3	8	2	Q5YLT8_SCIVICE	P06h0c6 isocetes fls	P84007 penaeus mon
875	7	14.3	8	2	Q7IMR4_BRANA	P06ylt8 scladopitys	P84007 penaeus mon
876	7	14.3	8	2	Q7TKES_9MYRT	P07imr4 brasilius sp	P84007 penaeus mon
877	7	14.3	8	2	Q87471_HAEIN	P07kes leptospermum	P84007 penaeus mon
878	7	14.3	8	2	Q949534_MYCHO	P087471 haemophilus	P84007 penaeus mon
879	7	14.3	8	2	Q6LAA8_SHIPL	P049534 mycoplasma	P84007 penaeus mon
880	7	14.3	8	2	Q71UF7_MORMO	P06laa8 shigella fl	P84007 penaeus mon
881	7	14.3	8	2	Q799V9_BACSH	P071uf7 morganella	P84007 penaeus mon
882	7	14.3	8	2	Q8GL21_BORBU	P0799v9 bacillus sp	P84007 penaeus mon
883	7	14.3	8	2	Q9RT72_ECOLI	P08gl21 borrelia bu	P84007 penaeus mon
884	7	14.3	8	2	Q92IE9_NEIME	P09rt72 escherichia	P84007 penaeus mon
885	7	14.3	8	2	Q7M124_KLUCI	P092ie9 naissaria m	P84007 penaeus mon
886	7	14.3	8	2	Q79AG6_ENTAG	P07m124 kluvera ci	P84007 penaeus mon
887	7	14.3	8	2	Q99NK9_HYDHY	P079ag6 enterobacte	P84007 penaeus mon
888	7	14.3	8	2	Q99P40_NOUSE	P099nk9 hydrochoeru	P84007 penaeus mon
889	7	14.3	8	2	Q9ET16_MEASU	P099p40 mus musculus	P84007 penaeus mon
890	7	14.3	8	2	Q9ET17_MUSCR	P09et16 mesocricetus	P84007 penaeus mon
891	7	14.3	8	2	Q9ET18_NUSSP	P09et17 mus caroli	P84007 penaeus mon
892	7	14.3	8	2	Q9YV15_9MURI	P09et18 mus spretus	P84007 penaeus mon
893	7	14.3	8	2	Q9QVJ8_9MURI	P09yv15 rattus sp.	P84007 penaeus mon
894	7	14.3	8	2	Q78ED1_RATT	P09qvj8 mus sp.	P84007 penaeus mon
895	7	14.3	8	2	Q62528_MUSSP	P078ed1 rattus norv	P84007 penaeus mon
896	7	14.3	8	2	Q56T42_9GEMI	P062528 mus spreitus	P84007 penaeus mon
897	7	14.3	8	2	Q83349_9CORO	P056t42 okra yellow	P84007 penaeus mon
898	7	14.3	8	2	QSYDW3_9PERC	P083349 mirine hepa	P84007 penaeus mon
899	7	14.3	8	2	Q6JUTW8_ONCMY	P09ydw3 xiphister m	P84007 penaeus mon
900	7	14.3	8	2	Q6DA69_CARCW	P06jutw8 oncorhynchus	P84007 penaeus mon
901	7	14.3	8	2	Q7L221_CHICK	P06da69 carassius c	P84007 penaeus mon
902	7	14.3	8	2	Q7LZ46_CTBEU	P07l221 gallus gallus	P84007 penaeus mon
903	7	14.3	8	2	Q7T282_GEONI	P07lz46 crenopharylon	P84007 penaeus mon
904	7	14.3	8	2	Q8JJ35_9PASS	P07t282 geochelone	P84007 penaeus mon
905	7	14.3	8	2	QTLZZ27_NAJOK	P08jj35 ficedula hy	P84007 penaeus mon
906	7	14.3	8	2	Q8GJ31_BORBU	P08tlzz27 naja naja	P84007 penaeus mon
907	7	14.3	8	1	Q51765_PSEFL	P08gj31 borbus bu	P84007 penaeus mon
					Q6YF34_RAT	P051765 pseudomona	P84007 penaeus mon

RESULT 1 Q05403_YEAST PRELIMINARY;																	
ID	Q05403_YEAST	PRT;	8 AA.														
DT	01-NOV-1996 (TREMBLrel. 01; Created)																
DT	01-NOV-1996 (TREMBLrel. 01; Last sequence update)																
DT	01-OCT-2002 (TREMBLrel. 22; Last annotation update)																
DB	Orf_0915_protein (Fragment).																
GN	Name=orf_0915;																
OS	Saccharomyces cerevisiae (Baker's yeast).																
OC	Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;																
OC	Saccharomycetales; Saccharomycetaceae; Saccharomyces.																
RN	[1] NCBI_TaxID=4932;																
RP	NUCLEOTIDE SEQUENCE.																
RC	"FYI679"; PubMed=8533473;																
RX	Medline=96021609; Pearson B.M., Kalogeropoulos A., Schweizer M.;																
RA	Zumstein E., Pearson B.M., Kalogeropoulos A., Schweizer M.;																
RT	more than twice as many unknown as known open reading frames.";																
RT	Yeast 11:975-986(1995).																
RL	EMBL; X83121; CAA58183.1.; -; Genomic_DNA.																
DR	NON_TER 8																
SQ	SEQUENCE 8 AA; 879 MW;																
Query Match 42.9%; Score 21; DB 2; Length 8;																	
Best Local Similarity 75.0%; Pred. No. 2.2e+06; Mismatches 1; Indels 0; Gaps 0;																	
Qy	6 VHNV 9																
Db	: 2 IHNV 5																
ALIGNMENTS																	
RESULT 3 Q4VS04_MANSE																	
ID	Q4VS04_MANSE PRELIMINARY;																
AC	Q4VS04_MANSE																
DT	13-SEP-2005 (TREMBLrel. 31; Created)																
DT	13-SEP-2005 (TREMBLrel. 31; Last sequence update)																
DT	13-SEP-2005 (TREMBLrel. 31; Last annotation update)																
DB	Calcium-activated potassium channel alpha subunit (Fragment).																
OS	Manduca Sexta (Tobacco hawkmoth) (Tobacco hornworm).																
OC	Bukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota; Neoptera; Endopterygota; Lepidoptera; Glossata; Sphingidae; Sphinginae; Manduca.																
OC	NCBI_TaxID=7130;																
RN	[1]																
RP	NUCLEOTIDE SEQUENCE.																
RA	Keyser M.R., Witten J.L.;																
RT	"Calcium-activated Potassium Channel of the Tobacco Hornworm Manduca sexta: Molecular Characterization and Expression Analysis."																
RT	sexta: Molecular Characterization and Expression Analysis."																
RL	Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.																
KW	Tonic channel.																
FT	NON_TER 1																
FT	NON_TER 8																
SQ	SEQUENCE 8 AA; 785 MW;																
Query Match 36.7%; Score 18; DB 2; Length 8;																	
Best Local Similarity 100.0%; Pred. No. 2.2e+06; Mismatches 0; Indels 0; Gaps 0;																	
RESULT 4 Q9J205_9HEPC																	
ID	Q9J205_9HEPC PRELIMINARY;																
AC	Q9J205_9HEPC																
DT	01-OCT-2000 (TREMBLrel. 15; Created)																
DT	01-OCT-2000 (TREMBLrel. 15; Last sequence update)																
DT	01-OCT-2000 (TREMBLrel. 15; Last annotation update)																
DB	Truncated polyprotein (fragment).																
OS	Hepatitis C virus.																
OC	Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae; Hepacivirus.																
OC	NCBI_TaxID=11103;																
RN	[1]																
RP	NUCLEOTIDE SEQUENCE.																
RC	STRAIN=IARI 3596; TISSUE=Mycelium;																
RA	Verna J., Ganesh S.V.;																
PL	Submitted (JUN-1997) to Swiss-Prot.																
CC	-1- ALLERGEN: Causes an allergic reaction in human.																
CC	This Swiss-Prot entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - European Bioinformatics Institute. There are no restrictions on its use as long as its content is in no way modified and this statement is not removed.																

DR EMBL; AFA99732; AAO47848.1; - ; mRNA. FT NON_TER 1 1 SQ SEQUENCE 9 AA; 978 MW; 25AQB685AB42C1P7 CRC64;	DR EMBL; AY190016; AA073818.1; - ; Genomic_DNA. FT NON_TER 8 8 SQ SEQUENCE 8 AA; 1013 MW; FE21EFB4771AAA6 CRC64;
Query Match 34.7%; Score 17; DB 2; Length 9; Best Local Similarity 42.9%; Pred. No. 2.2e+06; Matches 3; Conservative 3; Mismatches 1; Indels 0; Gaps 0; Qy 3 APPVHN 9 : : : Db 1 APHVYSM 7	Query Match 32.7%; Score 16; DB 2; Length 8; Best Local Similarity 40.0%; Pred. No. 2.2e+06; Matches 2; Conservative 2; Mismatches 1; Indels 0; Gaps 0; Qy 5 PVHN 9 : : Db 4 PYHHL 8
RESULT 9 ALL6_GYDPO CRYDPO STANDARD PRT; 8 AA. ID ALL6_GYDPO STANDAR PRT; 8 AA. AC P82157; DT 30-MAY-2000 (Rel. 39, Created) DT 30-MAY-2000 (Rel. 39, Last sequence update) DT 10-MAY-2005 (Rel. 47, Last annotation update) DB Cydiaeratin-6 OS Cydia pomonella (Codling moth). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi; OC Neoptera; Endopterygota; Lepidoptera; Glossata; Ditrysia; OC Tortricidae; Tortricidae; Olethreutinae; Cydia. OX NCBI_TaxID=82600; RN [1] RP PROTEIN_SEQUENCE. RC TISSUE=Larva; RX MEDLINE=98054539; PubMed=9392829; DOI=10.1016/S0196-9781(97)00188-5; RA Dube H.; Johnson A.H.; Maestro J.-L.; Scott A.G.; Winstanley D., Dave H.; Johnson A.H.; Maestro J.-L.; Scott A.G., Winstanley D., RT "Lepidopteran peptides of the allatostatin superfamily."; RT Peptides 18:1301-1309(1997). RL S43971: SA33971. CC -1- SUBCELLULAR_LOCATION: Secreted. CC -1- SIMILARITY: Belongs to the allatostatin Family. CC CC This Swiss-Prot entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL Outstation the European Bioinformatics Institute. There are no restrictions on its use as long as its content is in no way modified and this statement is not removed. CC CC Amidation; Direct protein sequencing; Neuropeptide. KW MOD_RES 8 8 Leucine amide. SQ SEQUENCE 8 AA; 936 MW; 0B2879C43B573767 CRC64;	RESULT 11 Q7M067_MOUSE PRELIMINARY PRT; 8 AA. ID Q7M067_MOUSE PRELIMINARY PRT; 8 AA. AC Q7M067; DT 01-MAR-2004 (TREMBLrel. 26, Created) DT 01-MAR-2004 (TREMBLrel. 26, Last sequence update) DT 01-MAR-2004 (TREMBLrel. 26, Last annotation update) DB Tumoz-associated antigen MUT1. OS Mus musculus (Mouse). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi; OC Mammalia; Eutheria; Rodentia; Sciurognathi; OC Muridae; Murinae; Mus. OX NCBI_TaxID=10390; RN [1] RP PROTEIN_SEQUENCE. RC MEDLINE=94217811; PubMed=8164742; DOI=10.1038/369067a0; RA Mandelboim O.; Berke G.; Fridkin M.; Feldman M.; Eisenstein M., RA Eisenbach L.; RT "CT1 induction by a tumour-associated antigen octapeptide derived from RT a murine lung carcinoma."; RL Nature 369:67-71(1994). PIR S43971: SA33971. DR S43971: S433971. SQ SEQUENCE 8 AA; 934 MW; 9976DDC1A456DB19 CRC64;
Query Match 32.7%; Score 16; DB 2; Length 8; Best Local Similarity 60.0%; Pred. No. 2.2e+06; Matches 3; Conservative 1; Mismatches 1; Indels 0; Gaps 0; Qy 5 PVHN 8 : : Db 2 PLYN 5	Query Match 32.7%; Score 16; DB 2; Length 8; Best Local Similarity 60.0%; Pred. No. 2.2e+06; Matches 3; Conservative 1; Mismatches 1; Indels 0; Gaps 0; Qy 1 STAPP 5 : : Db 4 NTAQP 8
RESULT 12 Q9P885_KLuytA PRELIMINARY PRT; 9 AA. ID Q9P885_KLuytA PRELIMINARY PRT; 9 AA. AC Q9P885; DT 01-OCT-2000 (TREMBLrel. 15, Created) DT 01-OCT-2000 (TREMBLrel. 15, Last sequence update) DT 01-MAR-2001 (TREMBLrel. 16, Last annotation update) DB HIS4_protein (Fragment). GN Name=HIS4; OS Kluyveromyces lactis (Yeast). OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Kluyveromyces. OC Saccharomycetales; Saccharomycetaceae; Kluyveromyces. OX NCBI_TaxID=28985; RN [1] RP NUCLEOTIDE_SEQUENCE. RC STRAIN=NRL-Y1440; RX MEDLINE=93448382; PubMed=10518937; DOI=10.1016/S0014-5793(99)01105-9; RA Lamas-Maceira M.; Esperanza Cerdan E.; Freire-Picos M.A.; RT "Kluyveromyces lactis HIS4 transcriptional regulation: similarities and differences to Saccharomyces cerevisiae HIS4 gene."; RL FEBS Lett. 458:72-76(1999); DR AJ238494; CAB57125.1; - ; Genomic_DNA. FT NON_TER 9 SQ SEQUENCE 9 AA; 1015 MW; 5770DD772D2D767 CRC64;	
Query Match 32.7%; Score 16; DB 2; Length 9; Best Local Similarity 75.0%; Pred. No. 2.2e+06; Matches 2; Conservative 2; Mismatches 0; Indels 0; Gaps 0; Qy 5 PVHN 9 : : Db 2 PLYN 5	Query Match 32.7%; Score 16; DB 2; Length 9; Best Local Similarity 75.0%; Pred. No. 2.2e+06; Matches 2; Conservative 2; Mismatches 0; Indels 0; Gaps 0; Qy 5 PVHN 9 : : Db 2 PLYN 5
RESULT 10 Q6Y2P2_CITSI CITSI PRELIMINARY PRT; 8 AA. ID Q6Y2P2_CITSI PRELIMINARY PRT; 8 AA. AC Q6Y2P2; DT 05-JUL-2004 (TREMBLrel. 27, Created) DT 05-JUL-2004 (TREMBLrel. 27, Last sequence update) DT 05-JUL-2004 (TREMBLrel. 27, Last annotation update) DB Vacuolar invertase (Fragment). OS Citrus sinensis (Sweet orange). OC Eukaryota; Viridiplantae; Streptophytina; Embryophytina; Tracheophytina; Spermatophytina; Magnoliophytina; eudicotyledons; core eudicots; rosids; OC eurosidae II; Sapindales; Rutaceae; Citrus. OX NCBI_TaxID=2711; RN RP NUCLEOTIDE_SEQUENCE. RA An X.; Zhang S.; Xu C.; Qin Q.; RL Submitted (DEC-2002) to the EMBL/GenBank/DDBJ databases.	RESULT 10 Q6Y2P2_CITSI CITSI PRELIMINARY PRT; 8 AA. ID Q6Y2P2_CITSI PRELIMINARY PRT; 8 AA. AC Q6Y2P2; DT 05-JUL-2004 (TREMBLrel. 27, Created) DT 05-JUL-2004 (TREMBLrel. 27, Last sequence update) DT 05-JUL-2004 (TREMBLrel. 27, Last annotation update) DB Vacuolar invertase (Fragment). OS Citrus sinensis (Sweet orange). OC Eukaryota; Viridiplantae; Streptophytina; Embryophytina; Tracheophytina; Spermatophytina; Magnoliophytina; eudicotyledons; core eudicots; rosids; OC eurosidae II; Sapindales; Rutaceae; Citrus. OX NCBI_TaxID=2711; RN RP NUCLEOTIDE_SEQUENCE. RA An X.; Zhang S.; Xu C.; Qin Q.; RL Submitted (DEC-2002) to the EMBL/GenBank/DDBJ databases.

OC Pan. NCBI_TaxID=37011;
 RN [1] NUCLEOTIDE SEQUENCE.
 RX MEDLINEB=22763540; PubMed=12777533; DOI=10.1093/molbev/msq134;
 RA Kitano T., Schwarz C., Nickel B.; Paabo S.;
 RT "Gene diversity patterns at 10 X-chromosomal loci in humans and
 chimpanzees";
 RL Biol. Biol. 20;1281-1289 (2003).
 DR EMBL; AB102364; BAC80863..1.; -; Genomic_DNA.
 DR EMBL; AB102365; BAC80864..1.; -; Genomic_DNA.
 DR EMBL; AB102366; BAC80865..1.; -; Genomic_DNA.
 DR EMBL; AB102367; BAC80866..1.; -; Genomic_DNA.
 DR EMBL; AB102368; BAC80867..1.; -; Genomic_DNA.
 DR EMBL; AB102369; BAC80868..1.; -; Genomic_DNA.
 DR EMBL; AB102370; BAC80869..1.; -; Genomic_DNA.
 SQ SEQUENCE 9 AA; 939 MW; D8CCG045B1F2CB862 CRC64;
 Query Match 32.7%; Score 16; DB 2; Length 9;
 Best Local Similarity 50.0%; Pred. No. 2.2e+06;
 Matches 2; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 FT NON-TER 1 1
 FT NON-TER 9 AA; 939 MW;
 SQ SEQUENCE 9 AA; 939 MW; CA1A55A1B771AB02 CRC64;
 Query 6 VENV 9
 DB 1| : 4 VHSI 7
 RESULT 17
 Q76FV1_9FLOR PRELIMINARY; PRT; 9 AA.
 ID Q76FV1_9FLOR PRELIMINARY; PRT; 9 AA.
 AC Q76FV1_9FLOR PRELIMINARY; PRT; 9 AA.
 DT 05-JUL-2004 (TREMBLrel. 27, Created)
 AC Q76FV1_9FLOR PRELIMINARY; PRT; 9 AA.
 DT 05-JUL-2004 (TREMBLrel. 27, Last sequence update)
 DT 01-FEB-2005 (TREMBLrel. 29, Last annotation update)
 DB Rubisco large subunit (Fragment).
 GN Name=rbcl;
 OS Plocamium telfairiae.
 OG Chloroplast.
 OC Bukaryota; Rhodophyta; Florideophyceae; Plocamiaceae;
 OC Plocamium.
 NCBI_TaxID=38522;
 RN [1] NUCLEOTIDE SEQUENCE.
 RA Yano T., Kamiya M., Arai S., Kawai H.;
 RL Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
 DR EMBL; AB104699; BACB8401..1.; -; Genomic_DNA.
 DR EMBL; AB104700; BACB82407..1.; -; Genomic_DNA.
 DR EMBL; AB104703; BACB82409..1.; -; Genomic_DNA.
 DR EMBL; AB104705; BACB82413..1.; -; Genomic_DNA.
 DR GO; GO:0005307; C:chloroplast; IEA.
 KW Chloroplast.
 FT NON-TER 1 1
 SQ SEQUENCE 9 AA; 993 MW; CA1A55A1B771AB02 CRC64;
 Query Match 32.7%; Score 16; DB 2; Length 9;
 Best Local Similarity 60.0%; Pred. No. 2.2e+06;
 Matches 3; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 FT NON-TER 1 1
 SQ SEQUENCE 9 AA; 993 MW; CA1A55A1B771AB02 CRC64;
 Query 5 PVHNV 9
 DB 1| : 5 PTSNV 9
 RESULT 18
 Q76FV1_9FLOR PRELIMINARY; PRT; 9 AA.
 ID Q76FV1_9FLOR PRELIMINARY; PRT; 9 AA.
 AC Q76FV1_9FLOR PRELIMINARY; PRT; 9 AA.
 DT 05-JUL-2004 (TREMBLrel. 27, Created)
 DT 01-FEB-2005 (TREMBLrel. 29, Last sequence update)
 DB Rubisco large subunit (Fragment).
 GN Name=rbcl;
 OS Plocamium ovicornis.
 OG Chloroplast.
 OC Bukaryota; Rhodophyta; Florideophyceae; Plocamiaceae;
 OC Plocamium.
 NCBI_TaxID=223158;
 RN [1] _TaxID=223158;

RP	NUCLEOTIDE SEQUENCE.	RT	virus.";
RA	Yano T., Kamiya M., Arai S., Kawai H.;	RL	J. Virol. 62:4627-4633 (1988).
RL	Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.	DR	EMBL; M25399; AAA42548.1; -; Genomic DNA.
DR	EMBL; AB104694; BAC82391.1; -; Genomic DNA.	FT	NON TER
DR	EMBL; AB104693; BAC82389.1; -; Genomic DNA.	SQ	SEQUENCE 9 AA; 1033 MW; 63AED767341B5A1 CRC64;
DR	GO; GO:000507; C:chloroplast; IEA.	Query Match	Score 16; DB 2; Length 9;
KW	Chloroplast.	Best Local Similarity	66.7%; Score 16; DB 2; Length 9;
FT	NON TER	Matches	4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
SQ	SEQUENCE 9 AA; 979 MW; CA1A55A1B771AAB2 CRC64;	Qy	1 STAPV 6
Query Match	Score 16; DB 2; Length 9;	Db	3 STRLPV 8
Best Local Similarity	60.0%; Pred. No. 2.2e+06;	RESULT 23	
Matches	3; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	ID	P83492_BIOC PRELIMINARY; PRT; 7 AA.
Qy	5 PVHNV 9	AC	P83492_
Db	5 PTSNV 9	DT	01-JUN-2003 (TREMBLrel. 24, Created)
RP	NUCLEOTIDE SEQUENCE.	DT	01-JUN-2003 (TREMBLrel. 24, Last sequence update)
ID	P76FV7_PLOCA PRELIMINARY; PRT; 9 AA.	AC	P83492_
AC	Q76FV7_PLOCA PRELIMINARY; PRT; 9 AA.	DT	01-MAR-2004 (TREMBLrel. 26, Last annotation update)
DT	05-JUL-2004 (TREMBLrel. 27, Created)	DB	Alkaline protease Gr3 (BC 3.4.21.-) (Fragment).
DT	05-JUL-2004 (TREMBLrel. 27, Last sequence update)	OS	Bionectria ochroleuca (Gliocladium roseum).
DT	01-FEB-2005 (TREMBLrel. 29, Last annotation update)	OC	Eukaryota; Fungi; Ascomycota; Pezizomycotina; Sordariomycetes;
DB	Rubisco large subunit (Fragment).	OX	Hypocreomycetidae; Hypocreales; Bionectriaceae; Bionectria.
GN	Name=rbCL;	[1]	NCBI TaxID:29856;
OS	Plocamium cartilagineum (Red comb weed).	RN	PROTEIN SEQUENCE, FUNCTION, AND SUBCELLULAR LOCATION.
OG	Bukaryota; Rhodophyta; Florideophyceae; Plocamiales; Plocamiaceae;	RP	PROTEIN SEQUENCE, FUNCTION, AND SUBCELLULAR LOCATION.
OC	Plocamium.	RC	STRAIN=Gr8;
OC	Plocamium.	RA	Zhao M.; Zhang K.;
OX	Plocamium.	RL	Submitted (DEC-2002) to Swiss-Prot.
RN	NCBI_TaxID:31452;	CC	- - FUNCTION: Acts as a serine protease.
RN	[1]	CC	- - SUBCELLULAR LOCATION: Secreted.
RP	NUCLEOTIDE SEQUENCE.	CC	- - SIMILARITY: BELONGS TO PEPTIDASE FAMILY S8.
RA	Yano T., Kamiya M., Arai S., Kawai H.;	DR	GO:0005576; C:extracellular region; NAS.
RA	Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.	DR	GO:0004252; F:serine-type endopeptidase activity; NAS.
DR	EMBL; AB104691; BAC82385.1; -; Genomic DNA.	DR	InterPro; IPR000209; Pept_S8_S53.
DR	EMBL; AB104692; BAC82387.1; -; Genomic DNA.	DR	Prosite; PS00136; SUBTILASE ASP; PARTIAL.
DR	EMBL; AB104690; BAC82383.1; -; Genomic DNA.	DR	Prosite; PS00137; SUBTILASE HIS; PARTIAL.
DR	GO; GO:0009507; C:chloroplast; IEA.	DR	Prosite; PS00138; SUBTILASE SER; PARTIAL.
KW	Chloroplast.	KW	Hydrolase; Serine protease.
FT	NON TER	FT	NON TER
SQ	SEQUENCE 9 AA; 993 MW; CA1A55A1B771AB02 CRC64;	SQ	SEQUENCE 7 AA; 688 MW; 776DD455A6C1ADBO CRC64;
Query Match	Score 16; DB 2; Length 9;	Query Match	Score 15; DB 2; Length 7;
Best Local Similarity	60.0%; Pred. No. 2.2e+06;	Best Local Similarity	75.0%; Pred. No. 2.2e+06;
Matches	3; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	Matches	3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy	5 PVHNV 9	Qy	1 STAP 4
Db	5 PTSNV 9	Db	4 SNAP 7
RESULT 22		RESULT 24	
Q64972_AVEVR	ACI_THUAI STANDARD; PRT; 8 AA.	ACI_THUAI STANDARD; PRT; 8 AA.	
ID	Q64972_AVEVR PRELIMINARY; PRT; 9 AA.	ID	ACI_THUAI STANDARD; PRT; 8 AA.
AC	01-NOV-1996 (TREMBLrel. 01, Created)	AC	P18591;
DT	01-NOV-1996 (TREMBLrel. 01, Last sequence update)	DT	01-NOV-1990 (Rel. 16, Created)
DT	01-DEC-2001 (TREMBLrel. 19, Last annotation update)	DT	01-NOV-1990 (Rel. 16, Last sequence update)
DE	Rous associated virus type 1 (RAV-1) mil protein, 3' end, and env	DT	10-MAY-2005 (Rel. 47, Last annotation update)
DE	protein (Fragment).	OS	Angiotensin-converting enzyme inhibitor.
OS	Avian rous-associated virus type 1.	OS	Thunnum albacare (Yellowfin tuna) (Neothunnum macropterus).
OC	Viruses; Retroviridae; Alpharetrovirus.	OC	Euteleostomi; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Acanthomorpha; Acanthopterygii; Teleostei; Euteleostei; Neoteleostei; Scombroidei; Scombridae; Thunnum.
NCBI_TaxID:11955;		OC	Actinopterygii; Neopterygia; Teleostei; Euteleostei; Neoteleostei; Scombroidei; Scombridae; Thunnum.
RP	NUCLEOTIDE SEQUENCE.	OC	RC
RX	MEDLINE=89037349; PubMed=2846875;	RN	PROTEIN SEQUENCE.
RA	Marx M., Crisanti A., Eychenne P., Bechade C., Laugier D., Ghysdael J., Pesacq B., Calichry G.;	RC	TISSUE=MUSCLE.
RA	"Activation and transduction of c-mil sequences in chicken neuroretina cells induced to proliferate by infection with avian lymphomatosis	RX	MEDLINE=89326522; PubMed=3415688;
RA	Kohama Y., Matsubamoto S., Oka H., Teramoto T., Okabe M., Mimura T.;	RA	Kohama Y., Matsubamoto S., Oka H., Teramoto T., Okabe M., Mimura T.;

RT	"Isolation of angiotensin-converting enzyme inhibitor from tuna muscle.";	Pred. No. 2.2e-06;	Indels 0;	Gaps 0;
RL	Biochim. Biophys. Res. Commun. 155:332-337(1988).			
CC	-!- FUNCTION: Inhibits angiotensin-converting enzyme.			
CC	This Swiss-Prot entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use as long as its content is in no way modified and this statement is not removed.			
CC	RESULTS 26			
CC	Q6J0RS_PARLI_Q6J0RS_PARLI PRELIMINARY;	PRTR;	8 AA.	
CC	ID Q6J0RS;			
CC	AC DT 05-JUL-2004 (TREMBUREL. 27, Created)			
CC	CC DT 05-JUL-2004 (TREMBUREL. 27, Last sequence update)			
CC	CC DT 05-JUL-2004 (TREMBUREL. 27, Last annotation update)			
CC	CC DB AUF similar protein (Fragment).			
CC	CC OS Paracentrotus lividus (Common sea urchin).			
CC	CC OC Paracentrotus; Meiozoa; Echinodermata; Eleutherocoza; Echinozoa; Echinoidea; Euchinoidea; Echinacea; Echinidae; Paracentrotus			
CC	CC OC NCBITaxonID=7656;			
CC	CC OX [1]			
CC	CC RN PubMed=15715984;			
CC	CC RX NUCLEOTIDE SEQUENCE.			
CC	CC RA Pulcrano G.; Leonardo R.; Antelio P.; Mancini P.; Pisacane M.,			
CC	CC RA Bruno M.; Fucci L.;			
CC	CC RA "PLA1P is a novel P. lividus sea urchin RNA-binding protein.";			
CC	CC RT Gene 34:19-20 (2005).			
CC	CC RL DRAY37156.1; AATR37156.1; - ; mRNA.			
CC	CC PT NON_TER 1			
CC	CC SQ SEQUENCE 8 AA; 816 MW; 83C763DC1A865A6 CRC64;			
CC	CC Query Match 30.6%; Score 15; DB 2; Length 8;			
CC	CC Best Local Similarity 75.0%; Pred. No. 2.2e-06;			
CC	CC Matches 3; Conservative 0; Mismatches 1; Indels 0; Gaps 0;			
CC	CC Qy 2 TAPP 5			
CC	CC Db 4 TAKP 7			
CC	CC RESULTS 27			
CC	CC Q7M1V6_SOLTU_Q7M1V6_SOLTU PRELIMINARY;	PRTR;	8 AA.	
CC	CC ID Q7M1V6;			
CC	CC AC DT 01-MAR-2004 (TREMBUREL. 26, Created)			
CC	CC CC DT 01-MAR-2004 (TREMBUREL. 26, Last sequence update)			
CC	CC DB Lectin (Fragment).			
CC	CC OS Solanum tuberosum (Potato).			
CC	CC OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons; asterids; lamiales; Solanaeae; Solanaceae; Solanum.			
CC	CC OC NCBI_TaxID=4113;			
CC	CC RN PROTEIN SEQUENCE.			
CC	CC RA Millar D.J.; Allen A.K.; Smith C.G.; Sidebottom C.; Slabas A.R..			
CC	CC RA Bolwell G.P.;			
CC	CC RT "Chitin-binding proteins in potato (Solanum tuberosum L.) tuber. Characterization, immunolocalization and effects of wounding.";			
CC	CC RL Biochem. J. 283:813-821(1992).			
CC	CC RN PubMed=1590771;			
CC	CC RA Millar D.J.; Allen A.K.; Smith C.G.; Sidebottom C.; Slabas A.R.,			
CC	CC RT Bolwell G.P.;			
CC	CC RT "Chitin-binding proteins in potato (Solanum tuberosum L.) tuber. Characterization, immunolocalization and effects of wounding.";			
CC	CC RL Biochem. J. 283:813-821(1992).			
CC	CC DR InterPro; IPR01484; Pyrokinin.			
CC	CC DR PROSITE; PS00539; PYROKININ; FALSE NEG.			
CC	CC DR Amidation; Direct protein sequencing; Neuropeptide; Pyrokinin.			
CC	CC PT MOD_RES 8 AA; 8 Leucine amide.			
CC	CC SQ SEQ 8 AA; C834176DP9D7775 CRC64;			
CC	CC Query Match 30.6%; Score 15; DB 1; Length 8;			

Nature 419:512-519 (2002).
 - I - CAUTION: The sequence shown here is derived from an EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is preliminary data.

HYPOTHETICAL PROTEIN; EAA19452-1; -; Genomic_DNA.
 SEQUENCE - 9 AA; 1013 MW; 4684D4724441E7 CRC64;
 Query Match 30 6%; Score 15; DB 2; Length 9;
 Best Local Similarity 66.7%; Fred. No. 2.2e+06;
 Matches 2; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 6 VHN 8
 Ddb 2 IHN 4

RESULT 32
 Q4X981_PLACH PRELIMINARY;
 ID Q4X981; PRT;
 AC 9 AA.
 DT 13-SEP-2005 (TREMBLrel. 31, Created)
 DT 13-SEP-2005 (TREMBLrel. 31, Last sequence update)
 DT 13-SEP-2005 (TREMBLrel. 31, Last annotation update)
 DE Hypothetical protein (Fragment).
 ORFNames=PC404684_00.0;
 GN Plasmidium chabaudi.
 OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.
 NCBI_TaxID=5825;
 RN [1]
 RPR NUCLEOTIDE SEQUENCE.
 RA Hall N., Karras M., Raine J.D., Carlton J.M., Koij T.W.A.,
 RA Berriman M., Florens L., Janssen C.S., Pain A., Christophides G.K.,
 RA James K., Rutherford K., Harris B., Harris D., Churcher C.,
 RA Quail M.A., Ormond D., Doggett J., Trueman A., Mendoza J.,
 RA Bidwell S.J., Rajandream M.A., Carucci D.J., Yates J.R., Kafatos F.C.,
 RA Janse C.J., Barrell B., Turner C.M.R., Waters A.P., Sinden R.S.,
 RA "A comprehensive survey of the Plasmodium life cycle by genomic,
 RT transcriptomic, and proteomic analyses.",
 RRL Science 307:82-86 (2005).
 - I - CAUTION: The sequence shown here is derived from an EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is preliminary data.

HYPOTHETICAL PROTEIN; CAH86543-1; -; Genomic_DNA.
 SEQUENCE 9 AA; 1010 MW; 495F4441E6905727 CRC64;
 Query Match 30 6%; Score 15; DB 2; Length 9;
 Best Local Similarity 66.7%; Fred. No. 2.2e+06;
 Matches 2; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 6 VHN 8
 Ddb 5 MHN 7

RESULT 33
 Q4YFU0_PLABE PRELIMINARY;
 ID Q4YFU0; PRT;
 AC 9 AA.
 DT 13-SEP-2005 (TREMBLrel. 31, Created)
 DT 13-SEP-2005 (TREMBLrel. 31, Last sequence update)
 DE Hypothetical protein.
 ORFNames=PB400205_00.0;
 GN Plasmidium berghei.
 OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.
 NCBI_TaxID=5821;
 RPR NUCLEOTIDE SEQUENCE.
 RA Hall N., Karras M., Raine J.D., Carlton J.M., Koij T.W.A.,
 RA Berriman M., Florens L., Janssen C.S., Pain A., Christophides G.K.,

RC STRAIN-596;	DT 05-JUL-2004 (TREMBLrel. 27, Last sequence update)
RA Kamiya M., West J.A., King R.J., Zuccarello G.C., Tanaka J., Hara Y.;	DT 05-JUL-2004 (TREMBLrel. 27, Last annotation update)
RT "Evolutionary divergence in the red algae <i>Caloglossa leprieurii</i> and <i>C.</i>	DE Rubisco large subunit (Fragment).
RT <i>apomeiotica</i> .",	GN Name=rbcl;
RT	OS Hypnea japonica.
RL J. Phycol. 34:361-370(1998).	OC Chloroplast.
RN [2]	OC Eukaryota; Rhodophyta; Florideophyceae; Gigartinales; Hypnaceae;
RP NUCLEOTIDE SEQUENCE.	OC Hypnea.
RC STRAIN-596;	OX NCBI_TaxID=105606;
RA Kamiya M., Tanaka J., King R.J., West J.A., Zuccarello G.C., Kawai H.;	RN [1]
RT "Reproductive and genetic distinction between broad and narrow	RP Nucleotide sequence.
entities of <i>Caloglossa continua</i> (<i>Delesseriaceae</i> , <i>Rhodophyta</i>).";	RA Yano T., Kamiya M., Arai S., Kawai H.;
RL Physiologia 38:356-367(1999).	RL Submitted (FEBS-2003) to the EMBL/GenBank/DBJ databases.
RN [3]	DR EMBL; AB104706; BAC82415.1; -; Genomic_DNA.
RP NUCLEOTIDE SEQUENCE.	DR GO:0009507; C:chloroplast; IEA.
RA West J.A., Zuccarello G.C., Kamiya M.;	KW Chloroplast.
RT "Reproductive patterns of <i>Caloglossa</i> species (<i>Delesseriaceae</i> ,	FT NON_TER 1 1 Score 15; DB 2; Length 9;
RT <i>Rhodophyta</i>) from Australia and New Zealand: multiple origins of	SEQUENCE 9 AA; 977 MW; CALA4DC1B771AB02 CRC64;
RT asexuality in <i>C. leprieurii</i> . Literature review on apomixis, mixed-	Query Match 30.6%; Score 15; DB 2; Length 9;
RT phase, bisexuality and sexual compatibility.",	Best Local Similarity 60.0%; Pred. No. 2.2e+06;
RT <i>Phycol. Res.</i> 49:183-200(2001).	Matches 3; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
DR EMBL; AB3431307.1; -; Genomic_DNA.	Qy 5 PVHNV 9
DR EMBL; AF340182; AAKB8091.1; -; Genomic_C_DNA.	Db 5 PTANV 9
GO; GO:000507; C:chloroplast; IEA.	RESULT 41
KW Chloroplast.	Q8HB3 9FLOR
FT NON_TER 1 1	ID Q8HB3_9FLOR PRELIMINARY; PRT; 9 AA.
SEQUENCE 9 AA; 977 MW; CALA4DC1B771AB02 CRC64;	AC Q8HB3;
Qy 5 PVHNV 9	AC Q8HB3_9FLOR PRELIMINARY; PRT; 9 AA.
Db 5 PTANV 9	AC Q8HB3_9FLOR PRELIMINARY; PRT; 9 AA.
RESULT 39	Q8HB3 9FLOR
Q6 EUV8 GERHY PRELIMINARY;	ID Q8HB3_9FLOR PRELIMINARY; PRT; 9 AA.
AC Q6EUUV-	AC Q8HB3_9FLOR PRELIMINARY; PRT; 9 AA.
DT 25-OCT-2004 (TREMBLrel. 28, Created)	AC Q8HB3_9FLOR PRELIMINARY; PRT; 9 AA.
DT 25-OCT-2004 (TREMBLrel. 28, Last sequence update)	AC Q8HB3_9FLOR PRELIMINARY; PRT; 9 AA.
DT 25-OCT-2004 (TREMBLrel. 28, Last annotation update)	AC Q8HB3_9FLOR PRELIMINARY; PRT; 9 AA.
DB Hypothetical protein.	AC Q8HB3_9FLOR PRELIMINARY; PRT; 9 AA.
OS Gerbera hybrida.	AC Q8HB3_9FLOR PRELIMINARY; PRT; 9 AA.
OC Eukaryota; Viridiplanteae; Streptophytina; Tracheophyta;	AC Q8HB3_9FLOR PRELIMINARY; PRT; 9 AA.
OC Magnoliophyta; eudicots; asterids; core eudicots; asterids;	AC Q8HB3_9FLOR PRELIMINARY; PRT; 9 AA.
OC campnospermales; Asteridae; Mutisioideae; Gerberidae.	AC Q8HB3_9FLOR PRELIMINARY; PRT; 9 AA.
OX NCBI_TaxID=18101;	AC Q8HB3_9FLOR PRELIMINARY; PRT; 9 AA.
RN Hypothetical protein.	AC Q8HB3_9FLOR PRELIMINARY; PRT; 9 AA.
RP NUCLEOTIDE SEQUENCE.	AC Q8HB3_9FLOR PRELIMINARY; PRT; 9 AA.
RA Uimari A., Kotilainen M., Elomaa P., Yu D., Albert V.A., Teeri T.H.;	AC Q8HB3_9FLOR PRELIMINARY; PRT; 9 AA.
RT "Integration of reproductive meristem fates by a SBPALLATA-like MADS	AC Q8HB3_9FLOR PRELIMINARY; PRT; 9 AA.
RT box gene.",	AC Q8HB3_9FLOR PRELIMINARY; PRT; 9 AA.
RT box gene."	AC Q8HB3_9FLOR PRELIMINARY; PRT; 9 AA.
RL Proc. Natl. Acad. Sci. U.S.A. 101:15817-15822(2004).	AC Q8HB3_9FLOR PRELIMINARY; PRT; 9 AA.
KW Hypothetical protein.	AC Q8HB3_9FLOR PRELIMINARY; PRT; 9 AA.
SQ SEQUENCE 9 AA; 1108 MW; 151D415A401F1AO CRC64;	AC Q8HB3_9FLOR PRELIMINARY; PRT; 9 AA.
Qy 7 HNV 9	AC Q8HB3_9FLOR PRELIMINARY; PRT; 9 AA.
Db 7 HNL 9	AC Q8HB3_9FLOR PRELIMINARY; PRT; 9 AA.
RESULT 40	Q8HB4 9FLOR
Q7 6FST 9FLOR	ID Q8HB4_9FLOR PRELIMINARY; PRT; 9 AA.
ID Q7 6FST 9FLOR PRELIMINARY;	AC Q8HB4_9FLOR PRELIMINARY; PRT; 9 AA.
AC Q7 6FST 9FLOR PRELIMINARY;	AC Q8HB4_9FLOR PRELIMINARY; PRT; 9 AA.
DT 05-JUL-2004 (TREMBLrel. 27, Created)	AC Q8HB4_9FLOR PRELIMINARY; PRT; 9 AA.
DT 01-MAR-2003 (TREMBLrel. 23, Last sequence update)	AC Q8HB4_9FLOR PRELIMINARY; PRT; 9 AA.
DT 01-FEB-2005 (TREMBLrel. 29, Last annotation update)	AC Q8HB4_9FLOR PRELIMINARY; PRT; 9 AA.

DE Ribulose-1,5-bisphosphate large subunit (Fragment).				
GN Name=rbCL;				
OS Gracilaria cliffonii.				
OC Chloroplast.				
OC Gracilaria.				
OX NCBI_TaxID=206548;				
RP NUCLEOTIDE SEQUENCE.				
RA Bryne K., Zuccarello G.C., West J.A., Liao M.-L., Kraft G.; "Gracilaria species (Gracilariaeae, Rhodophyta) from southeastern Australia, including a new species, <i>G. perplexa</i> sp. nov.: Morphology, molecular relationships and agar content."; Phycol. Res. 50:295-311(2002); EMBL; AY131302; AN07030.1.; -; Genomic_DNA.				
DR GO; GO:0009507; C:chloroplast; IEA.				
KW Chloroplast.				
FT NON_TER	1	1		
SQ SEQUENCE 9 AA; 977 MW; CALA4DC1B771AB02 CRC64;				
Query Match Score 15; DB 2; Length 9; Best Local Similarity 60.0%; Pred. No. 2.2e+06; Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;				
Qy 5 PVHNV 9				
Db 5 PTANV 9				
RESULT 43 QBBHB5_GRACH GRACH PRELIMINARY; ID QBBHB5_7 GRACH PRELIMINARY; AC 01-MAR-2003 (T-TREMBLrel. 23, Created) DT 01-MAR-2003 (T-TREMBLrel. 23, Last sequence update) DE Ribulose-1,5-bisphosphate large subunit (Ribulose-1,5-bisphosphate carboxylase/oxygenase large subunit) (Fragment). GN Name=rbCL; Gracilaria chilensis (Red alga).				
OG Chloroplast.				
OC Gracilaria.				
OX NCBI_TaxID=2775;				
RP NUCLEOTIDE SEQUENCE.				
RA Bryne K., Zuccarello G.C., West J.A., Liao M.-L., Kraft G.; "Gracilaria species (Gracilariaeae, Rhodophyta) from southeastern Australia, including a new species, <i>G. perplexa</i> sp. nov.: Morphology, molecular relationships and agar content."; Phycol. Res. 50:295-311(2002); EMBL; AY131299; AN07024.1.; -; Genomic_DNA.				
DR EMBL; AY131300; AN07026.1.; -; Genomic_DNA.				
DR EMBL; AY131301; AN07028.1.; -; Genomic_DNA.				
DR GO; GO:0009507; C:chloroplast; IEA.				
KW Chloroplast.				
FT NON_TER	1	1		
SQ SEQUENCE 9 AA; 977 MW; CALA4DC1B771AB02 CRC64;				
Query Match Score 15; DB 2; Length 9; Best Local Similarity 60.0%; Pred. No. 2.2e+06; Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;				
Qy 5 PVHNV 9				

Db	5	PTANV 9		
RESULT 44 QBHBJ3_9FLOR PRELIMINARY; ID QBHBJ3_9FLOR PRELIMINARY; AC 01-MAR-2003 (T-TREMBLrel. 23, Created) DT 01-MAR-2003 (T-TREMBLrel. 23, Last sequence update) DE Ribulose-1,5-bisphosphate large subunit (Fragment). GN Name=rbCL; Ptilophora prolifera.				
OC Chloroplast.				
OX NCBI_TaxID=143014;				
RN [1]				
RP NUCLEOTIDE SEQUENCE.				
RA Bryne K., Zuccarello G.C., West J.A., Liao M.-L., Kraft G.; "Gracilaria species (Gracilariaeae, Rhodophyta) from southeastern Australia, including a new species, <i>G. perplexa</i> sp. nov.: Morphology, molecular relationships and agar content."; Phycol. Res. 50:295-311(2002); EMBL; AY131312; AN07050.1.; -; Genomic_DNA.				
DR GO; GO:0009507; C:chloroplast; IEA.				
KW Chloroplast.				
FT NON_TER	1	1		
SQ SEQUENCE 9 AA; 977 MW; CALA4DC1B771AB02 CRC64;				
Query Match Score 15; DB 2; Length 9; Best Local Similarity 60.0%; Pred. No. 2.2e+06; Matches 3; Conservative 0; Mismatches 2; Indels 0; Gaps 0;				
Qy 5 PVHNV 9				
Db 5 PTANV 9				
RESULT 45 QBHJK0_9FLOR PRELIMINARY; ID QBHJK0_9FLOR PRELIMINARY; AC 01-MAR-2003 (T-TREMBLrel. 23, Created) DT 01-MAR-2003 (T-TREMBLrel. 23, Last sequence update) DE Ribulose-1,5-bisphosphate large subunit (Fragment). GN Name=rbCL; Gracilaria secundata.				
OC Gracilaria.				
OX NCBI_TaxID=172973;				
RP NUCLEOTIDE SEQUENCE.				
RA Bryne K., Zuccarello G.C., West J.A., Liao M.-L., Kraft G.; "Gracilaria species (Gracilariaeae, Rhodophyta) from southeastern Australia, including a new species, <i>G. perplexa</i> sp. nov.: Morphology, molecular relationships and agar content."; Phycol. Res. 50:295-311(2002); EMBL; AY131311; AN07048.1.; -; Genomic_DNA.				
DR GO; GO:0009507; C:chloroplast; IEA.				
KW Chloroplast.				
FT NON_TER	1	1		
SQ SEQUENCE 9 AA; 977 MW; CALA4DC1B771AB02 CRC64;				
Query Match Score 15; DB 2; Length 9; Best Local Similarity 60.0%; Pred. No. 2.2e+06; Matches 3; Conservative 0; Mismatches 2; Indels 0; Gaps 0;				
Qy 5 PVHNV 9				

01-JUN-2003 (TrEMBLref). 24, Last annotation update)
DT Ribulose-1,5-bisphosphate carboxylase/oxygenase large subunit
(Fragment).
DB Name=rbclL;
GN Porphrya linearis.
OS Chloroplast.
OC Eukaryota; Rhodophyta; Bangiophyceae; Bangiales; Bangiaceae; Porphyra.
OX NCBI_TaxID=60544;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Teasdale B. W., West A., Taylor H., Klein A.S.;
RL Submitted (AUG-2001) to the BMBL/Genbank/DDBJ databases.
DR BMBL; AF411598; AN00005.1; -; Genomic_DNA.
DR GO; GO:0009507; C:chloroplast; IEA.
KW Chloroplast.
FT NON_TER 1 1
SQ 9 AA; 977 MW; CAA14DC1B771AB02 CRC64;
Query Match 30.6%; Score 15; DB 2; Length 9;
Best Local Similarity 60.0%; Pred. No. 2.2e+06;
Matches 3; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Db 5 PVHNV 9
Qy |
|
|
|
|
Db 5 PTANV 9

Search completed: February 24, 2006, 10:18:15
Job time : 247 secs

This Page Blank (uspto)

Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM protein - protein search, using sw model

Run on: February 24, 2006, 10:14:46 ; Search time 38 Seconds

(without alignments)
22.788 Million cell updates/sec

Title: US-10-019-513-1
Perfect score: 49
Sequence: 1 STAPPVHN 9

Scoring table: BLASTM62

Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 791

Minimum DB seq length: 0

Maximum DB seq length: 9

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing First 1000 summaries

Database : PIR 80:
1: pir1:
2: pir2:
3: pir3:
4: pir4:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	18	36.7	8	B39745	endoglycosidase (
2	18	36.7	9	B41983	acid downstream to b
3	17	34.7	5	B37988	acid proteinase 1
4	17	34.7	9	PC7078	unidentified 18.7K
5	16	32.7	7	B61491	seed protein Vg-5
6	16	32.7	8	PT0530	T-cell receptor be
7	16	32.7	8	PT0559	T-cell receptor be
8	16	32.7	8	PT0559	tumor associated a
9	15	30.6	8	S21288	lectin pototo
10	15	30.6	8	A31570	angiotensin-conver
11	15	30.6	9	B30572	T-cell receptor be
12	15	30.6	9	S55696	phosphoenolpyruvat
13	14	28.6	7	PT0727	H2 class I protein
14	14	28.6	7	S71299	IICL2 protein - Par
15	14	28.6	7	S09027	carboxylesterase (
16	14	28.6	7	PT0283	Ig heavy chain CRD
17	14	28.6	7	A61081	tryptophyllin, bas
18	14	28.6	8	S16324	hypothetical prote
19	14	28.6	8	S10783	enamelin F - bovin
20	14	28.6	8	B47393	neuropeptide F - calla
21	14	28.6	9	S65433	bradykinin, horn
22	14	28.6	7	B38740	19 kappa chain C r
23	14	28.6	9	S26508	collagen alpha 2(V
24	14	28.6	9	A43065	hydroxyproline-3-b
25	14	28.6	9	PC7073	ubiquinol-cytochro
26	14	28.6	9	B60246	ornitho-Kinin - ch
27	14	28.6	9	A26744	bradykinin-like pe
28	14	28.6	9	A61057	Thr-6 bradykinin -
29	14	28.6	9	A60579	bradykinin-like pe

30	28.6	2	A61363
31	28.6	2	A61358
32	28.6	9	S15595
33	26.5	6	A44916
34	26.5	2	PT0654
35	26.5	7	A15398
36	26.5	7	A58725
37	24.5	4	A37832
38	24.5	5	T10954
39	24.5	5	JS0319
40	24.5	6	I51317
41	24.5	6	PT0280
42	24.5	7	PC1316
43	24.5	7	PT0246
44	24.5	9	A56029
45	24.5	9	S13889
46	24.5	9	S70332
47	24.5	9	PT0247
48	24.5	9	PI0139
49	24.5	9	S10920
50	24.5	9	S66419
51	22.4	4	A02147
52	22.4	4	A34626
53	22.4	4	S17255
54	22.4	5	JN0862
55	22.4	5	B60274
56	22.4	5	PQ0009
57	22.4	5	PS0324
58	22.4	5	S11127
59	22.4	5	E42364
60	22.4	5	G37195
61	22.4	6	A43765
62	22.4	6	B60110
63	22.4	6	B27696
64	22.4	6	S15596
65	22.4	6	PS0324
66	22.4	7	E48394
67	22.4	7	A39690
68	22.4	7	C39690
69	22.4	8	S53008
70	22.4	8	A39308
71	22.4	8	PQ0701
72	22.4	8	A42689
73	22.4	8	S59902
74	22.4	9	A61364
75	22.4	9	S35538
76	22.4	9	S63491
77	22.4	9	C41170
78	22.4	9	S39766
79	22.4	9	PT0268
80	22.4	9	PC2197
81	22.4	9	D48186
82	22.4	9	A12874
83	22.4	9	A11497
84	22.4	9	E41978
85	22.4	9	A60356
86	22.4	9	S11075
87	22.4	9	PD0443
88	22.4	9	PD0008
89	22.4	9	PT0618
90	20.4	5	A41225
91	20.4	5	PQ0663
92	20.4	5	PT0714
93	20.4	6	A61049
94	20.4	6	PT0714
95	20.4	6	PD0008
96	20.4	6	PT0618
97	20.4	6	PT0715
98	20.4	7	PQ0663
99	20.4	7	I40504
100	20.4	7	PN0150
101	20.4	7	A34026
102	20.4	7	S42620

14	28.6	2	bradykinin - commo
14	28.6	9	bradykinin-like pe
14	28.6	9	mosquitocidal-toxi
14	28.6	9	T-cell receptor be
14	28.6	9	choline oxidase (E)
14	26.5	6	virotoxin - destru
14	26.5	7	phenol - monoxyge
14	26.5	7	hypothetical prote
14	26.5	7	subesophageal gang
14	26.5	7	bHLH transcription
14	26.5	7	Ig heavy chain CRD
14	26.5	7	large granule L3 C
14	26.5	7	Ig heavy chain CRD
14	26.5	7	carbon-monoxide de
14	26.5	7	venom protein HR-
14	26.5	7	tetrameric protein
14	26.5	7	phagocytosis-stimu
14	26.5	7	RPCH-related neuro
14	26.5	7	ribosomal protein
14	26.5	7	peptidyl-dipeptida
14	26.5	7	major protein anti
14	26.5	7	angiogenesis-conver
14	26.5	7	ribulose-bisphosph
14	26.5	7	phosphoprotein, bo
14	26.5	7	flagellar protein
14	26.5	7	bradykinin-potenti
14	26.5	7	28K ubiquitin-immu
14	26.5	7	repetitive protein
14	26.5	7	contraction-inhibi
14	26.5	7	isozocin - common
14	26.5	7	ribosomal protein
14	26.5	7	diisulatory sulf
14	26.5	7	photosystem II pro
14	26.5	7	cardioactive pepti
14	26.5	7	19 heavy chain CRD
14	26.5	7	zymogen granule me
14	26.5	7	ATPase R1 subunit
14	26.5	7	transaldoase (EC
14	26.5	7	transaldoase (EC
14	26.5	7	callin/FMRPamide
14	26.5	7	118K stomach cance
14	26.5	7	alpha-2-macroglobu
14	26.5	7	3-oxoacid CoA-tran
14	26.5	7	pep-tachykinin - P
14	26.5	7	orf 1 rara 5'-regi
14	26.5	7	copper resistance
14	26.5	7	alcohol dehydrogen
14	26.5	7	T-cell receptor be
14	26.5	7	halo-toxin - Pseud
14	26.5	7	angiotensin-conver
14	26.5	7	T-cell receptor be
14	26.5	7	T-cell receptor be
14	26.5	7	membrane protein -
14	26.5	7	hypothetical prote
14	26.5	7	omega-gliadine 1'
14	26.5	7	acetylcholesterol
14	26.5	7	aggregcan - bovine

249	8	16.3	A25836	322	7	14.3	A58620
250	8	16.3	154017	323	7	14.3	S5310
251	8	16.3	S07205	324	7	14.3	S10596
252	8	16.3	S07204	325	7	14.3	PH1407
253	8	16.3	S07241	326	7	14.3	PL0184
254	8	16.3	E28854	327	7	14.3	S70727
255	8	16.3	JS0302	328	7	14.3	S22428
256	8	16.3	A60320	329	7	14.3	A39892
257	8	16.3	S66608	330	7	14.3	PT06272
258	8	16.3	T31612	331	7	14.3	PT05059
259	8	16.3	PT0272	332	7	14.3	PT0547
260	8	16.3	S65313	333	7	14.3	PT0716
261	8	16.3	PH1591	334	7	14.3	S29272
262	8	16.3	A42266	335	7	14.3	A11117
263	8	16.3	D57444	336	7	14.3	A14683
264	8	16.3	A29477	337	7	14.3	C61512
265	8	16.3	C41978	338	7	14.3	JS0317
266	8	16.3	PT0080	339	7	14.3	D47393
267	8	16.3	PH1406	340	7	14.3	S71919
268	8	16.3	S39437	341	7	14.3	B24749
269	8	16.3	JN0026	342	7	14.3	D58503
270	8	16.3	B45020	343	7	14.3	A28719
271	8	16.3	C41978	344	7	14.3	I48935
272	7	14.3	157650	345	7	14.3	164832
273	7	14.3	A33391	346	7	14.3	Ca2+-transporting
274	7	14.3	T78890	347	7	14.3	neuropeptide B - b
275	7	14.3	A31802	348	7	14.3	dihydroliopainamide
276	7	14.3	S5508	349	7	14.3	aspartate transami-
277	7	14.3	I51049	350	7	14.3	quinoline 2-oxidase
278	7	14.3	PT0240	351	7	14.3	thymic humoral fac-
279	7	14.3	154357	352	7	14.3	allopineptide A1
280	7	14.3	A35779	353	7	14.3	Ca2+-transporting
281	7	14.3	5	1	HOROHA	PT0288	
282	7	14.3	B22565	354	7	14.3	ATP-binding Protei-
283	7	14.3	A37114	355	7	14.3	gastrin - domestic
284	7	14.3	5	2	S53595	calliphMRPamide 10 -	
285	7	14.3	PT0267	356	7	14.3	collilMRPamide 11
286	7	14.3	PH10596	357	7	14.3	Gene c-mp1 protein
287	7	14.3	H44817	358	7	14.3	probable membrane
288	7	14.3	F44817	359	7	14.3	locustamyroropin I
289	7	14.3	D44817	360	7	14.3	calliphMRPamide 1 -
290	7	14.3	D44817	361	7	14.3	calliphMRPamide 10 -
291	7	14.3	A64411	362	7	14.3	calliphMRPamide 2 -
292	7	14.3	A55890	363	7	14.3	growth hormone rec-
293	7	14.3	S11556	364	7	14.3	ribosomal protein
294	7	14.3	A37765	365	7	14.3	fructose-bisphosph
295	7	14.3	6	2	PT0550	translocation elonga-	
296	7	14.3	A617345	366	7	14.3	sperm-activating P
297	7	14.3	165546	367	7	14.3	alpha-2-macroglobu-
298	7	14.3	PT0518	368	7	14.3	enamelin i - bovin
299	7	14.3	P10616	369	7	14.3	vitamin D3 26'-mono
300	7	14.3	PT0650	370	7	14.3	20K protein - Rick
301	7	14.3	A61324	371	7	14.3	T-cell receptor be-
302	7	14.3	C56662	372	7	14.3	put pentapeptide -
303	7	14.3	S21230	373	6	12.2	19 heavy chain CRD
304	7	14.3	PH1408	374	7	14.3	27.5 kDa structura
311	7	14.3	PT0524	375	6	12.2	27.5K structural P
312	7	14.3	A44428	376	6	12.2	28.5K structural P
313	7	14.3	PT0521	377	6	12.2	28.5K structural P
314	7	14.3	PT0683	378	6	12.2	28K structural pro-
315	7	14.3	PK0008	379	6	12.2	tram protein - Esc
316	7	14.3	S58797	380	6	12.2	fulicin - giant Af
317	7	14.3	B48394	381	6	12.2	318
318	7	14.3	S45648	382	6	12.2	319
319	7	14.3	BN0649	383	6	12.2	320
320	7	14.3	PA4787	384	6	12.2	321
321	7	14.3	S15597	385	6	12.2	322

395	PT0585	468	5	10.2	139966
396	J0355	469	5	10.2	139965
397	S29637	470	5	10.2	5
398	B61512	471	5	10.2	5
399	A31263	472	5	10.2	F22565
400	B31263	473	5	10.2	T14908
401	PT0532	474	5	10.2	150385
402	PT0587	475	5	10.2	PT0308
403	PT0593	476	5	10.2	C53284
404	S6293	477	5	10.2	PT0610
405	PC127	478	5	10.2	PT0525
406	PT0605	479	5	10.2	PT0597
407	A3129	480	5	10.2	PT0729
408	XEVDGD	481	5	10.2	PT0624
409	S71867	482	5	10.2	PT0625
410	S16364	483	5	10.2	PT0660
411	S16365	484	5	10.2	PT0656
412	B34818	485	5	10.2	PT0525
413	H3098	486	5	10.2	PT0699
414	PC2370	487	5	10.2	PT0553
415	S71867	488	5	10.2	PT0561
416	S16364	489	5	10.2	PT0690
417	S59622	490	5	10.2	PT0684
418	PA0035	491	5	10.2	PT0590
419	S78036	492	5	10.2	PT0577
420	S13661	493	5	10.2	PT0580
421	A42057	494	5	10.2	PT0700
422	PT0588	495	5	10.2	PT0713
423	PA0934	496	5	10.2	S69237
424	A37521	497	5	10.2	PT0644
425	B27867	498	5	10.2	PT0600
426	H41978	499	5	10.2	PT0601
427	A61467	500	5	10.2	PT0565
428	T18890	501	5	10.2	PT0701
429	E60588	502	5	10.2	PT0717
430	YFGC	503	5	10.2	JT0870
431	AQKQIM	504	5	10.2	S66195
432	A60957	505	5	10.2	S02617
433	A24244	506	5	10.2	B34835
434	D2180	507	5	10.2	JH0784
435	C2180	508	5	10.2	B26205
436	P28854	509	5	10.2	I59142
437	D28854	510	5	10.2	PT0510
438	S70334	511	5	10.2	PT0519
439	A24244	512	5	10.2	PT0512
440	D2180	513	5	10.2	PT0599
441	P28854	514	5	10.2	PT0630
442	D28854	515	5	10.2	PT0637
443	I52974	516	5	10.2	PT0621
444	PH0917	517	5	10.2	PT0619
445	PT0270	518	5	10.2	PT0641
446	PT0299	519	5	10.2	PT0657
447	PT0670	520	5	10.2	PT0662
448	PT0662	521	5	10.2	PT0668
449	I52974	522	5	10.2	PT0648
450	PT0334	523	5	10.2	PT0533
451	PH0921	524	5	10.2	PT0720
452	S78426	525	5	10.2	PT0560
453	S19523	526	5	10.2	PT0723
454	T173804	527	5	10.2	PT0718
455	PT0645	528	5	10.2	PT0589
456	A57444	529	5	10.2	PT0730
457	B37444	530	5	10.2	PD0028
458	A41199	531	5	10.2	S29881
459	T173804	532	5	10.2	A61068
460	PT0645	533	5	10.2	S19630
461	PT0661	534	5	10.2	S20446
462	PT0534	535	5	10.2	S25265
463	PT0698	536	5	10.2	PT0269
464	PT0551	537	5	10.2	B30608
465	PT0697	538	5	10.2	B33541
466	PT0566	539	5	10.2	PH1602
467	I39964	540	5	10.2	PT0611

541	10.2	PT0523	T-cell receptor be	8.2	614	I37013
542	10.2	PT0528	T-cell receptor be	8.2	615	I8439
543	10.2	PT0542	T-cell receptor be	8.2	616	PL0146
544	5 10.2	PT0620	T-cell receptor be	8.2	617	neuropeptide Antho-
545	5 10.2	PT0667	achatin-I - giant	8.2	618	Ig heavy chain CRD
546	5 10.2	PT0663	T-cell receptor be	8.2	619	T-cell receptor be
547	5 10.2	PT0704	T-cell receptor be	8.2	620	T-cell receptor be
548	5 10.2	PT0689	T-cell receptor be	8.2	621	T-cell receptor be
549	5 10.2	PT0719	T-cell receptor be	8.2	622	T-cell receptor be
550	5 10.2	PT0586	T-cell receptor be	8.2	623	T-cell receptor be
551	5 10.2	PT0569	T-cell receptor be	8.2	624	T-cell receptor be
552	5 10.2	PT076	T-cell receptor be	8.2	625	copper resistance
553	5 10.2	PT0579	T-cell receptor be	8.2	626	primase - Citrobac
554	5 10.2	PT0581	T-cell receptor be	8.2	627	prim. fimbrial regul
555	5 10.2	PT0702	T-cell receptor be	8.2	628	major protein anti-
556	5 10.2	PQ0776	NADH2 dehydrogenas	8.2	629	hypothetical prote
557	5 10.2	S09066	globulin IV lpha	8.2	630	zinc-binding prote
558	5 10.2	B35890	RNA-directed DNA p	8.2	631	neuropeptide - sea
559	5 10.2	A30812	sex pheromone ccr1	8.2	632	cocoase (BC 3-4)
560	5 10.2	PC2132	FMRPamide-related	8.2	633	Ig heavy chain CRD
561	5 10.2	S31244	neuromodulatory pe	8.2	634	synaptosomal-assoc
562	5 10.2	S31245	neuromodulatory pe	8.2	635	hypothetical protid
563	5 10.2	S31246	neuromodulatory pe	8.2	636	zinc-binding prote
564	5 10.2	PT0529	T-cell receptor be	8.2	637	T-cell receptor be
565	5 10.2	PT0544	T-cell receptor be	8.2	638	T-cell receptor be
566	5 10.2	T15382	hypothetical pepti	8.2	639	T-cell receptor be
567	5 10.2	A32523	peptidyl-dipeptida	8.2	640	T-cell receptor be
568	5 10.2	S61493	dissimilatory sulf	8.2	641	spinal cord peptid
569	5 10.2	S61494	protein QA0040 -	8.2	642	T-cell receptor be
570	5 10.2	PA0032	hypothetical prote	8.2	643	blood cell protein
571	5 10.2	T10952	T-cell receptor be	8.2	644	dnazX-like protein
572	5 10.2	PT0279	T-cell receptor be	8.2	645	T-cell receptor be
573	5 10.2	PH0803	T-cell receptor al	8.2	646	T-cell receptor be
574	5 10.2	PT0595	T-cell receptor be	8.2	647	T-cell receptor be
575	5 10.2	PT0522	T-cell receptor be	8.2	648	mitosis inhibiting
576	5 10.2	PT0631	T-cell receptor be	8.2	649	N-formyl oligopept
577	5 10.2	PT0163	T-cell receptor be	8.2	650	phosphoglycerate t
578	5 10.2	A36887	T-cell receptor ga	8.2	651	hydrogen sulfite re
579	5 10.2	B41594	aspارتate kinase (8.2	652	R-phycocerythrin be
580	5 10.2	A61496	ubiquitin - celery	8.2	653	antineoplastic gly
581	5 10.2	PC1002	leucine-tRNA ligas	8.2	654	H4 histone - Afric
582	5 10.2	S37141	rpsA Protein - Erw	8.2	655	protamine P1 - gor
583	5 10.2	D61512	variant surface 91	8.2	656	y protein - human
584	5 10.2	PL0162	paramoyosin - north	8.2	657	T-cell receptor be
585	5 10.2	JS0315	leukokinin V - Mad	8.2	658	T-cell receptor be
586	5 10.2	A41618	beta-galactosidase	8.2	659	Whey glycoprotein com
587	5 10.2	S61325	blood cell protein	8.2	660	fatty-acid synthas
588	5 10.2	S37142	leg haemoglobin III	8.2	661	alpha-tubulin - Ch
589	5 10.2	A61357	phylocaerulein -	8.2	662	T-cell receptor be
590	5 10.2	A44873	caldesmon - rabbit	8.2	663	T-cell receptor be
591	5 10.2	G41946	T-cell receptor ga	8.2	664	T-cell receptor be
592	5 10.2	PH0918	T-cell receptor be	8.2	665	T-cell receptor be
593	5 10.2	S02162	macrophage inhibit	8.2	666	T-cell receptor be
594	5 10.2	A61359	cell surface adhes	8.2	667	T-cell receptor be
595	5 10.2	A44874	dextrantrascurase (BC	8.2	668	T-cell receptor be
596	5 10.2	A32841	sucrose 3'-glucosyl	8.2	669	T-cell receptor be
597	5 10.2	S13333	alpha/beta gliadin	8.2	670	T-cell receptor be
598	5 10.2	JN027	(Phe-6)-mopact - 8	8.2	671	T-cell receptor be
599	5 10.2	A61386	macrophage inhibit	8.2	672	T-cell receptor be
600	5 10.2	S03049	thyroglobulin - do	8.2	673	T-cell receptor be
601	4 8.2	B324362	superhelical D	8.2	674	hypothetical prote
602	4 8.2	PQ0010	angiotensin-conver	8.2	675	hypothetical prote
603	4 8.2	PT0578	T-cell receptor be	8.2	676	glucan 1,4-alpha-9
604	4 8.2	PQ0027	T-cell receptor be	8.2	677	myosin-light-chain
605	4 8.2	A41840	protamine P1 - ora	8.2	678	18K protein 5507 -
606	4 8.2	A61300	19 mu chain V regi	8.2	679	unidentified 5.0/1
607	4 8.2	I40505	protein-glycinamide	8.2	680	formylglycinamide
608	4 8.2	T46627	formylglycinamide	8.2	681	formylglycinamide
609	4 8.2	A27897	formylglycinamide	8.2	682	formylglycinamide
610	4 8.2	S31390	formylglycinamide	8.2	683	formylglycinamide
611	4 8.2	I61883	formylglycinamide	8.2	684	formylglycinamide
612	4 8.2	S43959	formylglycinamide	8.2	685	formylglycinamide
613	4 8.2	A26209	formylglycinamide	8.2	686	formylglycinamide

687	4	8.2	S68004	hucolin, 75K chain	760	2	4.1	5 2	PQ0689
688	4	8.2	A11483	aspartate transami	761	2	4.1	5 2	B61445
689	4	8.2	PT0602	T-cell receptor be	762	2	4.1	5 2	A61445
690	4	8.2	PT0666	T-cell receptor be	763	2	4.1	6 2	B44510
691	4	8.2	PT0655	T-cell receptor be	764	2	4.1	6 2	B35640
692	4	8.2	PT0665	T-cell receptor be	765	2	4.1	7 2	A60224
693	4	8.2	PT0556	T-cell receptor be	766	2	4.1	8 2	PQ0012
694	4	8.2	PT0542	T-cell receptor be	767	2	4.1	8 2	A43001
695	4	8.2	PT0543	T-cell receptor be	768	2	4.1	9 2	PW1018
696	4	8.2	PT0722	T-cell receptor be	769	1	2.0	3 3	\$13894
697	4	8.2	PT0567	T-cell receptor be	770	1	2.0	3 3	B23751
698	4	8.2	PT0676	T-cell receptor be	771	1	2.0	4 2	D41654
699	4	8.2	PT0688	T-cell receptor be	772	1	2.0	4 2	I40870
700	4	8.2	PT0728	T-cell receptor be	773	1	2.0	4 2	A53284
701	4	8.2	PT0671	T-cell receptor be	774	1	2.0	4 2	B53284
702	4	8.2	A38671	peptidylglycine mo	775	1	2.0	4 2	\$47552
703	4	8.2	A25269	sex pheromone cAM3	776	1	2.0	4 2	A60418
704	4	8.2	S33567	tubulin beta-3 cha	777	1	2.0	4 2	ECNK
705	4	8.2	A58512	venom heptapeptide	778	1	2.0	5 2	A32516
706	4	8.2	PC4131	hypothetical prote	779	1	2.0	5 2	B45525
707	4	8.2	PT1097	158K exoantigen -	780	1	2.0	6 2	B33922
708	4	8.2	B33099	IG heavy chain CRD	781	1	2.0	7 4	PC2057
709	4	8.2	PT0298	IG heavy chain CRD	782	1	2.0	9 2	PH0942
710	4	8.2	PT0328	phosphatidylethano	783	0	0.0	3 3	B37196
711	4	8.2	PN0043	T-cell receptor al	784	0	0.0	3 3	F37196
712	4	8.2	A35768	T-cell receptor be	785	0	0.0	3 3	A23751
713	4	8.2	PT0527	T-cell receptor be	786	0	0.0	4 1	ECXAR
714	4	8.2	PT0653	T-cell receptor be	787	0	0.0	4 2	A25844
715	4	8.2	PT0557	T-cell receptor be	788	0	0.0	4 2	\$55238
716	4	8.2	PT0554	T-cell receptor be	789	0	0.0	5 2	A33882
717	4	8.2	PT0724	T-cell receptor be	790	0	0.0	5 2	\$65726
718	4	8.2	PT0725	T-cell receptor be	791	0	0.0	7 2	B33882
719	4	8.2	PC4372	telomeric and tetra					
720	4	8.2	S15651	probable Na+-trans					
721	4	8.2	A59495	vesicle associated					
722	4	8.2	PT0726	unidentified 4.5/4					
723	4	8.2	S11078	glucose-6-phosphate					
724	4	8.2	A21440	variant surface 91-					
725	4	8.2	JS0318	leucokinin VIII -					
726	4	8.2	T13818	cytochrome oxidase					
727	4	8.2	F60588	sperm-activating P					
728	4	8.2	G60588	sperm-activating P					
729	4	8.2	I55411	hypothetical histo					
730	4	8.2	PM0002	chlorophyll a/b-bi					
731	4	8.2	C36730	hutu protein - Kle					
732	4	8.2	PA0333	protein Qa30033 -					
733	4	8.2	PT0225	IG heavy chain CDR					
734	4	8.2	PT0315	IG heavy chain CDR					
735	4	8.2	S653865	collagen alpha 2(V					
736	4	8.2	S16850	IG heavy chain V					
737	4	8.2	PT0334	r-cell receptor be					
738	4	8.2	A35327	fructose-6-bisph					
739	4	8.2	PS0253	glycine cleavage S					
740	4	8.2	C57444	neuropeptide Grb-A					
741	4	8.2	D4787	calliflMRPamide 13					
742	4	8.2	F41978	calliflucanase F -					
743	4	8.2	G41978	alkanal monoxygen					
744	4	8.2	A15633	hypothetical prote					
745	4	8.2	A37027	NADH2 dehydrogenas					
746	4	8.2	A50427	protein kinase C i					
747	4	8.2	QDRB	tracylglycerol li					
748	3	6.1	E44823	trichodecenin I -					
749	3	6.1	S09478	Na+-transporting A					
750	3	6.1	I40804	tetraether lipid					
751	3	6.1	A44955	telomeric and tetr					
752	3	6.1	S09652	aldehyde dehydrogena					
753	3	6.1	T09512	protein kinase C i					
754	3	6.1	A59489	tracylglycerol li					
755	3	6.1	S57274	trichodecenin I -					
756	3	6.1	PC2056	Na+-transporting A					
757	3	6.1	S65296	tetraether lipid					
758	3	6.1	PC4373	telomeric and tetr					
759	2	4.1	A22565	R-phycocerythrin al					

ALIGNMENTS

RESULT 1
B39745 endoglycosylceramidae (EC 3.2.1.123) I - Rhodococcus sp. (fragment)
C;Species: Rhodococcus sp.
C;Date: 30-Dec-1991 #sequence_revision 30-Dec-1991 #text_change 31-Dec-1993
C;Accession: B39745
R;Ito, M.; Ikegami, Y.; Yamagata, T.
J. Biol. Chem. 266, 7919-7926, 1991.
A;Title: Activator proteins for glycosphingolipid hydrolysis by endoglycosidases. El
A;Reference number: A39745; PMID:9120321; PMCID: B39745
A;Accession: B39745
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-8 <ITO>
A;Cross-references: UNIPARC:UPI000017AD78
C;Keywords: glycosidase; hydrolase

Query Match Score 36.7%; DB 2; Length 8;
Best Local Similarity 100.0%; Pred. No. 2.8e-05;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 APP 5
Db 1 APP 3

RESULT 2
B41983 orf downstream to bacterioferritin - Azotobacter vinelandii (fragment)
C;Species: Azotobacter vinelandii
C;Date: 04-Mar-1993 #sequence_revision 18-Nov-1994 #text_change 09-Jul-2004
C;Accession: B41983
R;Grossman, M.J.; Hinton, S.M.; Minak-Barnero, V.; Slaughter, C.; Stieffel, E.I.
Proc. Natl. Acad. Sci. U.S.A. 89, 2419-2423, 1992
A;Title: Unification of the ferritin family of proteins.

A; Reference number: A41983 ; MUID:92196129 ; PMID:1549605
 A; Accession: B1983
 A; Status: preliminary; not compared with conceptual translation
 A; Molecule type: nucleic acid; protein
 A; Residues: 1-9 <GRO>
 A; Cross-references: UNIPROT:P25825; UNIPARC:UPI000013A27; GB:MB33692; NID:9142297; PIDN:
 A; Note: sequence extracted from NCBI backbone (NCBIP:88442)

Query Match Score 36.7%; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.8e+05;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 APP 5
 Db 2 APP 4

RESULT 3
 B37988
 acid proteinase light chain - slime mold (*Physarum polycephalum*) (fragment)
 C; Species: *Physarum polycephalum*
 C; Accession: B37988
 C; Date: 28-Jun-1991 #sequence_revision 28-Jun-1991 #text_change 30-Sep-1993
 R; Murakami-Murofushi, K.; Takahashi, T.; Minowa, Y.; Iino, S.; Takeuchi, T.; Kitagaki-Og
 J; Biol. Chem. 265, 19898-19903, 1990
 A; Title: Purification and characterization of a novel intracellular acid proteinase from
 A; Reference number: A37988 ; MUID:91060608; PMID:2246266
 A; Status: preliminary
 A; Molecule type: protein
 A; Residues: 1-5 <MUR>
 A; Cross-references: UNIPARC:UPI000017B19F

Query Match Score 34.7%; Length 5;
 Best Local Similarity 66.7%; Pred. No. 2.8e+05;
 Matches 2; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 4 PPV 6
 Db 3 PPI 5

RESULT 4
 PC7078
 unidentified 48.7K protein - mouse (fragment)
 C; Species: *Mus musculus* (house mouse)
 C; Accession: PC7078
 C; Date: 18-Aug-2000 #sequence_revision 18-Aug-2000 #text_change 09-Jul-2004
 R; Taugita, A.; Kawakami, T.; Uchida, T.; Sakai, T.; Kamo, M.; Matsui, T.; Watanabe, Y.;
 Electrophoresis 21, 1853-1871, 2000
 A; Title: Proteome analysis of mouse brain: Two-dimensional electrophoresis profiles of t
 A; Reference number: PC7072
 A; Accession: BC7078
 A; Molecule type: protein
 A; Residues: 1-9 <TSU>
 A; Cross-references: UNIPROT:Q9IY01; UNIPARC:UPI000017C9882
 A; Experimental source: strain C57BL/6Cr SIC, male; brain, striatum
 C; Keywords: brain

Query Match Score 34.7%; Length 9;
 Best Local Similarity 75.0%; Pred. No. 2.8e+05;
 Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 STAP 4
 Db 4 TTAP 7

RESULT 5
 E61491
 seed protein ws-5 - winged bean (fragment)
 C; Species: *Psophocarpus tetragonolobus* (winged bean)
 C; Date: 07-Oct-1994 #sequence_revision 07-Oct-1994 #text_change 07-Oct-1994

C;Accession: E61491
 R;Hirano, H.
 J. Protein Chem. 8, 115-130, 1989
 A;Title: Microsequence analysis of winged bean seed proteins electroblotted from two-dim
 A;Reference number: A61491 ; MUID:89351606; PMID:2765119
 A;Accession: E61491
 A;Status: preliminary
 A;Molecule type: protein
 A;Residues: 1-7 <HIR>
 A;Cross-references: UNIPARC:UPI000017B074
 C;Keywords: glycoprotein; seed

Query Match Score 32.7%; Length 7;
 Best Local Similarity 75.0%; Pred. No. 2.8e+05;
 Matches 3; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 STAP 4
 Db 1 STVP 4

RESULT 6
 PT0530
 T-cell receptor beta chain V-D-J region (100-4AK) - mouse (fragment)
 C;Species: *Mus musculus* (house mouse)
 C;Date: 17-Jul-1992 #sequence_revision 17-Jul-1992 #text_change 30-May-1997
 C;Accession: PT0530
 R;Feeley, A.J.
 J. Exp. Med. 174, 115-124, 1991
 A;Title: Junctional sequences of fetal T cell receptor beta chains have few N regions
 A;Reference number: PT0509 ; MUID:91277601; PMID:1711558
 A;Accession: PT0530
 A;Status: translation not shown
 A;Molecule type: mRNA
 A;Residues: 1-8 <PEE>
 A;Cross-references: UNIPARC:UPI000017C7BB
 A;Experimental source: adult thymus, strain BALB/c
 C;Keywords: T-cell receptor

Query Match Score 32.7%; Length 8;
 Best Local Similarity 75.0%; Pred. No. 2.8e+05;
 Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 STAP 4
 Db 2 SSAP 5

RESULT 7
 PT0559
 T-cell receptor beta chain V-D-J region (126-1BH) - mouse (fragment)
 C;Species: *Mus musculus* (house mouse)
 C;Date: 17-Jul-1992 #sequence_revision 17-Jul-1992 #text_change 30-May-1997
 C;Accession: PT0559
 R;Feeley, A.J.
 J. Exp. Med. 174, 115-124, 1991
 A;Title: Junctional sequences of fetal T cell receptor beta chains have few N regions
 A;Reference number: PT0509 ; MUID:91277601; PMID:1711558
 A;Accession: PT0559
 A;Status: translation not shown
 A;Molecule type: mRNA
 A;Residues: 1-8 <PEE>
 A;Cross-references: UNIPARC:UPI000017C90E
 A;Experimental source: day 18 fetal thymus, strain BALB/C
 C;Keywords: T-cell receptor

Query Match Score 32.7%; Length 8;
 Best Local Similarity 40.0%; Pred. No. 2.8e+05;
 Matches 2; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1 STAPP 5
 Db 1 ASGP 5

RESULT 8
 S43971 tumor-associated antigen MUT1 - mouse
 C;Species: Mus musculus (house mouse)
 C;Date: 20-Oct-1994 #sequence_revision 17-Nov-1995 #text_change 16-Aug-2004
 C;Accession: S43971
 R;Mandelboim, O.; Berk, G.; Fridkin, M.; Feldman, M.; Eisenbach, L.
 Nature 369, 67-71, 1994
 A;Title: CRM induction by a tumour-associated antigen octapeptide derived from a murine
 A;Reference number: S43971; MUID:94217811; PMID:8164742
 A;Accession: S43971
 A;Status: preliminary
 A;Molecule type: protein
 A;Residues: 1-8 <MAN>
 A;Cross-references: UNIPROT:Q7M067; UNIPARC:UPI000017A4FF

Query Match Score 16; DB 2; Length 8;
 Best Local Similarity 60.0%; Pred. No. 2.8e+05;
 Matches 3; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 STAPP 5
 Db 4 NTAQP 8

RESULT 9
 S21288 Lectin - potato (fragment)
 C;Species: Solanum tuberosum (potato)
 C;Accession: S21288
 R;Millar, D.J.; Allen, A.K.; Smith, C.G.; Sidebottom, C.; Slabas, A.R.; Bolwell, G.P.
 Biochem. J. 283, 813-821, 1992
 A;Chitin binding proteins in potato (Solanum tuberosum L.) tuber. Characterization
 A;Reference number: S21288; MUID:92272683; PMID:1590771
 A;Accession: S21288
 A;Molecule type: protein
 A;Residues: 1-8 <MIL>
 A;Cross-references: UNIPROT:Q7M1V6; UNIPARC:UPI000017B0BF

Query Match Score 15; DB 2; Length 8;
 Best Local Similarity 66.7%; Pred. No. 2.8e+05;
 Matches 2; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 3 APP 5
 Db 6 spp 8

RESULT 10
 A31570 angiotensin-converting enzyme inhibitor - yellowfin tuna
 C;Species: Thunnus albacares (yellowfin tuna)
 C;Accession: A31570
 R;Kohama, Y.; Matsumoto, S.; Oka, H.; Teramoto, T.; Okabe, M.; Mimura, T.
 Biochem. Biophys. Res. Commun. 155, 332-337, 1988
 A;Title: Isolation of angiotensin-converting enzyme inhibitor from tuna muscle.
 A;Accession number: A31570; MUID:88326322; PMID:3415688
 A;Molecule type: protein
 A;Residues: 1-8 <KOH>
 A;Cross-references: UNIPROT:P18691; UNIPARC:UPI0000035267
 A;Note: the source is designated as Neothunnus macropterus
 C;Keywords: angiotensin-converting enzyme inhibitor

Query Match Score 15; DB 2; Length 8;

Best Local Similarity 66.7%; Pred. No. 2.8e+05;
 Matches 2; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 5 PVH 7
 Db 1 PTH 3

RESULT 11
 B30572 T-cell receptor beta chain C region (CRTB29) - rat (fragment)
 C;Species: Rattus norvegicus (Norway rat)
 C;Date: 03-Apr-1989 #sequence_revision 03-Apr-1989 #text_change 30-May-1997
 C;Accession: B30572
 R;Williams, C.B.; Gutman, G.A.
 J. Immunol. 142, 1027-1035, 1989
 A;Title: T cell receptor beta-chain genes in the rat. Availability and pattern of utilization
 A;Reference number: A30563; MUID:89110038; PMID:2563271
 A;Accession: B30572
 A;Status: preliminary; not compared with conceptual translation
 A;Molecule type: mRNA
 A;Residues: 1-9 <WLI>
 A;Cross-references: UNIPARC:UPI000017C9D5
 C;Keywords: T-cell receptor

Query Match Score 15; DB 2; Length 9;
 Best Local Similarity 40.0%; Pred. No. 2.8e+05;
 Matches 2; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1 STAPP 5
 Db 5 TVTPP 9

RESULT 12
 S55696 phosphoenolpyruvate carboxykinase - Trypanosoma brucei
 C;Species: Trypanosoma brucei
 C;Accession: S55696
 C;Date: 28-Oct-1995 #sequence_revision 03-Nov-1995 #text_change 09-Jul-2004
 R;Hunt, M.; Koehler, P.
 Biochim. Biophys. Acta 1249, 15-22, 1995
 A;Title: Purification and characterization of phosphoenolpyruvate carboxykinase from Trypanosoma brucei
 A;Reference number: S55696; MUID:95284106; PMID:7766679
 A;Accession: S55696
 A;Status: preliminary
 A;Molecule type: protein
 A;Residues: 1-9 <HN>
 A;Cross-references: UNIPARC:UPI000017B599

Query Match Score 15; DB 2; Length 9;
 Best Local Similarity 50.0%; Pred. No. 2.8e+05;
 Matches 2; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 4 PPVH 7
 Db 2 PTH 5

RESULT 13
 PQ0727 H2 class I protein (imported) - rice (fragment)
 C;Species: Oryza sativa (rice)
 C;Accession: PQ0727
 C;Date: 20-Apr-2000 #sequence_revision 20-Apr-2000 #text_change 20-Apr-2000
 R;Komatsu, S.; Kajiwara, H.; Hirano, H.
 Theor. Appl. Genet. 86, 935-942, 1993
 A;Title: A rice protein library; a data-file of rice proteins separated by two-dimension
 A;Reference number: PQ0696
 A;Accession: PQ0727
 A;Status: preliminary
 A;Molecule type: protein
 A;Residues: 1-7 <KOM>

A;Cross-references: UNIPARC:UPI000017B10C
Query Match 28.6%; Score 14; DB 2; Length 7;
Best Local Similarity 75.0%; Pred. No. 2.8e+05;
Matches 3; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 3 APPV 6
Db 2 APAV 5

RESULT 14
S71299 ICL22 protein - *Paramaecium tetraurelia* (fragment)
C;Species: *Paramaecium tetraurelia*
C;Date: 11-Mar-1998 #sequence_revision 17-Apr-1998 #text_change 07-Dec-1999
C;Accession: S71299
R;Madeddu, L.; Klotz, C.; le Caer, J.P.; Beisson, J.
Bur. J. Biochem. 238, 121-128, 1996
A;Title: Characterization of centrin genes in *Paramaecium*.
A;Reference number: S71298; MUID:96248429; PMID:8665928
A;Accession: S71299
A;Molecule type: protein
A;Residues: 1-7 <WAD>
A;Cross-references: UNIPARC:UPI000017B66B
A;Experimental source: strain d4-2
C;Genetic code: SGCS

Query Match 28.6%; Score 14; DB 2; Length 7;
Best Local Similarity 100.0%; Pred. No. 2.8e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 4 PP 5
Db 3 PP 4

RESULT 15
S09277 carboxylesterase (EC 3.1.1.1) MK2, microsomal - crab-eating macaque (fragment)
C;Species: Macaca fascicularis (crab-eating macaque)
C;Date: 30-Sep-1991 #sequence_revision 30-Sep-1991 #text_change 28-Apr-1993
C;Accession: S09277
R;Hosokawa, M.; Maki, T.; Satoh, T.
Arch. Biochem. Biophys. 277, 219-227, 1990
A;Title: Characterization of molecular species of liver microsomal carboxylesterases of
A;Reference number: S09271; MUID:90179180; PMID:2310190
A;Accession: S09277
A;Molecule type: protein
A;Residues: 1-7 <HOS>
A;Cross-references: UNIPARC:UPI000017C058
C;Keywords: carboxylic ester hydrolase

Query Match 28.6%; Score 14; DB 2; Length 7;
Best Local Similarity 50.0%; Pred. No. 2.8e+05;
Matches 3; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
Qy 1 STAPPY 6
Db 2 SASPXY 7

RESULT 16
PT083 Ig heavy chain CRD3 region (clone 4-94B) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 16-Aug-1996
R;Yamada, M.; Wasserman, R.; Reichard, B.A.; Shane, S.; Caton, A.J.; Rovera, G.
J. Exp. Med. 173, 395-407, 1991
A;Title: Preferential utilization of specific immunoglobulin heavy chain diversity and
A;Reference number: PT0822; MUID:91108337; PMID:1889102

A;Accession: PT0283
A;Molecule type: DNA
A;Residues: 1-7 <XAM>
A;Cross-references: UNIPARC:UPI000017C206
A;Experimental source: B lymphocyte
C;Keywords: heterotetramer; immunoglobulin
Query Match 28.6%; Score 14; DB 2; Length 7;
Best Local Similarity 100.0%; Pred. No. 2.8e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 4 PP 5
Db 6 PP 7

RESULT 17
A61081 tryptophyllin, basic - Rohde's leaf frog
C;Species: *Phyllomedusa rohdei* (Rohde's leaf frog)
C;Date: 31-Dec-1993 #sequence_revision 31-Dec-1993 #text_change 05-Oct-2004
C;Accession: A61081
R;Montecuccchi, P.C.; Vincenti, M.; Lazzarini, A.M.; Rusconi, L.; Erbamer, V.
Int. J. Pept. Protein Res. 33, 391-395, 1989
A;Title: Isolation, structure determination and synthesis of a novel tryptophan-containing
A;Reference number: A61081
A;Accession: A61081
A;Molecule type: protein
A;Residues: 1-7 <MON>
A;Cross-references: UNIPARC:UPI000002C90
C;Comment: The biological activity of this peptide was not determined.
C;Keywords: amidated carboxyl end; hydroxyproline; skin
F13/Modified site: 4-hydroxyproline (Pro) #status experimental
F17/Modified site: amidated carboxyl end (Pro) #status experimental
Query Match 28.6%; Score 14; DB 2; Length 7;
Best Local Similarity 100.0%; Pred. No. 2.8e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 18
S16324 hypothetical protein 2 - *Arabidopsis thaliana*
C;Species: *Arabidopsis thaliana* (mouse-ear cress)
C;Date: 21-Nov-1993 #sequence_revision 12-May-1995 #text_change 21-Jul-2000
C;Accession: S16324
R;Ruberti, I.; Sesia, G.; Lucchetti, S.; Morelli, G.
EMBO J. 10, 1787-1791, 1991
A;Title: A novel class of plant proteins containing a homeodomain with a closely linked
A;Reference number: S16323; MUID:91266907; PMID:167563
A;Accession: S16324
A;Status: translation not shown
A;Molecule type: mRNA
A;Residues: 1-8 <RUB>
A;Cross-references: UNIPARC:UPI000011DF52; EMBL:X58821; NID:g16327; PID:CAA41654_1; PID
Query Match 28.6%; Score 14; DB 2; Length 8;
Best Local Similarity 100.0%; Pred. No. 2.8e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 19
S10783 enameil f - bovine (fragment)
C;Species: *Bos primigenius taurinus* (cattle)

C;Date: 19-Mar-1997 #sequence_revision 21-Nov-1998 #text_change 21-Nov-1998
 C;Accession: S10783
 R;Strawich, B.; Glincher, M.J.
 Eur. J. Biochem. 1991, 47-56, 1990
 A;Title: Tooth 'enamelins' identified mainly as serum proteins. Major 'enamelin' is albumin
 A;Reference number: S10780; PMID:90336641; MUID:2379503
 A;Accession: S10783
 A;Molecule type: protein
 A;Residues: 1-8 <STR>
 A;Cross-references: UNIPARC:UPI00017C505
 C;Keywords: enamel; phosphoprotein

Query Match 28.6%; Score 14; DB 2; Length 8;
 Best Local Similarity 100.0%; Pred. No. 2.8e+05; Indels 0; Gaps 0;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 PP 5
 Db 4 PP 5

RESULT 20
 E47393 neuropeptide callatosatin 5 - bluebottle fly (Calliphora vomitoria)
 C;Species: Calliphora vomitoria
 C;Accession: E47393
 C;Date: 16-Feb-1994 #sequence_revision 18-Nov-1994 #text_change 09-Jul-2004
 C;Accession: E47393
 R;Dove, H.; Johnson, A.H.; Scott, A.G.; Yu, C.G.; Yagi, K.J.; Tobe, S.S.; Thorpe, A.
 Proc. Natl. Acad. Sci. U.S.A. 90, 2456-2460, 1993
 A;Title: Callatosatins: neuropeptides from the blowfly Calliphora vomitoria with sequences similar to those of the leeches and human shh
 A;Reference number: A47393; MUID:93211980; PMID:8460157
 A;Status: Preliminary
 A;Molecule type: protein
 A;Residues: 1-8 <DUV>
 A;Cross-references: UNIPROT:P41841; UNIPARC:UPI000002EAB5
 A;Experimental Source: whole flies
 A;Note: sequence extracted from NCBI backbone (NCBIP:128482)

Query Match 28.6%; Score 14; DB 2; Length 8;
 Best Local Similarity 100.0%; Pred. No. 2.8e+05; Indels 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 PP 5
 Db 2 PP 3

RESULT 21
 S65433 bradykinin - horn fly (fragment)
 C;Species: Haematobia irritans (horn fly)
 C;Accession: S65433
 C;Date: 28-Oct-1996 #sequence_revision 13-Mar-1997 #text_change 13-Mar-1997
 R;Wijffels, G.; Fitzgerald, C.; Gough, J.; Riding, G.; Elvin, C.; Kemp, D.; Willadsen, F.
 Eur. J. Biochem. 237, 414-423, 1996
 A;Title: Cloning and characterization of angiotensin-converting enzyme from the dipteran
 A;Reference number: S65431; MUID:96215437; PMID:8647080
 A;Status: Preliminary
 A;Molecule type: protein
 A;Residues: 1-9 <WIU>
 A;Cross-references: UNIPARC:UPI000002CF4A
 A;Note: the source is designated as Haematobia irritans exigua

Query Match 28.6%; Score 14; DB 2; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.8e+05; Indels 0; Gaps 0;

Qy 4 PP 5
 Db 2 PP 3

RESULT 22
 B38740 19 kappa chain C region (PY20) - mouse (fragment)
 C;Species: Mus musculus (house mouse)
 C;Accession: B38740
 R;Ruff-Jamison, S.; Campos-Gonzalez, R.; Glenney Jr., J.R.
 J. Biol. Chem. 266, 6607-6613, 1991
 A;Title: Heavy and light chain variable region sequences and antibody properties of anti-A;Reference number: A38740; MUID:9117723; PMID:1706720
 A;Accession: B38740
 A;Status: preliminary
 A;Molecule type: mRNA
 A;Residues: 1-9 <RNP>
 A;Cross-references: UNIPARC:UPI000017CCD4

Query Match 28.6%; Score 14; DB 2; Length 9;
 Best Local Similarity 75.0%; Pred. No. 2.8e+05; Indels 0; Gaps 0;

Qy 3 APPV 6
 Db 4 APPV 7

RESULT 23
 S26508 collagen alpha 2(VI) chain - bovine (fragment)
 C;Species: Bos primigenius taurus (cattle)
 C;Accession: S26508
 R;Jander, R.; Rautenberg, J.; Glanville, R.W.
 Bur. J. Biochem. 133, 39-46, 1983
 A;Title: Further characterization of the three polypeptide chains of bovine and human skin
 A;Reference number: S26506; MUID:93209348; PMID:852033
 A;Accession: S26508
 A;Status: preliminary
 A;Molecule type: protein
 A;Residues: 1-9 <JAN>
 A;Cross-references: UNIPARC:UPI000017C4E6
 C;Keywords: hydroxyproline
 F;7/Modified site: hydroxyproline (Pro) #status experimental

Query Match 28.6%; Score 14; DB 2; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.8e+05; Indels 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 PP 5
 Db 6 PP 7

RESULT 24
 A43065 hydroxyproline-3-bradykinin - frog (Heleophryne purcelli)
 C;Species: Heleophryne purcelli
 C;Accession: A43065
 R;Nakajima, T.; Yasuhara, T.; Ersamer, G.F.; Visscher, J.
 Experientia 35, 1133, 1979
 A;Title: Occurrence of Hyp(3)-bradykinin in methanol extracts of the skin of the South American tree frog (Heleophryne purcelli)
 A;Reference number: A43065; MUID:8024376; PMID:488255
 A;Accession: A43065
 A;Molecule type: protein
 A;Residues: 1-9 <NAK>
 A;Cross-references: UNIPROT:Q7LZI7; UNIPARC:UPI000002CF4A
 C;Keywords: bradykinin; hydroxyproline; skin
 F;3/Modified site: hydroxyproline (Pro) #status experimental

Query Match 28.6%; Score 14; DB 2; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.8e+05; Indels 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 PP 5
 Db 2 PP 3

Qy 4 PP 5
Db 2 PP 3

RESULT 25
PC7073 ubiquinol-cytochrome-c reductase (EC 1.10.2.2) core protein II - mouse (fragment)
C;Species: Mus musculus (house mouse)
C;Date: 18-Aug-2000 #text_change 18-Aug-2000 #text_revision 18-Aug-2000 #text_sequence_revision 18-Aug-2004
C;Accession: PC7073
R;Tsugita, A.; Kawakami, T.; Uchida, T.; Sakai, T.; Kamo, M.; Matsui, T.; Watanabe, Y.;
Electrophoresis 21, 1853-1871, 2000
A;Title: Proteome analysis of mouse brain: Two-dimensional electrophoresis profiles of t
A;Reference number: PC7072
A;Accession: PC7073
A;Molecule type: protein
A;Residues: 1-9 <TSU>
A;Cross-references: UNIPROT:Q9CVK7; UNIPARC:UPI000017CDB7
C;Keywords: brain; core protein; oxidoreductase

Query Match Score 14; DB 2; Length 9;
Best Local Similarity 75.0%; Pred. No. 2.8e+05;
Matches 3; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3 APPV 6
Db 5 APKV 8

RESULT 26
B60246 ornitho-kinin - chicken
C;Species: Gallus gallus (chicken)
C;Date: 11-Dec-1992 #text_change 11-Dec-1992 #text_sequence_revision 11-Dec-1992 #text_sequence_revision 11-Dec-1992 #text_change 16-Aug-2004
C;Accession: B60246
R;Kimura, M.; Sueyoshi, T.; Morita, T.; Tanaka, K.; Iwanaga, S.
Adv. Exp. Med. Biol. 247A, 359-367, 1989
A;Title: Ornitho-Kininogen and Ornitho-kinin: isolation, characterization and chemical s
A;Reference number: A60246; MUID:90102072; PMID:2603803
A;Accession: B60246
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-9 <KIM>
A;Cross-references: UNIPROT:Q7LZ50; UNIPARC:UPI000017A4F8

Query Match Score 14; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.8e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 PP 5
Db 2 PP 3

RESULT 27
A26744 bradykinin-like peptide - garden dagger wasp
N;Alternate names: Thr-6-bradykinin
C;Species: Megascolla flavifrons (garden dagger wasp)
C;Date: 08-Mar-1989 #sequence_revision 08-Mar-1989 #text_change 05-Oct-2004
C;Accession: A26744
R;Yasuhara, T.; Mantel, P.; Nakajima, T.; Piek, T.
Toxicon 25, 527-535, 1987
A;Title: Two kinins isolated from an extract of the venom reservoirs of the solitary was
A;Reference number: A94322; MUID:87293024; PMID:3617083
A;Accession: A26744
A;Molecule type: protein
A;Residues: 1-9 <YAS>
A;Cross-references: UNIPARC:UPI000012DF29

Query Match Score 14; DB 2; Length 9;

Qy 4 PP 5
Db 2 PP 3

RESULT 28
A61057 Thr-6 bradykinin - scoliid wasp (Colpa interrupta)
C;Species: Colpa interrupta
C;Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 05-Oct-2004
C;Accession: A61057
R;Pielk, T.; Rue, B.; Mantel, P.; Nakajima, T.; Peihate, M.; Yasuhara, T.
Comp. Biochem. Physiol. C 96, 157-162, 1990
A;Title: Threonine(6)-bradykinin in the venom of the wasp Colpa interrupta (F.) presynap
A;Reference number: A61057; MUID:91130217; PMID:1980872
A;Accession: A61057
A;Molecule type: protein
A;Residues: 1-9 <PIB>
A;Cross-references: UNIPARC:UPI000012DF29
C;Keywords: bradykinin; presynaptic neurotoxin; venom

Query Match Score 14; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.8e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 PP 5
Db 2 PP 3

RESULT 29
A60579 bradykinin-like peptide - slider turtle
C;Species: Pseudemys scripta (slider)
C;Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 05-Oct-2004
C;Accession: A60579
R;Conlon, J.M.; Hicks, J.W.; Smith, D.D.
Endocrinology 126, 985-991, 1990
A;Title: Isolation and biological activity of a novel kinin ([Thr(6)]bradykinin) from the
A;Reference number: A60579; MUID:90126625; PMID:2298179
A;Accession: A60579
A;Molecule type: protein
A;Residues: 1-9 <CON>
A;Cross-references: UNIPARC:UPI000012DF29
C;Keywords: plasma

Query Match Score 14; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.8e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 PP 5
Db 2 PP 3

RESULT 30
A61363 bradykinin - common frog
C;Species: Rana temporaria (common frog)
C;Date: 09-Sep-1994 #sequence_revision 09-Sep-1994 #text_change 05-Oct-2004
C;Accession: A61363
R;Anastassi, A.; Bragamer, V.; Bertaccini, G.
Comp. Biochem. Physiol. A 14, 43-52, 1965
A;Title: Occurrence of bradykinin in the skin of Rana temporaria.
A;Reference number: A61363
A;Accession: A61363
A;Status: Preliminary
A;Molecule type: protein
A;Residues: 1-9 <ANR>

A;Cross-references: UNIPROT:Q7LZZ8; UNIPARC:UPI000002CP4A
 C;Keywords: skin

Query Match Score 14; DB 2; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.8e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 PP 5
 Db 2 PP 3

RESULT 31
 A61358
 bradykinin-like peptide I - Japanese pond frog
 C;Species: Rana nigromaculata (Japanese pond frog)
 C;Date: 09-Sep-1994 #sequence_revision 09-Sep-1994
 C;Accession: A61358
 R;Nakajima, T.
 Chem. Pharm. Bull. 16, 769-770, 1968
 A;Title: Occurrence of a new active peptide on smooth muscle and bradykinin in the skin
 A;Reference number: A61358; MUID:68412013; PMID:5677638
 A;Status: preliminary
 A;Molecule type: protein
 A;Residues: 1-9 <NAK>
 A;Cross-references: UNIPROT:Q7LZZ4; UNIPARC:UPI000017A4FO
 C;Keywords: skin

Query Match Score 14; DB 2; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.8e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 PP 5
 Db 2 PP 3

RESULT 32
 S15595
 orf 2 rara 5'-region - human
 C;Species: Homo sapiens (man)
 C;Date: 04-Jun-1999 #sequence_revision 04-Jun-1999
 C;Accession: S15595
 R;Brand, N.J.; Petkovich, M.; Chambon, P.
 Nucleic Acids Res. 18, 6799-6806, 1990
 A;Title: Characterization of a functional promoter for the human retinoic acid receptor
 A;Reference number: S15594; MUID:91088249; PMID:2175878
 A;Accession: S15595
 A;Molecule type: DNA
 A;Residues: 1-9 <BRA>
 A;Cross-references: UNIPARC:UPI00017C6EF; EMBL:X65057; NID:G35875
 A;Note: this ORF from Fig. 2 is not annotated in GenBank entry HSRARA1, release 111.0
 C;Comment: This sequence is not thought to be translated.
 C;Genetics:

A;Gene: GDB:RARA
 A;Cross-references: GDB:120337; OMIM:180240
 A;Map position: 17q12-17q12

Query Match Score 14; DB 4; Length 9;
 Best Local Similarity 60.0%; Pred. No. 2.8e+05;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 STAPP 5
 Db 4 STRAP 8

RESULT 33
 A44916
 mosquitoïdal toxin 21 - Bacillus sphaericus (fragment)
 C;Species: Bacillus sphaericus
 C;Date: 01-Apr-1993 #sequence_revision 18-Nov-1994 #text_change 23-Mar-1995

C;Accession: A44916
 R;Thanabalu, T.; Handley, J.; Berry, C.
 J. Bacteriol. 174, 5051-5056, 1992
 A;Title: Proteolytic processing of the mosquitoïdal toxin from *Bacillus sphaericus* SSII
 A;Reference number: A44916; MUID:92332441; PMID:1352768
 A;Accession: A44916
 A;Status: preliminary; not compared with conceptual translation
 A;Molecule type: nucleic acid
 A;Residues: 1-6 <TRNA>
 A;Cross-references: UNIPARC:UPI000017AA7
 A;Experimental source: SSII-1
 A;Note: sequence extracted from NCBI backbone (NCBIP:108973)

Query Match Score 13; DB 2; Length 6;
 Best Local Similarity 60.0%; Pred. No. 2.8e+05;
 Matches 3; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 STAPP 5
 Db 1 SMASP 5

RESULT 34
 PT0654
 T-cell receptor beta chain V-D-J region (121-18K) - mouse (fragment)
 C;Species: Mus musculus (house mouse)
 C;Date: 17-Jul-1992 #sequence_revision 17-Jul-1992 #text_change 30-May-1997
 C;Accession: PT0654
 R;Feeley, A.J.
 J. Exp. Med. 174, 115-124, 1991
 A;Title: Junctional sequences of fetal T cell receptor beta chains have few N regions.
 A;Reference number: PT0509; MUID:1277701; PMID:1711558
 A;Accession: PT0654
 A;Status: translation not shown
 A;Molecule type: mRNA
 A;Residues: 1-7 <PE>
 A;Cross-references: UNIPARC:UPI000017C7EA
 A;Experimental source: day 4 postnatal thymus, strain BALB/c
 C;Keywords: T cell receptor

Query Match Score 13; DB 2; Length 7;
 Best Local Similarity 75.0%; Pred. No. 2.8e+05;
 Matches 3; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 STAP 4
 Db 2 SGAP 5

RESULT 35
 A15398
 choline oxidase (EC 1.1.3.17) - Alcaligenes sp. (tentative sequence) (fragment)
 C;Species: Alcaligenes sp.
 C;Date: 05-Jun-1987 #sequence_revision 05-Jun-1987 #text_change 09-Jul-2004
 C;Accession: A15398
 R;Ohta-Fukuyama, M.; Miyake, Y.; Emi, S.; Yamano, T.
 J. Biochem. 88, 197-203, 1980
 A;Title: Identification and properties of the prosthetic group of choline oxidase from *A.*
 A;Reference number: A15398; MUID:81006769; PMID:6997283
 A;Accession: A15398
 A;Molecule type: protein
 A;Residues: 1-7 <OT>
 A;Cross-references: UNIPROT:P16101; UNIPARC:UPI00001278AA
 C;Keywords: oxidoeductase

Query Match Score 13; DB 2; Length 7;
 Best Local Similarity 50.0%; Pred. No. 2.8e+05;
 Matches 2; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 5 PVHN 8
 Db 3 PNHS 6

RESULT 36
 A58725 virotoxin - destroying angel
 C;Species: *Amanita virosa* (destroying angel)
 C;Accession: A58725
 R;Paulitich, H.; Buku, A.; Bodenmueller, H.; Wieland, T.
 A;Title: Virotoxins: actin-binding cyclic peptides of *Amanita virosa* mushrooms.
 A;Reference number: A58725 ; MUID:6893271 ; PMID:6893271
 A;Accession: A58725
 A;Status: preliminary
 A;Molecule type: protein
 A;Residues: 1-7 <FAU>
 A;Cross-references: UNIPARC:UPI000017CF29
 C;Keywords: D-amino acid, hydroxyproline, toxin, unencoded polypeptide
 P;1-/7/Cross-link: cyclopeptide (Val-Leu) #status experimental
 P;2/Modified site: D-threonine (Thr) #status experimental
 P;3/Modified site: D-serine (Ser) #status experimental
 P;4/Modified site: (3R,4S)-3,4-dihydroxyproline (Pro) #status experimental
 P;6/Modified site: 2'-methylsulfonyltryptophan (Trp) #status experimental
 P;7/Modified site: 4,5-dihydroxyleucine (Leu) #status experimental

Query Match 26.5%; Score 13; DB 4; Length 7;
 Best Local Similarity 66.7%; Pred. No. 2.8e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 TAP 4
 :|
 Db 2 TSP 4
 :|||

RESULT 37
 A37832 phenol 2-monoxygenase (EC 1.14.13.7) chain P5 - *Pseudomonas* sp. (strain CF600) (Fragment)
 C;Species: *Pseudomonas* sp.
 C;Accession: A37832
 R;Pawlowski, J.; Shingler, V.
 J;Bacteriol. 172, 683-684, 1990
 A;Title: In vitro analysis of polypeptide requirements of multicomponent phenol hydroxyl
 A;Reference number: A37832 ; MUID:91072231 ; PMID:2254259
 A;Accession: A37832
 A;Status: preliminary
 A;Molecule type: protein
 A;Residues: 1-4 <POW>
 A;Cross-references: UNIPARC:UPI000017A9AS
 C;Keywords: oxidoreductase

Query Match 24.5%; Score 12; DB 2; Length 4;
 Best Local Similarity 66.7%; Pred. No. 2.8e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 HNV 9
 :|||
 Db 2 YNV 4
 :|||

RESULT 38
 T10954 hypothetical protein 3 - spring vetch, taro
 C;Species: *Vicia sativa* (spring vetch, taro)
 C;Accession: T10954
 R;Christiansen, A.; Hanssen, A.C.; Vijn, I.; Pallisgaard, N.; Larsen, K.; Yang, W.C.; Biess
 Submitted to the EMBL Data Library, December 1995
 A;Description: A novel type of DNA binding protein interacts with a conserved sequence i
 A;Reference number: Z17228
 A;Accession: T10954
 A;Status: preliminary; translated from GB/EMBL/DDBJ
 A;Molecule type: mRNA
 A;Residues: 1-5 <CHR>

A;Cross-references: UNIPARC:UPI000011E9CD; EMBL:X95995; NID:gi1360633; PMID:e225862
 Query Match 24.5%; Score 12; DB 2; Length 5;
 Best Local Similarity 33.3%; Pred. No. 2.8e+05;
 Matches 1; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 Qy 6 VHN 8
 :|:
 Db 3 IHS 5
 :|||

RESULT 39
 JS0319 suboesophageal ganglion pentapeptide - house cricket
 C;Species: *Acheta domesticus* (house cricket)
 C;Date: 07-Sep-1990 #sequence_revision 07-Sep-1990 #text_change 09-Jul-2004
 C;Accession: JS0319
 R;Wicker, C.; Wicker, C.
 Comp. Biochem. Physiol. C 88, 185-187, 1987
 A;Title: Isolation and structure of a peptide isolated from the suboesophageal ganglion
 A;Reference number: JS0319
 A;Accession: JS0319
 A;Molecule type: protein
 A;Residues: 1-5 <WIC>
 A;Cross-references: UNIPARC:UPI00001361CE

Query Match 24.5%; Score 12; DB 2; Length 5;
 Best Local Similarity 50.0%; Pred. No. 2.8e+05;
 Matches 2; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 Qy 1 STAP 4
 :|||
 Db 1 AAAP 4
 :|||

RESULT 40
 I51317 bHLH transcription factor inhibitor - African clawed frog (fragment)
 C;Species: *Xenopus laevis* (African clawed frog)
 C;Accession: I51317
 R;Zhang, H.; Reynaud, S.; Kloc, M.; Ettinger, L.D.; Spohr, G.
 Mech. Dev. 50, 119-130, 1995
 A;Title: Id gene activity during Xenopus embryogenesis
 A;Reference number: I51316 ; MUID:9344398 ; PMID:7619724
 A;Accession: I51317
 A;Status: preliminary; translated from GB/EMBL/DDBJ
 A;Molecule type: mRNA
 A;Residues: 1-6 <ZNA>
 A;Cross-references: UNIPARC:UPI000011EA87; GB:S79038; NID:gi1042006; PMID:ARD14294.1; PID
 C;Genetics:
 A;Gene: Xidib

Query Match 24.5%; Score 12; DB 2; Length 6;
 Best Local Similarity 50.0%; Pred. No. 2.8e+05;
 Matches 2; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 Qy 1 STAP 4
 :|||
 Db 2 ATEP 5
 :|||

RESULT 41
 PT0280 Ig heavy chain CRD3 region (clone 4-91B) - human (fragment)
 C;Species: *Homo sapiens* (man)
 C;Accession: PT0280
 R;Yanada, M.; Wasserman, R.; Reichard, B.A.; Caton, A.J.; Rovera, G.
 J. Exp. Med. 173, 395-407, 1991
 A;Title: Preferential utilization of specific immunoglobulin heavy chain diversity and
 A;Reference number: PT0280

A;Molecule type: DNA
A;Residues: 1-6 <YAM>
A;Cross-references: UNIPARC:UPI000017C204
C;Experimental source: B lymphocyte
C;Keywords: heterotetramer; immunoglobulin

Query Match Score 12; DB 2; Length 6;
Best Local Similarity 66.7%; Pred. No. 2.8e+05;
Matches 2; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2 TAP 4
Db 4 SAP 6

RESULT 42
PC1316
large granule L3 chain - horseshoe crab (*Tachypleus tridentatus*) (fragment)
C;Species: *Tachypleus tridentatus*
C;Accession: PC1316
R;Shigenaga, T.; Takayenohi, Y.; Kawasaki, S.; Seki, N.; Muta, T.; Toh, Y.; Ito, A.; Iwa
J.; Biochem. 114, 307-316, 1993
A;Title: Separation of large and small granules from horseshoe crab (*Tachypleus tridentatus*)
A;Reference number: PC1309; PMID:94110249; PMID:911241; PMID:2148863
A;Molecule type: protein
A;Residues: 1-7 <SHI>
A;Cross-references: UNIPARC:UPI000017BDFA
C;Comment: This protein participates in immobilization of invading microbes.

Query Match Score 12; DB 2; Length 7;
Best Local Similarity 50.0%; Pred. No. 2.8e+05;
Matches 2; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 2 TAPP 5
Db 1 TSQP 4

RESULT 43
PT0246
19 heavy chain CRD3 region (clone 2-103D) - human (fragment)
C;Species: Homo sapiens (man)
C;Accession: PT0246
R;Yamada, M.; Wasserman, R.; Reichard, B.A.; Shane, S.; Caton, A.J.; Rovera, G.
J. Exp. Med. 173, 395-407, 1991
A;Title: Preferential utilization of specific immunoglobulin heavy chain diversity and J
A;Reference number: PT0222; PMID:91108337; PMID:1899102
A;Molecule type: DNA
A;Residues: 1-7 <YAM>
A;Cross-references: UNIPARC:UPI000017C1E5
A;Experimental source: B lymphocyte
C;Keywords: heterotetramer; immunoglobulin

Query Match Score 12; DB 2; Length 7;
Best Local Similarity 66.7%; Pred. No. 2.8e+05;
Matches 2; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 7 HNV 9
Db 1 HEV 3

RESULT 44
S6419
tetrameric proteinase precursor, 60K, dithiothreitol-sensitive - spinach (fragment)
C;Species: Spinacia oleracea (spinach)
C;Accession: S66419
R;Kuwabara, T.

Query Match Score 12; DB 2; Length 9;
Best Local Similarity 66.7%; Pred. No. 2.8e+05;
Matches 2; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 TAP 4
Db 1 TGP 3

RESULT 47
PT0247
Ig heavy chain CRD3 region (clone 2-106A) - human (fragment)

C;Species: Homo sapiens (man)
 C;Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 16-Aug-1996
 C;Accession: PT0247
 R;Yamada, M.; Wasserman, R.; Reichardt, B.A.; Shane, S.; Caton, A.J.; Rovera, G.
 J;Exp. Med.: 173, 395-407, 1991
 A;Title: Preferential utilization of specific immunoglobulin heavy chain diversity and
 A;Reference number: PT0222; PMID:1899102
 A;Accession: PT0247
 A;Molecule type: DNA
 A;Residues: 1-9 <YAM>
 A;Cross-references: UNIPARC:UPI000017C1E6
 A;Experimental source: B lymphocyte
 C;Keywords: heterotetramer; immunoglobulin

Query Match 24.5%; Score 12; DB 2; Length 9;
 Best Local Similarity 66.7%; Pred. No. 2.8e+05; Indels 0; Gaps 0;
 Matches 2; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2 TAP 4
 :|||
 Db 2 SAP 4

RESULT 48
 PL0139
 carbon-monoxide dehydrogenase (EC 1.2.99.2) large chain - Pseudomonas carboxydoflava (fr)
 C;Species: Pseudomonas carboxydoflava
 C;Accession: PL0139 #sequence_revision 07-Sep-1990 #text_change 09-Jul-2004
 R;Kraut, M.; Hugendieck, I.; Herwig, S.; Meyer, O.
 Arch. Microbiol. 152, 335-341, 1989
 A;Title: Homology and distribution of CO dehydrogenase structural genes in carboxydofr
 A;Reference number: PL0138; PMID:90055678; PMID:2818128
 A;Accession: PL0139
 A;Molecule type: protein
 A;Residues: 1-9 <KRA>
 A;Cross-references: UNIPROT:PI9913; UNIPARC:UPI000017A976
 A;Note: 2-Met is also found
 C;Comment: Cardon-monoxide dehydrogenase consists of three polypeptide chains: large, me
 C;Keywords: oxidoreductase

Query Match 24.5%; Score 12; DB 2; Length 9;
 Best Local Similarity 50.0%; Pred. No. 2.8e+05; Indels 0; Gaps 0;
 Matches 2; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 5 PVHN 8
 |||:
 Db 4 PVQD 7

RESULT 49
 S10920
 venom protein HR-3 - oriental hornet (fragment)
 C;Species: Vespa orientalis (oriental hornet)
 C;Date: 29-Jan-1993 #sequence_revision 29-Jan-1993 #text_change 09-Jul-2004
 C;Accession: S10920
 R;Tuishibaev, M.U.; Ahmedova, N.U.; Kazakov, I.; Korneev, A.S.; Gagel'gans, A.I.
 Biochemistry (N.Y.) 53, 183-190, 1988
 A;Title: Low-molecular-weight peptides of venom of the giant hornet Vespa orientalis. St
 A;Reference number: S06445
 A;Accession: S10920
 A;Molecule type: protein
 A;Residues: 1-9 <TUI>
 A;Cross-references: UNIPROT:QM471; UNIPARC:UPI000017BF07
 C;Keywords: venom

Query Match 24.5%; Score 12; DB 2; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.8e+05; Indels 0; Gaps 0;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 VH 7
 |||:
 Db 3 VH 4

This Page Blank (uspto)

98	25	51.0	4	AAM22285	HIV Pepti	171	24	49.0	8	ADS75348	Human C35
99	25	51.0	9	AAM22287	HIV Pepti	172	24	49.0	9	ADV13361	Human pho
100	25	51.0	9	ANU26574	Human Leu	173	24	49.0	9	ADX83757	C35 human
101	25	51.0	9	ABO07325	Human Muc	174	23	46.9	4	ADC2B447	Stain tar
102	25	51.0	9	ABW00337	Tumor-as	175	23	46.9	7	ADW37010	HLA bindi
103	25	51.0	9	ADW12136	Human BFA	176	23	46.9	4	ADY5624	Carotenoii
104	25	51.0	9	ADT74519	Human RSV	177	23	46.9	5	ABP54763	Peptide i
105	25	51.0	9	ADU99307	BFA4 tumo	178	23	46.9	5	AAE34886	HIV-1 Gag
106	24	49.0	6	AAP95608	Diabetoge	179	23	46.9	5	ABP95610	HIV GAG P
107	24	49.0	7	AAR96117	Peptide P	180	23	46.9	5	ABR82402	HIV Gag P
108	24	49.0	7	ABR83353	Viral rel	181	23	46.9	7	ADJ92025	Transport
109	24	49.0	7	ABR83358	Viral rel	182	23	46.9	6	AAW25661	Conserved
110	24	49.0	7	ADC2B005	Synthetic	183	23	46.9	6	AAW64516	Neurotoxi
111	24	49.0	7	ADY56374	Carotenoii	184	23	46.9	6	AAE26693	Decoy Pep
112	24	49.0	8	AAR35856	Hepatitis	185	23	46.9	6	Aau29476	Betapep-86
113	24	49.0	8	ABP20620	HIV A03 m	186	23	46.9	5	ABP54765	Peptide i
114	24	49.0	8	ABP20375	HIV A03 m	187	23	46.9	6	ABP96512	HIV GAG P
115	24	49.0	8	ABP17801	HIV B58 B	188	23	46.9	6	Abr41641	Mouse CLA
116	24	49.0	8	ABP17900	HIV B58 B	189	23	46.9	6	ABR82404	HIV Gag P
117	24	49.0	8	ADR05420	Savinase	190	7	ADJ92027	Transport		
118	24	49.0	9	AAR4271	Residues	191	23	46.9	7	ABP54771	Peptide i
119	24	49.0	9	AAR53611	Opioid pe	192	23	46.9	7	ABP95618	HIV GAG P
120	24	49.0	9	AAR97535	Antigenic	193	23	46.9	7	AEE32747	Human imm
121	24	49.0	9	AAY40199	Amino aci	194	23	46.9	7	AEE32746	Human imm
122	24	49.0	9	AAY40195	Amino aci	195	23	46.9	7	Abr84140	HIV Gag P
123	24	49.0	9	AAY53376	P53 epitope	196	23	46.9	7	ABR83356	Viral rel
124	24	49.0	9	AAY53372	P53 epitope	197	23	46.9	7	ABR83355	Viral rel
125	24	49.0	9	AAY26711	HLA-B7 bi	198	23	46.9	7	ADB79456	Parapoxvi
126	24	49.0	9	AAY26715	HLA-B8 bi	199	23	46.9	7	ADB79212	Parapoxvi
127	24	49.0	9	AAB26349	Human CAS	200	23	46.9	7	Ade11627	Ebola vir
128	24	49.0	9	AAB26349	Human CAS	201	23	46.9	7	Ade77779	Synthetic
129	24	49.0	9	AAB13019	Human C35	202	23	46.9	7	AAO23605	Colon tum
130	24	49.0	9	AAB13212	Human C35	203	23	46.9	7	ADJ92033	Transport
131	24	49.0	9	AAB13212	Human C35	204	23	46.9	7	ADP69378	Hair-bind
132	24	49.0	9	AAB13212	Human C35	205	23	46.9	7	ADP74865	Parapoxvi
133	24	49.0	9	AAB13147	Human C35	206	23	46.9	7	ADP75139	Parapoxvi
134	24	49.0	9	AAB13143	Human C35	207	23	46.9	7	ADS1407	Thrombin
135	24	49.0	9	AAB12592	Human C35	208	23	46.9	7	ADU69115	Gag peptide
136	24	49.0	9	AAB14350	Human C35	209	23	46.9	7	Aay66403	Gag prope
137	24	49.0	9	AAB11477	Human C35	210	23	46.9	7	ADY55676	Hair-bind
138	24	49.0	9	AAB14270	Human C35	211	23	46.9	8	AAR35857	Hepatitis
139	24	49.0	9	AAB13147	Human C35	212	23	46.9	2	Aar77556	HIV (B5)-
140	24	49.0	9	AAB11643	Human C35	213	23	46.9	8	AAR70535	HIV pepti
141	24	49.0	9	AAB12592	Human C35	214	23	46.9	7	AAY43398	C-reactive
142	24	49.0	9	AAB12642	Human C35	215	23	46.9	3	AAY66403	HIV B15-b
143	24	49.0	9	AAB11238	Human C35	216	23	46.9	8	AAM99070	Vaccine I
144	24	49.0	9	AAB14285	Human C35	217	23	46.9	8	AAGB4005	MAGE3 A24
145	24	49.0	9	AAB14015	Human C35	218	23	46.9	8	AAGB4000	MAGE3 HLA
146	24	49.0	9	AAB11297	Human C35	219	23	46.9	8	ABP20519	HIV A03 m
147	24	49.0	9	AAB11114	Human C35	220	23	46.9	8	ABP16115	HIV B07 s
148	24	49.0	9	AAB12642	Human C35	221	23	46.9	8	ABP20341	HIV GAG P
149	24	49.0	9	AAB13238	Human C35	222	23	46.9	8	ABP17868	HIV B58 B
150	24	49.0	9	AAB13409	Human C35	223	23	46.9	8	ABP17782	HIV B58 B
151	24	49.0	9	AAB14645	Human C35	224	23	46.9	8	ABP54773	Peptide i
152	24	49.0	9	AAB12977	Human C35	225	23	46.9	8	ABP54775	Peptide i
153	24	49.0	9	AAB11633	Human C35	226	23	46.9	8	ABP96520	HIV GAG P
154	24	49.0	9	AAB11633	Human C35	227	23	46.9	8	ABP96522	HIV GAG P
155	24	49.0	9	AAB13976	Human C35	228	23	46.9	8	ADAS029	Feyers pa
156	24	49.0	9	AAB17902	Human B58 B	229	23	46.9	8	ADCB2890	E-Cadherin
157	24	49.0	9	AAB22649	HIV A03 m	230	23	46.9	8	ADA5016	Human her
158	24	49.0	9	AAB20377	HIV A03 m	231	23	46.9	8	ADJ89091	Human her
159	24	49.0	9	AAB14503	HIV A03 m	232	23	46.9	8	ADJ89574	Ebola vir
160	24	49.0	9	AAB17174	HIV B27 B	233	23	46.9	8	ADJ88771	Ebola vir
161	24	49.0	9	AAB11661	HIV A01 B	234	23	46.9	8	ADBB88774	Transport
162	24	49.0	9	AAB20622	HIV A03 m	235	23	46.9	8	ADJ92035	Transport
163	24	49.0	9	AAB20376	HIV A03 m	236	23	46.9	8	ADJ88773	Ebola vir
164	24	49.0	9	AAB17802	HIV B58 B	237	23	46.9	8	ADJ88774	Ebola vir
165	24	49.0	9	AAB14503	HIV A03 m	238	23	46.9	8	ADJ92037	Transport
166	24	49.0	9	ABR27196	Human can	239	23	46.9	8	ADJ92037	Transport
167	24	49.0	9	Abr27862	Human can	240	23	46.9	8	ADJ92035	Transport
168	24	49.0	9	Abr27977	Human can	241	23	46.9	8	ADJ88573	Ebola vir
169	24	49.0	9	Abr28413	Human can	242	23	46.9	8	ADJ88090	Human her
170	24	49.0	9	Abr27653	Human can	243	23	46.9	8	ADJ88659	Hepatitis

244	46.9	23	ADJ886662	Hepatitis	Aam22189	HIV pepti	9	4
245	46.9	23	ADJ89088	Human her	Aam22192	HIV pepti	9	4
246	46.9	23	ADJ886661	Hepatitis	Aam22193	HIV pepti	9	4
247	46.9	23	ADJ885772	Ebola vir	Aam22180	HIV pepti	9	4
248	46.9	23	ADJ888901	Human her	Aab74375	A2 HIV-1	4	4
249	46.9	23	ADJ886660	Hepatitis	AAG84709	MAGE2 HLA	4	4
250	46.9	23	ADJ89089	Human her	AAG84709	MAGE2 HLA	4	4
251	46.9	23	ADJ888802	Human her	AAG84708	MAGE2 HLA	4	4
252	46.9	23	ADM73089	Human MAG	AAG84708	MAGE2 HLA	4	4
253	46.9	23	ADM73078	Human MAG	AAB02682	Human imm	4	4
254	46.9	23	ADM73087	Human MAG	Aae02691	Human imm	4	4
255	46.9	23	ADR12520	Anti-canc	Aae00472	Human imm	4	4
256	46.9	23	ADP80095	Human HLA	AAG62414	Immunogen	4	4
257	46.9	23	AAR41458	Antigenic	AAG62415	Immunogen	4	4
258	46.9	23	AAR46517	HIV rever	AAG62416	Immunogen	4	4
259	46.9	23	AAR59168	Peptide f	AAB04820	Human imm	4	4
260	46.9	23	AAR51904	HIV rever	Aag62035	Human WT1	4	4
261	46.9	23	AAR78899	HIV 1004-	AAG61993	Human WT1	4	4
262	46.9	23	AAR78828	HIV rever	AAG62109	Mouse WT1	4	4
263	46.9	23	AAR83946	MHC Class	Aam24971	Human MHC	4	4
264	46.9	23	AAR66946	HIV Pepti	AAb75946	HIV pol 4	4	4
265	46.9	23	AAR89162	Peptide P	Aab75955	HIV pol 4	4	4
266	46.9	23	AAR51909	Synthetic	AAB75957	HIV pol 4	4	4
267	46.9	23	AAR97514	Cytotoxic	AAb75948	HIV pol 4	4	4
268	46.9	23	AAR45184	C-reactiv	AAB75956	HIV pol 4	4	4
269	46.9	23	AAR83940	C-reactiv	AAB75950	HIV pol 4	4	4
270	46.9	23	AARW3401	C-reactiv	Aab75954	HIV pol 4	4	4
271	46.9	23	AARW1833	Selected	Aab75947	HIV pol 4	4	4
272	46.9	23	AAW07009	MAGE-2,29	Aab82069	HIV antig	4	4
273	46.9	23	AAW45652	Human imm	Aau00493	HIV-1 rev	4	4
274	46.9	23	AAW39437	Human imm	Abp25049	HIV A2 su	4	4
275	46.9	23	AAW39441	Human imm	Abp25225	HIV A2-su	4	4
276	46.9	23	AAW04633	HIV pol p	Aab75955	HIV pol 4	4	4
277	46.9	23	AAW04635	HIV pol-8	Aab75957	HIV pol 4	4	4
278	46.9	23	AAW54562	HIV1 rever	AAb20527	HIV A03 m	4	4
279	46.9	23	AAW54625	Peptide f	AAb16707	HIV B07 s	4	4
280	46.9	23	AAW68367	MHC bindi	AAb16710	HIV B07 s	4	4
281	46.9	23	AAW10431	HLA Class	AAb11664	HIV A01 s	4	4
282	46.9	23	AAW10432	HLA Class	AAb12765	HIV A02 s	4	4
283	46.9	23	AAW04633	HIV pol 8	AAb13400	HIV A02 s	4	4
284	46.9	23	AAW45652	HIV pol-8	AAb20562	HIV A24 s	4	4
285	46.9	23	AAW54625	HIV1 rever	AAb22627	HIV A11 m	4	4
286	46.9	23	AAW48190	Immuno	AAb25148	HIV deriv	4	4
287	46.9	23	AAY47732	Immuno	AAb20345	HIV A03 m	4	4
288	46.9	23	AAY46243	Immuno	AAb20328	HIV A03 m	4	4
289	46.9	23	AAY46244	Immuno	AAb11662	HIV A01 s	4	4
290	46.9	23	AAY46282	Immuno	AAb25148	HIV deriv	4	4
291	46.9	23	AAY03701	Amino aci	AAb22747	HIV A11 m	4	4
292	46.9	23	AAY25239	HIV pol p	AAb25286	HIV CTRL e	4	4
293	46.9	23	AAY53402	HIV-1 RT	AAb14502	HIV B08	4	4
294	46.9	23	AAY21692	HIV-1 pol	AAb14504	HIV A03 s	4	4
295	46.9	23	AAY26743	HIV-1 deriv	AAb15630	HIV A24 s	4	4
296	46.9	23	AAY46282	HLA bindi	AAb25398	Cytotoxic	4	4
297	46.9	23	AAW99477	HIV-1 rev	AAb82778	HIV-1 rev	4	4
298	46.9	23	AAY83924	HIV pol	Aau68802	Human Wil	4	4
299	46.9	23	AAY98703	WT1 deriv	Aau68876	Mouse Wil	4	4
300	46.9	23	AAY98777	WT1 deriv	Aau68760	Human Wil	4	4
301	46.9	23	AAY98661	Altered M	Aab15219	Immunogen	4	4
302	46.9	23	AAY52967	Altered M	AAb07001	HIV RT-po	4	4
303	46.9	23	AAY52667	Amino aci	Abp47460	N. mening	4	4
304	46.9	23	AAY52667	Altered M	Abp47370	N. mening	4	4
305	46.9	23	AAY66275	HLA-A2-bi	Abp76769	HIV epito	4	4
306	46.9	23	AAY66418	HLA-A2-bi	Aau96042	HIV epito	4	4
307	46.9	23	AAY52667	Altered M	Abj15227	Immunogen	4	4
308	46.9	23	AAY52566	HIV pol	Abp47460	N. mening	4	4
309	46.9	23	AAY73180	HIV-deriv	Abp47370	N. mening	4	4
310	46.9	23	AAM22179	HIV Pepti	Abg33272	Human WT1	4	4
311	46.9	23	AAM22186	HIV Pepti	Abg33346	Mouse WT1	4	4
312	46.9	23	AAM22184	HIV Pepti	Abg33230	Human WT1	4	4
313	46.9	23	AAM22181	HIV Pepti	Abb83244	Human BTV	4	4
314	46.9	23	AAM22195	HIV Pepti	Abb79848	MHC class	4	4
315	46.9	23	AAM22196	HIV Pepti	Abb80114	MHC class	4	4
316	46.9	23	AAM22183	HIV Pepti	Abp54777	Peptide i	4	4

390	23	46.9	5	ABP54776	Peptide i	463	23	46.9	9	ADA49658	Multi-epi
391	23	46.9	6	ABP96579	HIV deriv	464	23	46.9	9	ADB39052	Human tum
392	23	46.9	9	ABP72152	Peptide e	465	23	46.9	9	ADB67420	Human Wt1
393	23	46.9	9	ABU08176	MAGE-A3	466	23	46.9	9	ADB67494	Mouse Wt1
394	23	46.9	9	AAB35162	HIV CTL e	467	23	46.9	9	ADB67378	Human Wt1
395	23	46.9	9	ABP95523	HIV SAG P	468	23	46.9	9	ADD06456	HIV-Rt de
396	23	46.9	9	ABP96527	HIV SAG P	469	23	46.9	9	ADD96667	HIV-1 cro
397	23	46.9	9	ABPP6526	HIV SAG P	470	23	46.9	9	ADD96225	HIV-1 cro
398	23	46.9	9	ABP95524	HIV SAG P	471	23	46.9	9	ADET7781	Synthetic
399	23	46.9	9	ADAS0855	Ebola vir	472	23	46.9	9	ADG38119	Human imm
400	23	46.9	9	ADAS0817	Ebola vir	473	23	46.9	9	ADG38520	Human imm
401	23	46.9	9	ADAS0830	Ebola vir	474	23	46.9	9	ADG38621	Human imm
402	23	46.9	9	ADAS0843	Ebola vir	475	23	46.9	9	ADG38445	Human mel
403	23	46.9	9	ABR27179	Human can	476	23	46.9	9	ADG38137	Human mel
404	23	46.9	9	ABU70334	Human imm	477	23	46.9	9	ADG38629	Human imm
405	23	46.9	9	ABU69692	Human imm	478	23	46.9	9	ADJ80553	Wilm's tu
406	23	46.9	9	ABJ61602	184PE2-r	479	23	46.9	9	ADJ80127	Wilm's tu
410	23	46.9	9	ABJ62339	184PE2-r	480	23	46.9	9	ADJ80611	Wilm's tu
408	23	46.9	9	ABJ64128	184PE2-r	481	23	46.9	9	ADJ88665	Hepatitis
411	23	46.9	9	ABJ61189	184PE2-r	482	23	46.9	9	ADJ89096	Human her
410	23	46.9	9	ABJ62209	184PE2-r	483	23	46.9	9	ADJ88666	Hepatitis
411	23	46.9	9	ABJ63225	184PE2-r	484	23	46.9	9	ADJ88777	Ebola vir
412	23	46.9	9	ABJ63886	184PE2-r	485	23	46.9	9	ADJ88664	Ebola vir
413	23	46.9	9	ABJ62339	184PE2-r	486	23	46.9	9	ADJ88011	Ebola vir
414	23	46.9	9	ABJ64400	184PE2-r	487	23	46.9	9	ADJ88008	Ebola vir
415	23	46.9	9	ABJ64505	184PE2-r	488	23	46.9	9	ADJ88006	Ebola vir
416	23	46.9	9	ABJ53302	184PE2-r	489	23	46.9	9	ADJ89094	Human her
416	23	46.9	9	ABJ62340	184PE2-r	490	23	46.9	9	ADJ89094	Human her
417	23	46.9	9	ABJ57576	184PE2-r	491	23	46.9	9	ADJ92041	Transport
418	23	46.9	9	ABJ57867	184PE2-r	492	23	46.9	9	ADJ88576	Ebola vir
419	23	46.9	9	ABJ61241	184PE2-r	493	23	46.9	9	ADJ88093	Human her
420	23	46.9	9	ABJ57082	184PE2-r	493	23	46.9	9	ADJ88006	Human her
421	23	46.9	9	ABJ58744	184PE2-r	494	23	46.9	9	ADJ92338	Transport
422	23	46.9	9	ABJ59899	184PE2-r	495	23	46.9	9	ADJ88007	Human her
423	23	46.9	9	ABJ60648	184PE2-r	496	23	46.9	9	ADJ9244	Transport
424	23	46.9	9	ABJ61334	184PE2-r	497	23	46.9	9	ADJ88578	Ebola vir
425	23	46.9	9	ABJ60050	184PE2-r	498	23	46.9	9	ADJ88668	Hepatitis
426	23	46.9	9	ABJ00607	184PE2-r	499	23	46.9	9	ADJ89097	Human her
427	23	46.9	9	ABJ61382	184PE2-r	500	23	46.9	9	ADJ91288	Hepatitis
428	23	46.9	9	ABJ52349	184PE2-r	501	23	46.9	9	ADJ88579	Ebola vir
429	23	46.9	9	ABJ60648	184PE2-r	502	23	46.9	9	ADJ88667	Hepatitis
430	23	46.9	9	ABJ64690	184PE2-r	503	23	46.9	9	ADJ92339	Transport
431	23	46.9	9	ABJ64780	184PE2-r	504	23	46.9	9	ADL34428	MHC/HLA P
432	23	46.9	9	ABJ0430	184PE2-r	505	23	46.9	9	ADL34415	MHC/HLA P
433	23	46.9	9	ABJ61383	184PE2-r	506	23	46.9	9	ADW32558	HLA bindi
434	23	46.9	9	ABJ59169	184PE2-r	507	23	46.9	9	ADW31186	HLA bindi
435	23	46.9	9	ABJ59371	184PE2-r	508	23	46.9	9	ADW31214	HLA bindi
436	23	46.9	9	ABJ59434	184PE2-r	509	23	46.9	9	ADW3264	HLA bindi
437	23	46.9	9	ABJ58946	184PE2-r	510	23	46.9	9	ADW3264	HLA bindi
438	23	46.9	9	ABJ62440	184PE2-r	511	23	46.9	9	ADW3259	HLA bindi
439	23	46.9	9	ABJ55557	184PE2-r	512	23	46.9	9	ADW3262	HLA bindi
440	23	46.9	9	ABJ58829	184PE2-r	513	23	46.9	9	ADW31187	HLA bindi
441	23	46.9	9	ABJ57370	184PE2-r	514	23	46.9	9	ADW32456	HLA bindi
442	23	46.9	9	ABJ61358	184PE2-r	515	23	46.9	9	ADW31181	HLA bindi
443	23	46.9	9	ABJ62199	184PE2-r	516	23	46.9	9	ADW31189	HLA bindi
444	23	46.9	9	ABJ62787	184PE2-r	517	23	46.9	9	ADW31191	HLA bindi
445	23	46.9	9	ABJ63572	184PE2-r	518	23	46.9	9	ADW31192	HLA bindi
446	23	46.9	9	ABJ63308	184PE2-r	519	23	46.9	9	ADW31192	HLA bindi
447	23	46.9	9	ABJ57883	184PE2-r	520	23	46.9	9	ADW31021	HLA bindi
448	23	46.9	9	ABJ58589	184PE2-r	521	23	46.9	9	ADW3253	HLA bindi
449	23	46.9	9	ABJ59582	184PE2-r	522	23	46.9	9	ADW3265	HLA bindi
450	23	46.9	9	ABJ63726	184PE2-r	523	23	46.9	9	ADW3266	HLA bindi
451	23	46.9	9	ABJ65126	184PE2-r	524	23	46.9	9	ADW3252	HLA bindi
452	23	46.9	9	ABJ65220	184PE2-r	525	23	46.9	9	ADW3257	HLA bindi
453	23	46.9	9	ABJ58058	184PE2-r	526	23	46.9	9	ADW32456	HLA bindi
454	23	46.9	9	ABJ62663	184PE2-r	527	23	46.9	9	ADW3260	HLA bindi
455	23	46.9	9	ABJ60642	184PE2-r	528	23	46.9	9	ADW31189	HLA bindi
456	23	46.9	9	ABJ62576	184PE2-r	529	23	46.9	9	ADW31190	HLA bindi
457	23	46.9	9	ABJ65020	184PE2-r	530	23	46.9	9	ADW31192	HLA bindi
458	23	46.9	9	ABJ58059	184PE2-r	531	23	46.9	9	ADW31022	HLA bindi
459	23	46.9	9	ABU63005	HIV pol	532	23	46.9	9	ADW32263	HIV bindi
460	23	46.9	9	ABR2415	HIV gag	533	23	46.9	9	ADW31211	HIV bindi
461	23	46.9	9	ABR2416	HIV gag	534	23	46.9	9	ADW32159	HIV bindi
462	23	46.9	9	Ada49464	Multi-epi	535	23	46.9	9	ADW32256	HIV bindi

536	46.9	9	7	ADW32261	HLA bindi	Aaw79782	Proline-r
537	23	46.9	9	ADE97630	Immuno	Aaw99328	Human IgG
538	23	46.9	9	ADH48851	HIV-1. Pol	Aab17240	SH3 antag
539	23	46.9	9	ADJ79550	CTL epitope	Aay69880	Src SH3 r
540	23	46.9	9	ADK68777	Epitope 1	Aab61844	Human Ig
541	23	46.9	9	ADK69322	Epitope 1	Abb83464	Tissue In
542	23	46.9	9	ADK68752	Epitope 1	Abb83463	Tissue In
543	23	46.9	9	ADK68941	Epitope 1	Abb72333	Src homol
544	23	46.9	9	ADK69053	Epitope 1	Abp74997	Proteome
545	23	46.9	9	ADJ83647	Murine WT	Aao21192	Platelet-
546	23	46.9	9	ADJ83573	Human WT1	Adb211948	Parapoxvi
547	23	46.9	9	ADJ83531	Human WT1	Adj73387	SH3 antag
548	23	46.9	9	ADL57419	Human WT-	Adj51021	CH1 delet
549	23	46.9	9	ADL57461	Human WT-	Adj511982	CH1 delet
550	23	46.9	9	ADL57535	Mouse WT-	Adp71890	Parapoxvi
551	23	46.9	9	ADM73079	Human MAG	Adp80384	Human HLA
552	23	46.9	9	ADM73090	Human MAG	Aar84745	DYN domai
553	23	46.9	9	ADM73081	Human MAG	Aar97521	Antigenic
554	23	46.9	9	ADM73088	Human MAG	Aay40611	HLA derivat
555	23	46.9	9	ADM97216	Cytotoxic	Aab29950	Scaffold
556	23	46.9	9	ADO09016	Human WT1	Aau26888	Human Leu
557	23	46.9	9	ADO09090	Mouse WT1	Aep11520	HIV A01 b
558	23	46.9	9	ADO09874	Human WT1	Abp11954	HIV A02 b
559	23	46.9	9	ADN63657	HLA bindi	Aag89703	P53 epito
560	23	46.9	9	ADN63696	HLA bindi	Aag89880	P53 epito
561	23	46.9	9	ADO24142	HIV epitope	Aag89526	P53 epito
562	23	46.9	9	ADO23858	HBV Pepti	Adv12432	Human pho
563	23	46.9	9	ADO30651	Human imm	Aea14125	VEGF rela
564	23	46.9	9	ADQ11183	Synthetic	Aar44262	Residues
565	23	46.9	9	ADQ11403	Human imm	Aar44260	Residues
566	23	46.9	9	ADQ10851	Human imm	Aar59117	Peptide f
567	23	46.9	9	ADQ10575	Human imm	Aar84746	Dynamin r
568	23	46.9	9	ADQ10550	Human imm	Aar89165	Peptide P
569	23	46.9	9	ADP90883	HIV-1. ant	Aar97533	Antigenic
570	23	46.9	9	ADP9600	Human Wil	Aar97510	Cytotoxic
571	23	46.9	9	ADR12458	Anti-canc	Aar97505	Cytotoxic
572	23	46.9	9	ADQ10851	Human imm	Aaw39517	Human P53
573	23	46.9	9	ADR69770	Novel. hyb	Aaw71346	Glycolip
574	23	46.9	9	ADP10575	Novel.	Aaw46008	Peptide #
575	23	46.9	9	ADP10550	Human HLA	Aea12125	
576	23	46.9	9	ADP10551	HIV-1. ant	AAE97533	
577	23	46.9	9	ADP10552	Human Wil	Aar97510	
578	23	46.9	9	ADP10553	Anti-canc	Aar97505	
579	23	46.9	9	ADP10554	Novel.	Aay40182	Amino aci
580	23	46.9	9	ADP10555	Novel.	Aay40185	Amino aci
581	23	46.9	9	ADP10556	Novel.	Aay40202	Amino aci
582	23	46.9	9	ADP10557	Novel.	Aay47768	Immunogen
583	23	46.9	9	ADP10558	Novel.	Aay09158	Peptide s
584	23	46.9	9	ADP10559	Novel.	Aay53359	P53 epito
585	23	46.9	9	ADP10560	Novel.	Aay53379	P53 epito
586	23	46.9	9	ADP10561	Novel.	Aay53362	P53 epito
587	23	46.9	9	ADP10562	Novel.	Aay47768	HLA-A2 bi
588	23	46.9	9	ADP10563	Novel.	Aab33667	MHC class
589	23	46.9	9	ADP10564	Novel.	Aab33670	MHC class
590	23	46.9	9	ADP10565	Novel.	Aay79560	Human tum
591	23	46.9	9	ADP10566	Novel.	Aab85916	MHC class
592	23	46.9	9	ADP10567	Novel.	Aay54186	HLA bindi
593	23	46.9	9	ADP10568	Novel.	Aag93763	Human P53
594	23	46.9	9	ADP10569	Novel.	Aae02675	Human P53
595	23	46.9	9	ADP10570	Novel.	Aae02674	Human P53
600	23	46.9	9	ADP10571	Novel.	Aau06365	Human Leu
601	23	46.9	9	ADP10572	Novel.	Aab00464	Human tum
603	23	46.9	9	ADP10573	Novel.	Aae00465	Human tum
604	23	46.9	9	ADP10574	Novel.	Aau25903	Human Leu
605	23	46.9	9	ADP10575	Novel.	Aau25973	Human Leu
607	23	46.9	9	ADP10576	Novel.	Aab13888	Human C35
608	23	46.9	9	ADP10577	Novel.	Aab13605	Human C35
609	44.9	7	2	AAW79782			
610	22	44.9	7	AAW99328			
611	22	44.9	7	Aab17240			
612	22	44.9	7	Aay69880			
613	22	44.9	7	AAB61844			
614	22	44.9	7	ABB83464			
615	22	44.9	7	ABB83463			
616	22	44.9	7	ABB72333			
617	22	44.9	7	ABP74997			
618	22	44.9	7	AAO21192			
619	22	44.9	7	ADB79448			
620	22	44.9	7	ADJ73387			
621	22	44.9	7	ADJ51021			
622	22	44.9	7	ADJ511982			
623	22	44.9	7	ADP71890			
624	22	44.9	7	ADP80384			
625	22	44.9	7	AAR84745			
626	22	44.9	7	AAR97521			
627	22	44.9	7	AAY40611			
628	22	44.9	7	AAB29950			
629	22	44.9	7	AAU26888			
630	22	44.9	7	AEP11520			
631	22	44.9	7	ABP11954			
632	22	44.9	7	AAG89703			
633	22	44.9	7	AAG89580			
634	22	44.9	7	AAG89526			
635	22	44.9	7	AAU26888			
636	22	44.9	7	AER44262			
637	22	44.9	7	AAR44260			
638	22	44.9	7	AAR59117			
639	22	44.9	7	AAR84746			
640	22	44.9	7	AAR89465			
641	22	44.9	7	AAW78558			
642	22	44.9	7	AAR97533			
643	22	44.9	7	AAR97510			
644	22	44.9	7	AAR97505			
645	22	44.9	7	AAY40182			
652	22	44.9	7	AAY40185			
653	22	44.9	7	AAY40202			
654	22	44.9	7	AAY47768			
655	22	44.9	7	AAY09158			
656	22	44.9	7	AAY53359			
657	22	44.9	7	AAY53379			
658	22	44.9	7	AAY53362			
659	22	44.9	7	AAY26701			
660	22	44.9	7	AAY26698			
661	22	44.9	7	Aab33667			
662	22	44.9	7	Aab33670			
663	22	44.9	7	Aay79560			
664	22	44.9	7	Aay53884			
665	22	44.9	7	Aay54186			
666	22	44.9	7	Aay47768			
667	22	44.9	7	AAM22188			
668	22	44.9	7	AAM22189			
669	22	44.9	7	AAM22190			
670	22	44.9	7	AAM22191			
671	22	44.9	7	AAM22192			
672	22	44.9	7	AAM22193			
673	22	44.9	7	AAM22194			
674	22	44.9	7	AAM22195			
675	22	44.9	7	AAM22196			
676	22	44.9	7	AAM22197			
677	22	44.9	7	AAM22198			
678	22	44.9	7	AAM22199			
679	22	44.9	7	AAM22200			
680	22	44.9	7	AAM22201			
681	22	44.9	7	AAM22202			
682	22	44.9	7	AAM22203			
683	22	44.9	7	AAM22204			
684	22	44.9	7	AAM22205			
685	22	44.9	7	AAM22206			
686	22	44.9	7	AAM22207			
687	22	44.9	7	AAM22208			
688	22	44.9	7	AAM22209			
689	22	44.9	7	AAM22210			
690	22	44.9	7	AAM22211			
691	22	44.9	7	AAM22212			
692	22	44.9	7	AAM22213			
693	22	44.9	7	AAM22214			
694	22	44.9	7	AAM22215			
695	22	44.9	7	AAM22216			
696	22	44.9	7	AAM22217			
697	22	44.9	7	AAM22218			
698	22	44.9	7	AAM22219			
699	22	44.9	7	AAM22220			
700	22	44.9	7	AAM22221			
701	22	44.9	7	AAM22222			
702	22	44.9	7	AAM22223			
703	22	44.9	7	AAM22224			
704	22	44.9	7	AAM22225			
705	22	44.9	7	AAM22226			
706	22	44.9	7	AAM22227			
707	22	44.9	7	AAM22228			
708	22	44.9	7	AAM22229			

682	22	44.9	9	4	ABB13868	Human C35	755	22	44.9	9	7	ADW57337
683	22	44.9	9	4	ABP20245	HIV A03 m	756	22	44.9	9	7	ADW59146
684	22	44.9	9	4	ABP18359	HIV B58 s	757	22	44.9	9	7	ADW59173
685	22	44.9	9	4	ABP14097	HIV A02 s	758	22	44.9	9	8	ADB97779
686	22	44.9	9	4	AAG89388	p53 DR su	759	22	44.9	9	8	ADJ36383
687	22	44.9	9	4	AAG89521	p53 epito	760	22	44.9	9	8	ADJ36384
688	22	44.9	9	4	AAG89548	p53 epito	761	22	44.9	9	8	ADK05363
689	22	44.9	9	4	AAG89569	p53 epito	762	22	44.9	9	8	ADK05386
690	22	44.9	9	4	AAG89522	p53 epito	763	22	44.9	9	8	ADK03867
691	22	44.9	9	4	AAG89715	p53 epito	764	22	44.9	9	8	ADK05382
692	22	44.9	9	4	ADG89415	p53 epito	765	22	44.9	9	8	ADK05385
693	22	44.9	9	4	AAG89431	p53 DR su	766	22	44.9	9	8	ADK05330
694	22	44.9	9	4	AAG89493	p53 DR 3a	767	22	44.9	9	8	ADK03980
695	22	44.9	9	4	AAG89691	p53 epito	768	22	44.9	9	8	ADM57836
696	22	44.9	9	4	AAG89416	p53 DR su	769	22	44.9	9	8	ADM92966
697	22	44.9	9	4	AAG89600	p53 epito	770	22	44.9	9	8	ADN91673
698	22	44.9	9	5	AAM9929	Human D40	771	22	44.9	9	8	ADN91350
699	22	44.9	9	5	ABP47362	N. mening	772	22	44.9	9	8	ADN92445
700	22	44.9	9	5	ABP47438	N. mening	773	22	44.9	9	8	ADN90134
701	22	44.9	9	5	ABU57361	Immuno gen	774	22	44.9	9	8	ADN94224
702	22	44.9	9	5	ABU57363	P53 Pepti	775	22	44.9	9	8	ADN92666
703	22	44.9	9	6	ABR56430	p53 Prote	776	22	44.9	9	8	ADS75042
704	22	44.9	9	6	ABR56429	p53 Prote	777	22	44.9	9	8	ADV32789
705	22	44.9	9	6	ABR67415	Human act	778	22	44.9	9	8	ADV32455
706	22	44.9	9	6	ABR21583	Human can	779	22	44.9	9	8	ADV28003
707	22	44.9	9	6	ABR22987	Human can	780	22	44.9	9	8	ADV32648
708	22	44.9	9	6	ABR20186	Human can	781	22	44.9	9	8	ADV32927
709	22	44.9	9	6	ABJ64631	184PE2-r	782	22	44.9	9	8	Adv32822
710	22	44.9	9	6	ABJ65629	184PE2-r	783	22	44.9	9	8	ADU87393
711	22	44.9	9	6	ABJ61139	184PE2-r	784	22	44.9	9	8	ADU87394
712	22	44.9	9	6	ABJ65437	184PE2-r	785	22	44.9	9	9	ADU47996
713	22	44.9	9	6	ABJ58854	184PE2-r	786	22	44.9	9	9	ADW13795
714	22	44.9	9	6	ABJ63571	184PE2-r	787	22	44.9	9	9	ADW13796
715	22	44.9	9	6	ABJ64076	184PE2-r	788	22	44.9	9	9	ADY26215
716	22	44.9	9	6	ABJ61567	184PE2-r	789	22	44.9	9	9	ADY26218
717	22	44.9	9	6	ABJ61139	184PE2-r	790	22	44.9	9	9	ADZ50921
718	22	44.9	9	6	ABJ60291	184PE2-r	791	22	44.9	9	9	ADZ56791
719	22	44.9	9	6	ABJ62708	184PE2-r	792	22	44.9	9	9	ADZ56688
720	22	44.9	9	6	ABJ62438	184PE2-r	793	22	44.9	9	9	AEB30757
721	22	44.9	9	6	ABR44530	p53 Prote	794	21	42.9	4	5	ABG32439
722	22	44.9	9	6	ABR44531	p53 Prote	795	21	42.9	4	6	AEE35851
723	22	44.9	9	6	ABU96619	MHC Class	796	21	42.9	4	6	ADR38776
724	22	44.9	9	6	ABU96622	MHC Class	797	21	42.9	5	8	ADR90645
725	22	44.9	9	6	ABU63002	Human P53	798	21	42.9	6	2	AAR76135
726	22	44.9	9	6	ADK23941	Human P53	799	21	42.9	6	2	AAW73038
727	22	44.9	9	7	ADK24848	Human 98P	800	21	42.9	6	2	ADZ743161
728	22	44.9	9	7	ADK24838	Human 98P	801	21	42.9	7	7	AAR76171
729	22	44.9	9	7	ADK23337	Human 98P	802	21	42.9	7	2	AAR76132
730	22	44.9	9	7	ADW31379	HLA bindi	803	21	42.9	7	2	AAW75958
731	22	44.9	9	7	ADW56662	Human 98P	804	21	42.9	7	2	ADS14008
732	22	44.9	9	7	ADW60033	Human 98P	805	21	42.9	7	8	ADS14009
733	22	44.9	9	7	ADW60045	Human 98P	806	21	42.9	7	8	ADT40999
734	22	44.9	9	7	ADW55973	Human 98P	807	21	42.9	7	8	ADS80414
735	22	44.9	9	7	ADW60367	Human 98P	808	21	42.9	7	8	ADT35299
736	22	44.9	9	7	ADW61502	Human 98P	809	21	42.9	7	8	ABY03567
737	22	44.9	9	7	ADW55115	Human 98P	810	21	42.9	8	8	AAU26899
738	22	44.9	9	7	ADW55220	Human 98P	811	21	42.9	8	4	ABP12010
739	22	44.9	9	7	ADW56651	Human 98P	812	21	42.9	8	4	ABP17719
740	22	44.9	9	7	ADW57309	Human 98P	813	21	42.9	8	4	ABP17640
741	22	44.9	9	7	ADW57382	Human 98P	814	21	42.9	8	4	ABP17647
742	22	44.9	9	7	ADW60682	Human 98P	815	21	42.9	8	4	ABP12008
743	22	44.9	9	7	ADW51015	Human 98P	816	21	42.9	8	4	ADR17567
744	22	44.9	9	7	ADW57376	Human 98P	817	21	42.9	8	7	ABR62975
745	22	44.9	9	7	ADW61115	Human 98P	818	21	42.9	8	8	ADK01860
746	22	44.9	9	7	ADW56034	Human 98P	819	21	42.9	8	8	ADR17476
747	22	44.9	9	7	ADW57664	Human 98P	820	21	42.9	8	8	ADR71569
748	22	44.9	9	7	ADW61301	Human 98P	821	21	42.9	8	8	ADR71567
749	22	44.9	9	7	ADW57933	Human 98P	822	21	42.9	8	8	ADR17568
750	22	44.9	9	7	ADW60046	Human 98P	823	21	42.9	8	8	ADU08135
751	22	44.9	9	7	ADW55366	Human 98P	824	21	42.9	8	8	ADU04098
752	22	44.9	9	7	ADW59858	Human 98P	825	21	42.9	8	8	ADU04105
753	22	44.9	9	7	ADW60040	Human 98P	826	21	42.9	8	9	ADV12166
754	22	44.9	9	7	ADW600875	Human 98P	827	21	42.9	8	9	ADY95906

828	42.9	8	9	ADY95904	SARS	pept	901	21	42.9	4	AAG62107	Mouse	WT1	
829	21	42.9	8	9	ADY95913	Anti-Cdk8	902	21	42.9	4	AAG61974	Human	WT1	
830	21	42.9	8	9	ADY95905	SARS	pept	903	21	42.9	4	AAG61988	Human	WT1
831	21	42.9	8	9	ABA89885	Phage	dis	904	21	42.9	4	ABP17035	HIV	B27
832	21	42.9	9	2	AAR70553	HIV	Pepti	905	21	42.9	4	ABP15519		
833	21	42.9	9	2	AAR77571	HIV	-551-1	906	21	42.9	4	ABP12157	HIV	A02
834	21	42.9	9	2	AAW49318	Human	leu	907	21	42.9	4	ABP17034	HIV	B27
835	21	42.9	9	2	AAW49492	Human	leu	908	21	42.9	4	Aau68742	Human	WT1
836	21	42.9	9	2	AAW49493	Human	leu	909	21	42.9	4	Aau68741	Human	WT1
837	21	42.9	9	2	AAW49488	Human	leu	910	21	42.9	4	Aau6874	Mouse	WT1
838	21	42.9	9	2	AAW49490	Human	leu	911	21	42.9	4	Aau68755	Human	WT1
839	21	42.9	9	2	AAW49494	Human	leu	912	21	42.9	4	Aau68740	Human	WT1
840	21	42.9	9	2	AAW49478	Human	leu	913	21	42.9	4	ABP55704	OCIA	rela
841	21	42.9	9	2	AAW49492	Human	leu	914	21	42.9	5	ABP47409	N.	mening
842	21	42.9	9	2	AAW49489	Human	leu	915	21	42.9	5	ABP47404	N.	mening
843	21	42.9	9	2	AAW07026	Synthetic		916	21	42.9	5	ABP47478	N.	mening
844	21	42.9	9	2	AAR94442	HIV-1	GP1	917	21	42.9	5	ABP47372	N.	mening
845	21	42.9	9	2	AAR29913	Porcine	A	918	21	42.9	5	ABG33210	Human	WT1
846	21	42.9	9	2	AAY47760	ImmunoGen		919	20	42.9	5	ABG33344	Mouse	WT1
847	21	42.9	9	3	AAY98641	WT1	deriv	920	21	42.9	5	ABG33211	Human	WT1
848	21	42.9	9	3	AAY98642	WT1	deriv	921	21	42.9	5	ABG33212	Human	WT1
849	21	42.9	9	3	AAY98643	WT1	deriv	922	21	42.9	5	ABG33225	Human	WT1
850	21	42.9	9	3	AAY98644	HIV	-1GP1	923	21	42.9	5	ABP85452	HIV	proto
851	21	42.9	9	3	AAY98656	WT1	deriv	924	21	42.9	6	ABP85985	HIV	proto
852	21	42.9	9	3	AAY96941	Processed		925	21	42.9	6	ABP88129	HIV	proto
853	21	42.9	9	4	AAM22342	HIV	Pepti	926	21	42.9	6	ABP88149	HIV	proto
854	21	42.9	9	3	AAY98642	HIV	Pepti	927	21	42.9	6	ABP84846	HIV	proto
855	21	42.9	9	3	AAY98643	HIV	Pepti	928	21	42.9	6	ABP8915	HIV	proto
856	21	42.9	9	4	AAM23233	HIV	Pepti	929	21	42.9	6	ABP87108	HIV	proto
857	21	42.9	9	4	AAM23378	HIV	Pepti	930	21	42.9	6	ABP87612	HIV	proto
858	21	42.9	9	4	AAM22956	HIV	Pepti	931	21	42.9	6	ABP88757	HIV	proto
859	21	42.9	9	4	AAM23379	HIV	Pepti	932	21	42.9	6	ABP87434	HIV	proto
860	21	42.9	9	4	AAM22561	HIV	Pepti	933	21	42.9	6	ABP89469	HIV	proto
861	21	42.9	9	4	AAM23229	HIV	Pepti	934	21	42.9	6	ABP86515	HIV	proto
862	21	42.9	9	4	AAM23233	HIV	Pepti	935	21	42.9	6	ABP89324	HIV	proto
863	21	42.9	9	4	AAM23378	HIV	Pepti	936	21	42.9	6	ABP90451	HIV	proto
864	21	42.9	9	4	AAM22412	HIV	Pepti	937	21	42.9	6	ABP85487	HIV	proto
865	21	42.9	9	4	AAM23243	HIV	Pepti	938	21	42.9	6	ABP88504	HIV	proto
866	21	42.9	9	4	AAM23244	HIV	Pepti	939	21	42.9	6	ABP90521	HIV	proto
867	21	42.9	9	4	AAM22380	HIV	Pepti	940	21	42.9	6	ABP86186	HIV	proto
868	21	42.9	9	4	AAM22512	HIV	Pepti	941	21	42.9	6	ABP90326	HIV	proto
869	21	42.9	9	4	AAM23239	HIV	Pepti	942	21	42.9	6	ABP87014	HIV	proto
870	21	42.9	9	4	AAM22956	HIV	Pepti	943	21	42.9	6	ABP85155	HIV	proto
871	21	42.9	9	4	AAM23342	HIV	Pepti	944	21	42.9	6	ABP85859	HIV	proto
872	21	42.9	9	4	AAM23243	HIV	Pepti	945	21	42.9	6	ABP85211	HIV	proto
873	21	42.9	9	4	AAM22413	HIV	Pepti	946	21	42.9	6	ABJ43102	151P3D4	C
874	21	42.9	9	4	AAM23246	HIV	Pepti	947	21	42.9	6	ABJ43935	151P3D4	C
875	21	42.9	9	4	AAM22517	HIV	Pepti	948	21	42.9	6	ABJ49392	151P3D4	C
876	21	42.9	9	4	AAM22556	HIV	Pepti	949	21	42.9	6	ABJ42402	151P3D4	C
877	21	42.9	9	4	AAM23241	HIV	Pepti	950	21	42.9	6	ABJ42889	151P3D4	C
878	21	42.9	9	4	AAM23245	HIV	Pepti	951	21	42.9	6	ABJ47032	151P3D4	C
879	21	42.9	9	4	AAM22479	HIV	Pepti	952	21	42.9	6	ABJ47234	151P3D4	C
880	21	42.9	9	4	AAM23236	HIV	Pepti	953	21	42.9	6	ABJ33280	151P3D4	C
881	21	42.9	9	4	AAM23232	HIV	Pepti	954	21	42.9	6	ABJ49369	151P3D4	C
882	21	42.9	9	4	AAM23242	HIV	Pepti	955	21	42.9	6	ABJ40228	151P3D4	C
883	21	42.9	9	4	AAM22516	HIV	Pepti	956	21	42.9	6	ABJ45110	151P3D4	C
884	21	42.9	9	4	AAM23231	HIV	Pepti	957	21	42.9	6	ABJ47898	151P3D4	C
885	21	42.9	9	4	AAM23336	HIV	Pepti	958	21	42.9	6	ABJ43674	151P3D4	C
886	21	42.9	9	4	AAM22411	HIV	Pepti	959	21	42.9	6	ABJ43228	151P3D4	C
887	21	42.9	9	4	AAM22410	HIV	Pepti	960	21	42.9	6	ABJ44254	151P3D4	C
888	21	42.9	9	4	AAM22557	HIV	Pepti	961	21	42.9	6	ABJ47871	151P3D4	C
889	21	42.9	9	4	AAM23235	HIV	Pepti	962	21	42.9	6	ABJ48677	151P3D4	C
890	21	42.9	9	4	AAM23237	HIV	Pepti	963	21	42.9	6	ABJ41795	151P3D4	C
891	21	42.9	9	4	AAM22515	HIV	Pepti	964	21	42.9	6	ABJ43635	151P3D4	C
892	21	42.9	9	4	AAM23230	HIV	Pepti	965	21	42.9	6	ABJ43228	151P3D4	C
893	21	42.9	9	4	AAM22560	HIV	Pepti	966	21	42.9	6	ABJ46267	151P3D4	C
894	21	42.9	9	4	AAM22513	HIV	Pepti	967	21	42.9	6	ABJ44368	151P3D4	C
895	21	42.9	9	4	AAM22562	HIV	Pepti	968	21	42.9	6	ABJ42182	151P3D4	C
896	21	42.9	9	4	AAM23240	HIV	Pepti	969	21	42.9	6	ABJ48365	151P3D4	C
897	21	42.9	9	4	AAB49390	Simian	im	970	21	42.9	6	ABJ44534	151P3D4	C
898	21	42.9	9	4	AAU12507	Human	HIV	971	21	42.9	6	ABR22789	Human	can
899	21	42.9	9	4	AAG61975	Human	WT1	972	21	42.9	6	ABR22774	Human	can
900	21	42.9	9	4	AAG61973	Human	WT1	973	21	42.9	6	ABR21258	Human	can

ALIGNMENTS

KW Hodgkin's lymphoma; uterine cancer; cervical cancer; bladder cancer; kidney cancer; adenocarcinoma; breast cancer; prostate cancer; ovarian cancer; pancreatic cancer; epitope; vaccine; dendritic cell; tumour infiltrating lymphocyte; TIL; human leukocyte antigen; HLA; cytosolic; human.

CC disease (e.g. cancer, tumour, melanoma, thymoma, lymphoma, sarcoma, lung cancer, non-Hodgkin's lymphoma, leukaemia, Hodgkin's lymphoma, uterine cancer, cervical cancer, bladder cancer, kidney cancer, adenocarcinoma, breast cancer, prostate cancer, ovarian cancer and pancreatic cancer).
 CC The animal is further subjected to a cancer treatment including surgery, radiation, chemotherapy or gene therapy. The administration of (I),
 CC preferably dendritic cell is prior to, subsequent to or concurrent with,
 CC the cancer treatment. The present sequence is tumour antigen derived
 CC epitope for inclusion in the composition of the invention
 XX Sequence 9 AA;

Query Match 100.0%; Score 49; DB 5; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 STAPPVHNV 9
 YY ||||| |
 Db 1 STAPPVHNV 9
 AC ||||| |
 AC ADA50588 standard; peptide; 9 AA.

ADA50588
 ID ADA50588
 XX
 AC ADA50588;
 XX

DT 20-NOV-2003 (first entry)
 XX
 DE Mucin 1 (MUC-1) CTL epitope, SEQ ID NO:43.
 XX
 KW Nucleic acid vaccine; DNA vaccine; tumour antigen; cytokine adjuvant;
 KW humoral response; cellular response; immune response; immunotherapy;
 KW cancer; cytostatic vaccine; gene therapy; mucin 1; MUC-1;
 KW cytotoxic T lymphocyte; CTL epitope.
 XX
 OS Unidentified.
 PN WO2003031569-A2.
 XX
 PD 17-APR-2003.
 XX
 PF 18-SEP-2002; 2002WO-US0296440.
 XX
 PR 10-OCT-2001; 2001US-0322371P.
 XX
 PA (CENZ) CENTOCOR INC.
 XX
 PI Snyder L, Scallan B, Knight DM, McCarthy SG, Goletz TJ;
 PI Branigan PJ;
 XX
 DR WPI; 2003-393437/37.
 XX
 PT New nucleic acid vaccine, useful for eliciting an immune response to a
 PT cancer associated tumor protein in a mammal.
 XX
 PS Claim 1a; Page 45; 92pp; English.

XX The invention relates to nucleic acid vaccine comprising one or more
 CC tumour antigen-encoding nucleic acids and one or more cytokine adjuvant-
 CC encoding nucleic acids. The tumour antigen encoded by the vaccine is
 CC mucin 1 (MUC-1), the kallikrein KLK2, or prostate specific antigen (PSA,
 CC also known as KLK3), and the cytokine adjuvant encoded can be interleukin
 CC -12 (IL-12), granulocyte macrophage-colony stimulating factor (GM-CSF),
 CC or especially interleukin-18 (IL-18). The antigen-encoding nucleic acid
 CC is preferably under the control of a promoter such as the cytomegalovirus
 CC immediate early promoter, the dihydrofolate reductase promoter or the
 CC early or late SV40 promoters. The invention also encompasses the method
 CC of eliciting an immune response to a tumour antigen in a mammal using the
 CC vaccine of the invention. Coexpression of the antigen and adjuvant
 CC induces a humoral or cellular response to the tumour antigen, generating
 CC an immune response useful for treatment or prophylaxis of cancers. The
 CC present sequence represents a mucin 1 (MUC-1) polypeptide sequence which

CC is specifically claimed for use in the vaccine of the invention.
 XX Sequence 9 AA;

Query Match 100.0%; Score 49; DB 6; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 STAPPVHNV 9
 YY ||||| |
 Db 1 STAPPVHNV 9
 AC ||||| |

AC ADG99655 standard; peptide; 9 AA.

ADA99655
 ID ADA99655;
 XX
 AC ADG99655;
 XX

DT 11-MAR-2004 (first entry)
 XX
 DE Class I HLA-restricted widely expressed antigen #20.
 XX
 KW metastatic cancer cell differentiation; mutated fibronectin;
 KW metastatic cancer; class I HLA-restricted; widely antigen.
 XX
 OS Unidentified.
 XX
 PN WO2003100027-A2.
 XX
 PR 04-DBC-2003.
 XX
 PP 28-MAY-2003; 2003WO-US016736.
 XX
 PR 28-MAY-2002; 2002US-0383530P.
 XX
 PA (BAYT) BAYLOR COLLEGE MEDICINE.
 XX
 PI Wang R;
 XX
 DR WPI; 2004-035134/03.
 XX
 PT Identifying a cell that differentiates into a metastatic cancer cell.
 XX
 PT The invention comprises a method for identifying a cell that will
 PT differentiate into metastatic cancer cell, the method involves
 PT fibronectin in the cell. The method of the
 XX
 PS Disclosure; SEQ ID NO 98; 137pp; English.
 XX
 PT Identifying a cell that differentiates into a metastatic cancer cell, the method involves
 PT fibronectin in the cell. The method of the
 XX
 CC invention is useful for preventing metastatic cancer. The present amino
 CC acid sequence represents a Class I HLA-restricted widely expressed
 CC antigen.
 XX
 SQ Sequence 9 AA;

Query Match 100.0%; Score 49; DB 8; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 STAPPVHNV 9
 YY ||||| |
 Db 1 STAPPVHNV 9
 AC ||||| |

AC ADG99655 standard; peptide; 9 AA.

ADG99655
 ID ADG99655;
 XX
 AC ADG99655;
 XX

DT 11-MAR-2004 (first entry)

XX Antigenic peptide SEQ ID NO:35.
 DB ID ADU49630 standard; peptide; 9 AA.
 XX
 XX
 KW double-chimeric beta 2-microglobulin; antigenic peptide;
 KW antigen-presenting cell; beta 2-microglobulin;
 KW major histocompatibility complex class I epitope; MHC class I epitope;
 KW cytostatic; antibacterial; virucide; fungicide; protozoacide; vaccine;
 KW cytotoxic T lymphocyte induction; cancer; pathogenic organism;
 KW tumour associated antigen; pathogenic antigen.
 XX
 OS Synthetic.
 PN WO2003106616-A2.
 PD 24-DEC-2003.
 XX 12-JUN-2003; 2003WO-IL000501.
 XX 12-JUN-2002; 2002US-0388273P.
 PR 01-APR-2003; 2003WO-US010096.
 PA (GAVI-) -SAVISH-GALLIE BIO APPL LTD.
 XX
 PI Gross G, Margalit A;
 XX DR 2004-071554/07.
 PT Novel double-chimeric beta2-microglobulin polynucleotide useful for
 PT treating cancer, comprising sequence encoding polypeptide capable of
 PT presentation of antigenic peptides.
 XX
 PS Claim 16; SEQ ID NO 35; 86pp; English.
 XX
 The present invention describes a double-chimeric beta 2-microglobulin
 CC polynucleotide (I) comprising a sequence encoding a polypeptide (II) that
 CC is capable of high level presentation of antigenic peptides on antigen-
 CC presenting cells, where (II) comprising a beta 2-microglobulin molecule
 CC that is linked through its carboxyl terminal to a polypeptide stretch
 CC which allows the anchorage of the beta 2-microglobulin molecule to the
 CC cell membrane, and through its amino terminal to a antigenic peptide
 CC comprising major histocompatibility complex (MHC) class I epitope. The
 CC antigenic peptide is not related to an autoimmune disease. Also
 CC described: (1) an expression vector (III) comprising (I) and is a
 recombinant viral vector; (2) an antigen-presenting cell (IV) transfected
 CC with (I); (3) a DNA vaccine (V) comprising a (I) or (III); (4) a cellular
 CC vaccine (VI) for the prevention or treatment of cancer comprising (IV)
 CC which express (I) or tumour cells transfected with (I), where the cells
 CC have been pulsed with an antigenic peptide derived from one tumour
 CC associated antigen; and (5) a pharmaceutical composition (VII) comprising
 CC (I), (III) or (IV) as an active ingredient and carrier. (I) has
 CC cytostatic, antibacterial, virucide, fungicide and protozoacide
 CC activities, and can be used in vaccines, and for inducing cytotoxic T
 CC lymphocytes. (I) and (V) can be used for the prevention or treatment of
 CC cancer or for a disease caused by a pathogenic organism. (VI) is useful
 CC for prevention or treatment of cancer, or disease caused by a pathogenic
 CC organism, where (VI) presents one tumour associated antigen, or
 CC pathogenic antigen. (VII) is also useful for immunising a mammal against a
 CC tumour-associated antigen or a disease caused by a pathogenic organism,
 CC which involves immunising the mammal with (VI). (I) is useful for
 CC inducing class I-restricted CTL response in a mammal. The present
 CC sequence is used in the exemplification of the present invention.
 XX
 Sequence 9 AA;

SQ Query Match 100.0%; Score 49; DB 8; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 STAPPVHNV 9
 1 STAPPVHNV 9
 1 STAPPVHNV 9

SQ Sequence 9 AA;
 Query Match 100.0%; Score 49; DB 8; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 STAPPVHNV 9
 1 STAPPVHNV 9

RESULT 7

ID	ADX08605	standard; peptide; 9 AA.	KW	antiparasitic; cytotoxic T-lymphocyte; major histocompatibility complex;
XX	AC	ADX08605;	KW	antigen; cancer; bacterial infection; viral infection;
XX	DT	21-APR-2005 (first entry)	KW	parasitic infection; CP00.
DE	Class I HLA-restricted widely expressed antigen #20.	XX	OS	Homo sapiens.
XX	KW	vaccine; infection; viral infections; virucide; bacterial infection;	XX	
KW	antibacterial; yeast infection; fungicide; fungal infection;	PN	US2005048646-A1.	
KW	protozoal infection; protozoacide; cancer; cytostatic; melanoma;	PD	03-MAR-2005.	
KW	lung tumor; colon tumor; breast tumor; leukemia; autoimmune disease;	PP	29-JUL-2004; 2004US-0091067.	
KW	multiple sclerosis; neuroprotective; rheumatoic arthritis; antiarthritic;	XX		
KW	antirheumatic; systemic lupus erythematosus; antiinflammatory;	XX	25-AUG-2003; 2003JP-00341822.	
KW	dermatological; immunosuppressive.	PR	28-JAN-2004; 2004JP-00020436.	
XX	OS	XX	(MEDITE) MEDINET CO LTD.	
PN	W02005011730-A1.	PA	(MEDITE) MEDINET CO LTD.	
XX	WPI; 2005-195290/20.	XX		
PD	10-FEB-2005.	XX		
XX	PT	Inducing a cytotoxic T lymphocyte, useful for treating cancer or		
PF	30-JUL-2004; 2004WO-GB0032285.	PT	infectious disease, comprises contacting a cell line with an antigenic	
XX	PR	peptide and a lymphocyte.	PT	
XX	01-AUG-2003; 2003GB-00018096.	XX		
XX	PS	Disclosure; Page 7; 29pp; English.	XX	
PA (UNILQ) QUEEN MARY & WESTFIELD COLLEGE.	CC	The invention relates to a method of inducing a CTL (cytotoxic T		
XX	Wang P, Li S;	CC	lymphocyte) by contacting a cell line expressing at least one major	
XX	WPI; 2005-152360/16.	CC	histocompatibility antigen (MHC) class I molecule, an antigen, and a co-	
XX	DR	stimulatory molecule, where the cell line is transformed with at least		
XX	one co-stimulatory molecule or exogenous antigen, with an isolated or	CC	purified antigenic peptide and with a lymphocyte for a time and under	
XX	CC	conditions for inducing a CTL specific for the antigenic peptide. The		
PT	CC	method is useful for inducing a CTL. The CTL and method are useful for		
PT	CC	treating or preventing cancer or an infectious disease, e.g. a bacterial,		
PT	CC	viral, or parasitic infections. The present method provides CTLs having a		
XX	CC	high specificity for a disease site, thus allowing a highly effective		
CC	CC	treatment. also, compared to conventional method, the present method uses		
CC	CC	a synthetic peptide and thus imposes less burden on the patient. The CTLs		
CC	CC	induced using the present method are more likely to function specifically		
CC	CC	to individual disease antigens than the CTLs induced conventionally, thus		
CC	CC	can be used to stimulate the cytotoxic T-lymphocytes in the method of the		
CC	CC	invention. This sequence corresponds to a cancer antigenic peptide to		
CC	CC	stimulate the cytotoxic T-lymphocyte by the method of the invention.		
XX	SQ	Sequence 9 AA;	XX	
XX	Query Match	Score 49; DB 9; Length 9;	Query Match	100.0%; Score 49; DB 9; Length 9;
XX	Best Local Similarity	Pred. No. 2e+06;	Best Local Similarity	100.0%; Pred. No. 2e+06;
XX	Matches	Mismatches 0; Indels 0; Gaps 0;	Matches	Mismatches 0; Indels 0; Gaps 0;
XX	AC	AARE68013;	AC	AARE68013;
XX	DT	25-MAR-2003 (revised)	DT	25-MAR-2003 (revised)
XX	AC	05-SEP-1995 (first entry)	DT	05-SEP-1995 (first entry)
XX	DE	Mucin peptide p9-17.	DE	Mucin peptide p9-17.
XX	KW	KW	KW	KW
XX	OS	Ovary cancer; colon cancer; HIV.	OS	Ovary cancer; colon cancer; HIV.
XX	Synthetic.	Synthetic.	XX	Synthetic.
RESULT 8				
ID	ADY51475	standard; peptide; 9 AA.		
XX	AC	ADY51475 standard; peptide; 9 AA.		
XX	DT	19-MAY-2005 (first entry)		
XX	DE	HLA-A2 peptide modified MUC-1.1 for stimulating cytotoxic T-lymphocytes.		
XX	DE	immune stimulation; cytostatic; antimicrobial; antibacterial; virucide;		

PN	W09503825-A1.	PT	New preparations of microparticles - comprising a synthetic polymer
XX	09-FEB-1995.	PT	matrix and nucleic acid comprising an expression vector for use in gene
PD		PT	therapy.
XX		PT	
PF	29-JUL-1994;	PS	Disclosure; Page 10; 101pp; English.
XX	94WO-US008477.	XX	
PR	30-JUL-1993;	CC	A microparticle preparation (MP) has been developed, consisting of one or more synthetic polymers
XX	93US-00099354.	CC	microparticles having a diameter of less than 100 μm. The MP comprises:
PA	(FINN/) FINN O.J.	CC	(a) a polymeric matrix (PM) consisting of one or more synthetic polymers
(FONTE) FONTENOT J.D.		CC	having a solubility in water of less than 1 mg/l; and (b) an expression
PA (MONT/) MONTELARO R.C.		CC	vector selected from RNA molecules (at least 50% of which are closed
XX		CC	circles) or circular plasmid DNA (at least 50% of which are supercoiled).
Pi	Pinn OJ, Fontenot JD, Montelaro RC;	CC	Also described is a MP of at most 20 microns in diameter, comprising: (a)
PB	WPI: 1995-082033/11.	CC	a PM; and (b) a NAM comprising an expression control sequence operatively
DR		CC	linked to a coding sequence, where the coding sequence encodes an
XX		CC	expression product selected from: (1) a polypeptide at least 7 amino
PT		CC	acids in length, having a sequence identical to the sequence of: (i) a
PT		CC	fragment of a naturally occurring mammalian protein; or (ii) a fragment
PT		CC	of a naturally-occurring protein from an infectious agent which infects a
XX		CC	mammal; (2) a peptide having a length and sequence which permits it to
PS		CC	bind to an MHC class I or II molecule; and (3) the polypeptide or the
DS		CC	peptide linked to a trafficking sequence. AAW69763 to AAW69765, and
XX		CC	AAW8793 to AAW8897 are peptide fragments for use in the present
CC		CC	invention. The MPs are highly effective vehicles for the delivery of
CC		CC	polynucleotides into phagocytic cells. They can be used for gene therapy,
CC		CC	e.g., for treating genetic diseases, infections or tumours or for
CC		CC	deregulating an immune response
SQ	Sequence 9 AA;	XX	Sequence 9 AA;
		Query Match	79.6%; Score 39; DB 2; Length 9;
		Best Local Similarity	77.8%; Pred. No. 2e+06;
		Matches	0; Mismatches 2; Indels 0; Gaps 0;
Qy	1 STAPPVHN 9	Qy	1 STAPPVHN 9
Db	1 STAPPAHGV 9	Db	1 STAPPAHGV 9
		RESULT 11	
		AAW72715	
ID	AAW72715 standard; peptide; 9 AA.	ID	AAW72715 standard; peptide; 9 AA.
XX		XX	
AC	AAW72715;	AC	AAW72715;
XX		XX	
DT	11-JAN-1999 (first entry)	DT	11-JAN-1999 (first entry)
XX		XX	
DB	Mucin peptide preparation p-9-17.	DB	Mucin peptide preparation p-9-17.
XX		XX	
DE	MUC-1 protein fragment 9-17.	DE	MUC-1 protein fragment 9-17.
XX		XX	
KW	Microparticle; delivery; polymeric matrix; autoantigen; tumour antigen;	KW	Microparticle; muc-1; human; cancer; infectious disease; diagnosis;
KW	class I associated peptide; pathogen; gene therapy; genetic disease;	KW	multiple tandem repeat; pancreatic cancer; breast cancer; colon cancer.
KW	infection; downregulation; immune response.	KW	Homo sapiens.
XX		XX	OS
OS	Homo sapiens.	OS	Synthetic.
OS	Synthetic.	XX	PN US5527666-A.
XX		XX	PN
PN	W09831398-A1.	PN	27-OCT-1998.
XX		XX	
PR	23-JUL-1998 (First entry)	PR	10-AUG-1994;
XX		XX	94US-00288059.
DB	MUC-1 protein fragment 9-17.	DB	30-JUL-1993;
XX		XX	93US-0009354.
PF	22-JAN-1998;	PF	(UPF-) UNIV PITTSBURGH.
XX	98WO-US001499.	PF	Montelaro RC, Fontenot JD, Finn OJ;
PR	22-JAN-1997;	XX	XX
PR	97US-00787547.	PR	Montelaro RC, Fontenot JD, Finn OJ;
06-JAN-1998;	98US-0003253.	XX	XX
XX		XX	WPI: 1998-593988/50.
(PANG-) PANGAEA PHARM INC.		DR	Assay for cancer antibodies - using synthetic peptide comprising multiple
PA		XX	PT tandem repeats of muc-1.
PI	Hedley ML, Curley JM, Langer RS, Lunsford LB;	XX	PT
XX		XX	XX
DR	WPI: 1998-427556/36.	PS	Disclosure; Col 25; 45pp; English.
XX			

XX An assay has been developed for antibodies to pancreatic, breast or colon cancer in a sample. The assay comprises contacting the sample with a synthetic muc-1 peptide that comprises at least two 20 amino acid tandem repeats of muc-1 and is capable of attaining native conformation in the absence of glycosylation, and detecting any peptide-antibody complex formation. The assay can be used in the diagnosis of e.g. pancreatic, breast or colon cancer. The present sequence represents a mucin peptide preparation from the present invention.

SQ Sequence 9 AA;

Query Match 79.6%; Score 39; DB 2; Length 9;

Best Local Similarity 77.8%; Pred. No. 2e+06; 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 STAPPVHNV 9

Qy 1 STAPPVHNV 9
1 | | | | |
1 STAPPVHGV 9

RESULT 12

AAV46704 ID AAV46704 standard; peptide; 9 AA.

XX AC AAV46704;

XX DT 01-DEC-1999 (first entry)

XX Immunogenic peptide having a human leukocyte antigen binding motif #1315.

XX Human leukocyte antigen; binding; immunogenic; glycoprotein; MHC; HLA;

XX immune response; T cell activation; major histocompatibility complex;

XX cytotoxic T lymphocyte; CTL; tumour rejection; viral infection; cancer;

XX prostate cancer; hepatitis B; hepatitis C; AIDS; renal carcinoma;

XX vaccine; immunisation.

XX Synthetic.

OS Homo sapiens.

XX PN WO9945954-A1.

XX PD 16-SEP-1999.

XX PF 13-MAR-1998; 98WO-US005039.

XX PR 13-MAR-1998; 98WO-US005039.

XX PA (EPIM-) EPIMMUNE INC.

XX PI Sette A, Kubo RT, Sidney J, Celis E, Grey HM, Southwood S;

XX WPI; 1999-551214/46.

XX New immunogenic peptides with HLA binding motif, useful in treatment and diagnosis of cancers and viral diseases.

XX PS Claim 1; Page 82; 150pp; English.

XX AAY48214 represent specifically claimed immunogenic peptides having a human major histocompatibility complex (MHC) Class I (also known as human leukocyte antigen (HLA)) binding motif. The immunogenic peptides can bind to a specific HLA allele (i.e. HLA-A subtypes HLA-A2.1, A1, A3.2 or A24.1 or HLA-B or C) and induce a cytotoxic T cell response against the antigen from which the peptide is derived. Cytotoxic T lymphocytes (CTLs) which destroy antigen-bearing cells are normally induced by an antigen in the form of a peptide fragment bound to a HLA molecule rather than the intact foreign antigen itself, and are particularly important in tumour rejection and in fighting viral infections. The peptides are therefore useful therapeutically to treat or prevent viral infections and cancers in mammals (especially humans) e.g. prostate cancer, hepatitis B and C, AIDS, and renal carcinoma. They can be administered as vaccines to elicit an immune response in individuals susceptible or otherwise at risk

CC of viral infection or cancer, or used to treat chronic or acute CC conditions. They are also useful diagnostically, and can be used to CC induce a cytotoxic T cell response, by contacting a cytotoxic T cell with CC the peptide e.g. to produce CTLs ex vivo for infusion back into a CC patient. The polynucleotides encoding the immunogenic peptides are also CC useful therapeutically and for immunisation as above.

XX SQ Sequence 9 AA;

Query Match 79.6%; Score 39; DB 2; Length 9;

Best Local Similarity 77.8%; Pred. No. 2e+06; 0; Mismatches 0; Indels 2; Gaps 0;

Db 1 STAPPVHNV 9

Qy 1 STAPPVHNV 9
1 | | | | |
1 STAPPVHGV 9

RESULT 13

AAW67583 ID AAW67583 standard; peptide; 9 AA.

XX AC AAW67583;

XX DT 02-MAR-1999 (first entry)

XX DB T-cell activation peptide #1.

XX DT Activated T helper cell; CD4+; cytotoxic T cell; CD8+; liposome; epitope;

XX KW peripheral blood lymphocyte; antigen-presenting cell; APC; virus; tumour;

XX KW bacterium; parasite; cytokine; vaccine; cancer; malaria; HIV; hepatitis;

XX KW tuberculosis.

XX OS Synthetic.

XX PN WO950527-A1.

XX PD 12-NOV-1998.

XX PP 07-MAY-1998; 98WO-US009288.

XX PR 08-MAY-1997; 97US-0045949P.

XX PA (BIOM-) BIOMIRA INC.

XX PI Agrawal B, Krantz MJ, Reddish MA, Longenecker BM;

XX WPI; 1999-034715/03.

XX Disclosure; Page 6; 75pp; English.

XX PT Method of activation of T cells - by exposure to antigen-presenting cells

XX PT loaded with antigen in liposome, used for, e.g. treating cancer and

XX PT microbial infections.

XX XX Disclosure; Page 6; 75pp; English.

XX PT Peptides AAW67583-W67611 are used to produce activated T helper (CD4+) and cytotoxic (CD8+) T cells. The activated T cells are produced by

XX CC treating peripheral blood lymphocytes with liposome-encapsulated peptide

CC CC antigen to generate Ag-loaded antigen-presenting cells (APC), contacting

CC CC native or anergic T-cells with these APC, and isolating the resulting

CC CC activated T-cells. The cells are specific for a particular antigen,

CC CC particularly one derived from a tumour, but also those from viruses,

CC CC bacteria and other parasites. It can also be used to identify antigens

CC CC and epitopes able to generate an Ag-specific T-cell response (by

CC CC assessing proliferation and cytokine release). Also the Ag-loaded APC can

CC CC be used as cellular vaccines for treating cancer (claimed) or other

CC CC diseases (e.g. malaria, human immune deficiency virus infection,

CC CC hepatitis, tuberculosis). The activated T-cells can be used to treat the

CC CC same conditions by adoptive T-cell transfer therapy

XX SQ Sequence 9 AA;

Query Match 79.6%; Score 39; DB 2; Length 9;

Best Local Matches	Similarity 77.8%;	Pred. No. 2e+06;	Mismatches 0;	Indels 2;	Gaps 0;	XX	AC AAB9540;
Qy 1 STAPPVHN 9 1 STAPPAGV 9						XX	DT 19-NOV-2001 (first entry)
Db						XX	DE Human HLA-A*0201 T cell epitope.
RESULT 14						XX	KW Mucin; cytostatic; immunostimulant; cell mediated immune response; carcinoma; adenocarcinoma; breast cancer; dendritic cell; vaccine; gene therapy; human; HLA-A*0201 T cell epitope.
AAB33656						XX	KW carcinoma; mucin; gene therapy; Homo sapiens.
ID AAB33656	standard; peptide; 9 AA.					XX	OS Homo sapiens.
XX						XX	PN WO200157068-A1.
AC AAB33656;						XX	PD 09-AUG-2001.
XX	DT 26-JAN-2001 (first entry)					XX	DE MHC class I associated immunogenic peptide SEQ ID 55.
XX						XX	DE MHC class I; MHC II; MHC III; major histocompatibility complex; vaginal tissue; mucosal tissue.
XX						XX	PR 01-FEB-2000; 2000AU-00005369.
XX						PR 14-JUN-2000; 2000US-00593870.	OS Unidentified.
XX						XX	PA (AUST-) AUSTIN RES INST
PN WO200053161-A2.						XX	PI McKenzie IFC, Pietersz GA, Apostolopoulos V;
XX						XX	DR WPI: 2001-541537/60.
PD 14-SEP-2000.						XX	XX Immunostimulant peptide, used as an anti-carcinoma vaccine, comprises a peptide of the non-VNTR, non-leader region of a mucin.
XX	PP 10-MAR-2000; 2000WO-US006578.					XX	PT Disclosure; Page 23; 84pp; English.
XX	PR 11-MAR-1999; 99US-00266463.					XX	CC The patent discloses peptide or polypeptides capable of eliciting an immune response, comprising an amino acid sequence corresponding to an epitope of the non-central portion of varying numbers of an amino acid motif (VNTR), non-leader region of a mucin. The peptides of the invention, fusion proteins comprising the peptide and conjugate compounds with carbohydrate polymers are used to induce a cell mediated immune response against mucin in the prevention or treatment of carcinoma, preferably adenocarcinoma, most preferably breast cancer. They are also used to pulse dendritic cell for in vivo transfer and use as a vaccine. They are also used in gene therapy. The present sequence is HLA-A*0201 T cell epitope from human. This sequence is used for the prediction of T-cell epitopes for the VNTR region
XX	PR 27-MAY-1999; 99US-00321346.					XX	CC Sequence 9 AA;
XX	PA (ZYCO) ZYCOS INC.					XX	Query Match Best Local Similarity 79.6%; Score 39; DB 4; Length 9;
XX	PI Lumsford LB, Putnam D, Hedley ML;					XX	Matched 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX	DR 2000-638130/61.					XX	Qy 1 STAPPVHN 9 1 STAPPAGV 9
XX	WPI: 2000-638130/61.					DB 1 STAPPAGV 9	Db
XX	Microparticules useful for administering a nucleic acid into the mucosal tissue preferably vaginal tissue of an animal, comprises a polymeric matrix, a lipid and a nucleic acid molecule.						RESULT 16
XX	Disclosure; Page 14; 96pp; English.						XX
XX	The present invention relates to microparticules which are less than 20 microns in diameter, which comprise a polymeric matrix, a lipid and a nucleic acid molecule. The microparticule is specifically not encapsulated in a liposome and does not comprise a cell. The nucleotide sequence encodes an expression product that binds to major histocompatibility complex (MHC) type I or II molecules. Peptides AAB33602-B33647 represent MHC class II associated immunogenic peptides, and AAB33648-B33710 represent MHC class I associated immunogenic peptides. The peptides are examples of the expression products of the nucleotide sequences which can be included in the microparticules of the invention. Sequences AAB33711-B33716 represent alternative expression products and nuclear localisation signals also used in the invention. The microparticules are useful for administering a nucleic acid into the mucosal tissue preferably vaginal tissue of an animal.						ID AAB95902 standard; peptide; 9 AA.
XX	Sequence 9 AA;						XX
SQ	Query Match Best Local Similarity 79.6%; Score 39; DB 3; Length 9;						AC AAB95902;
Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0;							XX
Qy 1 STAPPVHN 9 1 STAPPAGV 9							DE MHC class-I associated MUC-1 epitope SEQ ID 9.
Db							XX
RESULT 15							XX Epitope; tumour antigen; antiviral; immunostimulatory; cervical cancer; human papillomavirus-associated disease; condyloma; cervical dysplasia; cervical dysplasia; major histocompatibility complex; MHC I.
AAE09540	standard; peptide; 9 AA.						XX Unidentified.
ID AAE09540							OS

PN	WO200119908-A1.	KW	antibody; vaccination; treatment; autoimmune disease;
XX		XX	immune response modulation.
PD	22-MAR-2001.	XX	
PF		OS	Homo sapiens.
PR	18-SBP-2000; 2000WO-US025559.	XX	
XX		PN	WO200136593-A1.
PR	16-SEP-1999; 99US-00398534.	XX	XX
PR	16-SEP-1999; 99US-014665P.	PD	25-MAY-2001.
PR	09-DEC-1999; 99US-0048173.	XX	XX
PR	09-DEC-1999; 99US-0163846P.	PP	17-NOV-2000; 2000WO-US031770.
XX		XX	XX
PA	(ZYCO-) ZYCOS INC.	PR	19-NOV-1999; 99US-00443654.
XX		XX	
PI	Hedley ML, Urban RC, Chicz RM;	PA	(ZYCO-) ZYCOS INC.
XX		XX	
DR	WPI; 2001-265996/27.	PI	Hedley ML, Hsu Y, Tyo M;
XX		XX	
PT	Novel nucleic acids encoding polyepitope polypeptides containing multiple epitopes from one or more proteins, useful for treating tumors and as vaccines against pathogenic agents.	DR	WPI; 2001-425203/45.
PT		XX	
PT	Disclosure; Page 7; 64pp; English.	PT	Continuous production of microparticles containing nucleic acid for e.g. gene therapy, comprises mixing a solution of polymeric material and nucleic acid with a surfactant solution, removing solvent and drying.
PS		PT	
CC	This invention relates to polynucleotides encoding a hybrid polypeptide comprising a signal sequence and three segments that are either contiguous or separated by a spacer amino acid or spacer peptide. The invention specifically details polynucleotides encoding a polyepitope peptide where the peptide segments are tumour antigens or a naturally occurring protein of a pathogenic agent. The polyepitope peptides exhibit antiviral and immunostimulatory activity. The polynucleotide and polyepitope peptides are useful for eliciting an immune response in a mammal. The polynucleotide and protein are useful as vaccines for treating tumours and pathogenic infections. The polynucleotide is also useful for preventing or treating human papillomavirus (HPV)-associated diseases, particularly exophytic condyloma, flat condyloma, cervical cancer, respiratory papilloma, conjunctival papilloma, genital-tract HPV infection, cervical dysplasia, high grade squamous intraepithelial lesions, and anal HPV infection. The polynucleotide and polypeptide are useful for generating or enhancing prophylactic or therapeutic immune response against pathogens, tumours or autoimmune diseases in a population of individuals having diverse MHC allotypes, as positive controls in T cell stimulation assays in vitro, and as tools to understand processing of epitopes within cells. Peptides AAB95834 - AAB96037 and AAB96048 represent major histocompatibility complex I (MHC I) associated tumour and pathogen antigens. The peptides can be used as part of the polyepitope proteins of the invention. Abo included are examples of the polyepitope proteins represented by AAB96050 - AAB9652, and localisation signal peptides AAB96038 - AAB96043 and AAB96049 which can be used in the construction of the polyepitope peptides	XX	DISCLOSURE; Page 11; 47pp; English.
CC		XX	
CC	This present sequence is that of a peptide of the invention. The invention relates to a method for scalable, continuous flow production of a nucleic acid containing microparticle that maintains the structural integrity of the associated nucleic acid and results in a microparticle having purity suitable for introduction into an animal host. Microparticles prepared according to the method can be used for delivery of a nucleic acid for gene therapy, antisense therapy, vaccination, treatment of autoimmune disease and either specific or non-specific modulation of an immune response. The microparticles may also be used to deliver nucleic acid encoding a protein or peptide useful in any kind of therapy. The method is economical, aseptic and scalable. The method also enables control over the size of microparticles. The microparticles produced are free of impurities such as organic solvents and are readily dispersed in a wide range of dispersing agents	XX	Sequence 9 AA:
CC		XX	
CC	Query Match Score 39; DB 4; Length 9; Best Local Similarity 77.8%; Pred. No. 2e+06; Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0	Qy	1 STAPPVHN 9 1 STAPPAGV 9
CC		Qy	
CC	RESULT 18 AAB86120 ID AAB86120 standard; peptide; 9 AA.	Db	
CC		XX	
CC	Query Match Score 39; DB 4; Length 9; Best Local Similarity 77.8%; Pred. No. 2e+06; Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	Qy	1 STAPPVHN 9 1 STAPPAGV 9
CC		Qy	
CC	RESULT 17 AAB93752 ID AAB93752 standard; peptide; 9 AA.	Db	
CC		XX	
CC	Query Match Score 39; DB 4; Length 9; Best Local Similarity 77.8%; Pred. No. 2e+06; Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	Qy	1 STAPPVHN 9 1 STAPPAGV 9
CC		Qy	
CC	RESULT 17 AAB93752 ID AAB93752 standard; peptide; 9 AA.	Db	
CC		XX	
CC	Human anti-MUC1 associated-epitope SEQ ID 1. MUC1; mucin; anti-MUC1; epitope; human; detection; immunogenic; antibody; breast cancer screening.	XX	
CC		XX	
DE	Human anti-MUC1 associated-epitope SEQ ID 1.	OS	Homo sapiens;...
DE		XX	
PN		PN	EP1096257-A2.
XX		XX	
PD	02-MAY-2001.	XX	
XX		XX	
PF	24-OCT-2000; 20000EP-00123053.	XX	
PR	29-OCT-1999;	PR	

XX	(SAUER/)	SAUER M.	XX	Wang R;	
PA	(WOLF/)	WOLFRUM J.	XX	WPI; 2002-627577/67.	
XX	PI	Sauer M, Wolfrum J;	XX	Novel composition for treating a disease in an animal, comprises an immune effector cell and cell penetrating peptide associated with an antigen or antibody.	
XX	XX	WPI; 2001-293137/31.	PT	Immune effector cell and cell penetrating peptide associated with an antigen or antibody.	
PT	Detecting molecules in solution e.g tumor markers for breast cancer screening, involves adding dye-labelled binding partner, applying electric field and detecting dye at anode or cathode.	XX	PT	Detecting molecules in solution e.g tumor markers for breast cancer screening, involves adding dye-labelled binding partner, applying electric field and detecting dye at anode or cathode.	
PS	Example 1; Page 8; 16pp; German.	XX	PS	Example 1; Page 8; 16pp; English.	
XX	This invention describes a novel method for detecting a molecule (1) in a solution which involves coupling another molecule (2) with a dye, selecting the net charge in the solution of dye-labelled molecule to be opposite to and less than that in the solution of molecule (1), adding dye-labelled molecule (2) to molecule (1), applying an electric field and detecting the dye at the anode or cathode (depending on the charge). The invention also describes a method for detecting a third molecule (3) in a solution which can bond to molecule (1) and to a second molecule (2) by coupling dye to (2) and selecting the net charge as above, forming a complex which can be detected at the cathode if the net charge in the solution is negative or at the anode if the net charge is positive. This sequence represents an immunogenic fragment of human MUC1 containing an epitope which is used to raise anti-MUC1 antibodies, used in screening for breast cancer. This sequence is used to illustrate the method described in the invention. The simple and reliable method for the detection of certain molecules (e.g. anti-MUC1 antibodies or tumor-specific MUC1 proteins) has a sensitivity 1000 times greater than that of ELISA tests.	CC	CC	The invention relates to a composition (I) comprising an immune effector cell and a cell penetrating peptide (CPP) associated with an antigen or antibody. Also included are (1) a vaccine comprising (II), CPP associated with an antigen, and a pharmaceutically acceptable carrier and (2) preparing a composition for a disease, by providing (I) and CPP associated with an antigen for disease, and introducing the antigen-associated CPP to (I), where antigen enters into the cell. The antigens are, for example, tumour antigen derived epitopes recognised by tumour infiltrating lymphocytes (TIL) of HLA (human leukocyte antigen) class I or II. The composition is useful for enhancing immunity in an animal to a disease, by administering a mature dendritic cell comprising CPP associated with an antigen to disease, to the animal, such that following administration, animal is protected from disease, where the animal comprises both CD4+ and CD8+ T cells. It is also useful for treating a disease (e.g. cancer, tumour, melanoma, thymoma, sarcoma, lung cancer, non-Hodgkin's lymphoma, leukaemia, Hodgkin's lymphoma, uterine cancer, cervical cancer, bladder cancer, kidney cancer, adenocarcinoma, breast cancer, prostate cancer, ovarian cancer and pancreatic cancer). The animal is further subjected to a cancer treatment including surgery, radiation, chemotherapy or gene therapy. The administration of (II), preferably dendritic cell is prior to, subsequent to or concurrent with, the cancer treatment. The present sequence is a tumour antigen derived epitope for inclusion in the composition of the invention.	
XX	Sequence 9 AA;	XX	XX	Sequence 9 AA;	
XX	Query Match	79.6%; Score 39; DB 4; Length 9;	XX	Query Match	79.6%; Score 39; DB 5; Length 9;
XX	Best Local Similarity	77.8%; Pred. No. 2e+06;	XX	Best Local Similarity	77.8%; Pred. No. 2e+06;
XX	Matches	0; Mismatches 2; Indels 0; Gaps 0;	XX	Matches	0; Mismatches 2; Indels 0; Gaps 0;
Qy	1 STAPPVHNV 9	Db	1 STAPPVHNV 9	Db	1 STAPPVHGV 9
Db					
RESUL.T 19	ABG79088	ID ABG79088 standard; peptide; 9 AA.	RESULT 20	AAU82062	ID AAU82062 standard; peptide; 9 AA.
XX	AC ABG79088;	XX	XX	AC AAU82062;	XX
XX	DT 15-NOV-2002 (first entry)	XX	XX	DT 09-APR-2002 (first entry)	XX
DB	Human MUC1 class I HLA widely expressed antigen peptide #1.	DE	DE	Antigenic peptide M1b associated with cancer (Muc1).	DE
XX	Cell penetrating peptide; cancer; tumour; melanoma; thymoma; antigen; lymphoma; sarcoma; lung cancer; non-Hodgkin's lymphoma; leukaemia; Hodgkin's lymphoma; uterine cancer; cervical cancer; bladder cancer; kidney cancer; adenocarcinoma; breast cancer; prostate cancer; ovarian cancer; pancreatic cancer; epipole; vaccine; dendritic cell; tumour infiltrating lymphocyte; TIL; human leukocyte antigen; HLA; cytostatic; human.	KW	KW	T-cell binding ligand; TCBL; peptide G'; human MHC class II beta chain; peptide J; human Beta-2-microglobulin; HIV-1; TBL peptide construct; immunological disorder; immune response; human immunodeficiency virus; herpes simplex virus infection; HSV; malaria; tuberculosis; cancer; CEA; acquired immunodeficiency syndrome; AIDS; allergy; autoimmune disease; autoimmune myocarditis; cytostatic; anticancer.	KW
OS	Homo sapiens.	XX	OS	Synthetic.	XX
XX	PN WO200264057-A2.	XX	PN	WO200189286-A2.	XX
XX	PD 22-AUG-2002.	XX	XX	PD 29-NOV-2001.	XX
PF 15-FEB-2002; 2002WO-US005212.	XX	PF 24-MAY-2001; 2001WO-US006793.	XX	PF 24-MAY-2000; 2000US-0205548P.	XX
PR 15-FEB-2001; 2001US-026887P.	XX	PR 24-MAY-2000; 2000US-0205548P.	XX		
PA (BAYLOR) BAYLOR COLLEGE MEDICINE.	PA				

PT	phagocytic cells, comprises polymeric matrix, lipid, and nucleic acid molecule.	XX	Best Local Similarity 77.8%; Pred. NO. 2e+06; Mismatches 0; Indels 0; Gaps 0;	
PT	Disclosure: Page 4; 37pp; English.	XX		
PS	The invention relates to a microparticle (microsphere) less than 20 microns in diameter that comprises: (1) a polymeric matrix; (2) a lipid; and (3) a nucleic acid molecule. The microparticle is not encapsulated in a liposome and the microparticle does not comprise a cell. The microparticles are used as vehicles for the delivery of polymucleotides into phagocytic cells. The microparticles can be used to express antigens to treat tumour cells or viral, bacterial, fungal or protozoan infections. The microparticles can be made without adversely affecting nucleic acid integrity. The present sequence represents the amino acid sequence of a major histocompatibility complex, MHC, class I associated peptide.	CC	RESULT 23 ADG89654 standard; peptide; 9 AA. ID ADG89654 standard; peptide; 9 AA. XX	Qy 1 STAPPVHNV 9 Db 1 STAPPAHGV 9
XX	Sequence 9 AA;	CC	XX	XX
Query Match 79.6%; Score 39; DB 6; Length 9; Best Local Similarity 77.8%; Pred. NO. 2e+06; Mismatches 0; Indels 0; Gaps 0;	CC	XX	XX	XX
Sequence 9 AA;	CC	XX	XX	XX
Qy 1 STAPPVHNV 9 Db 1 STAPPAHGV 9	CC	XX	XX	XX
XX	RESULT 23 ADG89654 standard; peptide; 9 AA. ID ADG89654 standard; peptide; 9 AA. XX	AC	XX	XX
AC ADG89654; AC ADG89654;	AC	XX	XX	XX
XX 11-MAR-2004 (first entry)	XX	XX	XX	XX
Class I HLA-restricted widely expressed antigen #19.	XX	XX	XX	XX
XX metastatic cancer cell differentiation; mutated fibronectin; KW metastatic cancer; class I HLA-restricted; widely antigen. OS Unidentified.	XX	XX	XX	XX
XX WO2003100027-A2.	XX	XX	XX	XX
XX 04-DEC-2003.	XX	XX	XX	XX
XX 28-MAY-2003; 2003WO-US016736.	XX	XX	XX	XX
XX 28-MAY-2002; 2002US-0383530P.	XX	XX	XX	XX
XX (BAYU) BAYLOR COLLEGE MEDICINE.	XX	XX	XX	XX
PI Wang R; XX DR WPI; 2004-035134/03.	PI	XX	XX	XX
XX Identifying a cell that differentiates into a metastatic cancer cell, PT useful for preventing metastatic cancer, comprises identifying a mutated PT fibronectin in the cell.	CC	XX	XX	XX
XX Disclosure; SEQ ID NO 97; 137pp; English.	CC	XX	XX	XX
CC The invention comprises a method for identifying a cell that will CC differentiate into a metastatic cancer cell, the method involves CC identifying a mutated fibronectin in the cell. The method of the CC invention is useful for preventing metastatic cancer. The present amino CC acid sequence represents a Class I HLA-restricted widely expressed CC antigen.	CC	XX	XX	XX
XX Sequence 9 AA;	CC	XX	XX	XX
Query Match 79.6%; Score 39; DB 8; Length 9;	CC	XX	XX	XX

DE Human MUC1 CTL helper epitope sequence.
 XX PSA; tumour-associated protein; prostate specific antigen; kallikrein-2;
 KW KKL2; mucin-1; MUC1; interleukin;
 KW granulocyte-macrophage colony-stimulating factor; immunostimulant;
 KW cytotoxic; vaccine; CTL epitope.
 OS Homo sapiens.
 XX WO2004096238-A1.
 XX PD 11-NOV-2004.
 XX PF 01-APR-2003; 2003WO-US010096.
 XX PR 01-APR-2003; 2003WO-US010096.
 XX PA (CENZ) CENTOCOR INC.
 PA (GOLE/) GOLETZ T J.
 PA (MCCA/) MCCARTHY S G.
 PA (SCAL/) SCALLON B J.
 PA (SNYD/) SNYDER L A.
 PA (BRAN/) BRANIGAN P J.
 XX PI Goletz TJ, McCarthy SG, Scallion BJ, Snyder LA, Branigan PJ;
 PI Knight DM;
 XX DR WPI: 2004-804620/79.
 DR N-PSDB; ADU49633.
 XX PT Composition comprising polynucleotide encoding antigenic determinant of
 PT tumor-associated protein (eg prostate specific antigen) and nucleic acid
 PT adjuvant (eg interleukin-18) useful for eliciting immune response to
 PT cancer associated tumor protein.
 XX Disclosure; SEQ ID NO 56; 105pp; English.
 XX The invention relates to a new composition that comprises a first
 CC isolated polynucleotide encoding or complementary to an antigenic
 CC determinant of a tumour-associated protein and a second isolated
 CC polynucleotide encoding or complementary to a nucleic acid adjuvant. The
 CC composition further comprises at least one promoter sequence controlling
 CC the expression of the polynucleotides and a carrier or adjuvant. The promoter
 CC polynucleotide is human cytomegalovirus immediate early promoter,
 CC dihydrofolatereductase promoter, early SV40 promoter or late SV40
 CC promoter. The tumour-associated protein is prostate specific antigen
 CC (PSA), kallikrein-2 (KLK2) or mucin-1 (MUC1). The nucleic acid adjuvant
 CC encodes human interleukin (IL)-18 IL-12, granulocyte-macrophage colony-
 CC stimulating factor or B7-1 or its variant. The first and second
 CC polynucleotides are contained in the same or separate nucleic acid
 CC vectors. The composition is useful in eliciting an immune response to a
 CC cancer associated tumour protein in a mammal. The present sequence
 XX represents a human MUC1 polypeptide CTL helper epitope.
 SQ Sequence 9 AA;

DE Class I HLA-restricted widely expressed antigen #19.
 XX vaccine; infection; viral infections; viricide; bacterial infection;
 KW antibacterial; yeast infection; fungicide; fungal infection;
 KW protozoal infection; protozoide cancer; cytoblastic melanoma;
 KW lung tumor; colon tumor; breast tumor; leukemia; autoimmune disease;
 KW multiple sclerosis; neuroprotective; rheumatoid arthritis; antiarthritic;
 KW antirheumatic; systemic lupus erythematosus; antiinflammatory;
 KW dermatological; immunosuppressive.
 XX PN Unidentified.
 XX OS XX
 XX PN WO2005011730-A1.
 XX PD 10-FEB-2005.
 XX PR 30-JUL-2004; 2004WO-GB003285.
 XX PA (UNLO) QUEEN MARY & WESTFIELD COLLEGE.
 XX PA (UNLO) QUEEN MARY & WESTFIELD COLLEGE.
 XX PI Wang P, Li S;
 XX DR WPI: 2005-152260/16.
 XX PR New vaccine composition comprises inverted microsomes from animal cells
 PR with an externally disposed peptide antigen and a protein of the Major
 PR Histocompatibility Complex (MHC), useful for treating or preventing, e.g.
 PR cancer.
 XX Disclosure; Page 53; 83pp; English.
 XX The invention comprises a vaccine composition that consists of isolated
 CC inverted microsomes from an animal cell (or its membrane fragments), in
 CC association with an externally disposed peptide antigen and a protein of
 CC the MHC. The vaccine composition of the invention is useful for the
 CC prophylaxis or treatment of: infection (e.g. viral, bacterial, yeast,
 CC fungal or protozoal), cancer (e.g. melanoma, lung adenocarcinoma, colon
 CC cancer, breast cancer or leukemic), autoimmune disease (e.g. multiple
 CC sclerosis, rheumatoid arthritis or systemic lupus erythematosus). The
 CC present amino acid sequence represents a class I HLA-restricted widely
 CC expressed antigen.
 XX Sequence 9 AA;
 XX Query Match 79.6%; Score 39; DB 9; Length 9;
 XX Best Local Similarity 77.8%; Pred. No. 2e+06;
 XX Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0; Gaps 0;
 XX AC ADY46204;
 XX DT 05-MAY-2005 (first entry)
 DE MHC Class I associated tumor and Pathogen Peptide, seq id 55.
 XX KW Immunosuppressive; microparticle; gene therapy; antisense therapy;
 KW vaccination; autoimmune disease; MHC Class I.
 XX OS Homo sapiens.
 XX PN US2005037086-A1.
 XX PD 17-FEB-2005.

RESULT 26
 ID ADX08604 Standard; peptide; 9 AA.
 XX AC ADX08604;
 XX DT 21-APR-2005 (first entry)

RESULT 27
 ID ADY46204 standard; peptide; 9 AA.
 XX AC ADY46204;
 XX DT 05-MAY-2005 (first entry)

XX	16-JAN-2004;	2004US-00758970.	PD	28-APR-2005.
PP			XX	14-OCT-2004;
XX	19-NOV-1999;	99US-0166516P.	PP	2004WO-US033988.
PR	17-NOV-2000;	2000US-00715708.	XX	14-OCT-2003;
XX	(ZYCO-)	ZYCOS INC.	PR	2003US-0510516P.
PA			PR	04-JUN-2004;
XX	PT		XX	2004US-0576624P.
PT	PI		PA	(BIOM-) BIOMIRA INC.
PT	XX		XX	XX
PT	XX	Kehoe-Whistance M,	PI	Kehoe-Whistance M,
PT	DR	Hedley ML;	MacLean G;	MacLean G;
PT	XX		XX	XX
PT	DR		DR	WPI; 2005-322772/33.
PT	XX		XX	
PT	PS	Scalable continuous preparation of nucleic acid-containing microparticles to treat autoimmune disease comprises solvent removal device and mixing chamber; and continuously supplying first emulsion and second aqueous solution to the chamber.	PS	Use of synergistic combination of anti-estrogenic steroids and immunological agents to treat breast cancer.
PT	PS		PS	
PT	PS	Disclosure; SEQ ID NO 55; 36pp; English.	PS	Disclosure; Page 28; 103pp; English.
PT	XX		XX	
PT	XX	The invention relates to the scalable continuous preparation of nucleic acid-containing microparticles (I) comprising providing a mixing chamber and a solvent removal device, continuously supplying a first emulsion and a second aqueous solution to the chamber, continuously transferring the second emulsion from the chamber to the solvent removal device, and removing the organic solvent from the second emulsion in the device to form an aqueous suspension of (I). (I) is used for delivery of a nucleic acid for gene therapy, antigenic therapy, vaccination, treatment of autoimmune disease, and either specific or non-specific modulation of an immune response (e.g. via cytokine regulation). The scalable, continuous flow production of (I) maintains the structural integrity of the associated nucleic acid and results in a microparticle having a purity suitable for introduction into an animal (e.g. human) host. The preparation of (I) provides an economical, aseptic, scalable procedure for producing a microparticle in amounts necessary for research, clinical, and other commercial uses. (I) produced using scalable, continuous flow process contains stable, active, potent, structurally intact nucleic acid, e.g. as supercoiled DNA. The method also provides efficient encapsulation of the nucleic acid in the microparticle and allows for efficient recovery of the nucleic acid. The current sequence represents an NHC Class I associated tumor and pathogen peptide sequence. This sequence could be an expression product of a microparticle of the invention.	XX	This sequence represents an antigenic peptide derived from the MUC1 repeat unit. MUC1 is a polymorphic antigen characterized by a variable number (typically 21-125, esp. 41 or 85) of perfect and imperfect repeats of peptide unit given in AD266304. MUC1 fragments may be used as immunogens in the method of the invention for treatment of breast cancer. The method comprises the administration of a combination of an anti-estrogenic steroid agent (A) (effective to reduce the level/activity of at least one estrogenic steroid) and an immunological agent (B) (effective to contribute to the development of a protective immune response to the breast cancer); where (A) and (B) are therapeutically effective against at least some breast cancers. (B) comprises at least one immunogen comprising at least one breast cancer-associated epitope; where at least one epitope is a MUC1 epitope or a carbohydrate epitope. The immunogen comprises STn-KH conjugate that is an aggregated conjugate having a NANA content of about 7 %. The antiestrogen comprises at least one (steroidal/non-steroidal) antiestrogen; where the steroidial antiestrogen is fulvestrant and the non-steroidal antiestrogen is tamoxifen, tamoxifen, droloxifene or trioxifene. The anti-estrogenic steroid agent comprises at least one aromatase inhibitor (analogluethimide, anastrozole, vorozole, letrozole, liarazole, megestrol, exemestane or formestane), preferably geoseline acetate or megestrol acetate. The method further comprises the administration of: at least one progestin (progesterone) that protects against breast cancer; at least one anti-progestin (progestrone) that protects against breast cancer; and at least one chemotherapeutic agent other than an anti-estrogenic steroid agent, where the chemotherapeutic agent is a taxane (paclitaxel or docetaxel). The combination of (A) and (B) is useful in the treatment of breast cancer (metastatic breast cancer) and in the manufacture of one or more compositions for the treatment of breast cancer. (B) is useful in the manufacture of a composition for the treatment of breast cancer in a subject who is receiving or has received treatment with an anti-estrogenic steroid agent, effective to reduce the level or activity of at least one estrogenic steroid in the subject. (A) is useful in the manufacture of a composition for the treatment of breast cancer in a subject who is receiving or has received treatment with an immunological agent, effective to contribute to the development of a protective immune response to the breast cancer. The combination of (A) and (B) is synergistically effective against breast cancer. The combination of (A) and (B) is effective in the treatment of cancer. The synergistic effect of the combination of (A) and (B) to treat breast cancer was tested in patients. The results showed that the patients treated with the immunogen and the anti-cancer hormone had better time to disease progression (TDP) and survival outcome when compared to groups treated with (A) or (B) alone.
PT	XX		XX	Sequence 9 AA;
PT	XX		XX	Query Match 79.6%; Score 39; DB 9; Length 9;
PT	XX	Best Local Similarity 77.8%; Pred. No. 2e+06;	XX	Best Local Similarity 79.6%; Score 39; DB 9; Length 9;
PT	XX	Matches 7; Conservative 0; Mismatches 2; Indels 0;	XX	Pred. No. 2e+06;
PT	Qy	1 STAPPVN 9	XX	Mismatches 0; Indels 0; Gaps 0;
PT	Db	1 STAPPAHGV 9	XX	Gaps 0;
PT	XX		XX	Sequence 9 AA;
PT	XX	RESULT 28	XX	Query Match 79.6%; Score 39; DB 9; Length 9;
PT	XX	ID AD266315	XX	Best Local Similarity 77.8%; Pred. No. 2e+06;
PT	XX	AD266315 standard: peptide; 9 AA.	XX	Mismatches 0; Indels 0; Gaps 0;
PT	AC	AD266315;	XX	
PT	XX	14-JUL-2005 (first entry)	XX	
PT	XX	MUC1 repeat unit (aa 14-20 + 1-2).	XX	
PT	Cytostatic; Aromatase inhibitor; Estrogen agonist; Estrogen antagonist; MUC1; Polymorphic antigen; immunogen; breast cancer; anti-estrogenic; steroid agent; estrogenic steroid; immunological agent; immune response.		XX	
PT	Homo sapiens.		XX	
PT	Synthetic.		XX	
PT	WO2005037261-A1.		XX	
PT	PN		XX	
PT	Db	1 STAPPAHGV 9	XX	

RESULT 29		DT 05-SEP-1995 (first entry)
AAW67603	XX	Mucin peptide p8-16.
ID AAW67603 standard; peptide; 9 AA.	XX	Mucin; multiple tandem repeat; vaccine; pancreas cancer; breast cancer;
XX	KW	ovary cancer; colon cancer; HIV.
AC AAW67603;	XX	
XX	OS	Synthetic.
DT 02-MAR-1999 (first entry)	XX	
DE Human MUC-1 derived T-cell activation 9-mer peptide.	PN WO9503825-A1.	
XX	XX	
XX Activated T helper cell; CD4+; cytotoxic T cell; CD8+; liposome; epitope;	PD 09-FEB-1995.	
XX peripheral blood lymphocyte; antigen-presenting cell; APC; virus; tumour;	PP 29-JUL-1994;	94WO-US008477.
XX bacterium; parasite; cytokine; vaccine; cancer; malaria; HIV; hepatitis;	PR 30-JUL-1993;	93US-00099354.
XX tuberculosis; mucin.	XX	
OS Synthetic.	PA (FINN/) FINN O.J.	
OS Homo sapiens.	PA (FONTENOT/) FONTENOT J.D.	
XX (MONT/) MONTELARO R.C.	PA	
PN WO950527-A1.	XX	
XX	PI Finn OJ, Fontenot JD, Montelaro RC;	
PD 12-NOV-1998.	XX	
XX	DR WPI; 1995-082033/11.	
PF 07-MAY-1998; 98WO-US009288.	XX	
XX	PT Synthetic multiple tandem repeat mucin-1 peptides and analogues - have	
PR 08-MAY-1997; 97US-0045849P.	XX	native conformation in the absence of glycosylation and are linked to
XX epitopes; for vaccines and tests of cancer, viruses and bacteria.	PT	
PA (BIOM-) BIOMIRA INC.	XX	
XX Disclosure; Page 54; 12pp; English.	PS	
PI Agrawal B, Krantz MJ, Reddish MA, Longenecker BM;	XX	
XX WPI; 1999-034715/03.	CC A synthetic peptide such as P105 (AAR68022) includes 5 tandem repeats of	
XX Method of activation of T cells - by exposure to antigen-presenting cells	CC the mucin peptide given in AAR68004. The DTR motif, located between the	
PT loaded with antigen in liposome, used for, e.g. treating cancer and	CC first 2 prolines of each repeat, is the target of an anti-mucin immune	
PT microbial infections.	CC response, and can be substituted by a sequence from a virus, tumor	
XX	CC antigen or autoantigen. Drugs based on 9-amino acid portions (AAR68007-21) of the mucin peptide were developed. (Updated on 25-MAR-2003 to	
PS Example 1; Page 30; 75pp; English.	CC correct PN field.)	
XX	XX Sequence 9 AA:	
CC Peptides AAW67583-W67611 are used to produce activated T helper (CD4+)	Query Match 71.4%; Score 35;	DB 2; Length 9;
CC and cytotoxic (CD8+) T-cells. The activated T cells are produced by	Best Local Similarity 85.7%; Pred. No. 2e+06;	
CC treating peripheral blood lymphocytes with liposome-encapsulated peptide	Matches 6; Conservative 0; Mismatches 1; Indels 0;	Gaps 0;
CC antigen to generate Ag-loaded antigen-presenting cells (APC), contacting	Qy 1 STAPPVH 7	
CC naive or anergic T-cells with these APC, and isolating the resulting	Db 2 STAPPAH 8	
CC activated T-cells. The cells are specific for a particular antigen,		
CC particularly one derived from a tumour, but also those from viruses,		
CC bacteria and other parasites. It can also be used to identify antigens		
CC and epitopes able to generate an Ag-specific T-cell response (by		
CC assessing proliferation and cytokine release). Also the Ag-loaded APC can		
CC be used as cellular vaccines for treating cancer (claimed) or other		
CC diseases (e.g. malaria, human immune deficiency virus infection,		
CC hepatitis, tuberculosis). The activated T-cells can be used to treat the		
CC same conditions by adoptive T-cell transfer therapy		
XX Sequence 9 AA:		
Query Match 73.5%; Score 36; DB 2; Length 9;	DT 25-MAR-2003 (revised)	
Best Local Similarity 66.7%; Pred. No. 2e+06;	ID AAR68014 Standard; peptide; 9 AA.	
Matches 6; Conservative 1; Mismatches 2; Indels 0; Gaps 0;	XX	
XX	DB Mucin peptide p10-18.	
XX	XX Mucin; multiple tandem repeat; vaccine; pancreas cancer; breast cancer;	
XX	KW ovary cancer; colon cancer; HIV.	
XX	OS Synthetic.	
Db 1 STAPPVHNV 9	XX	
Db 1 ATAPPAHGV 9	XX	
RESULT 30		
AAR68012	XX	
ID AAR68012 standard; peptide; 9 AA.	PW WO9503825-A1.	
XX	XX	
AC AAR68012;	PD 09-FEB-1995.	
XX	PP 29-JUL-1994;	94WO-US008477.
DT 25-MAR-2003 (revised)	PR 30-JUL-1993;	93US-00099354.

CC The patent discloses peptide or polypeptides capable of eliciting an
 CC immune response, comprising an amino acid sequence corresponding to an
 CC epitope of the non-central portion of varying numbers of an amino acid
 CC motif (VNTR), non-leader region of a mucin. The peptides of the
 CC invention, fusion proteins comprising the peptide and conjugate compounds
 CC with carbohydrate polymers are used to induce a cell mediated immune
 CC response against mucin in the prevention or treatment of carcinoma,
 CC preferably adenocarcinoma, most preferably breast cancer. They are also
 CC used to pulse dendritic cell for in vivo transfer and use as a vaccine.
 CC They are also used in gene therapy. The present sequence is a VNTR
 CC peptide of mucin-1 (MUC-1) protein from human
 XX

SQ Sequence 9 AA;

Query Match 71.4%; Score 35; DB 4; Length 9;
 Best Local Similarity 75.0%; Pred. No. 2e+06;
 Matches 6; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2 TAPPVAVV 9
 ||| |
 Db 1 TAPPVAVV 8

RESULT 37

ADS87178

ID ADS87178 standard; peptide; 9 AA.

XX AC ADS87178;
 XX PD 29-APR-2004.
 XX DT 18-NOV-2004 (first entry)
 XX DB Genetic vaccine/ubiquitin (Ub)/MUC1-related epitope peptide - SEQ ID 194.
 XX XX vaccine; ubiquitin; Ub; T-cell target; melanoma; sarcoma;
 XX Hodgkins lymphoma; non-Hodgkins; leukaemia; neuroblastoma; myeloma;
 XX lung cancer; stomach; skin; thyroid; ovary; prostate; womb; pancreas;
 XX colon; bladder; breast; oesophagus; kidney; brain; epitope; MUC1.
 OS Unidentified.
 XX PN WO2004035085-A1.
 XX PD 29-APR-2004.
 XX PF 16-OCT-2003; 2003WO-JP013279.
 XX PR 17-OCT-2002; 2002JP-00302816.
 XX PA (KYUSHU-) KYUSHU TLO CO LTD.
 XX XX Himeno K, Furue M, Maehara Y;
 XX PI WPI; 2004-357144/33.
 XX DR WPI; 2004-357144/33.
 XX PT Gene vaccine containing cancer antigen genes ligated to ubiquitin genes
 PT or cytokine genes for prevention and treatment of cancer.
 XX XX Disclosure: SEQ ID NO 193: 266pp; Japanese.
 XX PS Disclosure: SEQ ID NO 193: 266pp; Japanese.

XX The invention relates to a novel genetic vaccine containing the ubiquitin
 CC gene together with a gene encoding an antigenic protein containing a T-
 CC cell target sequence. The vaccine of the invention may be useful for
 CC prevention and treatment of cancers including melanoma, sarcoma, lymphoma
 CC (Hodgkins or non-Hodgkins), leukaemia, neuroblastoma, myeloma and cancer
 CC of the lung, stomach, skin, thyroid, ovary, prostate, womb, pancreas,
 CC colon, bladder, breast, oesophagus, kidney or brain. The current sequence
 CC is that of a genetic vaccine/ubiquitin (Ub)/MUC1-related epitope peptide
 CC of the invention.

XX SQ Sequence 9 AA;

Query Match 71.4%; Score 35; DB 8; Length 9;
 Best Local Similarity 85.7%; Pred. No. 2e+06;
 Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

PS Disclosure, SEQ ID NO 194; 266pp; Japanese.

XX PT Gene vaccine containing cancer antigen genes ligated to ubiquitin genes
 XX or cytokine genes for prevention and treatment of cancer.

XX PS Sequence 9 AA;

CC The invention relates to a novel genetic vaccine containing the ubiquitin
 CC gene together with a gene encoding an antigenic protein containing a T-
 CC cell target sequence. The vaccine of the invention may be useful for
 CC prevention and treatment of cancers including melanoma, sarcoma, lymphoma
 CC (Hodgkins or non-Hodgkins), leukaemia, neuroblastoma, myeloma and cancer
 CC of the lung, stomach, skin, thyroid, ovary, prostate, womb, pancreas,
 CC colon, bladder, breast, oesophagus, kidney or brain. The current sequence
 CC is that of a genetic vaccine/ubiquitin (Ub)/MUC1-related epitope peptide
 CC of the invention.

XX SQ Sequence 9 AA;

Query Match 71.4%; Score 35; DB 8; Length 9;
 Best Local Similarity 85.7%; Pred. No. 2e+06;

XX PS Disclosure, SEQ ID NO 194; 266pp; Japanese.

XX PT Gene vaccine/ubiquitin (Ub)/MUC1-related epitope peptide - SEQ ID 194.

XX XX Disclosure: SEQ ID NO 194 (first entry)

DE Genetic vaccine/ubiquitin (Ub)/MUC1-related epitope peptide - SEQ ID 194.

CC The patient discloses peptide or polypeptides capable of eliciting an
 CC immune response, comprising an amino acid sequence corresponding to an
 CC epitope of the non-central portion of varying numbers of an amino acid
 CC motif (VNTR), non-leader region of a mucin. The peptides of the
 CC invention, fusion proteins comprising the peptide and conjugate compounds
 CC with carbohydrate polymers are used to induce a cell mediated immune
 CC response against mucin in the prevention or treatment of carcinoma,
 CC preferably adenocarcinoma, most preferably breast cancer. They are also
 CC used to pulse dendritic cell for in vivo transfer and use as a vaccine.
 CC They are also used in gene therapy. The present sequence is a VNTR
 CC peptide of mucin-1 (MUC-1) protein from human
 XX

SQ Sequence 9 AA;

Query Match 71.4%; Score 35; DB 4; Length 9;
 Best Local Similarity 75.0%; Pred. No. 2e+06;

Matches 6; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 STAPPVH 7
 ||| |
 Db 2 STAPPVH 8

RESULT 38

ADS87177

ID ADS87177 standard; peptide; 9 AA.

XX AC ADS87177;
 XX DT 18-NOV-2004 (first entry)
 XX DB Genetic vaccine/ubiquitin (Ub)/MUC1-related epitope peptide - SEQ ID 193.

XX XX vaccine; ubiquitin; Ub; T-cell target; melanoma; sarcoma;
 XX Hodgkins lymphoma; non-Hodgkins; leukaemia; neuroblastoma; myeloma;
 XX lung cancer; stomach; skin; thyroid; ovary; prostate; womb; pancreas;
 XX colon; bladder; breast; oesophagus; kidney; brain; epitope; MUC1.

OS Unidentified.

XX PN WO2004035085-A1.

XX PD 29-APR-2004.

XX PF 16-OCT-2003; 2003WO-JP013279.
 XX PR 17-OCT-2002; 2002JP-00302816.

XX PA (KYUSHU-) KYUSHU TLO CO LTD.

XX XX Himeno K, Furue M, Maehara Y;

XX PI WPI; 2004-357144/33.

XX DR WPI; 2004-357144/33.

XX PT Gene vaccine containing cancer antigen genes ligated to ubiquitin genes
 PT or cytokine genes for prevention and treatment of cancer.

XX PS Disclosure, SEQ ID NO 194; 266pp; Japanese.

XX PT Gene vaccine containing cancer antigen genes ligated to ubiquitin genes
 XX or cytokine genes for prevention and treatment of cancer.

XX PS Sequence 9 AA;

Query Match 71.4%; Score 35; DB 8; Length 9;
 Best Local Similarity 85.7%; Pred. No. 2e+06;

Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 STAPPVH 7
 ||| |
 Db 3 STAPPVH 9

RESULT 39

ADS87166

ID ADS87166 standard; peptide; 9 AA.

XX AC ADS87166;

XX DT 18-NOV-2004 (first entry)

DE Genetic vaccine/ubiquitin (Ub)/MUC1-related epitope peptide - SEQ ID 182.

XX vaccine; ubiquitin; Ub; T-cell target; melanoma; sarcoma;
 KW Hodgkins lymphoma; non-Hodgkins; leukaemia; neuroblastoma; myeloma;
 KW lung cancer; stomach; skin; thyroid; ovary; prostate; womb; pancreas;
 KW colon; bladder; breast; oesophagus; kidney; brain; epitope; MUC1.
 XX Unidentified.
 OS
 XX
 PN WO2004035085-A1.
 XX
 PD 29-APR-2004.
 XX
 PF 16-OCT-2003; 2003WO-JP013279.
 XX
 PR 17-OCT-2002; 2002JP-0030816.
 XX
 PA (KYUSHU TLO CO LTD.
 XX
 PI Himeko K, Furue M, Maehara Y;
 XX
 DR 2004-357144/33.
 PT Gene vaccine containing cancer antigen genes ligated to ubiquitin genes
 PT or cytokine genes for prevention and treatment of cancer.
 XX Disclosure; SEQ ID NO 182; 266pp; Japanese.
 XX
 The invention relates to a novel genetic vaccine containing the ubiquitin
 CC gene together with a gene encoding an antigenic protein containing a T-
 CC cell target sequence. The vaccine of the invention may be useful for
 CC prevention and treatment of cancers including melanoma, sarcoma, lymphoma
 CC (Hodgkins or non-Hodgkins), leukaemia, neuroblastoma, myeloma and cancer
 CC of the lung, stomach, skin, thyroid, ovary, prostate, womb, pancreas,
 CC colon, bladder, breast, oesophagus, kidney or brain. The current sequence
 CC is that of a genetic vaccine/ubiquitin (Ub)/MUC1-related epitope peptide
 CC of the invention.
 XX Sequence 9 AA:
 SQ

Query Match Score 35; DB 8; Length 9;
 Best Local Similarity 71.4%; Pred. No. 2e+06;
 Matches 6; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Qy 2 TAPPVNV 9
 |||||
 Db 1 TAPPAHGv 8

RESULT 40
 ABG73822
 ID ABG73822 standard; peptide; 8 AA.
 XX
 AC ABG73822;
 XX DT 20-MAR-2003 (first entry)
 XX DE Human HLA-A2.1 restricted MUC-1 (mucin) peptide epitope.
 DB MUC1 associated epitope.
 KW Human; MUC1; mucin-1; cytosatic; antagonist; vaccine; tumour;
 KW tumour-associated mucin-1; cancer; breast carcinoma; colon carcinoma;
 KW oesophageal squamous cell carcinoma; pancreatic carcinoma;
 KW prostate carcinoma; multiple myeloma; adenocarcinoma.
 XX Homo sapiens.
 OS
 XX US2002132771-A1.
 PN
 PD 19-SEP-2002.
 XX
 PP 26-NOV-2001; 2001US-0099446.
 XX
 PR 18-AUG-1999; 99US-0149492P.
 PR 11-NOV-1999; 99US-0164714P.

PR 18-AUG-2000; 2000US-00641833.
 PR 28-NOV-2000; 2000US-0074094.
 PR 21-FEB-2001; 2001US-027456P.
 PR 21-FEB-2001; 2001US-0270471P.
 XX
 PA (MADI/) MADIYALAKAN R.
 XX
 PI Madiyalakan R;
 XX
 DR WPI; 2003-155598/15.
 XX
 PT New therapeutic compositions comprising a binding agent that binds to
 PT tumor-associated MUC1 epitope, useful for treating human tumors, e.g.
 PT breast carcinoma, prostate carcinoma or multiple myeloma.
 XX
 PS Example 24; Page 13; 27pp; English.
 XX
 CC The invention relates to new therapeutic compositions, which comprise a
 CC binding agent that specifically binds to an epitope of a tumour-
 CC associated mucin-1 (MUC1), are effective for treating a mammal bearing a
 CC tumour. Mice were implanted with 413BCR tumour cells 2 weeks after the
 CC start of the immunisation series (using either a conjugate of the binding
 CC agent, or a complex of the binding agent-MUC1). It was found that a
 CC humoral response was induced in mice treated with both the conjugated and
 CC complexed binding agent. A T2 cellular response to the binding agent was
 CC induced in these mice. A trend for reduction in tumour mass and size in
 CC mice treated with the conjugated or complexed binding agent was also
 CC demonstrated. The therapeutic compositions or the method is useful for
 CC treating a mammal (particularly a human) bearing a tumour, especially a
 CC tumour that expresses a tumour-associated MUC-1. In particular, the
 CC compositions are useful for treating adenocarcinomas, e.g. breast
 CC carcinoma, colon carcinoma, oesophageal squamous cell carcinoma,
 CC pancreatic carcinoma, prostate carcinoma, or multiple myeloma. The
 CC present sequence represents the mucin-1 associated epitope
 CC
 Sequence 8 AA:
 SQ Query Match Score 32; DB 6; Length 8;
 Best Local Similarity 71.4%; Pred. No. 2e+06;
 Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 Qy 1 STAPPVH 7
 :|||
 Db 2 TTAPPAH 8

RESULT 41
 AAE26804
 ID AAE26804 standard; peptide; 8 AA.
 XX
 AC AAE26804;
 XX DT 13-DEC-2002 (first entry)
 XX DE Human HLA-A2.1 restricted MUC-1 (mucin) peptide epitope.
 KW Human; cancer; breast cancer; ovarian cancer; HLA-A2.1.
 KW epitope; human leucocyte antigen; HLA-A2.1.
 OS Homo sapiens.
 XX PN WO200265992-A2.
 XX PD 29-AUG-2002.
 XX PP 19-FEB-2002; 2002WO-US005748.
 XX PR 20-FEB-2001; 2001US-0270252P.
 XX
 PA (ORTH) ORTHO-MCNEIL PHARM INC.
 XX
 PI Degraw J, Moriarty A, Leturcq DJ, Jackson MR, Peterson PA;
 PI Heiskala M;

XX WPI: 2002-667033/71.
 DR Treating a subject with cancer comprises combining the CD8+ cells, which
 XX are stimulated with non-naturally occurring antigen-presenting cell line,
 PT with adherent blood monocytes and inoculating the subject with CD8+
 PT suspension.
 XX PS Example 2; Page 93; 99pp; English.

XX The invention relates to a method of treating a subject with cancer. The
 CC method involves combining the CD8+ cells, which are stimulated with non
 CC naturally occurring antigen-presenting cell (nAPC) line, with adherent
 blood monocytes and inoculating the subject with CD8+ suspension. The
 CC method is useful for treating cancer e.g. ovarian cancer, breast
 CC and melanoma etc. It is also useful in cell therapy. The present sequence
 CC is human leukocyte antigen A2 (HLA-A2).1 restricted peptide epitope used
 CC to treat breast and ovarian cancer
 XX Sequence 8 AA;

Query Match Score 31.5%; DB 5; Length 8;
 Best Local Similarity 88.9%; Pred. No. 2e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 1; Gaps 1;
 Qy 1 STAPPVHN 9
 Db 1 STA-PVHN 8

RESULT 42

AE036310 Standard; Peptide: 8 AA.
 ID AE036310
 AC AEA36310;
 XX DT 11-AUG-2005 (first entry)
 XX Human MUC-1 950-958 cytotoxic T-lymphocyte epitope peptide.
 DE viral infection; virucide; cytostatic; tumor; neoplasm; cell therapy;
 KW antigen; MUC-1.
 XX OS Homo sapiens.
 XX JP2005139118-A.
 XX PD 02-JUN-2005.
 XX PF 07-NOV-2003; 2003JP-00377653.
 XX PR 20-FEB-2001; 2001US-0270252P.
 XX PA (ORTHO-MCNELL PHARM INC.).

PI Leturco DJ, Moriarty AM, Jackson MR, Peterson PA, Richards JM,
 XX WPI: 2002-667033/71.

XX Treating a subject with cancer comprises combining the CD8+ cells, which
 PT are stimulated with non-naturally occurring antigen-presenting cell line,
 PT with adherent blood monocytes and inoculating the subject with CD8+
 PT suspension.
 XX Disclosure; SEQ ID NO 20; 65pp; Japanese.

XX The invention relates to a novel method for treating viral infection in a
 CC subject. The method comprises preparing an antigen presentation cell
 CC lineage (nAPC), collecting CD8+ cells from the subject, stimulating CD8+
 CC cells using the nAPC, culturing CD8+ cells in the presence of
 CC intercell-2 (IL-2) and/or IL-7, mixing peripheral blood monocytes from
 CC the subject, subjecting the components to gamma irradiation, combining
 CC the CD8+ cells with adhesive peripheral blood monocytes and inoculating

CC the CD8+ suspended solid to the subject. The method of the invention
 CC demonstrates virucide and cytostatic activities and may be useful for
 CC treating a viral infection or tumor in a subject via cell therapy. The
 CC current sequence is that of a human MUC-1 cytotoxic T-lymphocyte epitope
 CC peptide of the invention which was incorporated into a Drosophila antigen
 CC presenting cell.

XX SQ Sequence 8 AA;

Query Match Score 31.5%; DB 5; Length 8;
 Best Local Similarity 88.9%; Pred. No. 2e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 1; Gaps 1;
 Qy 1 STAPPVHN 9
 Db 1 STA-PVHN 8

XX RESULT 43

AAW38247 Standard; peptide: 6 AA.
 ID AAW38247
 XX AC AAW38247;
 XX DT 19-MAR-1998 (first entry)
 XX DE Extended region between repeating loops of mucin.
 XX KW Multivalent chimeric peptide; tandem repeat unit; human; mucin 1; MUC1;
 KW Omega loop sequence; prophylaxis; therapy;
 KW pathogenic virus neutralisation; human immunodeficiency virus; HIV.

XX OS Homo sapiens.
 XX PN WO9728187-A2.
 XX PD 07-AUG-1997.
 XX PF 29-JAN-1997; 97WO-US017226.
 XX PR 31-JAN-1996; 96US-00594403.
 XX PR 15-OCT-1996; 96US-00730244.
 XX PA (POPUL-) POPULATION COUNCIL INC.
 XX PI Fontenot JD, Phillips DM;
 XX DR WPI: 1997-402551/37.
 XX PT New multivalent chimeric peptide(s) for neutralising pathogenic microbes
 PT - comprising a loop structure of human mucin 1 and an omega loop of an
 PT immunoglobulin superfamily protein.
 XX Disclosure; Page 39; 63pp; English.

XX The present sequence was used in the development of a novel multivalent
 CC chimeric peptide, comprising at least 2 tandemly repeated units, where
 CC the 1st portion of the repeated unit comprises a human mucin 1 (MUC1),
 CC sequence which forms an extended connector and a base of a loop structure
 CC of human MUC1, and a 2nd portion comprising an immunoglobulin super
 CC family protein Omega loop sequence. In the peptide, the natural structure
 CC of MUC1 tandem repeats can be used to present an Omega loop sequence in a
 CC functional conformation that is both multivalent and biologically active.
 CC It can provide prophylactic and therapeutic agents which have the binding
 CC specificity of an immunoglobulin super family member protein but do not
 CC have the entire protein's backbone. It can be used to neutralise
 CC pathogenic viruses, e.g. human immunodeficiency virus (HIV)

XX SQ Sequence 6 AA;

Query Match Score 31%; DB 2; Length 6;
 Best Local Similarity 83.3%; Pred. No. 2e+06;
 Matches 5; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy	2 TAPPVH 7 	KW MHC Class I; HLA-A2; human; Major Histocompatibility Complex; uroplakin;
Db	1 TAPPVH 6	KW prostate specific antigen; prostate; mucin; lactadherin;
		KW tertocarcinoma derived growth factor; PSA; PSMA; PAP; CRIPTO-1
		OS Homo sapiens.
		XX XX WO200006723-A1.
		XX PD 10-FEB-2000.
		XX AC 29-JUL-1999; 99WO-IL000417.
		XX DT 30-JUL-1998; 98IL-00125608.
		XX DE PA (YEDA) YEDA RES & DEV CO LTD.
		XX PA (BIO-T) BIO-TECHNOLOGY GEN CORP.
		XX PI Eisenbach L, Carmon L, Tirosh B, Bar-Haim E, Paz A, Fridkin M;
		XX PI Fitter-Attas C;
		XX WPI; 2000-203463/18.
		XX DR
		XX PT Tumor associated antigen peptides, especially derived from uroplakin,
		PT prevention and cure of cancer or cancer metastases. The cancer may be
		PT breast, bladder, prostate, pancreas, ovary, thyroid, colon, stomach, head
		PT or neck cancer or a carcinoma. The tumour associated antigens are
		XX CC presentable to the immune system by HLA-A2 molecules and are generally
		CC between 8 to 10 amino acids in length. The amino acids located at
		CC positions 2 and 9 of the tumour associated antigens are the anchor
		CC residues which participate in the binding to MHC class I molecules, more
		CC specifically HLA-A2. More tumour associated antigens are described in
		CC GENSEQ records AAY82806-Y82882. Those tumour associated antigens
		CC described in records AAY82806-Y82824 and AAY82855-YY82869 are derived
		CC from Uroplakin, such as Uroplakin II, Uroplakin Ia, Uroplakin III and
		CC Uroplakin Ib. Those described in records AAY82825-Y82829 are derived from
		CC prostate specific antigen (PSA). Those described in records AAY82830-
		CC Y82835 are derived from prostate specific membrane antigen (PSMA). Those
		CC described in records Y82836-AAY82839 are derived from prostate acid
		CC phosphatase (PAP). Those described in records AAY82840-Y82846 are derived
		CC from Lactadherin (BA-46). Those described in records AAY82847-Y82854 are
		CC derived from Mucin and those described in records AAY82871-Y82882 are
		CC derived from Teratocarcinoma derived growth factor (CRIPTO-1)
		XX SQ Sequence 9 AA:
		Query Match 63.3%; Score 31; DB 3; Length 9;
		Best Local Similarity 100.0%; Pred. No. 2e+06;
		Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy	2 TAPPVH 7 	Db Gaps 0;
		Qy 1 STAPPV 6 Db 4 STAPPV 9
		RESULT 45
		AAV82854 AAU00540 standard; peptide; 9 AA.
		XX ID AAU00540 standard; peptide; 9 AA.
		AC XX AAU00540;
		AC DT 12-SEP-2001 (first entry)
		XX DE Human MUC1 polypeptide derivative #1.
		XX KW MUC1; antigenic peptide; major histocompatibility complex; MHC-I;
		KW prevention; cure; anti-tumour vaccine; carcinoma; treatment;
		KW prostate; pancreas; ovary; thyroid; breast; metastases; stomach; carcinoma;
		KW glycoprotein; cytotoxic T lymphocytes; T cell response; cancer; vaccine;

KW cancer gene therapy; diagnosis; treatment; graft versus host disease;
 KW organ transplant rejection; graft versus host disease.
 XX Homo sapiens.
 OS Homo sapiens.
 XX Key Location/Qualifiers
 FH 2 .⁹
 FT /note= "Epitope"
 XX WO200118035-A2.
 XX PD 15-MAR-2001.
 XX PF 07-SSP-2000; 2000WO-EP008761.
 XX PR 08-SEP-1999; 99GB-00021242.
 PR 10-SEP-1999; 99EP-00402237.
 PR 03-MAR-2000; 2000US-0187215P.
 XX PA (TRGE) TRANSGENE SA.
 PA (IMCR) IMPERIAL CANCER RES TECHNOLOGY LTD.
 XX PI Taylor-Papadimitriou J, Heukamp LC, Offringa R, Melief CJM;
 PI Acres B, Thomas M;
 XX PS WPI; 2001-235187/24.
 DR N-PSDB; AAS00586.
 PT New antigenic polypeptides of MUC1 protein which activate cytotoxic T lymphocytes and their analogs, useful for identifying a major histocompatibility complex class I restricted T cell response and for diagnosing cancer.
 XX PS Claim 2; Page 6; 81PP; English.
 CC The sequence represents a human MUC1 polypeptide derivative. Derivative antigenic peptides of MUC1 protein bind at least one major histocompatibility complex class I (MHC-I) glycoprotein, which activates cytotoxic T lymphocytes to induce a protective response against tumours. Diagnosis of cancer involves determining the presence or absence in a host cell of MHC class I restricted T cell response to a MUC1 derivative, where the presence of the MHC class I restricted T cell response indicates that the host has cancer. Measurement of the level of MHC class I restricted T cell response is also useful to monitor the severity of cancer, a larger response indicating a more severe cancer. MUC1 derivatives are useful in cancer therapy and to follow MUC1 specific immune responses in patients during the course of disease and/or treatment. MUC1 DNA is useful in cancer gene therapy, vaccination and diagnosis. Compositions of the sequences are used in vaccines and treatments against cancer or diseases caused by an immune response, such as an inflammatory disorder, organ transplant rejection or graft versus host disease.
 XX SQ Sequence 9 AA;
 CC Query Match 63.3%; Score 31; DB 4; Length 9;
 CC Best Local Similarity 100.0%; Pred. No. 2e+06;
 CC Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 CC DE Human MUC1 peptide SEQ ID NO:8.
 CC RESULT 47
 CC ADB84181
 CC ID ADB84181 standard; peptide; 9 AA.
 CC XX AC ADB84181;
 CC XX DT 04-DEC-2003 (first entry)
 CC XX DE Human MUC1-derived peptide MUC(167-175) SEQ ID NO:8.
 CC SQ 1 STAPPY 6
 CC Db 4 STAPPY 9
 CC XX OS Homo sapiens.
 CC XX PN WO2003089574-A2.
 CC XX PD 30-OCT-2003.
 CC XX PP 09-APR-2003; 2003WO-US010750.
 CC XX PR 15-APR-2002; 2002US-0372105P.
 CC XX PR 06-MAY-2002; 2002US-0377595P.
 CC XX PA (BIOM-) BIOMIRIA INC.
 CC XX

XX This sequence represents an antigenic peptide derived from MUC1. MUC1 is
CC a polymorphic antigen characterized by a variable number (typically 21-
CC 125, esp. 41 or 85) of perfect and imperfect repeats of peptide unit
CC given in ADZ6304. MUC1 fragments may be used as immunogens in the method
CC of the invention for treatment of breast cancer. The method comprises the
CC administration of a combination of an anti-estrogenic steroid agent (A)
CC (effective to reduce the level/activity of at least one estrogenic
CC steroid) and an immunological agent (B) (effective to contribute to the
CC development of a protective immune response to the breast cancer); where
CC (A) and (B) are therapeutically effective against at least some breast
CC cancers. (B) comprises at least one immunogen comprising at least one
CC breast cancer-associated epitope; where at least one epitope is a MUC1
CC epitope or a carbohydrate epitope. The immunogen comprises STN
CC (an STN-KLH conjugate that is an aggregated conjugate having a NANA content of
CC about 7%). The antiestrogen comprises at least one (steroidal/non-
CC steroid) antiestrogen; where the steroid antiestrogen is fulvestrant
CC and the non-steroidal antiestrogen is toremifene, tamoxifen, droloxifene
CC or trioxifene. The anti-estrogenic steroid agent comprises at least one
CC aromatase inhibitor (aminoglutethimide, anastrozole, vorozole, letrozole,
CC liarozole, megestrol, exemestane or formestane), preferably geoselin
CC acetate or megestrol acetate. The method further comprises the
CC administration of: at least one progestin (progesterone) that protects
CC against breast cancer; at least one anti-progestin that protects against
CC breast cancer; and at least one chemotherapeutic agent other than an anti-
CC estrogenic steroid agent, where the chemotherapeutic agent other is an anti-
CC breast cancer reagent.

XX Disclosure; SEQ ID NO 8; 167pp; English.

XX The invention relates to a novel non-naturally occurring glycolipopptide
CC comprising at least 5 amino acids, at least one amino acid being a
CC glycosidated amino acid and at least one amino acid being a lipidated
CC amino acid, where at least one lipidated amino acid is an interior amino
CC acid, the glycolipopptide comprising at least one disease-associated
CC epitope. A peptide of the invention has cytostatic, antibacterial,
CC virucide and antiparasitic activity, and may have a use as a vaccine,
CC and in gene therapy. The glycolipopptide is useful as an
CC immunotherapeutic or as a vaccine against cancers and pathogens (e.g.
CC microbes, toxins, parasites or viruses) presenting cross-reactive
CC epitopes, or as diagnostic reagents. The lipidated amino acid is useful
CC for specific modulation of immune responses to an antigen. The present
CC sequence is used in the exemplification of the invention.

Sequence 9 AA;
? Sequence 9 AA;

Query Match 63.3%; Score 31; DB 7; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Conservative 6; Mismatches 0; Indels 0; Gaps 0;

CC treatment of breast cancer in a subject who is receiving or has received
CC treatment with an anti-estrogenic steroid agent, effective to reduce the
CC tumor size.

CC level or activity of at least one estrogenic steroid in the subject. (A)
CC is useful in the manufacture of a composition for the treatment of breast
CC cancer in a subject who is receiving or has received treatment with an

SULT 49
Z66308

CC immunological agent, effective to contribute to the development of a protective immune response to the breast cancer. The combination of (A) and (B) is numerically effective against breast cancer. The

ADZ66308 standard; peptide; 9 AA. ADZ66308 combination of (A) and (B) is effective in the treatment of cancer. The synergistic effect of the combination of (A) and (B) to treat breast

MUC1 (167-175).
CC treated with (A) or (B) alone.
XX Semiconc. 9 M.

Cytostatic; Aromatase inhibitor; Estrogen agonist; Estrogen antagonist; MUC1; polymorphic antigen; immunogen; breast cancer; anti-estrogenic; sequence > AA;
Query Match 63.3%; **Score** 31; **DB** 9; **Length** 9;

Homo sapiens .
steroid agent; estrogenic steroid; immunological agent; immune response.

Qy 1 STAPPY 6
 WO2005017261-A1

DD 4 STAPPY
NOZOOJ/201-AI.
28-APR-2005.

14-OCT-2004; 2004WO-US033988.
RESULT 50
AAB31282
תל אביב 1282 תַּל אָבִיב 1282

14-OCT-2003; 2003US-0510516P.
04-JUN-2004; 2004US-0576624P.
AAB31282;
AC
XX
AAB31282; Standard; peptide; o AM.

(BIOMIR-) BIOMIRA INC.
XX DT 20-APR-2001 (first entry)
XX

Kehoe-Whistram M, Maclean G; DE Antigenic peptide derived from a human MUC1 protein.
WDT: 2005-322272/33 XX

Use of synergistic combination of anti-estrogenic steroids and MUC1; epithelial cell mucin; tumour; MUC1 ligand; cancer.

XX
 PD 21-DEC-2000.
 XX
 PF 15-JUN-2000; 2000WO-CA000711.
 XX
 PR 15-JUN-1999; 99US-0139263P.
 XX
 PA (UYHE-) UNIV HEALTH NETWORK.
 XX
 PI Gariepy J, Yang S;
 XX
 DR WPI; 2001-091388/10.

XX Novel ligands that binds to MUC1, an epithelial cell mucin, useful for PT diagnosing, monitoring, treating and preventing cancer.

XX PS Example 2; Page 26; 60pp; English.

XX The present sequence represents a peptide derived from a human MUC1 protein. MUC1 is an epithelial cell mucin, which is found on, and shed from, the surface of many tumours. The specification describes ligands that bind to MUC1. These ligands were isolated using a phage display technique using MUC1 tandem repeats as the target. The MUC1 tandem target repeats comprise repeats of the peptide AAB1258. The ligands are useful for detecting the presence of MUC1 in a sample, to treat or prevent cancer associated with MUC1 and to prepare a medicament or diagnostic agent to treat, prevent or detect cancer associated with MUC1. By assaying for the binding between the MUC1 ligand and MUC1 in a sample diagnosis or monitoring of cancer can be carried out. The ligands may also be used to prepare antibodies

XX Sequence 8 AA;

```
Query Match Score 30; DB 4; Length 8;
Best Local Similarity 61.2%; Pred. No. 2e+06;
Matches 71.4%; Mismatches 0; Indels 0; Gaps 0;
Matches 5; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3 APPVHNV 9
Db | | | |
1 APPAHGV 7
```

Search completed: February 24, 2006, 10:14:28
 Job time : 208 secs